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Abstract
Neuropathic pain is a pervasive chronic condition that lacks adequate therapeutic
treatment, making the identification of new candidate targets for drug development a
priority. Underlying the development of this pathological pain state is a process of
neuronal plasticity, termed central sensitisation that results in hyperexcitability of sensory
neurons in the spinal cord. Stimulation of peripheral nociceptive inputs can cause
downstream activation of kinases in the spinal dorsal horn that may contribute to the
generation of this hyperexcitable state in the spinal cord. Here, using the chronic
constriction injury (CCI) model of neuropathic pain, the role played by p42/44 and p38
mitogen-activated protein (MAP) kinases was addressed. Inhibition of both the p42/44
and p38 MAP kinase pathways attenuated the behavioural reflex sensitisation seen
following nerve injury. The study explored the part played by spinal VPAC2 and NK2
receptors, (which respond to the afferent excitatory neuropeptides VIP and NKA
respectively), in addition to glially mediated events in the activation of these kinases.
Following nerve injury, both spinal activation of p42/44 and p38 MAP kinases and
behavioural sensitisation (which was sensitive to p42/44 and p38 pathway inhibitors) was
prevented by VPAC2, NK2 and NMDA receptor antagonists and glial or TNF-a
inhibitors.
The NMDA receptor, which is thought to be crucially involved in central sensitisation in
the spinal cord, binds to the multivalent adapter protein PSD-95; an interaction which is
necessary for the development of neuropathic behavioural reflex sensitisation. Here we
show that mutant mice expressing a single point mutation in the Src homology 3 (SH3)
domain of PSD-95 (PSD-95SH3W470L mutants), have intact neuropathic behavioural
reflexes but blunted inflammatory responses. These findings indicate that different
domains of the same protein may contribute selectively to different pain states.
Examining further the role played by PSD-95, we found that the expression of both PSD-
95 and one of its signalling partner kinases, Pyk 2, was increased in the same superficial
dorsal horn neurons following nerve injury. These studies suggest the importance of
specific receptors and signalling pathways, non-neuronal cells and of proteimprotein
v
complexes associated with the NMDA receptor in chronic pain states and point to their
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Pain is a complex sensation that is defined as "an unpleasant sensory and emotional
experience associated with actual or potential tissue damage or expressed in terms of such
damage" (Merskey and Bogduk, 1994). Pain sensation is a dynamic physiological process
that involves the transduction of sensory information at the point of stimulation, transmission
via peripheral nerve to the dorsal root ganglion then onto the spinal cord, which in turn relays
this information to various centres in the brain, where it is combined with cognitive and
emotional processing, resulting in the individual experience of pain. Nociception is the
physiological process of transducing such sensory stimuli by specialised peripheral receptors
and transmitting this information to the central nervous system, but is devoid of the
emotional aspect of pain perception.
The ability to experience pain serves a protective role to warn of possible or actual tissue
damage, thus allowing for the co-ordination of reflex and behavioural responses to limit the
extent of such damage and enable the recovery and healing of the injury. Such acute (short-
lasting) pain does not outlast the injury, to be precise the sensation of pain ceases once the
inflammatory process abates or the initial noxious stimulus is removed. However, if pain
sensation outlasts the injury or is out of proportion to the actual injury it is considered to be a
pathological pain state. Such a chronic pain state is a maladaptive nociceptive process, where
signal modulation and plasticity can occur at any stage of the process resulting in
hyperexcitability of the nervous system. This hyperexcitability can lead to long term changes
in nociception and the individual's perception of pain, thereby producing spontaneous and
hypersensitive pain syndromes which can be so debilitating that the individual's quality of
life is severely reduced. Chronic pain arising from damage to a peripheral nerve that is a
neuropathic form of chronic pain will be the focus of this study, with some comparisons to
chronic inflammatory pain being made. As the anatomy of sensory processing is essential to
understanding how the system works and how the process may be at fault, resulting in
hyperexcitability during chronic pain, each of these stages will be briefly discussed.
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1.2 Peripheral transduction of sensory information
Primary afferent axons terminate in specialised nerve endings that are in close contact with
well defined areas of skin from which they can be excited, this area is known as the receptive
field. Sensory information about changes in the external environment of the animal is
transmitted by a wide variety of cutaneous receptors and transduced into action potentials
(electro-chemical activity) in primary afferent axons. Cutaneous receptors have been
identified experimentally (by applying a series of test stimuli to the receptive field of the
skin) to respond to specific stimuli in distinguishable classes of non-nociceptors and
nociceptors (Lynn, 1994). Subgroups of receptors are activated by specific types of stimulus
such as heat, cold, fine touch, pressure, vibration, and stretch and tissue pH. Primary afferent
axons transmit the information evoked by stimulation of the skin to the first central synapse
in the dorsal horn of the spinal cord in which afferents have highly structured termination
patterns (Brown and Fuchs, 1975) thus forming an organised somatotopic map of peripheral
structures (Swett and Woolf, 1985).
1.2.1 Primary afferent axons
The primary afferent axons associated with these sensory receptors run uninterrupted from
their sensory endings in peripheral tissue to transmit sensory information to the spinal cord,
where they have highly structured termination patterns in the dorsal horn of the spinal cord
(Brown and Fuchs, 1975; Wall, 1960). These primary afferent axons can be subdivided into
three types, classified according to their axonal diameter and conduction velocity.
Ap-fibres have large diameters of greater than 10pm, are myelinated and are the most
rapidly conducting fibres with conduction velocities of 30-100m/sec. These fibres are
thought to be mostly non-nociceptive, innervating corpuscular endings or hair follicle
receptors and respond to a variety of innocuous tactile sensations including fine touch,
pressure, vibration, stretch, and hair movement under normal physiological conditions
(Willis and Coggeshall, 1991; Lynn and Carpenter, 1982).
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A8-fibres are also myelinated but have smaller axonal diameters of 2-6pm and therefore
slower conduction velocities ranging from 12-30m/sec. A5-fibres supply hair follicle
receptors or mechanical receptors and transmit both noxious and innocuous sensory
information, responding to light and heavy pressure, heat and cooling and to noxious
chemicals (Willis and Coggeshall, 1991). A5-fibre activation evokes a sensation termed
'first-pain' as it usually occurs rapidly after stimulation and is pricking or sharp in nature
(Torebjork and Ochoa, 1980). There are two sub-types; Type I A5 fibres are activated by
high-intensity mechanical stimuli in the noxious range and are also weakly responsive to
high-intensity heat and cold stimuli (Millan, 1999; Willis and Coggeshall, 1991). Type II A5
fibres are less common and display a lower threshold to noxious heat stimuli and can
therefore react more rapidly than type I (Willis and Coggeshall, 1991; Millan, 1999).
C-fibres have the smallest axonal diameters of 0.25-1.5pm, are unmyelinated and have slow
conduction velocities of l-2.5m/sec (Gasser, 1950). Many C-fibres are termed polymodal
fibres as they respond to a range of noxious mechanical, thermal and chemical stimuli (Willis
and Coggeshall, 1991). Stimulation of nociceptive C-fibres produces a sensation termed
'second pain' that usually has a relatively slow onset and is dull or burning in character
(Ochoa and Torebjork, 1989; Yaksh, 1986).
1.2.2 Non-nociceptive Mechanoreceptors
Cutaneous mechanoreceptors, which are usually associated with myelinated primary afferent
fibres, are highly sensitive receptors that respond to a variety of innocuous tactile sensations.
This diverse group of receptors can be further subdivided:
Rapidly adapting cutaneous receptors respond to light touch, pressure and vibration of the
receptive field of the skin but are not activated by hair movement. There are two classes of
rapidly adapting mechanoreceptors, those associated with Meissner corpuscles and those
associated with Pacinian corpuscles, both classes are associated with large Afl fibres.
Meissner corpuscles are thought to be responsible for fine or discriminative touch, while
Pacinian corpuscles respond to mechanical distortion of the cutaneous receptive field caused
by firm pressure (Willis and Coggeshall, 1991).
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Slowly adapting cutaneous receptors are involved in stretch perception and shape
discrimination, of which there are two types; slowly adapting type I and type II
mechanoreceptors. Type I mechanoreceptors are low threshold receptors associated with
Merkel cells and type II mechanoreceptors are associated with Ruffini corpuscles and
respond to smaller displacements of skin receptive field as a result of stretching, both types
are associated with Ap fibres (Willis and Coggeshall, 1991).
Hair follicle receptors. Hairy skin has specific receptors that innervate hair follicles and
respond to hair movement and bending (Brown and Iggo, 1967; Lynn and Carpenter, 1982).
They can be classified according to the type of hair which they innervate (Brown and Iggo,
1967) and are associated with myelinated A6 axons within rodent peripheral nerves (Lynn
and Carpenter, 1982). D-hair receptors respond to the slow movement of the fine down hairs
and are believed to have slowly conducting axons with large receptive fields, while G-hair
receptors have large axons with relatively small receptive fields and liable to be activated as
a result of fast movement of the guard hairs. The final class of receptor is the T-hair
receptors which are the least numerous and are excited by movement of the large tylotrich
hairs.
C-fibre mechanoreceptors. This class of mechanoreceptors is associated with unmyelinated
afferent C-fibres, which are a distinct group of C-fibres that are sensitive to gentle
mechanical stimulation and cooling of the skin (Bessou et al., 1971). They have a small
receptive field (Bessou et al., 1971), are rapidly adapting (Bessou and Perl, 1969) and are
found in the main on hairy skin. These receptors comprise approximately 15% of all C-fibres
present in the saphenous nerve (Lynn and Carpenter, 1982) with a greater occurrence of
approximately 30% in the sural nerve (Leem et al., 1993) in the rodent.
1.2.3 Non-nociceptive Thermoreceptors
Non-nociceptive cutaneous thermoreceptors respond to innocuous variations in temperature
and can be further divided into warm or cold thermoreceptors:
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Warm thermoreceptors are thought to be associated with unmyelinated axons (Iggo, 1959)
and respond to slight warming of the skin. These receptors are activated by mild warmth in
the non-noxious range, approximately 30-37°C.
Cold thermoreceptors are characterised by their sensitivity to miniscule reductions in skin
temperature [as little as 0.1 °C], the majority of which respond to stimuli in a restricted range
of innocuous cold temperature [approximately 20-30°C] (Heinz et al., 1990; Iggo, 1969).
These non-nociceptive cold cutaneous thermoreceptors are found in both the hairy and
glabrous skin (Iggo, 1969) and are associated with A8-fibres [and to a lesser extent with
cold-specific C-fibres] (Iggo, 1959; Iggo, 1969).
1.2.4 Nociceptors
Nociceptors respond to stimuli that can potentially or actually result in tissue damage, a
concept that was first proposed a hundred years ago by Sherrington (Sherrington, 1906).
Cutaneous nociceptors are functionally divided into two groups, the A8-fibre nociceptor or
the C-fibre polymodal nociceptor.
A5-fibre mechanonociceptors are associated with A5-fibres, respond to noxious or high
threshold mechanical stimulation of the skin such as pressure and pinch and are in both
glabrous and hairy skin. These receptors while not normally responsive to thermal stimuli
(Besson and Chaouch, 1987; Burgess and Perl, 1967) can become sensitized following a
long-lasting thermal stimulation and subsequently result in a response to future thermal
stimuli (Burgess and Perl, 1973; Fitzgerald and Lynn, 1977; Perl, 1984). A8-fibre
nociceptors also show responses to noxious cold stimuli (Simone and Kajander, 1996;
Simone and Kajander, 1997). In classifying A8-fibre nociceptors, the mechanonociceptors
were found to be dominant (73%; Leem et al., 1993). A8 nociceptive primary afferents
originating from high threshold A8 mechanonociceptors have been shown to terminate
predominantly in lamina I, IV and V with some branching to lamina II and X of the spinal
dorsal horn (see Figure 1.1 and Section 1.3.1 and 1.3.2 for description of Rexed's Laminae
and also Figure 1.2; Cervero et al., 1976; Light and Perl, 1979; Rethelyi et al., 1983).
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C-fibre polymodal nociceptors exist in both hairy and glabrous skin, have small receptive
fields and respond to multiple high threshold stimuli. C-fibre polymodal nociceptors can be
activated by high threshold heat stimulation (temperatures >42°C), by noxious mechanical
stimulation, in addition to being excited by irritant chemicals (Bessou and Perl, 1969;Perl,
1984) and in some cases intense cold (Cervero and Iggo, 1980; Simone and Kajander, 1996;
Willis and Coggeshall, 1991). Most C-fibre polymodal nociceptors have been shown to
terminate in lamina I-Il of the spinal dorsal horn (Figure 1.1 for Rexed Lamina and Figure
1.2; Cervero and Iggo, 1980; McMahon et al., 1984).
Other types of nociceptors have been identified including; cold nociceptors, that respond to
close to 0°C, which are stimuli associated with A5 nociceptors and possibly cold-sensitive C-
fibres; chemical nociceptors, which respond specifically to changes in extracellular pFl and
acidosis; and 'silent' nociceptors, which may be completely inactive until sensitised, for
example, by the onset of inflammation or the application of chemical irritants (Besson and
Chaouch, 1987; Bessou and Perl, 1969; Clark et al., 2003; Schmidt et al., 1995; Simone and
Kajander, 1996).
1.2.5 Sensory Neurones
The cell bodies of primary afferent fibres are located in the dorsal root ganglion (DRG)
located close to either side of the spinal cord or in the cranial nerve ganglia at the base of the
skull. Most afferent fibres pass through the dorsal root but some pass through the ventral root
(Coggeshall et al., 1975), which generally carries efferent fibres whose cell bodies of origin
are located in the spinal grey matter. There are different subpopulations of sensory neurones
that can be identified by their size (diameter of the cell body) and ultrastructure and by
immunocytochemical characteristics. The cell bodies of the primary afferent fibres can be
characterised by their response to growth factors [such as nerve growth factor (NGF); glial
cell-derived-neurotrophic factor (GDNF)] and by their expression of various substances.
Markers that are expressed in a cell type restricted pattern include; neurofilament (NF)
proteins, calcitonin gene related peptide (CGRP) and substance P (SP), nitric oxide synthase
(NOS) as well as binding sites for isolectin B4 (IB4) (Bergman et al., 1999; Petruska et al.,
2000). For example, Type I sensory neurones are large cells that do not express SP, account
-6-
for about 35% of cells and may be associated with A|3-fibres (Bergman et al., 1999; Petruska
et al., 2000). Type II sensory neurones are small cells identified by their binding of IB4,
account for approximately 50% of the cells and are mainly associated with C-fibres and Ad-
fibres (Bergman et al., 1999; Snider and McMahon, 1998). Another subpopulation is a small
cell peptide-expressing group, which express SP and/or CGRP but are not IB4 positive, and
are associated with C-fibres, these cells are dependent on NGF and so express the NGF
receptor TrkA (Braz et al., 2005).
1.3 Central transmission of sensory information
1.3.1 The Spinal Cord
The spinal cord is continuous rostrally with the medulla oblongata of the brain stem and is
located in the spinal canal of the vertebral column. The dorsal horn of the spinal cord is the
first stage involved in the processing of sensory information, providing the first central
synapse where this information is transmitted from nociceptive primary afferent neurones,
often onwards to the brain. The spinal cord in transverse section (see Figure 1.1) is composed
of an 'H' or butterfly-shaped area of grey matter within white matter that is arranged around
the central canal. The grey matter consists of neuronal cell bodies, fibres (axons and
dendrites) and associated non-neuronal cells that can be subdivided into two main regions,
namely the anterior or ventral horns and the posterior or dorsal horns. The work of Rexed
(Rexed, 1952) in the spinal cord of the cat classified the grey matter into laminae according
to their cytoarchitectonic characteristics. Rexed suggested an anatomical division of the
spinal cord grey matter into nine laminae that comprised the dorsal and ventral horns and a
tenth lamina surrounding the central canal (Rexed, 1952). Further investigations revealed that
the laminar arrangement of the grey matter remained consistent between mammalian species
(Molander et al., 1984). Rexed's laminae I to VI will be briefly discussed as these laminae
comprise the primary area for receiving somatosensory input to the dorsal horn. In addition
to this laminar organisation, the central terminals of primary afferent neurones in the dorsal
horn are topographically organised (Doubell and McCulloch, 1999; Swett and Woolf, 1985).
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1.3.2 Laminar organisation of the dorsal horn
Lamina I [The marginal zone]
Lamina I, also known as the 'marginal zone', is the thinnest and most superficial layer of the
dorsal horn (Brown, 1981; Molander et al., 1984). It is classically characterized by large,
horizontal neurones and a plexus of numerous horizontally arranged fine axons (Willis and
Coggeshall, 1991). Both myelinated A8-fibres and unmyelinated C-fibres terminate in lamina
I with A8-fibres being the predominant primary afferent input (Woolf and Doubell, 1994),
while input from the large myelinated Ap-fibres is not evident (Brown, 1981). Afferents from
lamina I project to the brainstem, midbrain, thalamic nuclei and other parts of the spinal cord
(Willis and Coggeshall, 1991). Lamina I is highly important in the transmission of noxious
sensory information, as it appears to contain a substantial number of noci-specific neurones,
which receive their projections from cutaneous high threshold AS-mechanoreceptors and C-
fibre thermal nociceptors (Cervero et al., 1976; Cervero et al., 1979; Christensen and Perl,
1970; Light and Perl, 1979; Rethelyi et al., 1983), while studies have also revealed a large
proportion of rat lamina I cells to be multireceptive (McMahon and Wall, 1983). Lamina 1
contains cells of origin of the spinothalamic (STT) and spinomesencephalic (SMT) tract
(Giesler et al., 1976; Lima and Coimbra, 1989; Mehler et al., 1960). Lamina I neurones can
be classified morphologically into three classes; firstlyfusiform cells that have small spindle
shaped somata and bipolar longitudinal dendritic arbors; secondly pyramidal cells with
triangular soma and three main dendritic origins with primarily longitudinal arborisation;
thirdly multipolar cells with larger multiangular somata and four or more radiating dendritic
arbors directed longitudally and mediolaterally (Lima et al., 1991; Zhang et al., 1996). The
dendrites of both fusiform and pyramidal cells remain in Lamina I whereas the dendrites of
multipolar cells can enter Lamina II or III (Lima and Coimbra, 1986).
Lamina II [The substantia gelatinosa]
Lamina II is located ventral to lamina I and is also called the 'substantia gelatinosa' due to its
gelatinous appearance as a result of the concentration of small neurones and the absence of
myelinated fibres (Brown, 1981; Willis and Coggeshall, 1991). Lamina II consists of an outer
zone (lamina II0) that contains densely packed small cells and a less compact inner zone
(lamina If; Light and Perl, 1979). Lamina II seems to be the main projection area for
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unmyelinated C-fibres with a sparse input from the myelinated AS fibres (Willis and
Coggeshall, 1991; Woolf and Doubell, 1994). While large myelinated Ap-fibres can
innervate this region, they appear largely excluded (Wilson and Kitchener, 1996). Lamina II
neurones can be classified into two structural groups; namely islet cells that have dendrites
which spread rostrocaudally within the lamina and axons that remain close to the cell body
and stalked cells with dendrites that fan out ventrally and axons that pass dorsally into lamina
I (Todd, 1988; Todd and Lewis, 1986). Very few (approximately 1%) lamina II neurones
project to the brainstem, some neurones project into lamina I or are mainly intrinsic
interneurones with extensive local integration (Giesler et al., 1976; Willis et al., 1979).
Lamina II is primarily involved with the processing of sensory information from the skin and
receives little input from non-cutaneous structures (such as muscle and viscera; Wilson and
Kitchener, 1996). Together lamina I and lamina II are known as 'the superficial dorsal horn'.
Lamina III - IV [The nucleus proprius]
Lamina III lies ventral to lamina II and forms a broad band across the dorsal horn and is
distinguished from lamina II by having slightly larger and more widely spaced cells (Rexed,
1952). There are two structural types of cells found in lamina III; firstly those that appear like
lamina II islet cells and secondly other cells that resemble inverted stalked cells with
dendrites which spread dorsally (Powell and Todd, 1992). Second order neurones send
dendrites from lamina III to lamina I and IV, and this lamina contains cells of origin of the
spinocervical (SCT), the postsynaptic dorsal column (PSDC) and STT tracts (Brown, 1981).
Lamina IV is a slightly thicker layer ventral to lamina III and is distinguishable from lamina
III by the heterogeneity of neuronal sizes in addition to the presence of some very large cells
(Molander et al., 1984). Many of the large scattered cells of lamina IV project dendrites into
lamina I-III; this distribution allows lamina IV cells to receive direct primary afferent input
from fibres that enter the superficial layers. Again lamina IV contains cells of origin of the
SCT, STT and the PSDC tracts. Lamina III-IV predominantly receives inputs from A[1
primary afferents of large hair follicles, slowly and rapidly adapting mechanoreceptors and
non-nociceptive A8-fibres, while also receiving input from visceral afferents (Brown and
Iggo, 1967; Gillette et al., 1994; Light and Perl, 1979) and is also known as the 'nucleus
proprius'.
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Lamina V - VI
Lamina V is a thick band across the narrowest part of the dorsal horn and can be identified by
the presence of many large diameter cells and of myelinated fibres due to A(3 fibres
terminating here (Molander et al., 1984; Willis and Coggeshall, 1991). Lamina VI exists only
in the cervical and lumbosacral enlargements of the spinal cord and consists of a medial zone
with small packed, compact cells and a lateral zone with slightly larger cells, with very few
primary afferents terminating here (Brown, 1981; Willis and Coggeshall, 1991). This layer
represents a transitional layer between the primary afferent-dominated dorsal horn and the
ventral horn. Both Lamina V and VI contain cells of origin of the STT, SMT and SCT tract
(Cao et al., 1993; Giesler et al., 1976; Mehler et al., 1960).
It is important to note that there are no precise cytoarchitectonic borderlines within the spinal
cord and that the laminae are recognized primarily as zones of particular cell types that may
have intermingled edges. Furthermore the borders between various laminae may differ
slightly between different segmental sections (Molander et al, 1984). The remaining laminae,
laminae VII-X which comprise the ventral horn are beyond the scope of this study.
1.3.3 Dorsal horn neurones
As outlined above the spinal dorsal horn is an important centre for the processing of sensory
information from the periphery to the central nervous system and contains a number of cells
of different sizes and appearance that can be categorised into three classes according to their
response to peripheral sensory stimuli (see Figure 1.2).
Class I [Non-nociceptive neurones]
Class I neurones do not respond to noxious stimulation but only to innocuous mechanical
stimulation of the receptive field via low threshold mechanosensitive A-fibres (Dubner and
Bennett, 1983; Iggo and Ramsey, 1974).
Class II [multireceptive neurones]
Class II or wide-dynamic range (WDR) neurones respond to both innocuous and noxious
cutaneous mechanical stimuli and or noxious thermal stimulation (Mendell, 1966; Price et
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al., 1976; Price et al., 1978). Indeed these cells can respond to stimulation of all types of
primary afferents, from the large myelinated Ap-fibres to unmyelinated C-fibres and are most
commonly found in laminae IV-VI of the dorsal horn, in particular lamina V (Besson and
Chaouch, 1987), however they have also been documented in the superficial layers of the
dorsal horn (McMahon and Wall, 1983; Menetrey and Besson, 1981; Woolf and Fitzgerald,
1983).
Class III [Noci-specific neurones]
Class III neurones appear to receive input only from myelinated (A8 -fibres) and non¬
myelinated (C-fibres) nociceptive afferents, thereby responding only to high-threshold
noxious stimuli (Cervero et al., 1976). These neurones have relatively small cutaneous
receptive fields and display little spontaneous activity (Perl, 1984). While they are
exclusively activated by noxious cutaneous stimulation, some of these noci-specific neurones
can also be driven by non-cutaneous inputs from the muscle or viscera (Cervero, 1983; Craig
and Kniffki, 1985). Noci-specific neurones tend to occur in lamina I and include neurones
that project to the thalamic and brain stem regions (Cervero et al., 1976; Cervero et al., 1979;
Christensen and Perl, 1970; Light and Perl, 1979). There is also a fourth class of dorsal horn
neurones, consisting of proprioceptive neurones that for example respond to joint movement
and pressure on deep tissues that will not be considered here.
In addition to the functional classification of dorsal horn neurones, they can also be grouped
according to their axon projections. Such groups are projecting neurones, local circuit
neurones and interneurones. Projecting neurones enter ascending spinal tracts and transmit
sensory information to higher brain centres. The majority of dorsal horn neurones are
interneurones, which can be excitatory or inhibitory. Dorsal horn neurones also receive
inputs from descending neurones from the brain to exert modulatory influences on sensory
information processing in the spinal cord. All of this is further discussed below.
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Figure 1.1
Schematic diagram of Rexed's cytoarchitectonic scheme applied to the spinal cord of
the rat.
The diagram represents a transverse section of the spinal grey matter. The laminae are





Schematic diagram of the cutaneous afferent input to and neuronal organisation of the
spinal dorsal horn.
A hypothetical cross section, showing the afferent fibres and neuronal elements found in the
first four laminae of the spinal dorsal horn. The laminar divisions of Rexed (Rexed, 1952) are
indicated to the right of the image. Afferent fibre types are listed to the left of the image,
which are shown to project onto neuronal types typical of laminae I-IV. The neurones shown
are a marginal cell, a substantia gelatinosa (SG) limiting cell, two SG central cells and two
neurones of the nucleus proprius, the more superficial of which has dendrites penetrating




























1.3.4 Ascending somatosensory tracts
Many dorsal horn neurones are projection neurones which send their axons, via ascending
tracts in the white matter to brainstem and midbrain regions. The main ascending tracts
involved in the transmission of nociceptive information include;
Spinothalamic Tract [STT]
The STT carries information from the spinal dorsal horn to the thalamic nuclei, with its cells
of origin located in laminae I, III and IV and V of the spinal dorsal horn (Giesler, Jr. et al.,
1979; Todd et al., 2000; Todd, 2002). STT cells usually respond to noxious mechanical
stimulation of the cutaneous receptive field but can also respond to innocuous mechanical
and temperature stimuli (Giesler et al., 1976), thereby the STT is not solely involved in
nociceptive transmission. Inhibition of the responses of STT cells from both noxious and
innocuous stimuli (from myelinated fibres) can be seen when various regions of the brain are
stimulated, such as the nucleus Raphe magnus (NRM; Willis et al., 1977).
Spinoreticular Tract [SRT]
The SRT projects from the dorsal horn in the ventrolateral region of the spinal cord to the
brain stem reticular formation, particularly within the medulla. SRT cells of origin appear to
be concentrated in laminae VII and VIII in the ventral horn (Chaouch et al., 1983) with few
cells found in the superficial layers of the dorsal horn. Studies revealed that some SRT cells
could be activated by noxious sensory stimuli (Menetrey et al., 1980).
Spinomesencephalic tract [SMT]
The SMT projects from cells of origin in laminae I, V and VI to the mesencephalic reticular
formation including the periaqueductal grey area (PAG) and to other sites in the midbrain
(Mehler et al., 1960). A significant proportion of SMT neurones which originate in lamina I
appear to be nociceptive in nature (Menetrey et al., 1980; Menetrey et al., 1982).
Dorsal Column Pathways
This ascending group can be divided into the postsynaptic dorsal column system (PSDC) and
the spinocervical tract (SCT). PSDC: The PSDC cells of origin are located primarily in
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lamina III of the spinal cord and projects through the dorsal funiculus to the nucleus gracilis
and nucleus cuneatus of the medulla (Giesler, Jr. et al., 1984). PSDC neurones are excited by
innocuous hair movement, pressure, pinching and cooling in addition to nociceptive stimuli
(Angaut-Petit, 1975). SCT: The SCT originates from cells in laminae III-VII and projects
ipsilaterally to the lateral funiculus (Cao et al., 1993). Some fibres of this tract project into
the PSDC or cross the mid-line into the contralateral ascending ventral funiculus (Cao et al.,
1993). Most SCT neurones respond to innocuous hair movement, however many are
multireceptive responding to nociceptive stimulation (Brown et al., 1983; Cervero et al.,
1979; Fleetwood-Walker et al., 1988).
1.3.5 Descending control
Dorsal horn neurones also receive efferent inputs from descending fibres, the effects of
which may be direct or indirect through involvement of interneurones at the spinal cord level.
Melzack and Wall were first to describe the existence of a specific modulatory system within
the CNS in their 'Gate Control Theory of Pain' (Melzack and Wall, 1965). They proposed
that spinal nociceptive transmission could be influenced by impulses from the brain which
had the potential to exert a form of descending control mediated by cutaneous stimulation of
large afferent fibres. This inhibitory influence by stimulation of large A fibres, on C-fibre and
noxious stimulation evoked excitation of dorsal horn neurones has been confirmed
experimentally (Besson and Chaouch, 1987; Woolf and Wall, 1982). Descending inhibitory
pathways from the brain may augment local inhibitory mechanisms to reduce nociceptive
transmission (Besson and Chaouch, 1987; Polgar et al., 2002). While many modifications of
the detail of this theory have been made, the hypothesis remains relevant when investigating
transmission of nociceptive information.
Tonic descending modulation
Many areas of the brain are known to be involved in the descending control of nociceptive
transmission, the exact origin of tonic descending inhibition is unclear. Lesion studies
revealed the lateral reticular nuclei in the brainstem as a source of descending pathways
(Foong and Duggan, 1986; Morton et al., 1983). Two regions in the brainstem, the medullary
nucleus raphae magnus (NRM) and adjacent structures of the rostral ventromedial medulla
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(RVM) are key regions involved in descending control of nociceptive transmission. The
NRM provides a major serotonergic input to laminae I, II and V cells of the dorsal horn
(Basbaum and Fields, 1984; Polgar et al., 2002). Electrical stimulation of this area has been
shown to produce analgesia to noxious stimuli (Duggan and Griersmith, 1979; Guilbaud et
al., 1977; Oliveras et al., 1974; Willis et al., 1977). Electrical stimulation in the RVM
produces a biphasic modulatory effect with facilitation at low intensities and inhibition at
higher intensities (Calejesan et al., 2000). Under mild noxious stimulation, RVM cells with
inhibitory projections to the dorsal horn may inhibit spinal dorsal horn relay neurones
(Gilbert and Franklin, 2001). However intense noxious stimulation may result in the release
of GABA onto RVM cells, which in turn inhibits descending inhibitory fibres to allow
transmission of nociceptive input via the dorsal horn (Gilbert and Franklin, 2001). The RVM
may also be activated via opioid-mediated activation of the RVM from higher brain centres
such as the amygdale (McGaraughty and Heinricher, 2002), the anterior cingulate cortex
(Calejesan et al., 2000). The locus coeruleus (LC) is also involved in modulating nociceptive
transmission through its actions on the parafascicular neurones (PF) of the thalamus (Zhang
et al., 1997a). The LC can exert two effects on nociceptive transmission through the PF;
firstly descending noradrenergic fibres from the LC to spinal cord play a predominantly
inhibitory role on nociceptive information transmitted rostrally from the spinal cord and
secondly ascending fibres play a facilitatory role on the responsiveness of PF to noxious
input (Zhang et al., 1997a). Thus descending modulation of nociceptive transmission in the
spinal cord requires the involvement of complex interactions between various brain regions.
Segmental controls
Segmental control is noted as the inhibitory effect produced by the large diameter A(S-fibres
on the responses of spinal neurones to nociceptive stimulation, which can selectively inhibit
C-fibre and noxious stimulation evoked excitation of dorsal horn neurones (Besson and
Chaouch, 1987; Woolf and Wall, 1982). Such an inhibitory influence can be exerted on both
multireceptive and noci-specific dorsal horn neurones either directly by activation of spinal
interneurones by primary afferent fibres or indirectly by activation of descending pathways
from the brain. Inhibitory transmitters present in the spinal cord and brainstem include the
amino acids y-aminobutyric acid (GABA), glycine and the endogenous opioids (discussed
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below). In addition to this, monoamines (such as serotonin and noradrenaline) can be directly
released by descending control systems to exert inhibitory effects (Besson and Chaouch,
1987).
y-aminobutyric acid (GABA)
GABA is an inhibitory neurotransmitter found in approximately one-third of laminae I-III
dorsal horn interneurones (Barber et al., 1982; Hunt et al., 1981; Todd and McKenzie, 1989),
in addition to neurones of the rostral ventral lateral medulla which projects to the spinal cord
(Reichling and Basbaum, 1990). GABA-like immunoreactivity is shown in 28% of lamina I,
31% of lamina II and 46% of lamina III cells (Todd and Sullivan, 1990) and is generally
considered to be present in interneurones (Todd and McKenzie, 1989). In addition a
proportion of GABAergic cells contain the cotransmitter glycine (Todd and Sullivan, 1990).
Ionophoretic application of GABA results in inhibition of dorsal horn neuron activity,
including lamina II neurones (Curtis et al., 1977; Zieglgansberger and Sutor, 1983).
Glycine
Glycine is another important neurotransmitter that is expressed in laminae I-III of the spinal
cord, where it is often colocalised with GABA (Todd and Sullivan, 1990). Ionophoretic
application of glycine can inhibit dorsal horn neuronal activity (Zieglgansberger and Sutor,
1983). Glycine can have opposing functions as it can exert (or gate) an excitatory action as a
co-agonist at the NMDA receptor in addition to having an inhibitory action by acting via the
strychnine-sensitive glycine receptor (Budai et al., 1992). Intrathecal application of glycine
has been shown to inhibit substance P (SP)-evoked biting and scratching behaviours, while
use of a glycine antagonist (strychnine) facilitates nociceptive flexor reflex (Beyer et al.,
1989; Sivilotti and Woolf, 1994).
Endogenous opioids
Endogenous opioid peptides such as enkephalin and dynorphin are present within the
synaptic terminals of the spinal dorsal horn (Cruz and Basbaum, 1985; Glazer and Basbaum,
1981; Willis and Coggeshall, 1991). The importance of this system is illustrated by the
powerful and long-lasting analgesic effects seen in animals after the intrathecal
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administration of morphine (Yaksh, 1981). This principle is further supported by studies
where ionophoretic application of opioids in lamina 11 produces a robust inhibition of dorsal
horn neuron response to noxious peripheral stimulation (Duggan and North, 1983;
Fleetwood-Walker et al., 1988). Opiate receptors; p. (mu), 8 (delta) and k (kappa) receptors
have been identified on primary afferent terminals and located in the superficial dorsal horn
(Atweh and Kuhar, 1977). In the rat spinal cord, p receptors represent 70% of the opioid
receptors while 5 receptors make up 24% and k receptors are the remaining 6% of opioid
receptors (Besse et al., 1990). The inhibitory action of the endogenous opioid peptides may
be pre-synaptic or may be an indirect action as a result of interneuron activation.
Endogenous cannabinoids
An alternative spinal modulatory system that can elicit selective antinociceptive effects is the
endogenous cannabinoid system (Fox et al., 2001; Herzberg et al., 1997; Richardson et al.,
1998). This system is of particular interest due to the evidence that natural and synthetic
cannabinoid compounds can exert analgesic effects in chronic pain states (Robson, 2001).
The thus far identified cannabinoid receptors are CBi and CB2 (Pertwee, 1997; Pertwee,
1998). CBi receptors have been identified in the CNS, in particular in an area associated with
nociceptive processing, namely the superficial laminae of the spinal cord (Farquhar-Smith et
al., 2000; Herkenham et al., 1991). CB2 receptors are believed to be largely restricted to the
peripheral nervous system. The endogenous cannabinoids have demonstrated an
antinociceptive role in both behavioural and electrophysiological studies of acute pain (Drew
et al., 2000; Lichtman and Martin, 1997; Smith and Martin, 1992), with initial studies into
the effect on neuropathic pain behaviours showing positive results (La Rana et al., 2006). It is
possible that cannabinoids and opioids may interact in their action on the processing of
nociceptive information, as CBi and p- opioid receptors are colocalised in lamina II
interneurones (Salio et al., 2001). The expression of CBi receptors has been shown to
increase in a time dependent manner following chronic constriction injury (CCI) of the
sciatic nerve primarily within the superficial dorsal horn of the spinal cord (Lim et al., 2003),
although CBi receptor knockout mice have similar pain behaviour responses following
partial nerve ligation (PNL) of the sciatic nerve to wild-type mice (Castane et al., 2006).
Expression of CB2 receptors is induced in the spinal cord following CCI nerve-injury but not
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as a result of peripheral inflammation (CFA model of persistent inflammation), with
expression thought to be localised to activated spinal microglia (Zhang et al., 2003b) and
expression is also increased ipsilaterally in the spinal nerve ligation model (SNL; Beltramo et
al., 2006). More recently an increase in the expression of CBi and CB2 receptors has been
shown ipsilaterally in skin, DRG and spinal cord in a new model of nerve-injury, namely the
saphenous partial ligation model (Walczak et al., 2005).
1.4 Neurotransmitters/peptides and their receptors involved in nociception
Primary afferent nociceptors as outlined above are composed of a cell body (located in the
DRG) and nerve fibres which project in a dual manner both centrally and peripherally (Willis
and Coggeshall, 1991). Peripheral stimuli of sufficient intensity, such as an intense
mechanical, thermal or chemical stimulus, trigger action potentials in the primary afferent
fibres resulting in the release of a variety of neurotransmitters and neuropeptides from their
nerve terminals. These neurotransmitters and neuropeptides act upon dorsal horn neurones,
via binding to postsynaptic receptors, to mediate the transmission of nociceptive information.
Excitatory amino acids (EAAs) and several peptides have been implicated in synaptic
transmission through primary afferents and many have been shown to co-exist within
primary afferents and sensory neurones (Ju et al., 1987; Smith et al., 1993). The dorsal horn
is an important centre for the processing of nociceptive input and thus the co-existence of
EAAs and peptides may allow for the co-release of various transmitters from primary
afferents at the same time, which in turn may act on a number of different postsynaptic
receptors to either differentially or similarly modulate the threshold of the postsynaptic
membrane of the dorsal horn neuron.
1.4.1 Glutamate
The excitatory amino acid, L-glutamate, is a neurotransmitter that elicits fast excitatory
responses in the CNS and appears to be the main neurotransmitter released from primary
afferents (Watkins and Evans, 1981). Electrical nerve stimulation causes glutamate release
from terminals of both myelinated and unmyelinated axons, consistent with the idea that
glutamate plays a role in the transmission of both noxious and non-noxious information
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(Davies et al., 1979; Duggan and Johnston, 1970). Ionophoretic application of glutamate
results in excitation of dorsal horn neurones (Curtis et al., 1959). Intrathecal administration of
glutamate can result in behavioural hyperalgesia and spontaneous nociceptive behaviour
(Aanonsen and Wilcox, 1986; Aanonsen and Wilcox, 1987). Glutamate has been found,
using immunocytochemistry, in all types of somatosensory fibres (De Biasi and Rustioni,
1988), in DRG (Salt and Hill, 1983) and in dorsal roots (Duggan and Johnston, 1970).
Glutamate has been identified as a key EAA neurotransmitter for primary afferent fibres
transmitting mechanical, chemical and thermal stimuli (Gerber and Randic, 1989; King and
Lopez-Garcia, 1993). This evidence indicates the importance of glutamate's role in the
transmission of nociceptive information. Glutamate can mediate its actions through several
receptor subtypes, which can be divided into two groups, firstly ionotropic glutamate
receptors and secondly metabotropic G-protein linked glutamate receptors (mGluRs).
1.4.2 Ionotropic glutamate receptors
The ionotropic group of receptors are ligand-gated ion channels that can be divided into two
groups as a result of their pharmacological response characteristics to various agonists; the
two groups are the N-methyl-D-aspartate (NMDA) and the non-NMDA ionotropic glutamate
receptors (Young and Fagg, 1990). The non-NMDA group of ionotropic glutamate receptors
comprises the a-amino-3-hydroxy-5-isoxazole-4-propionic acid (AMPA) and kainate (KA)
receptor subtypes.
Kainate receptors
KA receptors are composed of glutamate receptor subunits 5-7 (GluR5-7) and KA1-2
subunits, but their role in somatosensory processing has been difficult to study due to a lack
of selective agonists and antagonists (Lerma et al., 2001), as available pharmacological
agents mostly cross react with AMPA receptors. KA receptors (with a GluR5 subunit) have
been found on small diameter primary afferent neurones (Sato et al., 1993) and in the
superficial layers of the dorsal spinal cord (Hwang et al., 2001; Yung, 1998).
Electrophysiological studies have shown KA receptors on intrinsic dorsal horn neurones (Li
et al., 1999), that were a different type to those expressed on DRG neurones as most were
insensitive to the GluR5-preferring agonist ATPA (Kerchner et al., 2001a; Kerchner et al.,
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2001b). Electrophysiological investigations also showed KA receptors are selectively
activated by stimulation of high threshold (not low threshold) primary afferents, suggesting
the localisation of KA receptors to synapses receiving input from high threshold
(nociceptive) primary afferents (Li et al., 1999). A recent study suggests that KA receptor-
expressing nociceptive DRG neurones were approximately six times more likely to co-
express a non-peptidergic marker, the P2X3 purinergic receptor than a peptidergic marker
(substance P), and a possible role for presynaptic KA receptors in nociceptive processing
during neuropathic pain states has been proposed (Lucifora et al., 2006).
AMPA receptors
AMPA receptors are composed of various combinations of its four subunits, termed GluRl-4
(Wisden and Seeburg, 1993). AMPA receptors are thought to mediate the fast synaptic
transmission as a result of glutamate release and their activation leads to depolarization of
dorsal horn neurons (Gerber and Randic, 1989; Jahr and Jessell, 1985; Jessell et al., 1986).
Blocking AMPA receptors can attenuate the activation of dorsal horn neurones by noxious
and innocuous stimuli (Dougherty et al., 1992), indeed AMPA receptors are involved in the
fast transmission of both noxious and innocuous stimuli (Procter et al., 1998; Stanfa and
Dickenson, 1999). AMPA receptor subunits, in particular subunits GluRl and GluR2, have
been localized to the superficial spinal dorsal horn (Coggeshall and Carlton, 1997; Furuyama
et al., 1993; Henley, 1993; Popratiloff et al., 1996; Tolle et al., 1993). A high proportion of
GABA-positive neurones in the dorsal horn were also found to be positive for the expression
of the GluRl AMPA receptor subunit (Albuquerque et al., 1999; Kerr et al., 1998).
NMDA receptors
Due to the focus of this study on second messenger events downstream of the NMDA
receptor, this receptor will be considered more extensively. The NMDA receptor is an
ionotropic glutamate receptor that is permeable to calcium and sodium ions. The NMDA
receptor, which has two principal subunits termed NR1 and NR2, is thought to form a
tetramer with the NR1 subunit comprising the core functional unit and the NR2 subunit
subtypes (A-D) determining the specific channel characteristics (Monyer et al., 1992).
NMDA receptor subunits have been shown to be distributed throughout the brain and spinal
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cord, particularly in the superficial dorsal horn (Furuyama et al., 1993; Greenamyre et al.,
1984; Monaghan and Cotman, 1985). NMDA receptors are blocked in a voltage-dependent
manner by magnesium ions, thus during transmission of acute pain, NMDA receptors are
largely inactive (Nishiyama, 2000). However, following prolonged noxious stimulation,
NMDA receptors may be activated as a result of the dorsal horn neurones being sufficiently
depolarised to remove the magnesium block. The dorsal horn neuron may become
depolarised by alternative glutamate (such as AMPA) receptor activation or the receptor
itself may be phosphorylated via second messenger cascades triggered by activation of the
non-NMDA and peptidergic receptors. Therefore activation of the NMDA receptor occurs
following a reduction in the receptor's affinity for the magnesium ion, bought about either by
the progressive depolarization of the neuron or via a conformational change following
phosphorylation of the receptor itself. This illustrates the idea that glutamate produces a fast
excitatory potential when acting at the AMPA receptor and a long synaptic potential when
acting at the NMDA receptor site.
The NMDA receptor has been demonstrated to play a crucial role in activity-dependent
excitability changes such as long term potentiation (LTP), which may be necessary for spatial
learning and memory formation in the hippocampus (Collingridge et al., 1983; Morris et al.,
1986). NMDA receptor-dependent LTP may be considered to share some similarities with
events that occur during central sensitisation of the spinal cord in hyperalgesic pain states
(Dougherty et al., 1992; Ji et al., 2003; Zhou et al., 1996). It must be noted that there are
significant mechanistic differences between the two processes of LTP and central
sensitisation. Central sensitisation is the facilitation of neuronal activity in response to
heterosynaptic input that can be triggered by relatively low frequency (natural) input from
more than one source, whereas LTP requires high frequency neuronal stimulation (Ji et al.,
2003). indeed the similarities between LTP and central sensitisation have been shown to be
more complex, with evidence of different forms of plasticity in the spinal cord emerging, for
example while an LTP-like event could be triggered using high frequency stimulation in
spinal cord slices, it was not seen in the intact spinal cord (with the presence of segmental
and descending modulation in place; Chiang et al., 1998; Ji et al., 2003; Sandkuhler, 2000;
Sandkuhler and Liu, 1998).
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Application of NMDA can alter the excitability of spinal neurones (Chaplan et al., 1997;
Haley et al., 1990; Leem et al., 1996) and intrathecal administration of NMDA has been
shown to result in thermal hyperalgesia in the rat (Kolhekar et al., 1994). NMDA receptor
antagonists result in the inhibition of dorsal hom neuron responses induced by prolonged
chemical nociception, joint inflammation or by repetitive C-fibre stimulation ('wind-up')
(Davies and Lodge, 1987; Haley et al., 1990; Neugebauer et al., 1993). Pre and post-injury
administration of an NMDA antagonist may result in the prevention or attenuation of thermal
and mechanical hyperalgesia for a period of time after injury (Mao et al., 1992c; Mao et al.,
1992b; Smith et al., 1994). Studies in humans have demonstrated the potential of the NMDA
antagonist, ketamine in the treatment of various chronic pain conditions, however with
significant side effects (Hocking and Cousins, 2003). The effect of glutamate binding to the
NMDA receptor may be modulated by a regulatory glycine binding site (Kleckner and
Dingledine, 1988) as mentioned above (see section 1.3.5). Glycine may be important in
regulating a number of NMDA receptor-mediated responses and has been termed a co-
agonist of the NMDA receptor. Blocking the glycine recognition site on the NMDA receptor
(GlyNMDA site) has been shown to inhibit NMDA-induced thermal hyperalgesia, by
increasing the threshold to noxious radiant heat (Kolhekar et al., 1994). Antagonists to the
GlyNMDA site can decrease the enhanced responses of spinal neurones that occur as a result of
repetitive C-fibre stimulation (Dickenson and Aydar, 1991) and can block a neurokinin
(NKi) receptor facilitation of the NMDA receptor (Heppenstall and Fleetwood-Walker,
1997). The evidence outlined here indicates that the activation of NMDA receptors appears
to be central to the generation of prolonged states of nociception and of pain-related
behaviours as a result of nerve injury.
1.4.3 Metabotropic glutamate receptors
The mGluRs are members of the super family of seven transmembrane domain G protein-
coupled receptors. They are divided into three groups; Group I mGluRs which are coupled to
Gq/ii proteins, and consist of mGluRl and mGluR5. Group II mGluRs comprise mGluR2 and
mGluR3, group III mGluRs consist of mGluR4, 6, 7 and 8; both of the latter groups are
negatively coupled to adenylate cyclase via Gj/0 proteins (Abe et al., 1992; Aramori and
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Nakanishi, 1992; De Blasi et al., 2001; Pin and Duvoisin, 1995). Group II mGluRs and group
III mGluRs will not be further discussed here. Group I mGluRs are concentrated in the
superficial dorsal horn of the spinal cord (Berthele et al., 1999; Jia et al., 1999) and activation
of these receptors leads to activation of intracellular kinases such as protein kinase C (PKC),
release of intracellular calcium and possibly increasing intracellular cyclic adenosine
monophosphate (cAMP; Abe et al., 1992; Aramori and Nakanishi, 1992) all of which could
contribute to regulating cell excitability. The use of an antagonist to mGluRl resulted in a
marked reduction in the electrophysiological response of dorsal horn neurones to a noxious
(mustard oil) but not to an innocuous (brushing) stimulus (Young et al., 1997), and the
ionophoretic application of another selective mGluRl antagonist also reversed the
sensitisation observed in dorsal horn neurones following a noxious stimuli (Young et al.,
1995). Dorsal horn neurones were shown to have a normal response to innocuous stimuli and
a significant reduction in their response to noxious stimuli following the removal of mGluRl
via antisense ablation (Young et al., 1998). Intrathecal administration of a specific mGluR5
antagonist caused reversal of mechanical hyperalgesia in chronic inflammation and of
thermal hyperalgesia in neuropathic pain states (Dogrul et al., 2000; Walker et al., 2001).
These investigations illustrate the important role played by group 1 mGluRs in mediating
nociceptive transmission at the spinal cord level.
1.4.4 Neuropeptides
There are clearly numerous ways in which glutamate exerts its function as a neurotransmitter
in the spinal cord. However, neuropeptides are often co-released with glutamate from
peripheral afferent terminals and can lead to various synergistic effects on postsynaptic
dorsal horn neurones. A range of neuropeptides are synthesised in DRG neurones and play an
important role in nociceptive transmission. Indeed a key event that occurs following
peripheral nerve injury is the characteristic phenotypic changes that occur in many primary
afferent neurones, demonstrated by an altered expression of neuropeptides in their cell bodies
in DRG (Hokfelt et al., 1994; Villar et al., 1991), in their terminals and relevant receptors
within the dorsal spinal cord (Dickinson and Fleetwood-Walker, 1999). These long-lasting
changes in the production and expression of neuropeptides are thought to contribute to the
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altered sensory transmission observed in chronic pain states. Some of the main changes
observed following peripheral nerve injury will be discussed here.
Tachykinins
The tachykinins are a family of neuropeptides characterised by a common carboxy-terminal
sequence and consist of the peptides substance P (SP), neurokinin A (NKA), neurokinin B
(NKB), neuropeptides K (NPK) and neuropeptide y (NP y). The two preprotachykinin genes
responsible for this family are preprotachykinin I (PPT I) and preprotachykinin II (PPT II).
Firstly PPT I has three variants a-, P-, and y- PPT I of which a-PPT I encodes for SP only
and both (I- and y- PPT I encode for SP and NKA mRNA expression, while NPK is derived
from P-PPT I and y- PPT I results in NP y production (Krause et al., 1987; Nawa et al.,
1984). The PPT II gene results in the production of NKB (Bonner et al., 1987). In situ
hybridisation studies revealed PPT I to be expressed in lamina I and II while PPT II was
found to be expressed within lamina III (Warden and Young, III, 1988). Looking specifically
at each PPT I variant, a-PPT I mRNA expression accounted for approximately 0.5% of the
total level of PPT I mRNA expression, with p-PPT I accounting for 22% and y-PPT I 78% of
overall PPT I expression in the CNS (Carter and Krause, 1990). There are three receptors
through which tachykinins exert their effects, they are the NKi, NK2 and NK3 neurokinin
receptors for which SP, NKA and NKB are the preferential endogenous ligands respectively
(Maggi et al., 1993; Regoli et al., 1987).
SP has been found to be expressed in small diameter primary afferent neurones, in small
diameter DRG cells and in the superficial dorsal horn (and the ventral horn; Hokfelt et al.,
1975; Hokfelt et al., 1977; Hokfelt et al., 1980; Hokfelt et al., 1993; Gibson et al., 1981;Ju et
al., 1987). In DRG neurones, most SP-positive cells have been found to contain other
substances, such as calcitonin gene-related peptide (CGRP), somatostatin (SOM) and
glutamate (Battaglia and Rustioni, 1988; Ju et al., 1987). When SP is released, it mediates its
effects via the NKi receptor, which has been found to be expressed in the superficial layers
of the spinal cord, with a lower concentration detected in laminae III - V (Brown et al., 1995;
Helke et al., 1986; Nairn et al., 1997; Nasstrom et al., 1992; Quirion et al., 1983; Yashpal et
al., 1991). NKA has also been localised in the spinal cord and in small diameter primary
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afferent neurones (Dalsgaard et al., 1985; Kanazawa et al., 1984; Ogawa et al., 1985). NKB
has also been found in the spinal cord although it does not appear to be associated with
cutaneous afferent fibre (Kanazawa et al., 1984). NKA is the preferential ligand for NK2
receptors, which were found to be expressed in the dorsal horn of the spinal cord (Yashpal et
al., 1990; Yashpal et al., 1991). The distribution of the NK2 receptor was revealed to be
distinct from that of the NKi and NK3 receptors in the spinal cord, which appeared to be
expressed in neuronal cell bodies and dendrites (Ding et al., 1996; Mantyh et al., 1996;
Moussaoui et al., 1992; Zerari et al., 1995; Zerari et al., 1997), whereas a proportion of NK2
receptor expression was found to be localised to astrocytes, perhaps designating astroglial
cells as a major target for NKA (Zerari et al., 1998).
There is a large amount of evidence implicating the involvement of the tachykinins and their
receptors in nociceptive processing in the dorsal horn of the spinal cord. Intrathecal injection
of SP in naive animals evokes scratching and biting behaviours that may be indicative of
painful sensations and reduced tail-flick latency response to peripheral stimuli (Courteix et
al., 1993; Hayes and Tyers, 1979; Hylden and Wilcox, 1981; Yashpal and Henry, 1984).
Ionophoretic application of SP resulted in excitation of dorsal horn neurones (Henry, 1976;
Zieglgansberger and Tulloch, 1979). However NKi receptor antagonists have not been
shown to be greatly effective in reducing dorsal horn neuron responses to brief noxious
stimuli (Fleetwood-Walker et al., 1990), and do not appear to be particularly efficacious as
analgesic agents in clinical trials of chronic pain states (Hill, 2000). Interestingly noxious
mechanical and thermal stimuli can specifically evoke SP release from primary afferents
(Duggan et al., 1995; Duggan and Furmidge, 1994; Kuraishi et al., 1989). Ablation of SP-
containing dorsal horn neurones resulted in the attenuation of behavioural responses only to
highly noxious stimuli (Mantyh et al., 1997). The pre-emptive use of a NKi receptor
antagonist has recently been shown to prevent the development of mechanical and cold
allodynia following nerve injury (Cahill and Coderre, 2002). The mRNA of SP is
significantly decreased in its expression following axotomy in small to medium diameter
DRG neurons, with this reduction being most prominent ten to fourteen days after injury, and
accompanied by a parallel reduction in dorsal spinal SP levels (Barbut et al., 1981; Jessell et
al., 1979; Noguchi et al., 1993; Shehab and Atkinson, 1986). Such reduction in SP
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production in DRG is also noted following CCI, with a decrease in SP levels in the ipsilateral
spinal cord also observed (Cameron et al., 1991; Cameron et al., 1997; Kajander and Xu,
1995; Nahin et al., 1994). The reduction following CCI is not as great as that seen after
axotomy, which may be due to the fact that CCI results in a partial denervation compared to
axotomy. These findings of a reduction in SP may suggest a lesser role for SP in nociceptive
processing in neuropathic pain states.
NKA, the preferential ligand for NK2 receptors, is capable of producing spinal
hyperexcitability (Henry and Salter, 1987; Hokfelt et al., 1994; Xu et al., 1991). Application
ofNKA can facilitate dorsal horn neuron responses to noxious thermal stimuli, suggesting an
NKA involvement in the processing of inputs from thermal nociceptive afferents (Fleetwood-
Walker et al., 1990). NKA has been shown to be released from primary sensory terminals in
the dorsal horn as a result of peripheral noxious stimulation (Duggan et al., 1990). There is
evidence that NKA but not SP is able to diffuse a considerable distance from its primary
afferent site of release in the superficial dorsal horn following noxious stimulation in the
periphery, which may be due to the greater metabolic stability of NKA (compared with that
of SP; Duggan et al., 1988; Duggan et al., 1990; Hope et al., 1990; Regoli et al., 1994;
Theodorsson-Norheim et al., 1987). This potential ability of NKA to diffuse may allow for
this peptide to bind to the NK2 receptors located on astroglial cells when released from
primary afferents as a result of peripheral stimulation. Intrathecal administration of an NK2
receptor agonist evoked a reduction in the reaction time in the tail-flick in naive animals
(Picard et al., 1993), while NK2 receptor antagonists block both the increased dorsal horn
neuron excitability (including the attenuation of thermal nociceptive responses) and
behavioural sensitisation following nerve damage (Coudore-Civiale et al., 1998; Fleetwood-
Walker et al., 1990; Yashpal et al., 1996). The expression ofNKA following nerve injury has
not been determined, although the preferential receptor for this ligand, the NK2 receptor has
been demonstrated to have an important role in nociceptive processing, thereby suggesting a
role for NKA (Coudore-Civiale et al., 1998; Fleetwood-Walker et al., 1990; Fleetwood-
Walker et al., 1993; Munro et al., 1993; Yashpal et al., 1996). These results indicate an
important role for the tachykinins and their receptors in processing nociceptive inputs in the
dorsal spinal cord.
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Calcitonin gene related peptide [CGRP]
CGRP is found in approximately 30% of all primary afferent axons (Levine et al., 1993),
mainly in unmyelinated C-fibres or small diameter myelinated A8-fibres that terminate in
laminae I, II and V of the spinal cord (Carlton et al 1988). CGRP can be released into the
superficial dorsal horn as a result of noxious thermal and mechanical stimulation of primary
afferents (Morton and Hutchison, 1990). Subpopulations of CGRP-expressing DRG neurones
also contain SP, SOM or galanin, indeed a high proportion (approximately 80%) of SP-
expressing DRG neurones also contain CGRP (Battaglia and Rustioni, 1988; Ju et al., 1987;
Smith et al., 1993; Villar et al., 1989). These two peptides are largely co-released and CGRP
can potentiate the effects of SP (Mao et al., 1992a), possibly by inhibiting the degradation of
SP (Le Greves et al., 1985; Mao et al., 1992a). Ionophoretic application of CGRP results in a
slow-onset excitation of dorsal horn neurones that is long-lasting (Miletic and Tan, 1988).
However the application of CGRP can also increase the effect of SP on dorsal horn neurones
(Biella et al., 1991) and enhance the release of SP from spinal cord slices (Oku et al., 1987).
Administration of a selective CGRP receptor antagonist can result in the reversal of
mechanical hyperalgesia observed following cutaneous capsaicin injection (Sun et al., 2003).
Following axotomy, the expression of CGRP mRNA was markedly reduced in primary
sensory neurones, with maximal reduction observed seven to fourteen days after injury
(Noguchi et al., 1989; Noguchi et al., 1990; Noguchi et al., 1993; Shehab and Atkinson,
1986). A reduction in the expression levels of CGRP was also found in the superficial dorsal
horn (Carlton and Coggeshall, 1996). Similar reductions were also noted following CCI,
which resulted in an approximately 50% decrease in CGRP mRNA levels in DRG within
seven to fourteen days after nerve injury (Nahin et al., 1994). However spinal levels of
CGRP expression were not found to decrease until approximately sixty days post CCI injury
(Kajander and Xu, 1995).
Somatostatin [SOM]
Expression of SOM is seen in a population of small diameter primary afferents, different to
those that are SP-positive (Hokfelt et al., 1976; Nagy and Hunt, 1982), and in lamina II cells
of the dorsal horn (Finley et al., 1981; Hokfelt et al., 1976; Yin, 1995). SOM expression has
been found to be localised to lumbar DRG neurones that are IB4-positive neurones and
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express the GDNF receptor (Kashiba et al., 2001). The application of GDNF to the spinal
dorsal horn promotes an activity-induced release of SOM from the central terminals of
sensory neurones (Lever and Malcangio, 2002). However the role of SOM in nociceptive
processing is unclear as electrophysiological studies report both inhibitory and excitatory
actions on dorsal horn neurones (Macdonald and Nowak, 1981; Murase et al., 1982; Randic
and Miletic, 1978; Salt et al., 1982). Intrathecal administration of SOM has been reported to
increase dorsal horn neuron responses to mechanical and thermal stimuli (Wiesenfeld-Hallin,
1985). In contrast, intrathecal and epidural administration of SOM in humans results in
analgesia (Carlton et al., 2001). It has been proposed that SOM may modulate the effect of
other neurotransmitters (Macdonald and Nowak, 1981) perhaps acting in a pro-nociceptive or
analgesic manner depending on the circumstances, thus possibly explaining the discrepancies
noted in the above electrophysiological studies. SOM while normally present in about 20%
of small to medium diameter DRG (Ju et al., 1987; Smith et al., 1993), has been found to be
markedly decreased following nerve damage and a corresponding reduction in SOM levels is
seen in the superficial dorsal horn (Shehab and Atkinson, 1986; Villar et al., 1989; Zhang et
al., 1993b).
Cholecystokinin [CCK]
CCK is expressed in small DRG neurones, peripheral nerves and the superficial dorsal horn
of the spinal cord (Fuji et al., 1983), with expression seen in low levels in naive animals (Ju
et al., 1987; Noguchi et al., 1993). Although CCK has an excitatory role within the CNS, due
to the low concentration found in the naive state it may be predicted that its role will only
become important following injury when its levels are markedly up-regulated (Hokfelt et al.,
1994; Noguchi et al., 1989), with the expression of CCK mRNA increasing in primary
afferent neurones following nerve injury (Villar et al., 1989). While the exact role of CCK in
neuropathic pain states is not clear, it does appear to decrease the analgesic effect of both
morphine and ^-endorphin (Faris et al., 1983). The upregulation of CCK following nerve
injury may have a role in explaining the decreased effectiveness of opioid treatment observed
in many neuropathic patients.
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Galanin
Galanin is a peptide with a low level of expression in small to medium diameter DRG
neurones that co-exists with various neurotransmitters such as CGRP and SP (Baranowski et
al., 1994; Ju et al., 1987; Ma and Bisby, 1997; Zhang et al., 1993a). Galanin can be found
concentrated in laminae I-II1 and to a lesser extent in laminae 1V-V of the spinal cord (Kar
and Quirion, 1995). Galanin may act as a neuromodulator, as intrathecal administration of
galanin antagonises the excitatory effects of CGRP and SP when used as a pre-treatment
(Wiesenfeld-Hallin et al., 1991b; Xu et al., 1990). Galanin also inhibits the analgesic effect
of morphine on noxious thermal and mechanical stimuli in naive animals (Wiesenfeld-Hallin
et al., 1991a). Again as with SOM, galanin's main effects may occur following injury when
levels are up-regulated, with peripheral nerve injury resulting in an increase in galanin
mRNA expression in DRG cells in addition to an increase in expression in the ipsilateral
dorsal horn (Ma and Bisby, 1997; Nahin et al., 1994; Romualdi et al., 1990; Zhang et al.,
1995c). Furthermore the pattern of co-expression of galanin with other neuropeptides can
also alter following nerve injury, with reduced levels of galanin co-expressing with CGRP
and increased levels of galanin co-expressing with NPY and VIP (Nahin et al., 1994).
Galanin's inhibitory role has been found to be more pronounced following nerve injury
(Wiesenfeld-Hallin and Xu, 1996).
Neuropeptide Y [NPY]
NPY is not expressed by DRG neurones under normal conditions (Lundberg et al., 1983).
Nonetheless there are many NPY-positive fibres present in the superficial dorsal horn, which
originate both locally and from supraspinal descending tracts (Wakisaka et al., 1991), where
NPY may co-exist with galanin or GABA (Laing et al., 1994; Zhang et al., 1993a; Zhang et
al., 1993c). Intrathecally administered NPY appears to be excitatory at low doses, whereas
high doses produce an inhibitory effect (Scherer et al., 1994; Ullstrom et al., 1999).
Following nerve injury, administration of NPY antiserum enabled a reduction in the injury-
induced tactile hypersensitivity but not thermal hyperalgesia (Ossipov et al., 2002). NPY
may also have a modulatory role that occurs following an insult, as following nerve injury a
marked upregulation in the levels of NPY is seen not only in large or medium diameter
primary afferent neurons, but also in axons of laminae III-V of the spinal dorsal horn (Kar
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and Quirion, 1992; Nahin et al., 1994; Zhang et al., 1994). NPY may play an inhibitory role
within the CNS as systemic administration ofNPY resulted in marked antinociceptive effects
(Hua et al., 1991).
Vasoactive intestinal polypeptide [VIP] and pituitary adenylate cyclase-activating
polypeptide [PACAPJ
VIP and PACAP are widely expressed within the CNS (Yaksh et al., 1988). In normal
conditions a low level of VIP expression is observed in DRG neurones, in the spinal cord
(with a higher concentration in the superficial layers) and in spinal glial cells (Brenneman et
al., 1990; Gibson et al., 1981; Kar and Quirion, 1995; Knyihar-Csillik et al., 1991). Similarly
low levels of PACAP are expressed in the DRG and spinal cord of naive animals (Dun et al.,
1996; Moller et al., 1993; Nahin et al., 1994; Zhang et al., 1995a). VIP and PACAP share a
high degree of sequence homology. As a result they can combine with the same receptor
binding sites (Harmar and Lutz, 1994), to activate a family of three receptors, namely
VPACi, VPAC2 and PACi receptors (Hosoya et al., 1993; Ishihara et al., 1992; Lutz et al.,
1993). VIP activates both VPACi and VPAC2 receptors and to a lesser degree the PACi
receptor (Hashimoto et al., 1997; Ishihara et al., 1992), with the PACi receptor displaying a
higher affinity for PACAP than VIP (Hashimoto et al., 1993; Shivers et al., 1991). All three
receptors comprise seven trans-membrane domains with intracellular loops that couple to
signalling cascades involving Gs and/or Gq proteins, which when activated stimulate either
adenylate cyclase or PLC second messenger pathways respectively (Ishihara et al., 1992;
Lutz et al., 1993; Spengler et al., 1993). Expression of mRNA for VPACi, VPAC2 and PACi
receptors is seen in the spinal cord, in particular the superficial dorsal horn (Arimura and
Shioda, 1995; Ishihara et al., 1992; Lutz et al., 1993), with expression also found in
astrocytes (Grimaldi and Cavallaro, 1999; Jaworski, 2000; Joo et al., 2004).
Following injury, the levels of PACAP in DRG increase in the early stage returning to basal
levels seven to fourteen days following injury (Hokfelt et al., 1994; Zhang et al., 1995b).
Axotomy results in a major increase in PACAP mRNA in around 75% of DRG cells with a
maximal increase observed by day three that begins to decline by day ten following injury
(Zhang et al., 1995a). PACAP's role is not entirely clear as it may have inhibitory or
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excitatory properties, as intrathecal administration of PACAP-38 (which activates both
VPAC] 2 and PAQ receptors) can reverse thermal hyperalgesia at low doses yet causes
biting and scratching pain behaviours at higher doses (Narita et al., 1996). While
administration of the other PACAP variant (PACAP-27) resulted in a long-lasting
suppression of a C-fibre evoked reflex (Zhang et al., 1993c). Electrical stimulation of
afferents at or above C/A8-fibre intensity has been demonstrated to produce an increase in
VIP levels in the spinal cord, whereas low threshold fibre intensity stimulation did not have
this effect (Yaksh et al., 1982). The expression of VIP is dramatically increased in DRG
neurones following axotomy, and is often co-expressed with galanin (Nahin et al., 1994;
Zhang et al., 1995b). The level of VIP in the spinal dorsal horn has been found to increase
following nerve crush but returns to control levels when fibre regeneration occurs (Knyihar-
Csillik et al., 1991; Knyihar-Csillik et al., 1993). VIP has an excitatory role and as such this
peptide may take over the role of SP as the primary neuropeptide involved in the CNS in
neuropathic pain states, that is, there may be a functional switch from SP to VIP in mediating
some part of the C-fibre input. The rapid increase in PACAP expression suggests that it may
be important in the early onset of neuropathic pain. VIP levels have been shown to gradually
increase in the first weeks following injury but remain elevated for longer (Nahin et al.,
1994; Zhang et al., 1995c) and so may have an important role in the maintenance of
neuropathic pain states. Looking closer at the receptors for VIP, it has been shown that
selective antagonists for VPACi, VPAC2 and PACi receptors had no effect on innocuous
sensory transmission in nerve injured animals and the application of VPACi and PACi
receptors agonists did not increase the neuronal response observed as a result of nerve injury
(Dickinson et al., 1999). However, a VPAC2 receptor agonist significantly amplified the
response, and the expression of the receptor itself increased as a result of nerve injury
(Dickinson et al., 1999). Indeed experiments blocking the VPAC2 receptor resulted in
suppression of the neuronal response to noxious input in naive and nerve-injured animals
(Dickinson et al., 1999). Moreover the expression of the receptors to VIP and PACAP found
that following nerve injury only the expression of VPAC2 receptor increases in the spinal
cord, while the expression of the VPACi receptor is decreased and PACi receptor remains
unaltered (Dickinson et al., 1999). These findings suggest that the VPAC2 receptor is
important in the processing of nociceptive information especially following nerve injury.
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1.5 Neuropathic pain
Neuropathic pain is an intractable pervasive pain that does not serve to protect the individual
and is often debilitating. The development of neuropathic pain may be a result of various
factors such as damage to peripheral nerves, trauma to the spinal cord, as a consequence of
specific infections such as the herpes zoster virus and the human immunodeficiency virus
(HIV) or due to systemic nerve-injury disorders such as diabetes or rheumatoid arthritis
(Hewitt et al., 1997; Mohamed and Carr, 1994; Scadding, 1984). Independent of its origin,
neuropathic pain is characterised by a neuronal hyperexcitability in damaged areas of the
nervous system. The associated symptoms of neuropathic pain include numbness, weakness,
abnormal sensations and pain (Scadding, 1981). The pain experienced can be characterised
into different types of pain sensation, namely stimulus-independent pain (spontaneous pain)
or stimulus-evoked pain (hypersensitivity to a stimulus). Stimulus-evoked pain includes
hyperalgesia, which is an exaggerated response to a noxious stimulus and allodynia, which is
pain in response to normally innocuous stimuli. Neuropathic pain persists long after the
initiating event resolves and is not effectively treated by classical analgesics. Understanding
the mechanisms involved in neuropathic pain states requires the use of animal models of
nerve injury that mimic as far as possible the clinical conditions in man.
1.5.1 Animal models of chronic pain
Progress in understanding some of the mechanisms that underlie the hyperalgesia and
allodynia induced by nerve injury has involved the use of animal models of human pain
conditions. Several models of chronic pain have been developed to replicate the
pathophysiological changes present in man while ensuring the minimum of distress to the
animal. A number of investigations into chronic pain states use animal models that rely on
nerve injury involving the sciatic nerve for reasons of simplicity and reproducibility
(Boucher and McMahon, 2001). Analysis of the pain experienced in animal models involves
measuring the behavioural response to cutaneous stimuli, as the affective character of the
pain can not be readily assessed. The behavioural responses measured generally involve
spinal reflexes, specifically the nocifensive hindpaw flexor reflex; the magnitude of this
reflex as a result of electrical or physiological stimuli has been shown to correlate to spinal
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dorsal horn neuronal activity (Schouenborg and Sjolund, 1983). Alterations in the magnitude
and latency of this nocifensive reflex can be measured using a number of behavioural tests
that evaluate different sensory stimuli. Thermal hyperalgesia can be assessed using an
apparatus developed by Hargreaves that measures the latency of hindpaw withdrawal from a
calibrated heat source (Hargreaves et al., 1988; see section 3.4.4). Mechanical allodynia can
be assessed using calibrated Semmes-Weinstein Von Frey filaments, which exert a fixed
pressure before bending (see section 3.4.2). Cold allodynia can be measured by the animal's
response to iced water (4°C; see section 3.4.3). In the animal models most frequently studied
a mixture of intact and injured nerve fibres is created which allows for some correlation of
changes that occur as a result of the nerve injury with pain-related behavioural responses.
Behavioural tests as outlined above are performed to measure alterations in the behavioural
response of the affected (ipsilateral) hindlimb.
The chronic constriction injury model [CCI]
This chronic constriction injury model developed by Bennett and Xie (Bennett and Xie,
1988) is a frequently used model that is produced by tying four loose chromic cat gut
ligatures around the sciatic nerve at thigh level (see section 3.2.1). Animals guard the
affected limb in a protective manner, which is thought to be an abnormal behaviour
indicative of the presence of spontaneous pain. Neuropathic pain behaviours are observed
within one week of nerve injury, with the affected hindlimb demonstrating hyperalgesic and
allodynic behaviours. Indeed cold allodynia is a marked feature of this model. While these
behavioural changes can be observed within three to four days of nerve injury they are most
pronounced ten to fourteen days after nerve injury and can last for up to three months. Of
note in this model is that the loose tying of the ligatures does not sever the nerve, the blood
supply is maintained and many of the axons within the nerve remain viable. In this model
some selective involvement of the sympathetic nervous system is seen, as surgical
sympathectomy alleviates the increased response to thermal stimuli but has not been shown
to affect responses to mechanical stimuli (Attal et al., 1990; Desmeules et al., 1995).
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The partial nerve ligation model [PNL]
The partial nerve ligation model was developed by Seltzer and colleagues (Seltzer et al.,
1990), uses a single tight ligation of one third to one half of the sciatic nerve. Following this
injury, animals in addition to abnormal grooming (licking and biting) of the affected
hindlimb also hold the affected hindlimb in a protective manner, which may indicate the
presence of spontaneous pain. No signs of autotomy (where animals gnaw at the affected
hindlimb) are observed in this model. As a result of PNL, animals show signs of hyperalgesia
and mechanical allodynia within a few days of injury and can last for up to seven months and
can lead to the development of bilateral ('mirror') sensitivity (Seltzer et al., 1990). However
no signs of cold allodynia are observed in this model. An important contribution of the
sympathetic nervous system in the development of PNL induced is noted, as chemical or
surgical sympathectomy has been shown to reduce or prevent the development of such
neuropathic pain sensitisation (Shir and Seltzer, 1991).
The spinal nerve ligation model [SNL]
Developed by Kim and Chung (Kim and Chung, 1992) the spinal nerve ligation involves the
tight ligation of either the L5 or L5 and L6 spinal nerves from the common sciatic nerve just
distal to the DRG. SNL injured animals show no signs of autotomy and develop abnormal
grooming (licking and biting) behaviours which may indicate spontaneous pain presence (Na
et al., 1993). Animals show signs of hyperalgesia and mechanical allodynia within the first
few days of injury and can last for up to five months (Kim and Chung, 1992). In the SNL
model no signs of cold allodynia are observed. In this model the sympathetic nervous system
contributes significantly to the behavioural responses noted as surgical sympathectomy
almost completely abolishes these behaviours (Choi et al., 1994; Kim et al., 1993). This
model is especially useful for investigating the contribution of the sympathetic nervous
system in the development ofneuropathic pain.
The spared nerve injury model [SNI]
This model recently developed by Decosterd and Woolf (Decosterd and Woolf, 2000) is a
variant of partial denervation involving a lesion (where the nerve is ligated and cut) of two of
the three terminal branches of the sciatic nerve (tibial and common peroneal nerves) leaving
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the remaining sural nerve intact. The SNI model results in a rapid (one day post injury) and a
prolonged (up to six months) behavioural sensitisation in the skin area adjacent to the
denervation, with behavioural signs of mechanical and cold allodynia observed. The extent to
which the sympathetic nervous system contributes to the behavioural responses noted in this
model has not yet been assessed through either chemical or surgical sympathectomy.
In addition to the models involving peripheral nerve injury outlined above, other models of
neuropathic pain have been developed, including for example bone cancer, diabetic and viral
neuropathy, which are beyond the scope of this study. The CCI model by Bennett and Xie
(Bennett and Xie, 1988) was used in this investigation as it is displays many prominent signs
of ongoing pain, has a small selective involvement of the sympathetic nervous system and
has been widely studied (Kim et al., 1997b). In addition this model does not show bilateral
sensitisation of behavioural responses, allowing comparison of the responses of the affected
(ipsilateral) hindlimb to the contralateral hindlimb (in addition to control animals). It is of
interest to look briefly at some of the potential causes of nerve injury in this model of
neuropathic pain: The aetiology of nerve injury and subsequent development of behavioural
sensitisation in the CCI model may be due to a number of factors. In this model the type of
material used for the ligatures may be important. A study using either, chromic cat gut, plain
gut or polyglactin (Vicryl) sutures, for ligatures in the CCI model resulted in a number of
different outcomes (Kajander et al., 1996). The position of the affected hindpaw was altered
dependent upon the type of ligature used, with a greater effect seen with chromic cat gut
whereby animals held their affected paw in abnormal positions for longer (Kajander et al.,
1996). The use of chromic cat gut decreased the expression levels of CGRP and SP in the
spinal cord while the other ligatures did not affect their expression levels (Xu et al., 1996).
Since all types of ligatures induced the behavioural changes associated with this model it is
therefore thought that the physical constriction probably plays the most important part in the
development of such abnormal behavioural responses (with a constituent of chromic gut
having an additional influence). Indeed it has been suggested that provision of an acidic
environment around the sciatic nerve for seven days can lead to the development of thermal
hyperalgesia (Maves et al., 1995). Additional changes that may be important include
alterations in local blood flow in the injured nerve, as decreased blood flow is found at the
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site of nerve injury when thermal hyperalgesia is observed (Myers et al., 1993). The
inflammatory response is also essential in the development of neuropathic pain states,
illustrated by the finding that daily injections of dexamethasone (an anti-inflammatory
glucocorticoid) decreased not only the inflammatory response induced by chromic gut
ligatures but additionally decreased the guarding behaviour and thermal hyperalgesia
observed in this model (Clatworthy et al., 1995).
While the focus of this study is the neuropathic pain state, where possible, models of
inflammatory pain were utilised, to compare potential mechanistic differences between
inflammatory and neuropathic chronic pain states. Unlike neuropathic pain, which is a
formidable clinical problem, inflammatory pain responds to existing analgesics, for example
NSAIDs (non-sterodial anti-inflammatory drugs) and opioids, for example loperamide (an
mu opioid receptor agonist) has antinociceptive effects in inflammatory conditions (Kidd and
Urban, 2001). An element of many chronic pain states is the release of inflammatory
mediators which act on nociceptive transmission as outlined above, while most surgical
models of peripheral nerve injury incorporate a component of local inflammation, specific
models of chronic inflammation have been developed.
Formalin-induced model of inflammatory pain
The formalin model involves the subcutaneous injection of formalin into the hindpaw, which
results in a response characterised as flinching, flicking and licking of the affected hind paw.
The formalin test has been shown to elicit a biphasic nociceptive response (Dubuisson and
Dennis, 1977). The biphasic response consists of an early intense response (first phase)
produced by direct excitation of nociceptors at the site of injection (i.e. of peripheral origin).
The more prolonged response (second phase), which typically follows a small quiescent
interval is more complex involving both ongoing peripheral activity and central sensitisation
in the spinal cord (Chaplan et al., 1997; Coderre et al., 1990; Coderre and Melzack, 1992;
Dickenson and Sullivan, 1990; Haley et al., 1990; Villetti et al., 2003). This formalin-
induced model of inflammatory pain has been useful in the pharmacological characterisation
of pain since direct nociception and facilitated sensory processing can mainly be dissociated
into these two phases of the test.
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Models of persistent inflammatory pain
The use of irritant agents has been employed to develop models of persistent inflammation.
Examples of the irritant agents that can be used include Complete Freund's Adjuvant (CFA),
carrageenan, turpentine, acidic saline and capsaicin. This study uses CFA for subcutaneous
injection into the hindpaw. The CFA model of persistent inflammation results in a striking
increased sensitivity to innocuous mechanical stimuli (mechanical allodynia), in addition to
thermal hyperalgesia. Animals display such signs of behavioural sensitisation from as early
as a few hours after CFA injection, which can continue up to 2-3 days later, with recovery
observed from 5 days onwards following CFA injection (Ji et al., 2002b; Molliver et al.,
2005; Zhang et al., 2003a). However, unlike the formalin test, the CFA response cannot
distinguish which stage of the response is due to direct peripheral activity and/or central
sensitisation in the spinal cord.
1.6 Changes in the peripheral nervous system following nerve injury
1.6.1 Ectopic activity and remodelling of voltage-gated sodium channefexnression
Many changes occur in the peripheral nervous system as a result of nerve injury. Increasing
the excitability of the nociceptor terminal membrane (reducing the amount of depolarisation
required to initiate an action potential) occurs when terminals are exposed to sensitising
agents such as inflammatory mediators or neurotrophic factors released during tissue/nerve
damage (Woolf and Salter, 2000). Voltage-gated sodium channels are mainly responsible for
the rising phase of the action potential and are also important along with potassium channels
in determining the excitability of the nerve (Woolf and Costigan, 1999). After nerve injury,
sodium channels accumulate in the axon at the injury site and along its length, resulting in
foci of hyperexcitability and ectopic action potential discharge in the axon and cell body of
injured sensory neurones (Woolf and Mannion, 1999). Electrophysiological investigations
revealed an abnormally high level of spontaneous activity following nerve injury in primary
sensory neurones, which appeared to be mediated mainly by Ap and A8 fibres (Kajander et
al., 1992; Kajander and Bennett, 1992; Laird and Bennett, 1993; Palecek et al., 1992).
Spontaneous discharge from C-fibres contributes slightly later than that noted from A-fibres
(approximately from day 10 versus day 1-3 respectively after nerve injury), which
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corresponds to maximal behavioural sensitisation observed in the CCI model (Attal et al.,
1990; Bennett and Xie, 1988; Xie and Xiao, 1990). In addition to firing spontaneously,
ectopic pacemaker sites are often excited as a result of mechanical forces applied to them
during movement that can result in spontaneous and movement-evoked pain (Devor and
Seltzer, 1999). The exact site initiating this ectopic action potential discharge remains
unclear; investigations in primary afferents have indicated that the spontaneous activity
originates from the site of nerve injury (Xie and Xiao, 1990), while other reports show this
ectopic discharge to originate from the DRG (Kajander et al., 1992; Zhang et al., 1997b). It is
probable that both the nerve injury site and the DRG contribute to the ectopic firing of
primary afferents (Tal and Eliav, 1996). This can probably result in not only transmission to
the central nervous system (to trigger and maintain central sensitisation) but also to the
peripheral terminals leading to further excitation of the peripheral axons (Kim et al., 1998;
Xie et al., 1995).
Nerve injury can lead to an increased excitability of terminal membranes, which can be
brought about by the remodelling of expression and location of voltage-gated sodium (Na+)
and potassium (K+) ion channels in neuronal membranes. As Na+ channels are essential for
the propagation of action potentials and following nerve injury Na+ channels accumulate at
the injury site and along the axon, turning these sites into areas of hyperexcitability, they will
be briefly discussed (Devor and Seltzer, 1999; Matzner and Devor, 1994; Omana-Zapata et
al., 1997; Woolf and Mannion, 1999). Alterations in the expression of Na+ channels are
observed in DRG neurones as a result of various disease states, including chronic pain
(Waxman et al., 1999b). Normally DRG neurones express a number of Na+ channel
transcripts (Waxman et al., 1999b) that can be distinguished by their sensitivity to
tetrodotoxin (TTX) (Black and Waxman, 1996). For example some TTX-resistant NaT
channels, such as SNS 1/Nav1.8 (Akopian et al., 1996) and SNS 2/Nav1.9 (Tate et al., 1998)
have been shown to be specifically expressed in sensory neurones, thereby suggesting a
possible involvement in pain states (Akopian et al., 1996). Specifically, SNS 1/Nav1.8
channels are expressed in approximately 50% of small diameter unmyelinated cells and in
20% of larger diameter myelinated cells of the DRG, while SNS 2/Nav1.9 channels are only
expressed in unmyelinated cells of the DRG (Amaya et al., 2000). These two TTX-resistant
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Na+ channels produce slowly inactivating currents and the decrease in expression noted
following nerve injury may lead to a hyperpolarizing shift in resting potential allowing for a
possible increase in the TTX-sensitive channels available for activation (Akopian et al.,
1996; Decosterd et al., 2002; Dib-Hajj et al., 1999; Waxman et al., 1999a; Waxman et al.,
2000). A SNS l/Nav1.8-null mutation results in a partial analgesia to noxious mechanical and
thermal stimuli and delayed development of inflammatory induced thermal hyperalgesia in
mice (Akopian et al., 1999). Animals with a null mutation of SNS 1/Nav1.8 also show
neuropathic induced behaviours but do not show action potential spontaneous activity,
suggesting the involvement of this channel in the development of spontaneous activity in
sensitised nociceptors (Kerr et al., 2001; Laird et al., 2002; Roza et al., 2003). A TTX-
sensitive Na+ channel of interest, the brain type III Na+ channel/Navl.3 is normally found in
DRG neurones only during early development but its expression is upregulated in sensory
neurones following nerve injury (Black et al., 1999), which can lead to an enhancement of
TTX-sensitive currents (to produce a rapidly repriming current), that could sustain frequent
ectopic discharges (Cummins and Waxman, 1997; Waxman et al., 1999b). This suggests that
DRG neurones expressing brain type III Na+/Navl .3 channels may be able to sustain a greater
frequency of firing which in turn may lead to hyperexcitability of the cell.
1.6.2 Ephaptic interaction of peripheral nerve fibres
In normal conditions, a single sensory neuron represents an independent signal conduction
pathway. However following nerve injury, Schwann cells around myelinated fibres can
degenerate (Gautron et al., 1990), which can compromise the normal insulation of the fibre.
Nerve injury can result in cross-excitation in the peripheral nervous system (PNS), where a
stable electrical (ephaptic) interaction forms between neighbouring injured and uninjured
sensory axons (Seltzer and Devor, 1979; Tal and Eliav, 1996). Ephaptic interaction can occur
in neuromas, regenerating nerve and at patches of demyelination (Rasminsky, 1978). This
ephaptic interaction can occur between neighbouring fibres of different origins, for example
A8-fibres may now be stimulated by the large Afl-fibres, suggesting that pathways normally
only activated via noxious stimulation may now be activated by non-noxious stimuli or
movement in the periphery (Fried et al., 1993; Seltzer and Devor, 1979). This cross-
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excitation may underlie changes in excitability of uninjured afferents that perhaps cannot be
explained by alterations in ion channels alone.
1.6.3 Morphological changes in the sciatic nerve in the CCI model
The sciatic nerve originates from the spinal segments L4-L6 and comprises fibres of sensory,
motor and sympathetic origin. At mid thigh level the nerve is composed of approximately
27,000 axons of which 48% are unmyelinated sensory axons and 23% are myelinated sensory
axons (with a further 6% motor and 23% unmyelinated sympathetic axons; Schmalbruch,
1986). Following CCI there are striking morphological changes in the fibre composition of
the sciatic nerve. There are two main stages involved in these changes (Coggeshall et al.,
1993). Firstly an early degenerative phase occurs, which may be a result of the inflammation
and swelling at the nerve injury site where the chromic cat gut ligatures were applied, leading
to a slow strangulation of the axons. This swelling becomes maximal by three days and can
last for up to twenty-eight days after CCI injury, by which time a neuroma is often evident
(Coggeshall et al., 1993). Changes also occur in the sciatic nerve distal to the site of injury;
by three days post injury a steady and extensive reduction in axon numbers of all types
occurs. The main change is a profound loss of the large myelinated axons, the AP-fibres, with
the smaller myelinated and unmyelinated fibres being relatively less affected. The few
remaining large diameter AP-fibres were found to be in an advanced state of degeneration
(Basbaum et al., 1991). It could be suggested that this great loss of the large myelinated
fibres distal to the injury may lead to some loss of the central inhibitory input (normally
exerted via these afferents). The morphology of the sciatic nerve proximal to the site of
injury appears normal, with no evidence of degenerating fibres being observed (Basbaum et
al., 1991; Coggeshall et al., 1993; Gautron et al., 1990).
The second stage of change observed is a regenerative phase that occurs from around four
weeks onwards following CCI injury by which point the sutures have been reabsorbed
(around fourteen days) and the neuroma and swelling are diminishing (Coggeshall et al.,
1993). During this phase there is a gradual recovery of axonal numbers and an eventual
recovery of normal sensation in the affected hindlimb (seen by a recovery of neuropathic
pain behaviours; Guilbaud et al., 1993). The time course of the phases of morphological
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changes in the injured nerve have been studied alongside the development of behavioural
changes, revealing hyperalgesia to be maximal around ten to fourteen days after injury,
corresponding to the time point for the degenerative phase (Attal et al., 1990; Basbaum et al.,
1991; Bennett and Xie, 1988; Coggeshall et al., 1993; Gautron et al., 1990). The onset of
allodynia also appears maximal around two weeks after injury, with progressive recovery
noted from three to four weeks following injury (Guilbaud et al., 1993). It has been shown
that at week two (post injury) there is a massive Wallerian degeneration of the large
myelinated fibres and recovery is observed from three weeks onwards, coinciding with
recovery of behavioural changes (Ramer et al., 1997). Nevertheless the largest fibres had not
recovered by fifteen weeks after the injury, which does not correspond with the recovery of
the behavioural changes seen around eight to ten weeks post injury (Guilbaud et al., 1993).
This indicates that while the morphological changes observed is an important link to the
development and maintenance of neuropathic behavioural sensitisation, additional factors
must also be involved given the discrepancy between the time courses of change outlined
above.
1.6.4 Sympathetic nervous system
A number of investigations have suggested a link between the sympathetic nervous system
and the development of nerve injury-induced behavioural sensitisation. As outlined above
(section 1.5.1) surgical or chemical sympathectomies have resulted in a reduction in the
development of abnormal pain behaviours associated with a number of different animal
models of neuropathy (Kim et al., 1997b; Kim et al., 1993; Kim and Chung, 1991; Shir and
Seltzer, 1991). These findings suggest that the sympathetic nervous system may be involved
to some extent in the development of neuropathic pain states. However this involvement is
variable and may be dependent upon the site of nerve injury and distance of injury from the
spinal cord in addition to the type of injury (Kim et al., 1997b), all of which may explain why
the treatment of neuropathic pain involving the manipulation of sympathetic inputs has
variable results (Loh and Nathan, 1978; Luo and Wiesenfeld-Hallin, 1995). Additionally,
following nerve injury, sympathetic axons have been shown to sprout into the DRG from the
injured nerve (Chung and Chung, 2001) in a manner that parallels the development of
behavioural sensitisation (McLachlan et al., 1993; Ramer and Bisby, 1997). In axotomised
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animals, noradrenergic axons were found to sprout into the DRG, where they form 'baskets'
around the cell bodies of sensory neurones which provides a coupling pathway for
sympathetic-sensory fibres within the DRG (McLachlan et al., 1993). In the CCI model, a
slightly more rapid sprouting of sympathetic axons in DRG was noted (Ramer and Bisby,
1997). A direct coupling of sympathetic and somatosensory systems has been implicated
from findings showing the ectopic discharge of injured axons can be altered by electrical
stimulation of the sympathetic nervous system (Devor et al., 1994; Habler et al., 1987;
Korenman and Devor, 1981). However this coupling in DRG may change over the time
course of the nerve injury (Michaelis et al., 1996). These findings reveal the role played by
the sympathetic nervous system in the neuropathic pain states and how this role may change
during the course of the nerve injury, which may aid in the recovery of normal sensitisation.
1.6.5 Neuropeptides
Some of the characteristic alterations in the expression of neuropeptides in their cell bodies in
DRG, in their terminals and relevant receptors within the dorsal spinal cord observed
following peripheral nerve injury have been discussed above (Section 1.4.4).
1.6.6 Neurotrophic factors
Neurotrophins are a family of molecules that promote survival, growth and maintenance of
populations of neurones and are essential for normal neuronal development. The classic
neurotrophin family includes nerve growth factor (NGF), brain derived neurotrophic factor
(BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) (Thoenen, 1991).
Neurotrophins have been found to play a role in the development of normal functional
properties of sensory neurones, such as the ability to respond to peripheral stimuli (Carroll et
al., 1998). These neurotrophins signal via binding to their relevant tyrosine kinase receptors
which are the trkA (NGF), trkB (BDNF and NT-4/5) and trkC (NT-3) and the p75 receptor
which is capable of binding all neurotrophins with low affinity (Mendell et al., 2001). A
second family of neurotrophic factors is the glial cell line-derived neurotrophic factor
(GDNF) family, which are also important for the normal functioning of sensory neurones and
include GDNF, neurturin, artemin and persephin. These neurotrophins all signal through a
tyrosine kinase receptor, ret (Boucher and McMahon, 2001). Peripheral nerve injury has been
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shown to result in altered expression of the neurotrophins and their receptors in DRG
neurones (Cameron et ah, 1997; Nahin et al., 1994; Sebert and Shooter, 1993). The
expression of SP in DRG neurones has been shown to depend on the availability of NGF
(Lindsay and Harmar, 1989; Otten et al., 1980; Verge et al., 1995). While the expression of
VIP in cultured DRG neurones appears to be independent of NGF's presence or absence
(Mulderry and Lindsay, 1990), the expression of VIP in vivo following axotomy may be
dependent on the reduced availability of NGF as a result of axotomy (Shadiack et al., 2001).
Intrathecal administration of NGF can prevent axotomy-induced reductions in the levels of
SP and CGRP (Fitzgerald et al., 1985). In the SNL model, NGF appears to increase after
injury and application of anti-NGF antibodies to the spinal nerve adjacent to the site of spinal
nerve ligation can prevent development of thermal hyperalgesia for up to six days following
injury (Fukuoka et al., 2001). GDNF also plays a role, as demonstrated by the observation
that continuous administration of GDNF during either PNL or SNL prevents the development
of subsequent abnormal pain behaviours (Bennett et al., 2000). While the precise role of
these neurotrophic factors in neuropathic pain states is under investigation, it is clear from
some of the conflicting evidence shown here that a particular balance of neurotrophic factors
may be needed for normal functioning of sensory neurones.
1.7 Changes in the central nervous system following nerve injury
Stimulus-evoked pain, such as mechanical hyperalgesia, is one of the most common
manifestations of neuropathic pain and is the consequence of an increased central response to
primary afferent input. Following nerve injury the changes in the periphery, such as the
appearance of ectopic discharges, results in an altered input to the CNS that induces changes
in the sensory processing mechanisms within the spinal dorsal horn. This gives rise to the
phenomenon of central sensitisation resulting from the increased afferent input generated by
injury and noxious stimuli. This increased excitability of nociceptive neurones in the dorsal
horn leads to an exaggerated and extended response to subsequent sensory inputs (Ji and
Woolf, 2001). As a result, stimuli that would normally be innocuous now result in the
sensation of pain. Central sensitisation manifests in three ways: enlargement of the area in
the periphery where sensory neurones are activated by a noxious stimulus (i.e. the peripheral
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receptive field); increasing the response to a suprathreshold input; and prior subthreshold
inputs reaching threshold to initiate action potential discharge.
1.7.1 A-flbre sprouting in the dorsal horn
Central terminals of A-fibres exist in all the laminae of the dorsal spinal cord apart from
lamina II of the superficial dorsal horn, which receives input exclusively from C-fibres. After
nerve injury, sprouting of A(3-fibre central terminals into lamina II can occur (Lekan et al.,
1996; Woolf et al., 1992). This sprouting of AP-fibres that normally transmit innocuous
stimuli into an area involved in nociceptive processing may lead to misinterpretation of
information, whereby innocuous stimuli is interpreted as noxious. Sprouting ofAP-fibres was
observed to be maximal at two weeks following nerve injury and persisted for over six
months (Woolf et al., 1992). However it must be noted that doubts are emerging about these
findings, as sprouting was assessed by an anterograde labeling technique that utilizes cholera
toxin B subunit (CTb) as a selective tracer for A-fibres (Tong et al., 1999). The selectivity of
this tracer is in doubt, as recent studies have shown that CTb also labels unmyelinated C-
fibre afferents in lamina II (Bao et al., 2002; Shehab et al., 2003). Another study using intra-
axonal neurobiotin, as a label for sciatic A-fibres in both intact and axotomised nerves,
revealed no fibres extending further dorsally than the ventral aspect of lamina II (Hughes et
al., 2003). Nonetheless, despite the lack of concrete evidence for sprouting of A-fibres, it
appears that Ap-fibres have the ability to monosynaptically excite neurones in the superficial
dorsal horn after nerve injury (Kohama et al., 2000). It has also been demonstrated that
following sciatic nerve section (in a spinal cord slice preparation for electrophysiology) large
myelinated A-fibres can establish synaptic contact with interneurones and newly transmit
innocuous information to the substantia gelatinosa (Okamoto et al., 2001). This finding
represents a functional reorganization of the spinal cord circuitry and may account in part for
associated sensory abnormalities in neuropathic pain (Okamoto et al., 2001).
1.7.2 Inhibition and central sensitisation
Inhibitory mechanisms are active both locally within the dorsal horn and from descending
pathways (Sotgui, 1993). Loss of this inhibitory input onto excitatory neurones may aid
central sensitisation. However, evidence regarding the effects of CCI on the levels of
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inhibitory transmitters is conflicting. A marked loss of GABA-positive cells in lamina I-III in
the ipsilateral dorsal horn has been noted (Ibuki et al., 1997) and an increase in glycine and
GABA levels within the spinal cord has also been observed following nerve injury (Satoh
and Omote, 1996). Conversely, others have found that the proportion of cells in laminae I-III
that are GABA and or glycine positive was unaltered as a result of nerve injury (Polgar et ah,
2003). Another study revealed the return of GABA expression to pre-injury levels with
recovery from CCI (Ibuki et ah, 1997). It is possible that the inhibitory effects of GABA and
glycine may be altered at different stages in the development of nerve injury induced
sensitisation, which may explain why differences were found in the above studies. Altered
activity in descending pathways may also play a role in central sensitisation, in particular the
rostral ventromedial medulla (RVM) and the medullary nucleus raphe magnus (NRM) are
key regions involved in descending modulatory projections to the spinal cord (Calejesan et
ah, 1998; Zhuo and Gebhart, 1990). Loss of specific RVM cells that project to the spinal
cord to inhibit or facilitate transmission of noxious information both prevents and reverses
development of experimental neuropathic pain behaviours (Porreca et ah, 2001). Inactivation
of RVM or spinal transection results in the suppression of mechanical allodynia following
nerve injury (Bian et ah, 1998; Kauppila et ah, 1998; Sung et ah, 1998).
1.7.3 NMDA receptor complex and central sensitisation
Central sensitisation is an immediate onset, activity-dependent increase in the excitability of
nociceptive neurones in the spinal dorsal horn as a result of (and outlasting) an intense
peripheral noxious stimulus, tissue injury or nerve damage (Baranauskas and Nistri, 1998; Ji
et ah, 2003; Woolf, 1996). Some of the factors leading to central sensitisation as discussed
above include: presynaptic transmitter/peptide release (such as glutamate, SP, VIP) acting on
various metabotropic and ionotropic receptors (such as NMDA, mGlu, AMPA, NKi, VPAC2
receptors) in the dorsal horn to result in increased intracellular calcium and trigger
production of second messengers (Ji and Woolf, 2001; Woolf and Costigan, 1999; Woolf and
Mannion, 1999). While clearly a number of receptors and subsequent signalling pathways are
involved in central sensitisation, changes in NMDA receptor activation are consistently
thought to be a crucial factor underlying central sensitisation (Chaplan et ah, 1997;
Dickenson and Sullivan, 1987; Woolf and Costigan, 1999). Indeed the NMDA receptor has
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been shown to be involved in central sensitisation occurring as a result of inflammation of
tissues or joints, from repetitive low frequency electrical stimulation of afferents ('wind-up'),
from demyelination of afferents as well as peripheral nerve injury (Davies and Lodge, 1987;
Gillespie et al., 2000; Haley et al., 1990; Mao et al., 1993; Neugebauer et al., 1993; Tal and
Bennett, 1993; Wallace et al., 2003).
NMDA receptors as outlined above (section 1.4.2) are expressed in the superficial dorsal
horn of the spinal cord, an area essential for processing of nociceptive information
(Furuyama et al., 1993; Greenamyre et al., 1984). The NMDA receptor requires a
combination of the NR1 subunit (the core functional unit) with at least one of the NR2 (a-d)
subunits (Monyer et al., 1992; Mori and Mishina, 1995). The NMDA receptor is a bi-ligand
gated receptor, activated by binding of glycine and glutamate (Laube et al., 1997; Moriyoshi
et al., 1991). The NMDA receptor is usually blocked in a voltage-dependent manner by
magnesium ions and is activated by the progressive depolarization of the neuron or by a
reduction in the receptor's affinity for the magnesium ion when both binding sites of the
receptor are ligand-bound. Studies have shown that many properties of the NMDA receptor,
such as sensitivity to magnesium block, susceptibility to modulation by glycine, kinetic
differences, phosphorylation, affinity for agonists and antagonists may be dependent upon
the type of NR2 subunit found in the receptor's heteromeric complex (Cull-Candy et al.,
2001; Yamakura and Shimoji, 1999). An example of such a subunit-dependent property of
the NMDA receptor can be seen when assessing the channel conductance and sensitivity to
magnesium block. NMDA receptors incorporating an NR2A or NR2B subunit generate high-
conductance channel openings that have a high sensitivity to the magnesium block, whereas
receptors containing an NR2C or NR2D subunit have low-conductance channel openings
with a lower sensitivity to magnesium block (Ciabarra et al., 1995; Nishi et al., 2001; Sucher
et al., 1995). NR1 receptor subunit protein levels have been found to be reduced in the
superficial dorsal horn following CCI (Hama et al., 1995; Wilson et al., 2005), while the
levels of NR2B increase in the superficial dorsal horn following nerve injury (Boyce et al.,
1999a; Wilson et al., 2005), suggesting a possible role for this subunit in nociceptive
processing.
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NMDA receptor antagonists can attenuate behavioural sensitisation and can reduce neuronal
responses to noxious stimuli and electrical stimulation of afferents (see section 1.4.2; (Davies
and Lodge, 1987; Haley et al., 1990; Mao et al., 1992b; Mao et al., 1992c; Neugebauer et al.,
1993; Smith et al., 1994; Dickenson and Aydar, 1991; Woolf and Thompson, 1991; Mao et
al., 1993: Sotgiu and Biella, 2000). These findings illustrate the importance of NMDA
receptor activation in the plastic changes underlying nociceptive processing and behavioural
sensitisation as a result of nerve injury. NMDA receptors are embedded in the postsynaptic
density (PSD), a structure that is visible by electron microscopy as a thickening of the
postsynaptic membrane, containing the NMDA receptor complex (Sheng and Kim, 2002).
The signalling pathways acting downstream from NMDA receptors that are crucial to the
development of the neuropathic pain state are under investigation. One challenge in
understanding these pathways is the composition of NMDA receptor complexes, which in
overview represent multi-protein complex of receptors, adhesion and associated adaptor
proteins in addition to signalling enzymes, all of which are currently believed to total around
185 proteins (Grant et al., 2005). Different varieties of complex may well occur in different
situations. The proteins that can interact with the NMDA receptor have numerous functions,
such as adapter, scaffolding, cytoskeletal or signalling functions (Husi et al., 2000). Of all the
various proteins interacting with the NMDA receptor, one of the multivalent adapter proteins
was noteworthy, because of its prominent presence in central synapses, namely postsynaptic
density 95kDa protein (PSD-95). PSD-95 interacts with the cytoplasmic carboxy (C>-
terminal tail of NR2 subunits of the NMDA receptor (Kornau et al., 1995; Niethammer et al.,
1996).
Membrane associated guanylate kinases (MAGUK)
PSD-95 belongs to the membrane associated guanylate kinases (MAGUK) family of
multivalent adapter proteins (Sheng, 1996). In mammals, the MAGUK family of proteins
comprises of PSD-95 (also known as synapse-associated protein 90, SAP-90), synapse
associated protein 97 (SAP-97), postsynaptic density 93 (PSD-93, also known as chapsyn
110) and synapse associated protein 102 (SAP-102) (Garner et al., 2000; Sheng and Kim,
1996). All four MAGUK proteins share approximately 70% sequence homology and contain
multiple protein interaction domains, namely three N-terminal PDZ (PSD-Dlg-ZO-1
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homology) domains, an SH3 (Src homology 3) domain and a GK (guanylate kinase-like)
domain in their C-terminal region. It is the PDZ domains of the MAGUK proteins that have
been found to bind to motifs within the C-terminal of NR2 subunits of the NMDA receptor
(Garner et al., 2000; see Figure 1.3). This family of proteins can cluster ion channels on
postsynaptic membranes at excitatory synapses and also interact with signalling molecules
and the cytoskeleton (Sheng, 2001; Sheng and Kim, 2002). All the MAGUK proteins have
been found in glutamatergic synapses but their expression in the spinal cord appear to have
distinct patterns. Both PSD-95 and SAP-102 are mainly found in lamina I and outer lamina II
of the superficial dorsal horn (Garry et al., 2003; Tao et al., 2000) and PSD-93 is expressed
mostly in laminae I and II and outer lamina III (Tao et al., 2003b; Zhang et al., 2003).
Localisation of these MAGUKs in the superficial dorsal horn of the spinal cord, the primary
area for processing noxious information, encourages the idea of their potential role in
nociceptive processing. On the other hand the expression of SAP-97 has not yet been
localised to specific laminae of the spinal cord (Tao et al., 2001; Zhang et al., 2003a). The
expression of either the mRNA or protein of all four MAGUKs was not reported in dorsal
root ganglion (Tao et al., 2000; Tao et al., 2003b; Zhang et al., 2003a). The expression of
PSD-95 and PSD-93 is of interest as their distribution overlaps with that of the NMDA
receptor subunits, in particular NR2B, which is found in lamina I and II, whereas NR2A has
a wider dorsal horn distribution (Boyce et al., 1999b; Dickenson and Aydar, 1991; Tao et al.,
2000), suggesting that PSD-95 and PSD-93 could possibly associate with NMDA receptor
complexes of different subunit composition.
Two of the MAGUK proteins, PSD-95 and PSD-93, have through genetic and antisense
techniques been implicated in chronic pain states (Garry et al., 2003; Tao et al., 2003b; Tao
et al., 2001; Tao et al., 2003a;Tao et al., 2000 Zhang et al., 2003a), the role SAP-102 or -97
may play has yet to be addressed and is beyond the scope of this study. PSD-93 plays a role
in the mechanism of both chronic inflammatory and neuropathic pain. PSD-93 mutant mice
and knockdown of spinal PSD-93 prevented the development of behavioural sensitisation
observed following CFA injection and the SNL model of nerve injury (Tao et al., 2003b;
Zhang et al., 2003a). Spinal knockdown of PSD-95 resulted in a reduction in both the
development and maintenance of SNL nerve injury induced behavioural sensitisations (Tao
et al., 2001; Tao et al., 2003a). While investigations using PSD-95 mutant mice resulted in a
complete absence of behavioural sensitisation to mechanical, thermal and cold stimuli
following CCI nerve injury, normal responses to the formalin test were displayed (Garry et
al., 2003). A closer inspection of the genetic mutations show that PSD-93 and PSD-95
mutant mice have different disruptions, that is different PDZ domains were targeted in each
mutation. The PSD-93 mutant construct has a complete deletion of the second PDZ domain,
whereas the PSD-95 construct, leaves the first two PDZ domains intact (McGee et al., 2001b;
Migaud et al., 1998). This difference may explain why PSD-93 was implicated in both
chronic inflammatory and neuropathic pain states whereas PSD-95 appeared to be involved
in neuropathic pain states. Furthermore, the second PDZ domain (in addition to the first PDZ
domain) can bind directly to the NMDA receptor, which might explain the differences noted
between these two strains of mice. That is, the impaired cell surface expression of NR2A and
NR2B subunits and impaired functioning of synaptic NMDA receptors in PSD-93 mutants
may be a result of the site of mutation, which is not seen in the PSD-95 mutant mice. Migaud
et al (Migaud et al., 1998) state that the expression and localisation of NR1, 2A and 2B is the
same in wild type and PSD-95 mutant mice and NMDA receptor channel properties are
unaffected by the mutation and the receptor is normally localised to synapses in the mutants.
In the two mutants, the PSD-93 mutant has impaired expression ofNMDA subunits whereas
the PSD-95 mutant does not have such an impairment, while the surface localisation of PSD-
95 itself was unaltered (as it is ~10fold less in 95 mutants), this might explain the differences
seen in the prevention of behavioural sensitisation (Migaud et al., 1998; Tao et al., 2003b). In
order to fully ascertain if these proteins have different roles in chronic pain states, equivalent
mutant or knockdown animals would have to be assessed using identical models of chronic
pain.
The interaction of PSD-95 with the NMDA receptor in the spinal dorsal horn has been
revealed by our lab to be necessary for neuropathic reflex sensitisation (Garry et al., 2003).
Given the larger number of proteins incorporated in the NMDA receptor complex and the
fact that PSD-95 has multiple protein interaction domains, the list of potential binding
partners of PSD-95 is vast, with more and more interactions being continually discovered.
PSD-95, in addition to its involvement in anchoring and clustering the NMDA receptor at
-52-
synapses, can couple the NMDA receptor to signalling proteins to mediate downstream
signalling. One of the potential binding partners is neuronal nitric oxide synthase (nNOS),
which is a Ca2+/calmodulin-regulated enzyme. The PDZ ligand motif of nNOS can bind to
the second PDZ domain of PSD-95, and a ternary complex of NR2-PSD-95-nNOS has been
identified in the spinal cord (Tao et al., 2000). However the role played by spinal nNOS in
nociceptive signalling in chronic pain states is unclear. Treatment with nNOS inhibitor did
not prevent the development of allodynia as a result of nerve injury, whereas a general NOS
inhibitor did inhibit allodynia in nerve injured animals (Luo et al., 1999; Yoon et al., 1998).
Another protein of interest in this complex is the Ca2+/calmodul in-dependent kinase II
(CaMKII), which can interact directly with NR2A and NR2B subunits of the NMDA
receptor (Gardoni et al., 1999; Garry et al., 2003; Strack and Colbran, 1998). CaMKII does
appear to play a role in nociceptive processing, CaMKII coimmunoprecipitation with NR2A
and NR2B subunits is increased following nerve injury and use of CaMKII antagonists
prevented development of behavioural sensitisation as a result of nerve injury (Garry et al.,
2003). The disruption of CaMKII interaction with PSD-95 and the NMDA receptor is
thought to be responsible for the lack of neuropathic pain in the PSD-95 mutant mice (Garry
et al., 2003). CaMKII expression has also been found to increase in DRG cells as a result of
the formalin model of inflammatory pain (Carlton, 2002) and to increase in the superficial
dorsal horn and DRG cells following injection of capsaicin (Fang et al., 2002). These
findings indicate that CaMKII may play a role downstream of the NMDA receptor-PSD-95
complex to bring about a sensitized state following nerve injury. In addition to its effect on
the NMDA receptor, CaMKII can regulate other proteins, such as GluRl subunits, leading to
an enhancement ofAMPA receptor currents and contributing to the translocation of GluRl to
synapses (Derkach et al., 1999; Hayashi et al., 2000).
SynGAP is another PDZ domain-interacting protein that has been demonstrated to be of
importance in hippocampal plasticity (Kim et al., 2003; Komiyama et al., 2002). SynGAP is
a Ras-GTPase activating protein, which is involved in regulation of the MAPK cascade, thus
providing a potential functional link between the NMDA receptor and the MAPK pathway
(O'Brien et al., 1998). However this protein has not been detected in the spinal cord by our
lab and will not be discussed further (unpublished communication). Cysteine-rich interactor
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of PDZ3 (CRIPT) has been identified to bind selectively to the third PDZ domain of PSD-95,
CRIPT also binds directly to microtubulues thereby linking the mictotubule cytoskeleton to
PSD-95, which may contribute to the synaptic clustering of PSD-95 (Passafaro et al., 1999).
There are many other PDZ domain binding proteins that theoretically might interact with
PSD-95, including for example, subunits of various ion channels and receptors other than the
NMDA receptor, scaffolding, cytoskeletal and cell-adhesion proteins, which are beyond the
scope of this study.
The two remaining interacting domains of PSD-95 are the GK and SH3 domains. The GK
(guanylate kinase) domain does not have a conserved ATP binding site, therefore exhibits no
enzymatic activity, but the domain can bind GMP in a relatively specific manner (Kistner et
al., 1995). Kim and colleagues (Kim et al., 1997a) hypothesized that in the absence of
enzymatic (catalytic) activity, the GK domain's primary function was as a protein binding
site and using a yeast two hybrid screen, they cloned a novel binding partner, guanylate
kinase-associated protein, GKAP (also called synapse-associated protein 90-associated
protein, SAPAP). GKAP is believed to function as a scaffolding protein that anchors and
links glutamate receptors and other PSD proteins to synaptic proteins (Romorini et al., 2004).
Indeed, GKAP has been shown to bind to the SHANK family of proteins, which in turn, via
binding to the mGluR-interacting protein Homer, results in a physical link between the
NMDA receptor complex and metabotropic glutamate receptors (mGluR), thereby possibly
connecting the NMDA receptor complex to downstream effectors in the mGluR signalling
pathway (Takeuchi et al., 1997; Tu et al., 1999). Whether such a connection occurs in the
spinal cord or if it is involved in the processing of nociceptive information remains to be
determined.
The remaining domain of PSD-95 is the SH3 domain (see section 5.1), which has a binding
specificity for proline-rich sequences containing a PXXP motif (Erpel et al., 1995; Lim and
Richards, 1994; Mayer and Eck, 1995; Pawson and Scott, 1997). The majority of SH3
domains characterized to date recognize class I and/or class II peptides that share a core
PXXP motif (Cohen et al., 1995; Mayer, 2001; Sparks et al., 1998). However, it must be
noted that the SH3 domain of PSD-95 has an atypical structure (Borchert et al., 1994;
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Guruprasad et al., 1995; Musacchio et al., 1992; Musacchio et al., 1994; Noble et al., 1993).
A novel feature found in the SH3 domain of PSD-95 include the ability of the SH3 domain to
interact with the GK domain at a site that does not involve the proline binding site of the SH3
domain, and it is thought that this intramolecular binding may be favoured over
intermolecular binding (McGee and Bredt, 1999; Nix et al., 2000; Shin et al., 2000; Tavares
et al., 2001). The SH3 and GK domains form an integrated structural unit, whereby four p
strands (A-D) of the SH3 domain are followed by a large hinge region (separating p strands
D and E) and the GK domain is inserted between P strands E and F (Shin et al., 2000;
Tavares et al., 2001; see Figure 1.4). The recent development of mutant mice with a single
point mutation of the SH3 domain of PSD-95, that targets the highly conserved tryptophan
residue (tryptophan 470; see Figure 1.4) in SH3 domains, which is thought to be crucial for
the interaction of SH3 domains with proline-rich ligands (Erpel et al., 1995) by Prof. Seth
Grant and colleagues [Section 5.2] enables evaluation of the possible role of the SH3 domain
of PSD-95 in the development and maintenance of neuropathic behavioural sensitisation.
Binding partners of the SH3 domain include: Pyk 2, a non-receptor tyrosine kinase (Huang et
al., 2001; Seabold et al., 2003), the KA2 subunit of kainate receptor (Garcia et al., 1998),
Huntingtin protein (Sun et al., 2001), A-Kinase-anchoring Protein (AKAP) 79/150 (Colledge
et al., 2000) and Mixed lineage kinases (MLK) 2 and 3 (Savinainen et al., 2001; see also
Section 6.1). The focus of this study is the binding partner proline-rich tyrosine kinase 2, Pyk
2 (Huang et al., 2001; Seabold et al., 2003).
-55-
Figure 1.3
Schematic diagram of the NMDA receptor complex, in the postsynaptic density
assembled by PSD-95
The PDZ domains of PSD-95, a member of the MAGUK (membrane-associated guanylate
kinase) family of proteins, interact with the cytoplasmic carboxy (C-) terminal tail of the
NMDA receptor NR2 subunits. The PDZ domains of PSD-95 can also interact with, for
example, the PDZ domain of neuronal nitric oxide synthase (nNOS) and with Cysteine-rich
interactor of PDZ3 (CRIPT). The Src homology region 3 (SH3) domain of PSD-95 can bind
to the proline-rich tyrosine kinase 2, Pyk 2. The guanylate kinase (GK) domain can link the
NMDA receptor complex to the metabotropic glutamate (mGlu) receptor via a scaffold
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Schematic diagram of the integrated structural unit formed by the SH3 and GK
domains of PSD-95.
The integrated unit formed is comprised of four P strands (A-D) of the SH3 domain, followed
by a large hinge region (separating p strands D and E) and the GK domain is inserted
between P strands E and F (from McGee et al., 2001a). A point is marked to illustrate the
single point targeted mutation of the SH3 domain of PSD-95 that resulted in the development
of the psD-95SH350W470L mutant mouse used in this study [Generated by Prof. Seth Grant's
laboratory (Wellcome Trust Sanger Institute, Cambridgeshire, UK)].
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Proline-rich tyrosine kinase 2 [Pyk 2]
Proline-rich tyrosine kinase 2 (Pyk 2) is a non-receptor protein tyrosine kinase which is
intracellularly located and is classified based on its sequence similarity and distinct structural
characteristics into the focal adhesion kinase family, a subfamily of the non-receptor protein
tyrosine kinases (Hanks and Quinn, 1991). The focal adhesion family is composed of focal
adhesion kinase (FAK) and Pyk 2 (Neet and Hunter, 1996). Pyk 2 is also known as cell
adhesion kinase (1 (CAK-j3), calcium-dependent tyrosine kinase (CADTK), related adhesion
focal tyrosine kinase (RAFTK) and focal adhesion kinase 2 (FAK2) (Avraham et al., 1995;
Herzog et al., 1996; Lev et al., 1995; Sasaki et al., 1995; Yu et al., 1996). Pyk 2 displays a
high degree of sequence similarity with that of FAK (Lev et al., 1995; Sasaki et al., 1995).
The structure of Pyk 2 comprises an N-terminus, a centrally located protein tyrosine kinase
domain and two proline-rich regions at the C-terminus; these two proline rich motifs are sites
for SH3 mediated protein-protein interactions (Avraham et al., 2000). While FAK is
expressed in most tissues, Pyk 2 is predominantly expressed in the central nervous system
and cells derived from hematopoietic lineages, whereas its alternatively spliced isoform (Pyk
2-H) is specifically expressed in T and B lymphocytes, monocytes, and natural killer cells
(Avraham et al., 2000; Dikic et al., 1998; Lev et al., 1995).
Pyk 2 is phosphorylated in response to various external stimuli (such as depolarization,
growth factor receptor activation) that increase the intracellular calcium concentration, as
well as by protein kinase C (PKC) activation (Lev et al., 1995; Park et al., 2000). Pyk 2 is
also activated for example by adhesion-mediated signalling in platelets and B cells (Astier et
al., 1997; Tokiwa et al., 1996). It has also been shown that Pyk 2 (but not FAK) can be
activated in response to stress signals (such as tumor necrosis factor-a, changes in
osmolarity) and in such cases can trigger activation of the Jun N-terminal kinase (JNK)
cascade (Tokiwa et al., 1996; Yu et al., 1996). Activation of Pyk 2 in response to an increase
in intracellular free Ca2r can be prevented by use of PKC inhibitors (Hiregowdara et al.,
1997; Ohba et al., 1998; Raja et al., 1997; Siciliano et al., 1996; Soltoff et al., 1998),
although the precise mechanism of PKC's involvement is not known. An increase in
intracellular free Ca2+, via receptor activation resulting in release of calcium from
intracellular stores and an increase in calcium influx into the cell, can trigger activation of
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calcium-dependent enzymes, such as protein kinase C (PKC) and calcium/calmodulin-
dependent protein kinase II (CaMKII discussed above), calcium-dependent adenylate cyclase
isoforms and tyrosine kinases (Bortolotto and Collingridge, 1998; Malmberg et al., 1997;
Munro et al., 1994; Silva et al., 1992). These kinases may act to regulate membrane bound
receptors and ion channels, such as the NMDA receptor. Indeed kinase activation by G
protein-coupled metabotropic receptors is believed to lead to phosphorylation of the NMDA
receptor resulting in a conformational change that diminishes the Mg2+ blockade (Bleakman
et al., 1992; Bond and Lodge, 1995; Chen and Huang, 1992) and leads to increased NMDA
receptor-mediated influx of Ca++ into the cell. Such calcium influx through the NMDA
receptor may then activate the nitric oxide/cGMP/PKG pathways, and blockade of these
pathways has been found to alleviate pain induced by formalin (Coderre and Yashpal, 1994)
and peripheral nerve injury (Meller et al., 1992). Similarly, calcium-dependent camp
generation would lead to the activation of protein kinase A (PKA), which has also been
implicated in central sensitisation, as it is required for the second phase of formalin-induced
inflammatory mechanical allodynia (Coderre and Yashpal, 1994).
Pyk 2 is a possible mediator of various extracellular signals that elevate intracellular Ca2+
concentration. Pyk 2 was recently shown to directly interact with PSD-95 in rat brain
(independent of the presence of the NMDA receptor) and, through GST fusion protein
constructs, it was shown that Pyk 2 bound specifically to the SH3 domain only and not to the
GK domain (Huang et al., 2001; Seabold et al., 2003). Whether association of Pyk 2 with the
SH3 domain binding of PSD-95 occurs in the spinal cord will be looked at in this study, as
well as its possible activation in pain models. Whichever stimulus is involved, Pyk 2 is
activated by autophosphorylation at Tyr402 (tyrosine402) and Tyr579/580 sites, this then
enables Pyk 2 to bind to the SH2 domain of Src (another family of the non-receptor protein
tyrosine kinases) (Dikic et al., 1996) leading to the activation of Src by relieving
autoinhibition (Thomas and Brugge, 1997; Xu et al., 1997). Activation of Pyk 2, leading to
the recruitment of Src, can also result in modulation of ion channel function and trigger a
number of further signalling pathways, such as activation of the MAPK signalling cascade
(Avraham et al., 1995; Lev et al., 1995). Pyk 2 can act with Src to link G protein-coupled
receptors via Grb2 to the Ras/MAP kinase signalling pathway (Dikic et al., 1996; Girault et
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al., 1999). Src itself has a number of important substrates which include the NMDA receptor
(Wang and Salter, 1994; Zheng et al., 1998), GABAa receptors (Moss et al., 1995) and
voltage-gated K+ channels (Holmes et al., 1996; Huang et al., 1993). Pyk 2/Src-mediated
regulation of NMDA receptors may play an important role in regulating synaptic plasticity
(Huang et al., 2001). Pyk 2 has also been suggested to be important in pathological
conditions such as ischaemia and convulsions (Liu et al., 2005; Tian et al., 2000). Pyk 2
activation may therefore play a significant part in the array of mechanisms for calcium-
dependent signalling events (Lev et al., 1995), making Pyk 2 a candidate for the coupling of
depolarisation and activation of various receptors (such as the NMDA receptor) to
downstream signalling pathways, such as the MAP kinase pathway.
Mitogen-activated protein [MAP] kinase pathway
Long lasting changes in neuronal excitability occur through activation of transcription factors
via signalling pathways, to result in the alteration of gene expression and protein synthesis in
the DRG and spinal dorsal horn (Hokfelt et al., 1994; Ji and Woolf, 2001). Indeed the effect
of nerve damage on gene expression has recently, through cDNA microarray techniques,
demonstrated an alteration in the expression of numerous genes following injury, some of
which are known to be involved in neurotransmission, signal transduction, myelination and
transcriptional regulation (Rabert et al., 2004). A key signalling pathway involved in the
activation of such transcription factors is the mitogen-activated protein (MAP) kinase
cascade (Widmann et al., 1999). MAP kinases are serine/threonine protein kinases localized
in the cytoplasm until activated by dual phosphorylation on both threonine and tyrosine
residues when they can translocate towards the nucleus (Raingeaud et al., 1995; Seger and
Krebs, 1995; Widmann et al., 1999). They are crucially involved in many important
intracellular signalling pathways transmitting signals from the cell surface to the nucleus
(Derkinderen et al., 1999). The better characterised members of the MAP kinase family are
firstly the p42/44 MAP kinases, known also as extracellular signal regulated kinase (ERK)
ERK1/2, secondly, the p38 MAP kinase and finally c-Jun N-terminal kinase (JNK) also
known as stress-activated protein kinase (SAPK). JNK/SAPK originally identified by its
response to cellular stressors, was found to be associated with the apoptotic pathway of cell
death and has recently been investigated in persistent pain states. JNK MAP kinase activation
-62-
(in addition to ERK activation) has been reported in astrocytes of the spinal dorsal horn in the
PNL model of neuropathic pain (Ma and Quirion, 2002). Peripheral axotomy has been shown
to induce JNK/SAPK activation in DRG neurones (Kenney and Kocsis, 1998). JNK
activation is also observed in injured DRG neurones following the SNL model of neuropathic
pain (in addition to ERK and p38 activation) and use of a JNK inhibitor reversed the SNL-
induced mechanical allodynia (Obata et al., 2004b). More recently it has been shown that
SNL induced the activation of JNK in injured DRG neurones and in spinal cord astrocytes
and SNL-induced mechanical allodynia was reversed by use of a JNK inhibitor (Zhuang et
al., 2006).
While the p42/44 MAP kinases have been clearly implicated in neuronal plasticity states,
such as long-term potentiation, learning and memory (Impey et al., 1999; Sweatt, 2001) they,
along with p38 MAP kinase, are also involved in the plasticity underlying chronic pain states.
Indeed p38 MAP kinase activation occurs in DRG neurones as a result of both peripheral
inflammation and nerve injury (Ji et al., 2002b; Kim et al., 2002; Mizushima et al., 2005;
Schafers et al., 2003), in addition to activation of p38 MAP kinase occurring in the spinal
dorsal horn (Bessou et al., 1971; Brown and Iggo, 1967; Jin et al., 2003; Kim et al., 2002;
Svensson et al., 2003). Indeed it has been shown that p38 MAP kinase inhibition results in
the reduction of both inflammation and nerve injury induced behavioural sensitisation (Ji et
al., 2002b; Jin et al., 2003; Schafers et al., 2003). The activation of p42/44 MAP kinase as a
result of peripheral inflammation occurs in the spinal dorsal horn and use of p42/44 MAP
kinase inhibitors prevents the development of inflammatory behavioural sensitisation (Galan
et al., 2002; Ji et al., 1999; Ji et al., 2002a; Leem et al., 1993; Sammons et al., 2000).
Recently, it has also been found that activation of p42/44 MAP kinase is localised to both
dorsal spinal cord and DRG neurones as a result of peripheral nerve injury (Obata et al.,
2004a; Obata et al., 2004b; Zhuang et al., 2005). Additionally p38 MAP kinase activation
can be localised to microglia after peripheral inflammation and nerve injury (Jin et al., 2003;
Kawasaki et al., 1997; Kim et al., 2002; Svensson et al., 2003; Tsuda et al., 2004) and p42/44
MAP kinase activation can be seen in astrocytes and microglia following nerve injury (Ma
and Quirion, 2002; Zhuang et al., 2005). These findings clearly illustrate the important role
the MAP kinase cascade plays in the neuropathic pain state; some of the receptors possibly
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involved in their activation will be investigated in this study. In addition, it seems likely that
not just neurons, but also glia may well play an important role in chronic sensitised pain
states.
1.8 Spinal Glia
The central nervous system is comprised of neurones and glial cells. There are three types of
glial cells in the CNS, termed astrocytes, microglia and oligodendrocytes. Traditionally glial
cells were thought of as cells that provide support and protection for neuronal cells and
became known as the 'supporting cells' of the nervous system. However, glial cells are now
known to communicate bidirectionally with neurones, express multiple types of
neurotransmitter receptors, play a role in transmitter uptake and release a number of bioactive
substances, therefore they may play a more direct role in modulating neuronal transmission
than previously believed (Millan, 1999). Indeed the activation of spinal cord glial cells,
namely microglia and astrocytes, has recently been implicated in the pathogenesis of pain,
ending the idea that pain hypersensitivity results solely from altered neuronal function
(DeLeo and Yezierski, 2001; Meller et al., 1994; Watkins et al., 1997; Watkins et al., 2001b;
Watkins et al., 2001a). Astrocytes and microglia can be activated by several substances,
including excitatory amino acids (EAAs), prostaglandins and adenosine triphosphate (ATP);
however these substances can also activate neurones (Bezzi et al., 1998; Hide et al., 2000;
Takuma et al., 1996). Astrocyte activation is characterised by an increase in the production of
filaments (involving proteins such as glial fibrillary acidic protein, GFAP) and also by an
increased release of pro-inflammatory substances (Pekny, 2001). The activation of microglia
results in numerous responses which include alterations in receptor expression, cell-surface
markers and production ofpro-inflammatory substances (Watkins and Maier, 2003). The first
studies to implicate glial activation in neuropathic pain states showed that spinal glial cell
activation was prevented by an NMDA receptor antagonist, which also prevented the
behavioural sensitisation noted following peripheral nerve chronic constriction injury
(Garrison et al., 1991; Garrison et al., 1994). These initial findings suggesting that glial
activation aided the development of neuropathic behavioural sensitisation needed to be tested
rigorously before glia could be considered as a possible therapeutic target. The use of two
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pharmacological agents to disrupt glial function, namely fluorocitrate, which disrupts glial
function and minocycline, which prevents the activation of microglia, blocked the
development of both allodynia and hyperalgesia following various models of nerve injury
(Ledeboer et al., 2005; Meller et al., 1994; Milligan et al., 2003; Raghavendra et ah, 2003a;
Watkins et ah, 1997). The mechanisms of how glial activation can enhance neuronal
transmission are not fully understood. It is believed that activated glia release substances that
affect neurones either directly to increase excitation, or indirectly to induce the release of
other transmitters to act on nociceptive neurones or cause upregulation of neuronal receptors.
It is known that activated glia can release the pro-inflammatory cytokines, tumor necrosis
factor-alpha (TNFa), interleukin-1 (IL-1) and interleukin-6 (IL-6), which have been shown
to activate neurones as well as glia via binding to specific receptors on these cells (Sawada et
ah, 1989; Vitkovic et ah, 2000). TNFa, IL-1 and IL-6 are grouped as pro-inflammatory
cytokines not because of structural similarities but due to their co-ordinated responses to
infection and injury (Watkins and Maier, 2003). Injection of pro-inflammatory cytokines
around the spinal cord enhances dorsal horn neuronal responses to noxious stimuli (Onda et
ah, 2002; Reeve et ah, 2000). Inhibiting these pro-inflammatory cytokines by intrathecal
injection of antagonists resulted in the prevention or reversal of allodynia and hyperalgesia in
models of both inflammation and nerve injury (Milligan et ah, 2003; Sweitzer et ah, 2001a;
Watkins et ah, 1997). Furthermore, thalidomide (a selective inhibitor of TNFa synthesis) and
propentofylline (an inhibitor of glial function possibly via adenosine-independent or
adenosine-dependent mechanisms; Sweitzer et ah, 2001b) can also prevent behavioural
sensitisation seen following peripheral nerve injury (George et ah, 2000; Raghavendra et ah,
2003b; Sommer et ah, 1998; Sweitzer et ah, 2001b). Release of pro-inflammatory cytokines
results in the activation of intracellular pathways, one of which is the p38 MAP kinase
cascade (see section 1.7.3; Clark et ah, 2003; Watkins et ah, 1999), where a reduction in
nerve injury-induced p38 activation can be seen by blocking the pro-inflammatory cytokine,
TNFa (Svensson et ah, 2005). The anti-inflammatory cytokine, IL-10, which can suppress
the production and actions ofTNFa, IL-1 and IL-6, is under investigation for its potential use
as an analgesic. Current research into glial cell involvement in chronic pain states is also
trying to establish the role of astrocytes and microglia by using markers for activation of
astrocytes (GFAP) and microglia (OX-42). This work, looking at the pattern of glial
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activation following nerve injury, has led to the idea that early microglial activation may lead
to astrocyte activation, which could then maintain the chronic pain state (Colburn et al.,
1999; Hashizume et al., 2000; Raghavendra et al., 2003a; Winkelstein and DeLeo, 2002).
The complex role played by glial cells in modulating nociceptive processing is still being
investigated.
1.9 Aims
This study will examine some of the possible mechanisms involved in the development and
maintenance of neuropathic pain. The sciatic chronic constriction injury (CCI) model
(Bennett and Xie, 1988) will be used in this study and at times compared to the formalin-
induced model of inflammation and the Complete Freund's Adjuvant model of persistent
inflammation to look at possible mechanistic differences involved in neuropathic and
inflammatory chronic pain states. It is clear from previous investigations that several receptor
types are involved in the mechanisms of central sensitisation. Of all these receptors, the
ionotropic glutamate NMDA receptor and the peptidergic NK.2 and VPAC2 receptors, all of
which have been crucially implicated in mediating nociceptive processing in neuropathic
pain states, will be further investigated here. The involvement of these receptors in activating
the MAP kinase signalling pathway and the involvement of the p42/44 and p38 MAP kinases
in the development of neuropathic pain will be addressed. Given the importance of glial cells
in neuropathic pain states, their potential participation in the activation of the p42/44 and p38
MAP kinases will also be examined. Following on from the work of Garry and colleagues
(Garry et al., 2003) into the role of the NMDA receptor complex adapter protein, PSD-95 in
neuropathic pain states, the potential association of this protein with a downstream signalling
partner Pyk 2, in addition to the involvement of the SH3 domain of PSD-95 in the
neuropathic pain state, will be examined. This study was designed to add to our current
understanding of the intracellular mechanisms involved in neuropathic pain, thereby




• Adult male Wistar rats (250-320g; Charles River, UK)
• Adult male and female MF1 mice either PSD-95SH3W470L mutant or wild-type
littermates (20-30g; Gift from Seth Grant, Wellcome Trust Sanger Institute,
Cambridgeshire, UK).
2.2 Anaesthetics
• Halothane (Merial Animal Health Ltd., Essex, UK)
• Sodium pentobarbital (Sagatal; Rhone Merieux Ltd., Hertfordshire, UK)
2.3 Materials for animal models
• 4/0 Chromic cat gut sterilized surgical ligatures (SMI AG, Belgium)
• 5/0 Sterile surgical chromic cat gut ligatures (Medgut, South Africa)
• Hibitane (Zeneca Ltd., Cheshire, UK)
• 5.0 Coated vicryl absorbable suture with curved needle (Ethicon, Edinburgh, UK)
• 1ml microsyringe (Terumo, Belgium)
• 25-gauge needle (Terumo, Belgium)
• Micro fine 0.3ml Insulin syringe U100 with attached needle (BD Medical,
Oxford, UK)
• Complete Freund's adjuvant (CFA; Sigma, UK)
• Formalin (36.5-38% formaldehyde; Sigma, UK)
• Saline, Sodium chloride solution 0.9% (Sigma, UK)
• All surgical instruments (Fine Science Tools, Germany)
2.4 Behavioural Somatosensory Reflex Testing Equipment
• Semmes-Weinstein von Frey filaments (Stoelting Co., Wood Dale, Illinois, USA)
• Hargreaves' thermal stimulator (Ugo Basile Model; Linton Instrumentation, UK)
• Clear Perspex box with raised aluminium floor for cold test (made on site)
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2.5 Materials for intrathecal injections
• 25-gauge needle (Terumo, Belgium)
• 1ml microsyringe (Terumo, Belgium)
• Saline, Sodium chloride solution 0.9% (Sigma, UK)
• Dimethylformamide (DMF; Sigma, UK)
2.6 Drugs used for intrathecal administration and spinal cord incubation [Table 2.1]
• p38 MAP kinase inhibitor SB 203580 (Merck Biosciences, UK)
• p42/44 MAP kinase pathway inhibitor PD 098059, (Merck Biosciences, UK)
• p42/44 MAP kinase pathway inhibitor U 0126, (Merck Biosciences, UK)
• p42/44 MAP kinase pathway inhibitor less active analogue U 0124, (Merck
Biosciences, UK)
• Glial inhibitor propentofylline (PPT; Sigma, UK)
• TNF-a receptor antagonist, WP9QY (Merck Biosciences, UK)
• VPAC2 receptor antagonist, ([des(l-4), Arg16]-Ro 25-1553; Gift from P.
Robberecht, Free University of Brussels, Belgium)
• VPACi receptor antagonist, ([Ac-His1, D-Phe2, Lys15, Arg16, Leun]-VIP(3-
7)GRF(8-27) ; Gift from P. Robberecht, Free University of Brussels, Belgium)
• PACi receptor antagonist, PACAP6-38 (Bachem UK Ltd., UK)
• NKi receptor antagonist, RP 67580 (Gift from C Garret, Rhone-Poulenc Rorer,
France)
• NK2 receptor antagonist, SR 48968 (Gift from X. Emonds-Alt, Sanofi Recherche,
France)
• NMDA receptor antagonist, (R)-CPP (3-((R)-2-carboxypiperazine-4-yl)-propyl-l-
phosphonic acid; Tocris, Cookson Ltd., UK)
• NK2 receptor agonist GR 64349 (Gift from P. Birch, Glaxo, Smith-Kline, UK)
• VPAC2 receptor agonist, Ro 25-1553 (Gift from P. Robberecht, Free University
of Brussels, Belgium)
• TNF-a synthesis inhibitor, Thalidomide (Sigma, UK)
• Saline, Sodium chloride solution (Sigma, UK)
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2.7 Western Immunoblotting
• Hand-held mini-borosilicate glass homogenisers (Fisher Scientific, Ltd., UK)
• NuPage Novex pre-cast 4-12% Bis-Tris Gels, 1.0mm xl2 well pH6.4 (Invitrogen
Ltd., UK)
• NuPage XCell SW-eLock™ Minicell gel electrophoresis system (Invitrogen Ltd.,
UK)
• Immobilon-Psq, polyvinylidene difluoride (PVDF) transfer membranes (Millipore,
USA)
• See blue Plus 2 prestained protein standard (Invitrogen Ltd., UK)
• Polyoxyethylenesorbitan monolaurate (Tween-20, Sigma, UK)
• LumiGLO reagent (luminol chemiluminescent substrate) and peroxide (Cell
Signaling, UK)
• High performance chemiluminesence film (Amersham, USA)
• Lammeli Lysis buffer (2% SDS, 50mM Tris-hydroxymethylaminoethane pH7.5,
5% P-mercaptoethanol)
• Coomassie brilliant blue R-250 protein stain (Pierce, Perbio Science Ltd., UK)
• Destaining reagent (10% (v/v) acetic acid, 30% (v/v) methanol)
• Protein transfer buffer (500mM Bicine, 500mM Bis-Tris, 20.5mM EDTA; pH7.2)
• NuPage MOPS (1M Tris Base, 1M MOPS, 20.5mM EDTA 69.3mM SDS; pH7.7)
or MES (1M Tris Base, 1M MES, 20.5mM EDTA 69.3mM SDS; pH7.3) Running
Buffers for electrophoresis (Invitrogen Ltd., UK)
• Blocking buffer, 5% (w/v) non-fat milk (Marvel) made up in PBS containing
0.1% Tween 20
• Albumin Bovine Serum Fraction V (BSA; Sigma, UK)
• Primary Antibody buffers, 5%, 3% (w/v) non-fat milk (Marvel) or 2% or 5%
(w/v) bovine serum albumin (BSA; Sigma, UK) made up in PBS containing 0.1%
Tween 20
• Secondary Antibody buffers, 5%, 3% (w/v) non-fat milk (Marvel) or 2% (w/v)
BSA (Sigma, UK) made up in PBS containing 0.1% Tween 20
-69-
• Phosphate Buffered Solution (PBS; Di-Sodium hydrogen orthophosphate
dihydrate (Fisher Scientific, UK); Sodium dihydrogen orthophosphate dihydrate
(Fisher Scientific, UK); Sodium Chloride (Fisher Scientific, UK); made up in
ultra high purity water, pH 7.4)
• PBS-Tween (PBS containing 0.1% (v/v) Tween 20)
2.8 Immunohistochemistry
• Agar (VWR International Ltd., UK)
• Freezing microtome: Leitz Kryomat 1700 (Leitz, Germany)
• Heparin (Sigma, UK)
• Paraformaldehyde (Sigma, UK)
• Perfusion pump (Watson-Marlow Ltd., UK)
• Sucrose (Sigma, UK)
• To-Pro-3 iodide, nuclear marker (Molecular Probes, UK)
• Normal goat serum (Vector Laboratories, USA)
• Fish skin gelatin (Sigma, UK)
• Triton X-100 (Sigma, UK)
• Vecta-Shield (Vector Laboratories, USA)
• Glass coverslips (22 x 50mm) (Merck-BDH, UK)
• Glass slides pre-coated with poly-L-lysine (VWR International, UK)
• Fluorescein Tyramide Reagent Kit (Perkin Elmer, USA)
• PBS as above
2.9 Primary Antibodies [see Table 2.2]
• Rabbit polyclonal anti-phospho-[Thrl80/Tyrl82]-p38 MAP kinase (Cell
Signaling, UK)
• Rabbit polyclonal anti-p38 MAP kinase ('pan': phosphorylation state-
independent; Cell Signaling, UK)
• Rabbit polyclonal anti-phospho-[Thrl202/Tyr204]-p42/44 MAP kinase (Cell
Signaling, UK)
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• Rabbit polyclonal anti-p42/44 MAP kinase ('pan': phosphorylation state-
independent; 1: Cell Signaling, UK)
• Rabbit polyclonal anti-NRl (Chemicon, UK)
• Rabbit polyclonal anti-NR2A (Upstate, UK)
• Rabbit polyclonal anti-NR2B (Chemicon, UK)
• Mouse monoclonal anti-PSD-95 (Transduction Labs, USA)
• Mouse monoclonal anti-PSD-95 (Upstate, UK)
• Rabbit polyclonal anti-SAP-97 (Abeam, UK)
• Rabbit polyclonal anti-SAP-102 (Chemicon, UK)
• Rabbit polyclonal anti-PSD-93/Chapsyn 110 (Chemicon, UK)
• Rabbit polyclonal anti-phospho-(Tyr402)-Pyk 2 (Cell Signaling, UK)
• Rabbit polyclonal anti-Pyk 2 (Upstate, UK)
• Mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Chemicon, UK)
2.10 Secondary antibodies [see Table 2.2]
• Goat-anti-rabbit Alexa Fluor 568 (Molecular Probes, UK)
• Peroxidase-linked goat-anti-rabbit (Cell Signaling, UK)
• Peroxidase-linked goat-anti-mouse (Chemicon, UK)
• Peroxidase-linked goat-anti-rabbit (Chemicon, UK)
2.11 Analysis programs
• Leica TCSNT Confocal system (Leica Microsystems, Germany)
• Scion Image (Scion Image Beta 4.02 Win, Scion Corporation, USA)
• LCS-lite software Version 2051347a (Leica Microsystems, Germany)
• Adobe Photoshop Version 7.0 (Adobe Systems Inc., USA)
• SigmaStat for windows v2.03 (SPSS Inc., UK)
• Scan analysis software (Scion Image GelPro, Scion Corporation, USA)
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Table 2.1
Drugs used for intrathecal administration and/or spinal cord incubation
The table presented provides a brief summary of all the drugs used in investigating the
involvement of spinal VPAC2 and NK2 receptors and glially mediated events in the
activation of both p38 and p42/44 MAP kinases in an experimental model of
mononeuropathy (Results presented in Chapter 4). This table provides the name and
source of all drugs in addition to the specific dose used for either intrathecal (IT)
administration or for incubation on the spinal cord (Incubation) and general information
on the action of each compound.
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Antibodies used for western immunoblot and immunohistochemical investigations
The table presented provides a brief summary of all the antibodies used throughout this
thesis (Results presented in Chapter 4, 5 and 6). This table shows the name, source and
product number of all primary and secondary antibodies used for Western immunoblot
(WB) and immunohistocehmical (IHC) investigations in addition to the dilution factor used














































































































All experiments were carried out in accordance with the U.K. Animals (Scientific
Procedures) Act 1986. The use of animals in this thesis was necessary to explore the
underlying mechanisms involved in the development of chronic pain states, which is
crucial for the advancement of novel efficacious analgesics.
3.1 Animals
Studies were carried out using adult male Wistar rats (250-320g), which were housed in
groups of three to five per cage. For studies using mice, adult male and female MF1 mice
either PSD 95SH3W470L mutant or wild-type littermates (20-30g) were housed in groups of
two to six per cage. In all cases free access to water and food was provided and all cages
were housed in a controlled environment of a 12-hour light/dark cycle and a temperature
range of 22-24°C.
3.2. Surgical preparation of animal models
All surgical procedures were carried out under aseptic conditions.
3.2.1 The chronic constriction injury (CCD model of experimental mononeuropathv
Adult male Wistar rats were anaesthetised with halothane and oxygen (oxygen flow rate
of 2L/min), always ensuring that the pinch reflex of the front limb was abolished and
assessing the respiratory rate before continuing with surgery. The right hind limb was
shaved and the skin sterilised by wiping with Hibitane skin disinfectant (0.5% in 70%
alcohol). A small (1cm) skin incision was made over the sciatic nerve at the mid-thigh
level. The sciatic nerve was exposed by blunt dissection and approximately 1cm of the
nerve was freed from surrounding tissues. Using an operating microscope (x40 objective
lens), four chromic cat gut ligatures (4.0) were loosely tied, around the tibial and peroneal
branches of the sciatic nerve leaving the smallest sural branch of the sciatic nerve intact,
at approximately 1mm intervals.
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For studies using mice, due to the greater susceptibility to inhalation anaesthetic adult
mice were anaesthetised with sodium pentobarbital (Sagatal; 0.3ml 25% Sagatal in sterile
saline (0.9%); intraperitoneal injection) and supplemented with halothane and oxygen
(oxygen flow rate of 2L/min), no difference was noted in the post-surgical recovery time
for either methods of anaesthesia, again the pinch reflex of the front limb was ensured to
be abolished and the respiratory rate was assessed before continuing with surgery. The
right hind limb was shaved and the skin sterilised by wiping with Hibitane skin
disinfectant (0.5% in 70% alcohol). A small (0.5cm) skin incision was made over the
sciatic nerve at the mid-thigh level. As with the rats, the sciatic nerve was exposed by
blunt dissection and approximately 0.5cm of the nerve was freed from surrounding
tissues and three chromic cat gut ligatures (5.0) were loosely tied around the tibial and
peroneal branches of the sciatic nerve leaving the smallest sural branch of the sciatic
nerve intact, at approximately 1mm intervals, viewed under an operating microscope
(x40 objective lens).
In both cases the chromic cat gut ligatures were tightened to prevent slippage without
blocking the circulation through the superficial epineurium. The overlying muscle and
skin were closed with resorbable sutures (5.0 vicryl) using a continuous subcutaneous
technique. The wound was re-sterilised with Hibitane to prevent any infection, and the
animals were allowed to recover from surgery and anaesthesia before returning to their
original cages. The animals were checked regularly and allowed five days (in the case of
the rats) and three days (in the case of the mice) to recover before behavioural testing
commenced.
3.2.2 Complete Freund's adjuvant model of experimental persistent inflammation
For studies using adult rats and mice, both were briefly anaesthetised with halothane and
oxygen (oxygen flow rate of 2L/min). Complete Freund's adjuvant (CFA) was injected
subcutaneously into the dorsum surface of the right hind paw, 80pl for the rats and 20pl
for the mice. Control animals were injected with the same volume of saline (0.9%) in the
same manner. The animals were checked regularly and allowed to recover before
behavioural testing commenced 30 minutes after injection.
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3.2.3 Formalin-induced model of inflammatory pain
For studies using adult rats and mice, both were briefly anaesthetised with halothane and
oxygen (oxygen flow rate of 2L/min). Formalin was injected subcutaneously into the
dorsum surface of the right hind paw, 70pi of a 5% solution in saline (0.9%) for the rats
and lOpl of a 1.5% solution in saline (0.9%) for the mice. Control animals were injected
with the same volume of saline (0.9%) in the same manner. Animals were allowed five
minutes to recover from anaesthesia before responses to formalin were assessed.
3.3 Formalin-induced behavioural response
To assess the formalin-induced behavioural response, animals were placed in perspex
cages on a glass table with mirrors in place to ensure the animals hind paws were clearly
visible at all times. The response to formalin is characterised as flinching, flicking and
licking of the affected hind paw. The formalin-induced response was measured as the
number of flinches, flicking and licking per minute and counted every five minutes until
recovery.
3.4 Behavioural Somatosensory Reflex Tests
The behavioural signs investigated represent three different components of neuropathic
pain: mechanical allodynia, cold allodynia and thermal hyperalgesia. Behavioural testing
was carried out prior to surgery to establish a baseline for comparison to post-surgical
values, with values for the uninjured contralateral and injured ipsilateral paw measured
from day five for the rats and day three for the mice following CCI surgery or from 30
minutes following CFA injection. Behavioural testing was carried out to assess the
development and progression of these chronic pain states, animals that displayed injury-
induced behavioural reflex sensitisation were used for further pharmacological or
biochemical study, in order to explore the underlying mechanisms involved in the




Inspections were made on a regular basis, to assess the animal's posture, gait and
condition of the injured hind limb and normal behaviour (for example exploratory,
feeding and grooming behaviours). If any animal displayed signs of autotomy, such as
biting or gnawing of the injured paw or leg (rarely observed), this resulted in immediate
euthanasia. All animals used in this study showed, normal behaviours, posture and gait.
3.4.2 Mechanical allodynia
To assess mechanical allodynia each animal was placed on a metal mesh floor allowing
the experimenter to reach the plantar surface of the hind paw from beneath unobserved by
the animal (Figure 3.1a). The paw withdrawal threshold (PWT) in response to normally
innocuous mechanical stimuli was measured by presenting to the mid-plantar surface of
the hindpaw calibrated Semmes-Weinstein Von Frey filaments, which exert a fixed
bending force ranging from 318.19mN/mm2 to 4830.62 mN/mm2. Each filament was
applied perpendicularly to the mid-plantar surface of the foot until it flexed. The
filaments were applied in ascending order (starting from the weakest) with each
application repeated 10 times at two second intervals. The response was characterized as
a quick paw flick with or without shaking. Threshold was defined as the indentation
pressure (mN/mm2) required to elicit a response/paw withdrawal to at least 5 out of the
10 applications (i.e. to at least 50% of application). Each test was carried out three times
alternatively on each paw with a minimum of five minutes between tests.
3.4.3 Cold allodynia
Cold allodynia was detected by the animal's response to iced water (4°C). Animals were
placed in a perspex box on an aluminium floor (elevated by a wire-mesh stage) where the
depth of the iced water was approximately 1cm above the aluminium floor to ensure that
both the glabrous and hairy skin of the animal's hindpaw were submerged (Figure 3.1b).
The animals were allowed 10 seconds to acclimatise then measurements of the
Suspended Paw Elevation Time (SPET) were taken during a 20 second time period
(Figure 3.1c), that is the number of seconds the animal raised its hind paw above the
water during the test period. Each test was repeated three times with a minimum 10
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minute interval between test periods to allow the animal's paws to return to body
temperature before the next test.
3.4.4 Thermal Hyperalgesia
Animals were placed in perspex cages on a glass table and allowed to acclimatise to their
environment. Thermal hyperalgesia was monitored using a Hargreaves' thermal
apparatus, to determine the paw withdrawal latency (PWL) to a noxious heat stimulus
(42°C). The Hargreaves' thermal apparatus consists of a moveable infra red heat source
connected to a thermal detector and electronic timer (Figure 3.Id). The radiant heat
source was placed under the mid-plantar surface of the animal's hind paw beneath the
glass table and switched on, causing both the timer and heat source to activate, which are
automatically cut off with the withdrawal of the animal's paw. This enables the PWL to
be measured to the nearest 0.1 of a second and a standard cut-off limit of 20 seconds was
employed to ensure there was no tissue damage when the animal did not respond. The
withdrawal response was characterized as a brief paw flick. Testing was carried out five
times alternatively on each paw with a minimum of five minutes between tests.
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Figure 3.1
Apparatus used for assessment of behavioural somatosensory reflex tests
(A) Illustrates the calibrated Semmes-Weinstein Von Frey filaments, which exert a fixed
bending force (mN/mm2) and the elevated metal mesh floor used to assess the paw
withdrawal threshold to mechanical stimuli. (B) Shows the perspex tank used for
measurement of suspended paw elevation time in response to iced water (4°C; at a depth
of approx. 1 cm). (C) Showing an experimental animal (that has undergone a unilateral
CCI of the sciatic nerve, Section 3.2.1) exhibiting an elevated paw in response to the iced
water/cold stimulus. (D) Illustrates the Hargreaves' thermal apparatus used for the
measurement of paw withdrawal latency to a noxious radiant heat source, showing the
moveable infra red heat source connected to a thermal detector and electronic timer. [See
Section 3.4 for information on behavioural somatosensory reflex tests illustrated]
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3.5 Intrathecal administration of drug
Naive animals were used for intrathecal injections of agonists and combinations of
agonist and antagonist/inhibitor. Animals that had undergone a unilateral chronic
constriction injury of the sciatic nerve and were at the peak of neuropathic behavioural
reflex sensitisation were used for intrathecal injections of antagonists/inhibitors. For all
injections, baseline measurements for mechanical allodynia and thermal hyperalgesia
were recorded prior to injection. All animals were briefly anaesthetised with halothane
and oxygen (oxygen flow rate of 2L/min) and injected intrathecally at the L4/5 level of
the spinal cord using a 25-gauge needle microsyringe with the pharmacological agent of
interest at a volume of 50pi in sterile saline. Injections were performed blinded to the
pharmacological agent used so as to eliminate bias. In each experimental group there was
a minimum of six animals used, with no one animal used for more than three injections.
If an animal was injected on more than one occasion, there was a minimum 48-hour
interval between injections with pre-injection behavioural measurements taken to ensure
there was no residual effect from the previous injection. To determine the effects of each
drug on both mechanical allodynia and thermal hyperalgesia, quantitative sensory reflex
testing (as outlined above Section 3.4.2 and 3.4.4) began 15 minutes following injection.
This allowed for recovery from anaesthesia, testing continued every 5 minutes thereafter
until recovery to pre-injection values.
Animals that had undergone chronic constriction injury and were at the peak of
neuropathic behavioural reflex sensitisation were used for intrathecal administration of
the following drugs:
• The p38, p42/44 MAP kinase pathway inhibitors
The p38 MAP kinase inhibitor SB 203580 was injected at a concentration of 5nmol in
sterile saline (0.9%) with 0.3% dimethylformamide (DMF). The p42/44 MAP kinase
pathway inhibitors PD 098059, U 0126 and its less active analogue U 0124 were injected
at a concentration of 2.5nmol in sterile saline (0.9%) with 0.3% DMF, 1.5nmol in sterile




The glial inhibitor propentofylline (PPT) was injected at a concentration of 0.5pmol in
sterile saline (0.9%).
• TNF-a receptor antagonist
The TNF-a receptor peptide antagonist WP9QY was injected at a concentration of 25pg
in sterile saline (0.9%).
• VPACi, VPAC2 and PACi receptor antagonists
The selective VPACi receptor antagonist, [Ac-His1, D-Phe2, Lys15, Arg16, Leu17]-VIP(3-
7)GRF(8-27), VPAC2 receptor antagonist, [des(l-4), Arg16]-Ro 25-1553 and PACi
receptor antagonist, PACAP^g were all injected at a concentration of 0.1 nmol in sterile
saline (0.9%).
• NKi, and NK2 receptor antagonists
The selective NKj receptor antagonist, RP 67580, and NK2 receptor antagonist, SR
48968 were both injected at a concentration of 5nmol in sterile saline (0.9%).
Naive animals were used to assess the effect of intrathecal administration of the
following drugs:
• VPAC2 receptor agonist
The selective VPAC2 receptor agonist, Ro 25-1553 was injected at a concentration of
0.5nmol in sterile saline (0.9%).
• NK2 receptor agonist
The NK2 receptor agonist GR 64349 was injected at a concentration of 1.5nmol in sterile
saline (0.9%).
• Combination of agonist and inhibitor
The following drugs were combined and injected at the same concentration as outlined
above. All combined drug injections were carried out in nai've animals. The VPAC2
receptor agonist Ro 25-1553 was combined with the p38 MAP kinase inhibitor SB
203580. The NK2 receptor agonist GR 64349 was combined with the p42/44 MAP kinase




Animals were terminally anaesthetised under a halothane oxygen mix as outlined above
(section 3.2.1) prior to and during dissection of all tissues, while under anaesthetic a
laminectomy of the lumbar region was performed. The spinal cord from L3 -L6 was
hemisected to separate ipsilateral and contralateral sides in experimental animals, with
spinal cords from naive animals taken intact (unhemisected). Spinal cord samples were
rapidly removed and homogenized in Laemmli lysis buffer on ice in hand-held glass
homogenisers to prepare whole lysates and denatured at 100°C for five minutes, allowed
to cool and stored at -70°C.
3.6.2 Tissue preparation of spinal cord incubated with drug
Animals were terminally anaesthetised under a halothane oxygen mix as outlined above
(section 3.2.1) prior to and during dissection of all tissues, while under anaesthetic a
laminectomy of the lumbar region was performed. Animals were maintained on
anaesthetic, while the spinal cord was incubated with sterile saline (500pl, 0.9%) or with
the pharmacological agent of interest (500pl in sterile saline 0.9%) for 30minutes at room
temperature. After which the spinal cord from L3 -L6 was hemisected to separate
ipsilateral and contralateral sides in experimental animals or in naive animals
unhemisected spinal cords were prepared as outlined above (section 3.6.1).
Naive spinal cords were incubated with the following: sterile saline (0.9%) as a control,
VPAC2 receptor agonist, Ro 25-1553 (30pM), the NK2 receptor agonist, GR 64349
(50pM) or with a combination of the VPAC2 receptor agonist Ro 25-1553 or the NK2
receptor agonist GR 64349 and the glial inhibitor, propentofylline (PPT; lOmM). In
nerve-injured animals (CCI model of experimental mononeuropathy see section 3.2.1; in
animals that were at the peak of neuropathic behavioural reflex sensitisation), the spinal
cords were incubated with the following: sterile saline (0.9%) as a control, the selective
VPAC2 receptor antagonist, [des(l-4), Arg16]-Ro 25-1553 (2pM), the selective NMDA
receptor antagonist, (R)-CPP (lOpM), the selective NK2 receptor antagonist, SR 48968
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(100fj.M), or with the glial inhibitor, propentofylline (PPT; lOmM), the TNF-a receptor
antagonist, WP9QY (0.5mg/ml) or with the TNF-a synthesis inhibitor, thalidomide
(200pM).
3.6.3 Immunobloting procedure
Samples (as prepared above; Section 3.6.1) were separated by electrophoresis on pre-cast
4-12% Bis-Tris Gels using the NuPage XCell SwreLock™ Minicell gel electrophoresis
system, then transferred to polyvinylidene difluoride (PVDF) membranes. Prior to
immunoblotting, membranes were temporarily stained with a prestained standard
(Coomassie brilliant blue R-250 protein stain and destained with destaining reagent (10%
(v/v) acetic acid, 30% (v/v) methanol) to ensure even protein loading and protein transfer.
Membranes were blocked overnight at 4°C in 5% Marvel, containing 0.1% Tween 20
(unless otherwise stated). Blots were washed in phosphate buffered saline (PBS; pH7.4,
containing 0.1% Tween 20), and incubated with antibodies diluted in primary antibody
buffer containing 2% bovine serum albumin (BSA, in PBS containing 0.1% Tween 20) at
room temperature for 90 minutes (unless otherwise stated). Antibodies were used at the
following concentrations: rabbit polyclonal anti-phospho-[Thrl80/Tyrl82]-p38 MAP
kinase (1:250, Cell Signalling) and rabbit polyclonal anti-p38 MAP kinase ('pan':
phosphorylation state-independent; 1:500, Cell Signalling), rabbit polyclonal anti-
phospho-[Thr!202/Tyr204]-p42/44 MAP kinase (1:250, Cell Signalling) and rabbit
polyclonal anti-p42/44 MAP kinase ('pan': phosphorylation state-independent; 1:500,
Cell Signalling), rabbit polyclonal anti-NRl (Chemicon; 1:100; incubated overnight at
4°C), rabbit polyclonal anti-NR2A (Upstate; 1:100; incubated overnight at 4°C), rabbit
polyclonal anti-NR2B (Chemicon; 1:100; incubated overnight at 4°C), mouse
monoclonal anti-PSD-95 (Transduction Labs; 1:100), rabbit polyclonal anti-Sap 97
(Abeam; 1:100; incubated overnight at 4°C), rabbit polyclonal anti-Sap 102 (Chemicon;
1:100; incubated overnight at 4°C), rabbit polyclonal anti-PSD-93/Chapsyn 110
(Chemicon; 1:100; incubated overnight at 4°C in 5% marvel containing 0.1% Tween 20),
rabbit polyclonal anti-phospho-(Tyr402)-Pyk2 (1:100; Cell Signalling; incubated
overnight at 4°C in 5% BSA containing 0.1% Tween 20), rabbit polyclonal anti-Pyk2
(1:100; Upstate; incubated overnight at 4°C in 3% marvel containing 0.1% Tween 20)
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and mouse monoclonal anti-glyceraldehyde -3-phosphate dehydrogenase (GAPDH,
1:750; Chemicon) a ubiquitous housekeeping protein used as a control for protein level
normalisation. In all cases detection was by peroxidase-linked secondary antibodies,
goat-anti-rabbit (1:2000; Cell Signalling), goat-anti-mouse (1:10,000; Chemicon) or goat-
anti-rabbit (1:5000; Chemicon), incubated in 2% BSA containing 0.1% Tween 20 for 50
minutes at room temperature, [except for anti-phospho-(Tyr402)-Pyk2 (Cell Signalling)
where the secondary antibody was incubated in 5% marvel containing 0.1% Tween 20 for
60 minutes at room temperature and anti-Pyk2 (Upstate) with the secondary antibody
incubated in 3% marvel containing 0.1% Tween 20 for 90 minutes at room temperature]




Experimental and nai've animals were terminally anaesthetized with halothane and
oxygen (oxygen flow rate of 2L/min) and were transcardially perfused with 200mls of
heparinised vascular flush (0.1M PBS containing 0.6mg/ml heparin) using a small rotary
pump at 30mls/minute, followed by 250-300mls of fixative solution (0.1M PBS
containing 4% paraformaldehyde). Post perfusion a laminectomy was performed of the
lumbar region and L3-L6 of the spinal cord was dissected out under an operating
microscope (x20 objective lens). Tissue samples were post-fixed with post-fixative
solution (0.1M PBS containing 4% paraformaldehyde) overnight at 4°C, transferred
through increasing concentrations of sucrose solutions (sucrose in 0.1 M PBS) to a 30%
solution overnight, then transferred to a 0.1 M PBS solution and stored at 4°C.
3.7.2 Immunohistochemistrv procedure
Spinal cords were embedded in 0.25% agar (in 0.1M PBS) and sectioned (at -15°C;
40pm thickness) on a freezing micortome (Leitz Kyromat 1700). Experimental spinal
cords were marked in the contralateral ventral horn by a pinhole to identify ipsilateral and
contralateral dorsal horns. Spinal cord sections were transferred to a 36 well plate
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containing 0.1M PBS. The free-floating sections were washed in 0.1M PBS, quenched in
a hydrogen peroxide solution (1.5% in 0.1M PBS) for 20 minutes at room temperature,
followed by an antigen retrieval step of suspending the sections in a 3M Urea solution for
10 minutes at 75°C, and blocked for 90 minutes at room temperature with blocking buffer
(0.5% blocking reagent in 0.1M PBS; part of Fluorescein Tyramide Reagent Kit, Perkin
Elmer). Primary antibody was incubated overnight at room temperature with agitation,
antibodies were used at the following concentrations: mouse monoclonal anti-PSD 95
(Upstate; 1:50 in 0.1M PBS) and rabbit polyclonal anti-Pyk2 (Upstate; 1:50 in 0.1M
PBS). Sections were incubated with the appropriate secondary antibodies in 0.1M PBS
for 90 minutes at room temperature at the following concentrations: fluorescent goat-anti-
rabbit (Alexa Fluor 568; Molecular Probes; 1:1000) and peroxidase-linked goat-anti-
mouse (1:200; Cell Signalling), Sections were washed in 0.1M PBS and incubated in
fluorescein tyramide (amplification reagent) for 25 minutes at room temperature (1:50 in
lx amplification dilutent, part of Fluorescein Tyramide Reagent Kit, Perkin Elmer).
Following washing with 0.1M PBS sections were incubated with To-pro (To-pro-3-
iodide; Molecular Probes; 1:1000) for 1-2 minutes at room temperature. Two final
washes in deionised water were conducted prior to mounting of sections onto pre-coated
microscope slides (with poly-L-lysine) and cover-slipped with Vecta Shield (mounting
medium), sealed with clear varnish and stored at 4°C in a light sensitive box before
confocal microscopy. Control sections were processed as above omitting the primary
antisera (see Figure 3.2 and 3.3).
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3.8 Analysis
3.8.1 Analysis of behavioural studies
In each behavioural study, data was pooled for each test day, with group averages shown
± the standard error of the mean (SEM). For responses to mechanical stimulus (Von Frey
filaments) differences between paw withdrawal thresholds (PWT) ipsilateral to
contralateral were determined by a Wilcoxon test (significance set at p<0.05) and
differences between post-operative and pre-operative values were determined by a
Friedman test on ranks followed by Dunn's post-hoc analysis (significance set at p<0.05).
Tests conducted on mechanical data were non-parametric in nature due to Von Frey
forces being a graded series of forces in intervals. For responses to a noxious thermal
stimulus, differences between paw withdrawal latency (PWL) ipsilateral to contralateral
were determined by a Student's t-test (significance set at p<0.05) and differences
between post-operative and pre-operative values were determined by a one-way repeated
measures ANOVA followed by a Dunnett's post-hoc analysis (significance set at
p<0.05). These tests conducted on thermal data are parametric as thermal data is
continuous. For responses to cold stimulus, differences between suspended paw elevation
time (SPET) scores ipsilateral to contralateral were determined by a Wilcoxon test
(significance set at p<0.05) and differences between post-operative and pre-operative
values were determined by a Friedman test on ranks followed by Dunn's post-hoc
analysis (significance set at p<0.05). In all cases no significant difference was noted in
the contralateral response.
For analysis of the formalin response in mice where the PSD 95SH3W470L mutant response
was compared to wild type littermates response, significant differences were determined
by a student's t-test (significance set at p<0.05) and for the formalin response in rats,
differences between pre-injection to post-injection values were determined by a one way
repeated measures ANOVA followed by Dunnett's post hoc analysis (significance set at
p<0.05).
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3.8.2 Analysis of behavioural studies following intrathecal administration
In each intrathecal study, data was pooled for each test time, with group averages shown
± SEM. For responses to mechanical stimulus (Von Frey filaments), differences between
paw withdrawal thresholds ipsilateral to contralateral were determined by a Wilcoxon test
(significance set at p<0.05) and differences between post-injection and pre-injection
values were determined by a Friedman test on ranks followed by Dunn's post-hoc
analysis (significance set at p<0.05). For thermal behavioural tests differences between
paw withdrawal latencys ipsilateral to contralateral were determined by a Student's t-test
(significance set at p<0.05) and differences between post-injection and pre-injection
values were determined by a one-way repeated measures ANOVA followed by a
Dunnett's post-hoc analysis (significance set at p<0.05). In all cases there was no
significant alteration seen in the contralateral response and full recovery to pre-drug
response levels were observed.
3.8.3 Analysis of western immunobloting studies
Exposed chemiluminescence films were scanned and densitometry was performed using
'Scan Analysis' software, whereby grey levels of positive protein bands and background
grey levels were quantitatively measured, with the absolute numerical values derived
being arbitrary. All densities were measured relative to the ubiquitous housekeeping
enzyme GAPDH and all samples that were compared were run on the same gels or run
under similar conditions. In the case of the phosphorylated form of both p38- and p42/44-
MAP kinases the grey levels were calculated as densitometric ratios against 'pan'
(phosphorylation state-independent) p38- and p42/44-MAP kinase levels.
3.8.4 Analysis of immunohistochemical studies
Spinal cord sections were examined using the Leica TCSNT Confocal system to aquire
single optical section images (slice width 0.8pm) at both low and higher (with x5 and x20
objective lens) magnification. Digital images captured were stored on TDK CD-R media
for analysis using LCS-lite software and Scion Image analysis. Single optical section
images were acquired at low magnification (x5 objective lens) of whole dorsal spinal
cord sections and at high magnification (x20 objective lens) of each spinal dorsal horn.
-90-
Images captured at low magnification, are 2000 x 2000pm in size as such were able to
include both dorsal horns in the one image. Images captured at high magnification are
500 x 500pm in size therefore only lamina I to III of the spinal dorsal horn was captured,
with the lateral aspect of the dorsal horn on each image, that is where the superficial
laminae of the dorsal horn curve in a ventral direction. In analyzing all images the
experimenter was blinded as to whether images were from experimental or naive animals
as all images when captured were labeled with a coded name.
Capturing images using the Leica TCSNT Confocal system involves sequentially
scanning the section with individual lasers to detect fluorescence in each channel
ensuring that any possible spectral bleed through is minimized to produce an accurate
merged image of fluorophore distribution. Control sections were prepared (processed as
experimental sections as outlined above (Section 3.7.2) omitting the primary antisera).
Omitting the primary antisera and labeling the section with each fluorophore acts as a
control for assessing possible spectral bleed through. Sample control sections at low
magnification (x5 objective lens; Figure 3.2) and at higher magnification (x20 objective
lens; Figure 3.3) show a clear signal for the nuclear marker To-pro (blue) whereas the
fluorescent signal for either PSD-95 (green) or Pyk 2 (red) is not observed.
For analysis of the expression of PSD-95 and Pyk 2 in the spinal dorsal horn at low
magnification (x5 objective lens), Scion Image analysis was used to measure the mean
fluorescent intensity of PSD-95 or Pyk 2 in lamina I and II or lamina III, or IV of the
ipsilateral and contralateral sides in CCI injured and naive spinal dorsal horns. Analysis
was carried out within the region's of interest (ROI) that is from the mediolateral region
to the start of the curved lateral region of the dorsal horn, thus focusing the area of
attention on the region of afferent input from the hind limb (see Figure 3.2 for illustration
of ROIs). Analysis was carried out on 8-10 randomly selected sections from each of 4
nai've animals and of 6 CCI injured animals. Within Lamina I and II, the area was
subdivided into three, the mediolateral, intermediate and lateral regions for analysis (see
Figure 3.2). The fluorescence intensity (arbitrary values) was measured, data was pooled
for each experimental group, with the mean fluorescence intensity shown ± SEM (in
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arbitrary units). Differences between fluorescent intensity ipsilateral to contralateral were
determined by a Student's paired t-test (significance set at p<0.05) and differences
between experimental compared to naive were determined by a Student's unpaired t-test
(significance set at p<0.05).
For analysis of the cellular expression of PSD-95 and Pyk 2 in the spinal dorsal horn,
images were captured at higher magnification (x20 objective lens), cells were analyzed in
the ROI from the mediolateral region to the start of the curved lateral region of the dorsal
horn (to focus analysis in the area of afferent input from the hind limb). Analysis was
carried out in the following manner using LCS-lite software; within each ROI, the
number of PSD-95 immunopositive cells (green) and the number of Pyk 2-
immunopositive cells (red) were counted from 6-8 randomly selected sections from each
of 4 naive and 6 CCI injured animals (see Figure 3.3 for illustration of ROIs). The
number of PSD-95 or Pyk 2-immunopositive cells were counted in lamina I, II and III,
(see Figure 3.3) where only cells that were associated with To-pro staining (nuclear
marker) and whose intensity was at least twice background intensity were counted as
immunopositive (data expressed as the total cell number of immunopositive cells per ROI
± SEM). Differences between the number of immunopositive cells in each laminae
ipsilateral compared to contralateral were determined by a Student's paired t-test
(significance set at p<0.05) and experimental compared to naive were assessed by a
Student's unpaired t-test (significance set at p<0.05).
Colocalisation analysis was carried out using a profile tool on the LCS-lite software,
which enabled each cell in the region of interest to be profiled at the same time for the
intensity of each fluorochrome, thereby measuring the intensity of fluorescence of PSD-
95 (green), Pyk2 (red) and the nuclear marker To-pro (blue; see Figure 3.4). Profiling
each cell involved a line of approx. 16pm in length being drawn through each cell and the
intensity of each fluorochrome was measured along the line. The resulting intensities
were graphed and colocalisation was determined to be positive, if the fluorochrome graph
for PSD-95 and Pyk 2 overlapped in a cell that again was To-pro positive and signal was
at least twice background intensity for both PSD-95 and Pyk 2. If the profile of the cell
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showed the intensities not to overlap then the cell was counted as a non-colocalised cell
that was either PSD-95 or Pyk 2 immunopositive. The number of colocalised and non-
colocalised cells were counted within each ROI, namely lamina I, II and III as outlined
above (see Figure 3.3) from 6-8 randomly selected sections from each of 4 naive and 6
CC1 injured animals. Data is expressed as the total number of colocalised cells per ROI ±
SEM or the total number of non-colocalised cells (that are either PSD-95 or Pyk 2
immunopositive) per ROI ± SEM. Differences between the number of colocalised and
non-colocalised cells in each laminae ipsilateral compared to contralateral were
determined by a student's paired t-test (significance set at p<0.05) and experimental




Immunohistochemical analysis of fluorescence intensity in the spinal dorsal horn of
naive and CCI injured animals at low magnification
(A) An example of the spinal cord at low magnification (x5 objective lens) is illustrated
(for demonstration purposes showing PSD-95 immunoreactivity (green)). The image
shows the regions of interest (ROI of equal size) used in analysis; Area A, B and C are
within laminae I and II, showing the (A) mediolateral, (B) intermediate and (C) lateral
regions used for analysis of intensity of PSD-95 and Pyk 2 fluorescent staining. Area D
shows the ROI used to assess intensity of PSD-95 and Pyk 2 fluorescent staining in
lamina III. Area E illustrates the ROI used to assess intensity of PSD-95 and Pyk 2
fluorescent staining in lamina IV. The mean fluorescence intensity (arbitrary values) was
measured using Scion Image analysis, from ipsilateral and contralateral sides in CCI
injured and naive dorsal horns from 8-10 randomly selected sections from naive or CCI
injured animals. (L= Lateral edge of the dorsal horn, M= medial edge of the dorsal hom;
scale bar 45pm; Results of analysis presented in Chapter 6, see Figure 6.7 and 6.8). (B)
Image illustrates a control spinal cord section at low magnification (x5 objective lens),
whereby sections were processed as in Section 3.7.2 omitting the primary antisera but
with the nuclear marker (To-pro; blue), with an example of the pinhole in the
contralateral ventral horn. The signal for To-pro (blue) is clearly visible whereas the
fluorescent signal for either PSD-95 (green) or Pyk 2 (red) cannot be seen. (L= Lateral
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Figure 3.3
Immunohistochemical analysis of the cellular expression of PSD-95 and Pyk 2 in the
spinal dorsal horn of naive and CCI injured animals
(A) An example image of the spinal dorsal horn with boundaries marked for Lamina I, II
and III used in counting PSD-95 or Pyk 2 immunopositive cells is illustrated (for
demonstration purposes showing PSD-95 immunoreactivity (green) and To-pro
immunoreactivity (blue)). The total numbers of PSD-95 and Pan Pyk 2 immunopositive
cells were counted in lamina I to III, where only cells that were associated with To-pro
staining (nuclear marker) and whose intensity was at least twice background intensity
were counted as immunopositive using LCS-Lite software, from 6-8 randomly selected
sections per 4 naive animals and 6 CCI injured animals. (L= Lateral edge of the dorsal
horn; scale bar 20pm; Results of analysis presented in Chapter 6, see Figure 6.9 to 6.12).
(B) Image illustrates a control spinal cord section, whereby sections were processed as in
Section 3.7.2 omitting the primary antisera, captured at higher magnification (x20
objective lens). The spinal dorsal horn is visible with a strong signal for To-pro (blue),
and with no clear fluorescent signal for either PSD-95 (green) or Pyk 2 (red) observed,
when compared to signal observed in experimental sections (see Figure 6.9 and 6.11 for




Immunohistochemical analysis of the colocalisation of PSD-95 and Pyk 2 in the
spinal dorsal horn of naive and CCI injured animals
The images illustrate sample cells from Lamina II (for demonstration purposes) of the
spinal dorsal horn showing PSD-95 (green), Pyk 2 (red) and To-pro (nuclear marker;
blue) immunoreactivity. Colocalisation was determined by profiling each cell using LCS-
Lite software, whereby the intensity of each fluorochrome was measured in each cell and
graphed, the corresponding fluorochrome intensity graphs of each cell is shown below
each image. The graphs show the intensity of each fluorochrome channel, either green
(PSD-95), red (Pyk 2) or blue (Nuclear marker) on the y-axis and the length of the profile
line drawn on the x-axis (16pm). (A) An example of a PSD-95 immunopositive cell with
the corresponding graphs of each fluorochrome below. The blue channel (nuclear marker)
shows the cell is To-pro positive, the red channel (Pyk 2) shows that the fluorescent
intensity is not twice background, whereas the green channel (PSD-95) shows fluorescent
intensity to be at least twice that of background level, thereby demonstrating this cell to
be PSD-95 immunopositive. (B) An example of a Pyk 2 immunopositive cell with the
corresponding graphs of each fluorochrome below. The blue channel (nuclear marker)
shows the cell is To-pro positive, the red channel (Pyk 2) shows fluorescent intensity is at
least twice that of background level, while the green channel (PSD-95) illustrates the
fluorescent intensity is not twice background, thereby demonstrating this cell to be Pyk 2
immunopositive. (C) An example of a colocalised cell with the corresponding graphs of
each fluorochrome below. The blue channel (nuclear marker) shows the cell is To-pro
positive, the red channel (Pyk 2) and the green channel (PSD-95) show fluorescent
intensity at least twice that of background level, the graphs also illustrates that the red and
green fluorescent signal overlap indicating that PSD-95 is colocalised with Pyk 2 in this
















4. Involvement of spinal VPAC2 and NK2 receptors and glially-mediated events in
the activation of both p38 and p42/44 MAP kinases in an experimental model of
mononeuropathy
4.1 Introduction
Mitogen-activated protein kinases (MAP kinases) are serine/threonine protein kinases
that are instrumental in many important intracellular signalling pathways transmitting
signals from the cell surface to the nucleus (reviewed in Section 1.7.3; Derkinderen et al.,
1999). These kinases are localized in the cytoplasm until activated by dual
phosphorylation on both threonine and tyrosine residues (Raingeaud et al., 1995; Seger
and Krebs, 1995; Widmann et al., 1999). The focus of this study was to look at the
involvement of two members of the MAP kinase family, firstly the p42/44 MAP kinases,
known also as extracellular signal regulated kinase (ERK), with ERK1 being p44 MAP
kinase and ERK2 being p42 MAP kinase and secondly the p38 MAP kinase. The p42/44
MAP kinases are known to be one of the intracellular signalling pathways implicated in
neuronal plasticity, such as long-term potentiation, learning and memory (Impey et al.,
1999; Sweatt, 2001). It is thought p38 MAP kinase exerts effects in the hippocampus that
may oppose that of p42/44 MAP kinase, indeed the p38 MAP kinase pathway has been
shown to be involved in the induction of metabotropic glutamate receptor-dependent
long-term depression (Bolshakov et al., 2000). Chronic pain also involves neuronal
plasticity that leads to the development of a hyperalgesic state in spinal cord sensory
neurons. Although repetitive afferent activity plays a key part in this, multiple mediators
are involved and the changes are heterosynaptic, so the process is not identical to LTP.
Nevertheless, there is accumulating evidence that both the p42/44 and p38 classes of the
MAP kinase family are believed to be involved in the mechanisms of sensitisation in
chronic pain states.
Peripheral inflammation and nerve injury induce activation of p38 MAP kinase in
primary sensory neurons of the dorsal root ganglion (Ji et al., 2002b). In addition to this,
peripheral inflammation and nerve injury also activate p38 MAP kinase in the dorsal horn
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of the spinal cord ipsilateral to injury (Jin et al., 2003; Kim et al., 2002; Svensson et al.,
2003). Inhibition of p38 MAP kinase reduces inflammation and nerve injury-induced
behavioural sensitisation (Ji et al., 2002b; Jin et al., 2003; Schafers et al., 2003). It has
also been shown that p42/44 MAP kinases are activated in spinal dorsal horn neurons
following selective C-fibre stimulation (Ji et al., 1999). A number of studies have
revealed that peripheral inflammation results in phosphorylation of p42/44 MAP kinase
in the spinal dorsal horn and inflammatory behavioural sensitisation is prevented by use
of p42/44 MAP kinase inhibitors (Galan et al., 2002; Ji et al., 1999; Ji et al., 2002a;
Sammons et al., 2000). It has also been demonstrated recently that p42/44 MAP kinase is
activated following peripheral nerve injury in both dorsal spinal cord and primary sensory
neurons (Obata et al., 2004; Zhuang et al., 2005) and noxious stimulation similarly
induces phosphorylation of p42/44 MAP kinase in the trigeminal nucleus (Huang et al.,
2000). Activation of both p38 and p42/44 MAP kinases in the spinal dorsal horn
following nerve injury is believed to be localised not only to neurons but also to spinal
glial cells (Jin et al., 2003; Ma and Quirion, 2002; Tsuda et al., 2004; Zhuang et al.,
2005). Glial cells are non-neuronal cells, which are not overtly electrically excitable; the
major types in the central nervous system are astrocytes, oligodendrocytes, and microglia,
which are traditionally thought to play a supportive role to neurons. Following peripheral
inflammation and nerve injury it has been shown that p38 MAP kinase activation can be
localised to microglia (Jin et al., 2003 ;Kawasaki et al., 1997; Kim et al., 2002; Svensson
et al., 2003; Tsuda et al., 2004) and activation of p42/44 MAP kinase has been shown in
astrocytes (Ma and Quirion, 2002), with a more recent study reporting activation of
p42/44 MAP kinase occurring in both microglia and astrocytes following nerve injury
(Zhuang et al., 2005).
Pain hypersensitivity has previously been thought to result exclusively from altered
neuronal activity, however the activation of spinal cord glial cells, including microglia
and astrocytes, has increasingly been implicated in the pathogenesis of pain (DeLeo and
Yezierski, 2001; Meller et al., 1994; Watkins et al., 1997; Watkins et al., 2001b; Watkins
et al., 2001a). The idea that glial cells could be activated (and be functionally important)
in pain states originated when peripheral nerve damage was shown to activate spinal cord
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glia and that this activation was inhibited by an NMDA receptor antagonist that also
inhibited the behavioural sensitisation observed (Garrison et al., 1991; Garrison et al.,
1994). This was the first study to link glial activation to the functional outcome
(behavioural sensitisation) of peripheral nerve injury. To discover whether glia are
necessary for the development of behavioural sensitisation, several studies have
investigated whether such sensitisation would occur if glial function was disrupted. Two
inhibitors were utilised, firstly fluorocitrate, which disrupts glial function and secondly
minocycline, which prevents the activation of microglia in particular; both agents were
effective in attenuating allodynia and hyperalgesia in various nerve injury models
(Ledeboer et al., 2005; Meller et al., 1994; Milligan et al., 2003; Raghavendra et al.,
2003a; Watkins et al., 1997).
It is not completely understood how activation of spinal glia contributes to hyperalgesia
and allodynia; which substances glia release to act on neurons and the subsequent actions
of these substances are not clear and in need of further investigation. The actions of these
substances could be manifold, such as acting directly on neurons to increase excitability,
acting to induce the release of other transmitters that then influence nociceptive neurons
or by acting to upregulate neuronal receptors. Activated glia, for example, can release the
pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-oc), interleukin-1 (IL-1)
and interleukin-6 (IL-6), which can activate neurons as well as glia via binding to specific
receptors on these cells (Vitkovic et al., 2000), suggesting a possible way in which glia
can transmit signals to neurons. A selective inhibitor of TNF-a synthesis, thalidomide,
has proven to be effective in delaying sensitisation development induced by peripheral
nerve injury (George et al., 2000; Sommer et al., 1998a). Inhibition of these pro¬
inflammatory cytokines, by intrathecal injection of antagonists also prevented or reversed
allodynia and hyperalgesia in models of inflammation and nerve injury (Milligan et al.,
2003; Sweitzer et al., 2001a; Watkins et al., 1997), suggesting that these proteins induced
by glial activation may be involved in the maintenance of behavioural sensitisation
observed in such pain models. In addition to this, the inhibitor of glial-generation of pro¬
inflammatory cytokines, propentofylline, which has been shown to reduce microglial and
astrocyte activation in the spinal cord, was also reported to have an analgesic effect on
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sensitisation caused by nerve injury (Raghavendra et al., 2003b; Sweitzer et al., 2001b).
Another approach to control the effects of pro-inflammatory cytokines is to block the
intracellular pathways that are activated upon the binding of these cytokines to their
receptors. Although many cascades are activated, one known pathway, which has been
implicated in both pro-inflammatory cytokine signalling and production, is the p38 MAP
kinase cascade (Clark et al., 2003; Watkins et al., 1999). Indeed it has recently been
demonstrated that blockade of TNF-a can reduce nerve injury-induced p38 activation
(Svensson et al., 2005).
A number of events can result in the downstream activation of the p38 and p42/44 MAP
kinase pathways, for example an increase in intracellular calcium, pro-inflammatory
cytokines (which can be released by activated glia), activation of calcium-permeable
ionotropic glutamate receptors such as the NMDA receptor (Kawasaki et al., 1997; Xia et
al., 1996), as well as a number of G protein-coupled receptors (GPCRs) (Marinissen and
Gutkind, 2001; Yamauchi et al., 1997). As previously elaborated (Section 1.4.2 and
1.7.3) the NMDA receptor is crucially involved in sensitisation of spinal dorsal horn
neurons (Coderre and Melzack, 1992; Davies and Lodge, 1987; Dickenson and Sullivan,
1987; Suzuki et al., 2001; Woolf and Thompson, 1991). Examples of GPCRs that may be
involved include the peptidergic GPCRs for neurokinin peptides (NK receptors) and for
vasoactive intestinal polypeptide (VPAC and PAC receptors). Both of these types of
peptidergic receptor, which were reviewed in chapter one (Section 1.4.4) are importantly
involved in nociception and behavioural sensitisation (Coderre and Melzack, 1992;
Dickinson and Fleetwood-Walker, 1999; Laird et al., 1993). The neurokinin receptors
(NKi, NK2, and NK3) are activated by the tachykinins substance P (SP), neurokinin A
(NKA) and neurokinin B (NKB) respectively. The focus of this investigation is the NK2
receptor whose ligand NKA, is localised to unmyelinated C-fibres, is capable of
producing spinal hyperexcitability and depletion of which occurs following nerve
transection (Dalsgaard et al., 1985; Hokfelt et al., 1994; Ogawa et al., 1985; Xu et al.,
1991). NK2 receptor antagonists have been demonstrated to block both the increased
dorsal horn neuron excitability and behavioural sensitisation following nerve damage
(Coudore-Civiale et al., 1998; Fleetwood-Walker et al., 1990; Yashpal et al., 1996). NK2
- 103 -
receptors are located in the spinal cord where a proportion are believed to be localised to
astrocytes (Quirion and Davey, 1988; Zerari et al., 1998). There are three receptors that
respond to the excitatory peptide VIP, namely the VPAQ, the VPAC2 and PAQ
receptors, in the spinal cord. The expression of VIP in fine afferents and of the VPAC2
receptor in the spinal dorsal horn increases following nerve injury (Dickinson et al., 1999;
Nahin et al., 1994). The VPAC2 receptor (in addition to the other VPAC and PAC
receptors) has also been demonstrated to be localised to astrocytes (Brenneman et al.,
1990). As a result of these investigations showing that the VPAC2 receptor is upregulated
in neuropathic pain states, this receptor will be focused on in this investigation. (Grimaldi
and Cavallaro, 1999; Jaworski, 2000; Joo et al., 2004).
This study aims to investigate the activation of both the p38 and p42/44 MAP kinases in
the spinal cord following the induction of an experimental model of mononeuropathy and
to explore their functional role in behavioural sensitisation as a result of such nerve
injury. The contribution of the NK2, VPAC2 and NMDA receptors and spinal glia to the
effects of nerve injury-induced activation of both the p38 and p42/44 MAP kinases was
also assessed.
4.2 Methods
Experiments were carried out using adult male Wistar rats (180-250g). As detailed in
Chapter three; Animals (n=25) underwent a unilateral chronic constriction injury to the
sciatic nerve, a model of experimental mononeuropathy (CCI; Section 3.2.1). All animals
were assessed behaviourally prior to surgery (to obtain baseline values) and post surgery
(from day 6) until recovery (day 19-25 post surgery) from CCI induced-injury (Section
3.4). All animals were tested for signs of mechanical allodynia using calibrated Von Frey
filaments (Section 3.4.2) and for signs of thermal hyperalgesia using the Hargreaves'
thermal apparatus (Section 3.4.4) and for cold allodynia by use of iced water (Section
3.4.3). For analysis of the effects of intrathecal administration of specific inhibitors,
receptor antagonists and agonists on somatosensory behavioural reflexes; naive animals
were used for intrathecal injections of receptor agonists and combinations of agonist and
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inhibitor and animals that had undergone chronic constriction injury and were at the peak
of neuropathic behavioural reflex sensitisation were used for intrathecal injections of
receptor antagonists and inhibitors.
Prior to intrathecal injection of drugs, measurements of mechanical allodynia (Section
3.4.2) and thermal hyperalgesia (Section 3.4.4) were recorded to obtain baseline values.
All animals were briefly anaesthetised with halothane and oxygen and injected
intrathecally at the L4/5 level of the spinal cord with the pharmacological agent of
interest (Section 3.5). To determine the effects of each drug, quantitative sensory reflex
testing began 15 minutes post injection for signs of mechanical allodynia (Section 3.4.2)
and thermal hyperalgesia (Section 3.4.4), with testing continuing every 5 minutes
thereafter until recovery to pre-injection values. The following drugs were used on
animals displaying peak behavioural reflex sensitisation following CCI: MAPK pathway
inhibitors, p38 MAP kinase inhibitor, SB 203580 (5nmol; n=6) and p42/44 MAP kinase
pathway inhibitors PD 098059 (2.5nmol; n=6), U 0126 (1.5nmol; n=8) and its less active
analogue U 0124 (1.5nmol; n=6; Section 3.5.1). The glial inhibitor propentofylline (PPT;
0.5pmol; n=5; Section 3.5.2). The TNF-a receptor antagonist WP9QY (25pg; n=5;
Section 3.5.3). The selective VPAC2 receptor antagonist ([des(l-4), Arg'6]-Ro 25-1553);
0.1 nmol; n=7), the VPACi receptor antagonist ([Ac-His1, D-Phe2, Lys15, Arg16, Leu17]-
VIP(3-7)GRF(8-27); 0.1 nmol; n=6) and the PACi receptor antagonist ((PACAP6-38); 0.1
nmol; n=6; Section 3.5.3). The antagonist for NK] (RP 67580; 5 nmol; n=6; Section
3.5.3) and for NK2 (SR 48968; 5 nmol; n=5; Section 3.5.3) receptors. The following
drugs were used on naive animals: The selective VPAC2 receptor agonist, (Ro 25-1553;
0.5 nmol; n=6; Section 3.5.4). The NK2 receptor agonist (GR 64349; 1.5 nmol; n=6;
Section 3.5.5). The following combinations of drugs were also assessed: The VPAC2
receptor agonist (Ro 25-1553; 0.5 nmol) was combined with the p38 MAP kinase
inhibitor (SB 203580; 5nmol; n=6; Section 3.5.6) and the NK2 receptor agonist (GR
64349; 1.5 nmol) was combined with the p42/44 MAP kinase pathway inhibitor (U 0126;
1.5nmol; n=6; Section 3.5.6). The effects of the intrathecal administration of the drugs
were analysed as described above (Section 3.8.2).
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Using phospho-specific (activation state-dependent) antibodies, the expression of total
and activated p38 MAP kinase and of total and activated p42/44 MAP kinase proteins in
the spinal cord was assessed in naive (n=5) and in animals displaying peak behavioural
reflex sensitisation following CCI nerve injury (n=5). Animals were terminally
anaesthetised prior to and during dissection of all tissues and a laminectomy of the
lumbar region of the rats was performed and spinal cord tissue was homogenised in
Laemmli lysis buffer to prepare spinal cord extracts (Section 3.6.1). In the case of
incubation of drugs on the spinal cord, animals were terminally anaesthetised prior to and
during dissection of all tissues, following a laminectomy the spinal cord was incubated
with saline or of the pharmacological agent of interest (Section 3.6.2) then spinal cord
tissue was homogenised in Laemmli lysis buffer to prepare the spinal cord extracts
(Section 3.6.1). The following drugs were incubated on naive spinal cords: saline (0.9%;
n=5), the agonists for VPAC2 receptor (Ro 25-1553; 30 pM; n=5), the NK2 receptor
agonist (GR 64349; 50 pM; n=5) and a combination of the VPAC2 receptor agonist (Ro
25-1553; 30 pM) or the NK2 receptor agonist (GR 64349; 50 pM) with the glial inhibitor,
propentofylline (PPT; 10 mM; n=5; Section 3.6.2). In nerve-injured (CCI see section
3.2.1) animals, spinal cords were incubated with the following: saline (0.9%; n=5), the
VPAC2 receptor antagonist ([des(l-4), arg16]-Ro 25-1553; 2pM; n=5), the NK2 receptor
antagonist (SR 48968; lOOpM; n=5), the NMDA receptor antagonist, ((R)-CPP; 10 pM;
n=5), the glial inhibitor, propentofylline (PPT; lOmM; n=5) and with the TNF-a receptor
antagonist (WP9QY; 0.5mg/ml; n=5) or with the TNF-a synthesis inhibitor, thalidomide
(200pM; n=5; Section 3.6.2). Prepared spinal cord extracts were then separated by
electrophoresis and transferred to PVDF membranes, blocked and probed for rabbit
polyclonal anti-phospho-[Thrl80/Tyrl82]-p38 MAP kinase, rabbit polyclonal anti-p38
MAP kinase ('pan': phosphorylation state-independent), as well as rabbit polyclonal anti-
phospho-[Thr202/Tyr204]-p42/44 MAP kinase and rabbit polyclonal anti-p42/44 MAP
kinase ('pan': phosphorylation state-independent) and detected by peroxidase-1 inked
secondary antibodies (goat-anti-rabbit) and enhanced chemiluminescence (Section 3.6.4).
Densitometry was performed to measure quantitatively the grey levels of positive protein
bands and background grey levels to give a ratio of phosphorylated p38 or p42/44 to total
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(pan) p38 or p42/44 MAP kinase (with the absolute numerical values derived being
arbitrary; Section 3.8.3).
4.3 Results
4.3.1 Analysis of the development of behavioural reflex sensitisation ipsilateral to
sciatic nerve injury in the chronic constriction injury (CCI) model of experimental
mononeuropathy.
The majority of nerve-injured animals showed the behavioural changes characteristic of
the CCI model. All of the animals that underwent CCI surgery (Section 3.2.1) held the
affected limb in a protective manner, keeping it held flexed with claws tightly clasped.
The animals developed a limp gait and favoured the contralateral hind limb in
locomotion. These abnormalities are thought to be indications of spontaneous pain71.
Apart from these changes post-operative animals appeared healthy, had no signs of
weight loss and were handled without any distress being evident. During this study none
of the animals developed any signs of autotomy.
Thermal hyperalgesia [see Figure 4.1 A]
All animals were behaviourally tested for signs of thermal hyperalgesia, using the
Hargreaves' thermal apparatus (Section 3.4.4). In a series of experiments designed to
characterise the behavioural reflex changes occurring, baseline (pre-surgical) paw
withdrawal latency (PWL) was measured as ipsilateral, 13.0 ± 1.8 seconds and
contralateral 12.8 ± 1.7 seconds (mean latency ± SEM ; n=25). At all time points from
the sixth day until the twenty fourth day post-surgery, all animals showed significantly
reduced PWL ipsilateral to the injury as compared to the contralateral side (p<0.05 by
Student's t-test) and a significant reduction in PWL was also seen between post-surgical
and pre-surgery values (p<0.05; One Way Repeated Measures ANOVA followed by
Dunnett's post-hoc analysis), no significant difference remained in the PWL by the
twenty fifth day post-surgery. All animals reached a peak of thermal hyperalgesia
between the thirteenth and nineteenth days post-surgery when the ipsilateral PWL was
3.4 ± 0.1 seconds and contralateral was 11.9 ± 1.2 seconds (mean latency ± SEM). The
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contralateral PWL showed no significant alterations in its response. In addition to
developing such a reduced ipsilateral response to a noxious heat stimulus, the animals
also altered their response from a rapid flick of the hind paw returning to a resting posture
(observed in pre-operative animals) to that of a flick where the animals tended to hold the
limb elevated for a longer period or shake and or lick the affected paw before returning to
a resting posture (observed in post-operative animals).
Mechanical allodynia [see Figure 4.1 B]
All animals were tested for signs of mechanical allodynia using calibrated Von Frey
filaments (Section 3.4.2). The baseline (pre-surgical) paw withdrawal threshold (PWT)
required to elicit a paw withdrawal response was ipsilateral 4831 ± 0 mN/mm2 and
contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM; n=25). The baseline values here
with zero error bars is due to the sensitivity of the Von Frey apparatus, which have a wide
range of forces, with each filament having a fixed bending force, here a force of 4381
mN/mm2 was required to elicit a paw withdrawal and a lower graded force applied to the
mid-plantar hindpaw could not elicit such a paw withdrawal. The Von Frey filaments
range of forces is not discreet enough to detect At all time points from the sixth day until
the nineteenth day post-surgery, all animals demonstrated an increased sensitivity to
mechanical stimuli with a significantly reduced PWT ipsilateral to the injury as compared
to the contralateral side (p<0.05 Wilcoxon test) and a significant reduction in PWT was
also seen between post-surgical and pre-surgery values (p<0.05; Friedman test on ranks
followed by Dunn's post-hoc analysis). Animals reached a peak of mechanical allodynia
around the fourteenth day post-surgery when the ipsilateral PWT was 1429 ± 117
mN/mm2 and the contralateral was 4831 ± 44 mN/mm2 (mean threshold ± SEM).
Contralateral PWT responses showed no significant alterations.
Cold allodynia [see Figure 4.1 C]
All animals were tested for signs of cold allodynia by detecting the animal's response to
iced water (4°C; Section 3.4.3), measuring the Suspended Paw Elevation Time (SPET)
during a 20 second time period. Prior to surgery naive rats showed no behavioural
response to iced water with both an ipsilateral and contralateral baseline value of 0 ± 0
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seconds (mean SPET ± SEM; n=25). At all time points from the sixth day until the
nineteenth day post-surgery, all animals demonstrated an increased sensitivity to a cold
stimulus with a significantly increased SPET ipsilateral to the injury (for example to 7.0 ±
0.6 seconds [mean SPET ± SEM] on day eight post nerve injury) as compared to the
contralateral side (of 0 ± 0 seconds [mean SPET ± SEM]; p<0.05; Wilcoxon test) and a
significant increase in SPET was also seen between post-surgical and pre-surgery values
(p<0.05; Friedman test on ranks followed by Dunn's post-hoc analysis). Animals reached
a peak of cold allodynia around the thirteenth day post-surgery when the ipsilateral SPET
was 14.0 ±1.3 mN/mm2 and contralateral remained unaffected at 0 ± 0 SPET (mean ±
SEM responses). No significant increases were observed in the SPET response of the
contralateral limb.
4.3.2 Intrathecal administration of either the p38 or p42/44 MAP kinase pathway
inhibitors attenuated nerve-injury induced behavioural reflex sensitisation
The effects of the intrathecal administration of the p38 MAP kinase inhibitor, SB 203580
or the p42/44 MAP kinase pathway inhibitors, PD 098059 or U 0126 (and its less active
analogue U 0124) on nerve injury-induced thermal hyperalgesia and mechanical
allodynia were assessed. Intrathecal administration of all drugs was carried out in animals
that displayed peak ipsilateral behavioural reflex sensitisation, with the effects of all
drugs being assessed until recovery to pre-injection values. None of the drugs tested had
any significant effects on responses from the contralateral hindpaw. Previous series of
experiments in the lab had shown that intrathecal injection of the vehicle used for these
experiments (0-0.3% dimethylformamide (DMF) in saline) had no effect on any
behavioural reflex responses in CCI or naive animals with all animals assessed here and
previously being of the same age, sex, weight and strain it was felt unwarranted here to
repeat such experiments again.
The p38 MAP kinase inhibitor SB 203580 [see Figure 4.2 A and B]
The p38 MAP kinase inhibitor SB 203580 (5nmol) was injected in animals at the peak of
ipsilateral behavioural reflex sensitisation following CCI. The baseline (pre-injection)
paw withdrawal latency (PWL) was measured as ipsilateral, 9.4 ± 0.5 seconds and
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contralateral 14.8 ± 1.3 seconds (mean latency ± SEM; n=6). Injection of SB 203580
caused a significant reversal of the thermal hyperalgesia that had been seen prior to
injection, for up to 75 min post-injection (f p<0.05; One Way Repeated Measures
ANOVA followed by Dunnett's post-hoc analysis), with maximal reversal of ipsilateral
thermal hyperalgesia to 18.1 ± 0.7 seconds and contralateral was 17.3 ± 1.2 seconds
(mean latency ± SEM) at 35 minutes post injection. The baseline (pre-injection) paw
withdrawal threshold (PWT) required to elicit a response was ipsilateral 1610 ± 273
mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM; n=6). Injection of
SB 203580 caused a significant reversal of the mechanical allodynia seen prior to
injection for 55 minutes post-injection (t p<0.05; Friedman test on ranks followed by
Dunn's pos- hoc analysis), with maximal reversal of ipsilateral mechanical allodynia to
3929 ± 368 mN/mm2 and contralateral was 4831 ± 0 mN/mm2 (mean threshold ± SEM)
at 15 minutes post injection.
The p42/44 MAP kinase pathway inhibitor PD 098059 [see Figure 4.2 C and D]
The p42/44 MAP kinase pathway inhibitor PD 098059 (2.5nmol) was injected in animals
at the peak of ipsilateral behavioural reflex sensitisation following CCI. The baseline
(pre-injection) paw withdrawal latency (PWL) was measured as ipsilateral, 9.6 ± 0.4
seconds and contralateral 15.5 ± 0.3 seconds (mean latency ± SEM; n=6). Injection of PD
098059 caused a significant reversal of the thermal hyperalgesia that had been seen prior
to injection, for up to 55 min post-injection (+ p<0.05; One Way Repeated Measures
ANOVA followed by Dunnett's post-hoc analysis), with maximal reversal of ipsilateral
thermal hyperalgesia to 17.2 ± 1.1 seconds and contralateral was 15.4 ± 0.5 seconds
(mean latency ± SEM) at 20 minutes post injection. The baseline (pre-injection) paw
withdrawal threshold (PWT) required to elicit a response was ipsilateral 978 ± 126
mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM; n=6). Injection of
PD 098059 caused a significant reversal of the mechanical allodynia seen prior to
injection for 40 minutes post-injection (f p<0.05; Friedman test on ranks followed by
Dunn's post-hoc analysis), with maximal reversal of ipsilateral mechanical allodynia to
3929 ± 368 mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM) at 35
minutes post injection.
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The p42/44 MAP kinase pathway inhibitor U 0126 [see Figure 4.3 A and B]
The p42/44 MAP kinase pathway inhibitor U 0126 (1.5nmol) was injected in animals at
the peak of ipsilateral behavioural reflex sensitisation following CCI. The baseline (pre-
injection) paw withdrawal latency (PWL) was measured as ipsilateral, 8.8 ± 0.5 seconds
and contralateral 13.2 ±1.4 seconds (mean latency ± SEM; n=8). Injection of U 0126
caused a significant reversal of the thermal hyperalgesia that had been seen prior to
injection, for up to 60 min post-injection (f p<0.05; One Way Repeated Measures
ANOVA followed by Dunnett's post-hoc analysis), with maximal reversal of ipsilateral
thermal hyperalgesia to 19.1 ± 0.6 seconds and contralateral was 16.2 ± 3.1 seconds
(mean latency ± SEM) at 25 minutes post injection. The baseline (pre-injection) paw
withdrawal threshold (PWT) required to elicit a response was ipsilateral 1294 ± 182
mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM; n=8). Injection of
U 0126 caused a significant reversal of the mechanical allodynia seen prior to injection
for 35 minutes post-injection (f p<0.05; Friedman test on ranks followed by Dunn's post-
hoc analysis), with maximal reversal of ipsilateral mechanical allodynia to 3274 ±658
mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM) at 15 minutes
post injection.
U 0124, an less active analogue of U 0126 [see Figure 4.3 C and D]
The less active analogue of U 0126, U 0124 (1.5nmol) was injected in animals at the peak
of ipsilateral behavioural reflex sensitisation following CCI. The baseline (pre-injection)
paw withdrawal latency (PWL) was measured as ipsilateral, 9.2 ± 0.7 seconds and
contralateral 17.3 ±0.1 seconds (mean latency ± SEM; n=6). Injection of U 0124 caused
a significant reversal of the thermal hyperalgesia that had been seen prior to injection, at
20-25 minutes post-injection (t p<0.05; One Way Repeated Measures ANOVA followed
by Dunnett's post-hoc analysis), with maximal reversal of ipsilateral thermal hyperalgesia
to 13.1 ± 3.0 seconds and contralateral 18.1 ± 1.1 seconds (mean latency ± SEM) at 20
minutes post injection. This reversal of thermal hyperalgesia seen was to a very much
smaller extent than that seen with the active compound U 0126 and indeed had a greater
error margin. The baseline (pre-injection) paw withdrawal threshold (PWT) required to
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elicit a response was ipsilateral 1827 ± 286 mN/mm2 and contralateral 4831 ± 0 mN/mm2
(mean threshold ± SEM; n=6). Injection of U 0124 did not cause a significant reversal of
the mechanical allodynia seen prior to injection.
4.3.3 The activation of p38 and p42/44 MAP kinases following nerve injury
compared to naive controls [see Figure 4.4 and Table 4.1 A]
The levels of phosphorylated (activated) p38 and p42/44 and corresponding pan (i.e.
total) p38 and p42/44 expression in the spinal cord extracts of animals displaying peak
behavioural reflex sensitisation following CCI were assessed by immunoblot, on the
ipsilateral (Ipsi) and contralateral (Con) sides of nerve injured animals and in naive
animals. Following CCI there was an ipsilateral increase in the level of phospho-p38 and
phospho-p42/44 compared to the contralateral side and naive animals. No significant
alterations occurred in the overall levels of p38 (pan-p38) or p42/44 (pan-p42/44) as a
result of nerve injury. The densitometric ratio of phosphorylated to pan p38
immunoreactivity showed a significant increase, due to CCI to 63.5 ± 5.7 arbitrary
density units ipsilateral compared to contralateral value of 48.4 ± 6.2 arbitrary density
units and naive value of 44.6 ± 4.6 arbitrary density units (mean ± SEM; values derived
from quantitative densitometry; p<0.05; Wilcoxon test; n=5 in all cases). The
densitometric ratio of phosphorylated to pan p42/44 immunoreactivity also showed a
significant increase due to CCI, to 56.1 ± 4.8 arbitrary density units ipsilateral compared
to contralateral value of 35.9 ± 3.6 arbitrary density units and naive value of 39.6 ± 7.1
arbitrary density units (mean ± SEM; p<0.05 Wilcoxon test; n=5 in all cases). The levels
of phosphorylated p38 expression and p42/44 expression on the contralateral side of CCI
were not significantly different from those in naive animals.
4.3.4 Intrathecal administration of either the glial inhibitor propentofvlline (PPT) or
the TNF-a receptor antagonist (WP9QY) attenuated nerve-injury induced
behavioural reflex sensitisation
The effects of intrathecal administration of the glial inhibitor propentofylline, PPT and of
the TNF-a receptor antagonist, WP9QY on nerve injury-induced thermal hyperalgesia
and mechanical allodynia were assessed. Intrathecal injections were made in animals that
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displayed peak ipsilateral behavioural reflex sensitisation, with the effect of all drugs
assessed until recovery to pre-injection values. Neither of these drugs had any significant
effects on responses mediated by the contralateral hindpaw.
The glial inhibitor propentofylline, PPT [see Figure 4.5 A and B]
When the glial inhibitor PPT (0.5pmol) was injected in CC1 animals, the baseline (pre-
injection) paw withdrawal latency (PWL) was measured as ipsilateral, 9.8 ± 0.5 seconds
and contralateral 16.5 ± 0.5 seconds (mean latency ± SEM; n=5). Injection of PPT caused
a significant reversal of the thermal hyperalgesia that had been seen prior to injection for
up to 40 min post-injection (f p<0.05; One Way Repeated Measures ANOVA followed
by Dunnett's post-hoc analysis), with maximal reversal of ipsilateral thermal hyperalgesia
to 15.9 ± 0.5 seconds and contralateral 14.4 ± 1.2 seconds (mean latency ± SEM) at 20
minutes post injection. The baseline (pre-injection) paw withdrawal threshold (PWT)
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required to elicit a response was ipsilateral 1610 ± 573 mN/mm and contralateral 4831 ±
0 mN/mm2 (mean threshold ± SEM; n=5). Injection of PPT caused a significant reversal
of the mechanical allodynia seen prior to injection for 45 minutes post-injection (f
p<0.05; Friedman test on ranks followed by Dunn's post-hoc analysis), with maximal
reversal of ipsilateral mechanical allodynia to 3256 ± 931 mN/mm2 and contralateral
4831 ± 0 mN/mm2 (mean threshold ± SEM; n=5) at 20 minutes post injection.
The TNF-a receptor antagonist, WP9QY [see Figure 4.5 C and DJ
When the TNF-a receptor peptide antagonist, WP9QY (25pg), which efficiently
antagonises the effect of TNF-a binding to the TNF receptor 1 (Takasaki et al., 1997),
was injected in CCI animals, the baseline (pre-injection) paw withdrawal latency (PWL)
was measured as ipsilateral, 9.9 ± 0.7 seconds and contralateral 15.7 ± 0.9 seconds (mean
latency ± SEM; n=5). Injection of WP9QY caused a significant reversal of the thermal
hyperalgesia that had been seen prior to injection for up to 35 min post-injection (f
p<0.05; One Way Repeated Measures ANOVA followed by Dunnett's post-hoc
analysis), with maximal reversal of ipsilateral thermal hyperalgesia to 16.2 ± 1.2 seconds
and contralateral 14.9 ±1.3 seconds (mean latency ± SEM) at 35 minutes post injection.
The baseline (pre-injection) paw withdrawal threshold (PWT) required to elicit a
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response was ipsilateral 1610 ± 126 mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean
threshold ± SEM; n=5). Injection of WP9QY caused a significant reversal of the
mechanical allodynia seen prior to injection for 30 minutes post-injection (f p<0.05;
Friedman test on ranks followed by Dunn's post-hoc analysis), with maximal reversal of
ipsilateral mechanical allodynia to 3929 ± 658 mN/mm2 and contralateral 4831 ± 0
mN/mm2 (mean threshold ± SEM) at 15-20 minutes post injection.
4.3.5 The activation of p38 and p42/44 MAP kinases following nerve injury is
attenuated by incubation of the spinal cord with the glial inhibitor propentofvlline
(PPT) or the TNF-a receptor antagonist (WP9QY) and the TNF-q synthesis
inhibitor thalidomide compared to saline controls [see Figure 4.6 and Table 4.2 A, C]
CCI nerve injury results in an ipsilateral increase in the level of activated
(phosphorylated) p38 and p42/44 as shown above (Section 4.3.3). Glial cells are known
to express p38 and p42/44 MAP kinases, so the effect of glial blockade on MAP kinase
activation was examined. Incubation of the spinal cord with of the glial inhibitor
propentofylline, PPT (lOmM), the TNF-a receptor antagonist, WP9QY (0.5mg/ml) and
the TNF-a synthesis inhibitor, thalidomide (200pM), to the dorsal surface of the spinal
cord for 30 minutes resulted in the suppression of increased activation of both p38
(phospho-p38) and p42/44 (phospho-p42/44) MAP kinases that occurs following nerve
injury when compared to saline controls. In saline (0.9%) controls the densitometric ratio
of phosphorylated to pan p38 MAP kinase immunoreactivity showed a significant
ipsilateral increase to 63.5 ±5.7 arbitrary density units compared to a contralateral value
of 48.4 ± 6.2 arbitrary density units (mean ± SEM; values derived from quantitative
densitometry; p<0.05 Wilcoxon test; n=5). The densitometric ratio of phosphorylated to
pan p42/44 MAP kinase immunoreactivity also shows a significant increase to 56.1 ± 4.8
arbitrary density units compared to contralateral value of 35.9 ± 3.6 arbitrary density
units in saline controls (mean ± SEM; p<0.05 Wilcoxon test; n=5).
The incubation of the spinal cord with PPT suppressed this increased level of
phosphorylated p38 to a phospho:pan densitometric ratio of 37.4 ± 5.9 arbitrary density
units ipsilateral, similar to the contralateral level of 39.8 ± 4.4 arbitrary density units and
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phosphorylated p42/44 to 30.9 ± 4.3 arbitrary density units ipsilateral, similar to the
contralateral level of 38.3 ± 4.6 arbitrary density units (mean ± SEM; n=5). The
incubation of the spinal cord with WP9QY suppressed the CCI-induced increased level of
phosphorylated p38 to 40.3 ± 5.0 arbitrary density units ipsilateral, similar to the
contralateral level of 36.3 ± 7.5 arbitrary density units and phosphorylated p42/44 to 41.3
± 8.3 arbitrary density units ipsilateral, similar to the contralateral level of 34.8 ± 5.2
arbitrary density units (mean ± SEM; n=5). The incubation of the spinal cord with
thalidomide suppressed a CCI-induced increased level of phosphorylated p38 to 41.5 ±
6.8 arbitrary density units ipsilateral, similar to the contralateral level of 39.6 ± 4.8
arbitrary density units (mean ± SEM; n=5). Thalidomide also suppressed the level of
phosphorylated p42/44 to 35.0 ± 6.2 arbitrary density units ipsilateral, similar to the
contralateral level of 45.9 ± 6.9 arbitrary density units (mean ± SEM). The incubation of
the spinal cord with each of these drugs suppressed the nerve injury-induced increase in
phosphorylated p38 and p42/44 MAP kinases resulting, such that there was now no
statistically significant difference between ipsilateral and contralateral values for each
drug or with the contralateral side of the saline treated control (as determined by
Wilcoxon test). There was no significant change in the overall (pan) levels of p38 or
p42/44 MAP kinase following the application of any of these drugs.
4.3.6 The effect of intrathecal administration of the selective antagonists for the
VPACi, VPAC?, PACi, NKi and NK? and the receptors on nerve injury-induced
behavioural reflex sensitisation
The effects of the intrathecal administration of the selective antagonists for VPACj ([Ac-
His1, D-Phe2, Lys15, Arg16, Leu17]-VIP(3-7)GRF(8-27)), VPAC2 ([des(l-4), Arg16]-Ro
25-1553), PACi (PACAP6.38), NKi (RP 67580) and NK2 (SR 48968) receptors on nerve
injury-induced thermal hyperalgesia and mechanical allodynia was assessed. Animals
that displayed peak ipsilateral behavioural reflex sensitisation were used for the
intrathecal administration of all drugs, with the effect of all drugs being assessed until
recovery to pre-injection values. None of the drugs tested had any significant effects on
the contralateral hindpaw. Marked effects were seen only with the VPAC2 and NK2
receptor antagonists.
- 115 -
VPAC2 receptor antagonist [see Figure 4.7A andB and Table 4.3]
The selective antagonist for the VPAC2 receptor [des(l-4), Argl6]-Ro 25-1553 (O.lnmol)
was injected in animals at the peak of ipsilateral behavioural reflex sensitisation
following CCI. The baseline (pre-injection) paw withdrawal latency (PWL) was
measured as ipsilateral, 12.2 ± 1.0 seconds and contralateral 19.8 ± 0.4 seconds (mean
latency ± SEM; n=7). Injection of [Des(l-4), Arg16]-Ro 25-1553 caused a significant
reversal of the ipsilateral thermal hyperalgesia seen prior to injection for 70 min post-
injection (f p<0.05; One Way Repeated Measures ANOVA followed by Dunnett's post-
hoc analysis), with maximal reversal of ipsilateral thermal hyperalgesia to 20.0 ±1.1
seconds and contralateral 18.1 ± 1.8 seconds (mean latency ± SEM) at 15-40 minutes
post injection. The baseline (pre-injection) paw withdrawal threshold (PWT) required to
elicit a response was ipsilateral 1610 ± 126 mN/mm2 and contralateral 4831 ± 0 mN/mm2
(mean threshold ± SEM; n=7). Injection of [Des(l-4), Arg16]-Ro 25-1553 caused a
significant reversal of the mechanical allodynia seen prior to injection for 35 minutes
post-injection (f p<0.05; Friedman test on ranks followed by Dunn's post-hoc analysis),
with maximal reversal of ipsilateral mechanical allodynia to 3256 ± 658 mN/mm2 and
9 • . • •
contralateral 4831 ± 0 mN/mm (mean threshold ± SEM) at 15-25 minutes post injection.
The mean percent reversal of ipsilateral sensitisation from 15-30 min following
intrathecal administration of [Des(l-4), Arg16]-Ro 25-1553 was 93.6 ± 5.2% for thermal
hyperalgesia (*p < 0.05, One Way Repeated Measures ANOVA followed by Dunnetf s
pot-hoc analysis test) and 41.2 ± 6.1% for mechanical allodynia (*p < 0.05, Friedman test
on ranks followed by a Dunn's post-hoc test; means ± SEM).
NK2 receptor antagonist [see Figure 4.7 CandD and Table 4.3]
The selective antagonist for the NK2 receptor SR 48968 (5nmol) was injected in animals
at the peak of ipsilateral behavioural reflex sensitisation following CCI. The baseline
(pre-injection) paw withdrawal latency (PWL) was measured as ipsilateral, 9.3 ± 0.2
seconds and contralateral 15.9 ± 0.5 seconds (mean latency ± SEM; n=6). The NK2
receptor antagonist caused a significant reversal of the ipsilateral thermal hyperalgesia
seen prior to injection for 35 mins post-injection (f p<0.05; One Way Repeated Measures
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ANOVA followed by Dunnett's post-hoc analysis), with maximal reversal of ipsilateral
thermal hyperalgesia to 13.8 ± 1.8 seconds and contralateral 14.3 ± 0.9 seconds (mean
latency ± SEM) at 15-25 minutes post injection. The baseline (pre-injection) paw
withdrawal threshold (PWT) required to elicit a response was ipsilateral 1294 ± 141
mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM; n=6). Injection of
SR 48968 caused a significant reversal of the ipsilateral mechanical allodynia seen prior
to injection for 45 minutes post-injection (f p<0.05; Friedman test on ranks followed by
Dunn's post-hoc analysis), with maximal reversal of ipsilateral mechanical allodynia to
4079 ± 589 mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM) at 20
minutes post injection. The mean percent reversal of ipsilateral sensitisation from 15-30
min following intrathecal administration of SR 48968 was 89.6 ± 4.3% for thermal
hyperalgesia (*p < 0.05, One Way Repeated Measures ANOVA followed by Dunnett's
post-hoc analysis) and 73.2 ± 6.5% for mechanical allodynia (*p < 0.05, Friedman test on
ranks followed by a Dunn's post-hoc test; means ± SEM).
VPACi receptor antagonist [see Table 4.3]
The selective antagonist for the VPACi receptor ([Ac-His1, D-Phe2, Lys15, Arg16, Leu17]-
VIP(3-7)GRF(8-27); 0.1 nmol) was injected in animals at the peak of ipsilateral
behavioural reflex sensitisation following CCI. The baseline (pre-injection) paw
withdrawal latency (PWL) was measured as ipsilateral, 8.9 ± 0.5 seconds and
contralateral 15.0 ± 0.5 seconds (mean latency ± SEM; n=6). Injection of [Ac-His1, D-
Phe2, Lys15, Arg16, Leu17]-VIP(3-7)GRF(8-27) did not result in a significant reversal of
the ipsilateral thermal hyperalgesia seen prior to injection, with values remaining similar
to baseline values. The baseline (pre-injection) paw withdrawal threshold (PWT) required
to elicit a response was ipsilateral 978 ± 0 mN/mm2 and contralateral 4831 ± 0 mN/mm2
(mean threshold ± SEM; n=6). Injection of [Ac-His1, D-Phe2, Lys15, Arg16, Leu17]-VIP(3-
7)GRF(8-27) did not cause a significant reversal of the ipsilateral mechanical allodynia
seen prior to injection, values remained similar to baseline values. The mean percent
reversal of ipsilateral sensitisation from 15-30 min following intrathecal administration of
[Ac-His1, D-Phe2, Lys15, Arg16, Leu1?]-VIP(3-7)GRF(8-27) was 8.3 ± 2.0% for thermal
hyperalgesia and 12.4 ± 4.6% for mechanical allodynia (means ± SEM).
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PACi receptor antagonist [see Table 4.3J
The selective antagonist for the PACi receptor (PACAP6.38; 0.1 nmol) was injected in
animals at the peak of ipsilateral behavioural reflex sensitisation following CCI. The
baseline (pre-injection) paw withdrawal latency (PWL) was measured as ipsilateral, 7.9 ±
0.7 seconds and contralateral 14.9 ± 0.6 seconds (mean latency ± SEM; n=6). Injection of
PACAP6_38 caused a significant reversal of the ipsilateral thermal hyperalgesia seen prior
to injection for 30 min post-injection (f p<0.05; One Way Repeated Measures ANOVA
followed by Dunnetf s post-hoc analysis), with maximal reversal of ipsilateral thermal
hyperalgesia to 10.3 ± 1.1 seconds and contralateral 13.1 ± 1.8 (mean latency ± SEM) at
15 minutes post injection. The baseline (pre-injection) paw withdrawal threshold (PWT)
required to elicit a response was ipsilateral 978 ± 126 mN/mm2 and contralateral 4831 ± 0
mN/mm2 (mean threshold ± SEM; n=6). Injection of PACAP^s caused a significant
reversal of the ipsilateral mechanical allodynia seen prior to injection for 25 minutes post-
injection (f p<0.05; Friedman test on ranks followed by Dunn's post-hoc analysis), with
maximal reversal of ipsilateral mechanical allodynia to 2182 ± 573 mN/mm2 and
contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM) at 15-25 minutes post injection.
The mean percent reversal of ipsilateral sensitisation from 15-30 min following
intrathecal administration of PACAP6-38 was 27.6 ± 4.1% for thermal hyperalgesia (*p <
0.05, One Way Repeated Measures ANOVA followed by Dunnetf s pot-hoc analysis) and
19.5 ± 3.3% for mechanical allodynia (*p < 0.05, Friedman test on ranks followed by a
Dunn's post-hoc test; means ± SEM). The significant reversal of thermal hyperalgesia
and mechanical allodynia observed here was notably less than that produced by the
intrathecal injection of the selective antagonist for the VPAC2 receptor.
NKi receptor antagonist [see Table 4.3]
The selective antagonist for the NKi receptor (RP 67580; 5nmol) was injected in animals
at the peak of ipsilateral behavioural reflex sensitisation following CCI. The baseline
(pre-injection) paw withdrawal latency (PWL) was measured as ipsilateral, 9.2 ± 1.0
seconds and contralateral 16.0 ± 0.9 seconds (mean latency ± SEM; n=6). Injection of RP
67580 did not result in a significant reversal of the ipsilateral thermal hyperalgesia seen
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prior to injection, with values remaining similar to baseline values. The baseline (pre-
injection) paw withdrawal threshold (PWT) required to elicit a response was ipsilateral
1609 ± 126 mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean threshold ± SEM; n=6).
Injection of RP 67580 caused a significant reversal of the ipsilateral mechanical allodynia
seen prior to injection for 30 minutes post-injection (f p<0.05; Friedman test on ranks
followed by Dunn's post-hoc analysis), with maximal reversal of ipsilateral mechanical
allodynia to 3829 ± 501 mN/mm2 and contralateral 4831 ± 0 mN/mm2 (mean threshold ±
SEM) at 15-20 minutes post injection. The mean percent reversal of ipsilateral
sensitisation from 15-30 min following intrathecal administration of RP 67580 was 11.6
± 4.8% for thermal hyperalgesia (not significant) and 22.9 ± 6.1% for mechanical
allodynia (*p < 0.05, Friedman test on ranks followed by a Dunn's post-hoc test; means ±
SEM). The significant reversal of mechanical allodynia observed here was notably less
than that produced by the intrathecal injection of the selective NK2 receptor antagonist.
4.3.7 The activation of p38 and p42/44 MAP kinases following nerve injury is
prevented by incubation of the spinal cord with selective antagonists for VPACT.
NK? or NMDA receptors /see Figure 4.8 and Table 4.2 B, CI
CCI nerve injury results in an ipsilateral increase in the level of both phosphorylated p38
and p42/44 as shown above (Section 4.3.3). The incubation of the spinal cord with the
selective antagonists for VPAC2 ([des(l-4), Arg16]-Ro 25-1553; 2pM), NK2 (SR 48968;
lOOpM) or NMDA ((R)-CPP; 10pM) receptors to spinal cord resulted in suppression of
increased activation of both p38 (phospho-p38) and p42/44 (phospho-p42/44) MAP
kinases that occurred following nerve injury when compared to saline controls. As
outlined above (Section 4.3.5) the incubation of the spinal cord with saline had no effect
on the CCI-induced increase in phosphorylated p38 to 63.5 ±5.7 arbitrary density units
compared to contralateral value of48.4 ± 6.2 arbitrary density units (mean ± SEM; values
derived from quantitative densitometry; p<0.05 Wilcoxon test; n=5), or on the increase in
phosphorylated p42/44 to 56.1 ± 4.8 arbitrary density units compared to contralateral
value of 35.9 ± 3.6 arbitrary density units in saline controls (mean ± SEM; p<0.05
Wilcoxon test; n=5). The incubation of the spinal cord with [des(l-4), Argl6]-Ro 25-1553
suppressed this CCI-induced activation of p38 to 39.3 ± 7.3 arbitrary density units
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ipsilateral, similar to the contralateral level of 35.8 ± 6.0 arbitrary density units and
p42/44 to 39.7 ± 4.4 arbitrary density units ipsilateral, similar to the contralateral level of
41.4 ± 5.0 arbitrary density units (mean ± SEM; n=5). SR 48968 suppressed the CCI-
induced activation of p38 to 47.3 ± 5.5 arbitrary density units ipsilateral, similar to the
contralateral level of 45.6 ± 4.8 arbitrary density units (mean ± SEM; n=5). SR 48968
also suppressed the CCI-induced activation of p42/44 to 37.9 ± 3.9 arbitrary density units
ipsilateral, similar to the contralateral level of 37.1 ± 5.2 arbitrary density units (mean ±
SEM n=5). In addition, incubation of the spinal cord with (R)-CPP suppressed the CCI-
induced activation of p38 to 42.3 ± 7.6 arbitrary density units ipsilateral, similar to the
contralateral level of 44.1 ±7.1 arbitrary density units and of p42/44 to 39.6 ± 4.9
arbitrary density units ipsilateral, similar to the contralateral level of 42.8 ± 4.3 arbitrary
density units (mean ± SEM n=5). The incubation of the spinal cord with each of these
drugs were sufficient to fully suppress the nerve injury induced increase in
phosphorylated p38 and p42/44 MAP kinases resulting in no statistically significant
difference between ipsilateral and contralateral values for each drug or compared with the
contralateral side of the saline treated control (as determined by Wilcoxon test). There
was no significant change in the overall (pan) levels of p38 or p42/44 MAP kinase
following the application of any of these drugs.
4.3.8 Intrathecal administration of VPAC? or NK? receptor agonist results in
behavioural reflex sensitisation, which is prevented by co-administration of either
p38 or p42/44 MAP kinase pathway inhibitors in naive animals
The effects of the intrathecal administration of agonists for the VPAC2 or NK2 receptor
(Ro 25-1553 and GR 64349 respectively) on naive animal's responses to a noxious heat
stimulus were measured as (bilateral) paw withdrawal latency (due to time constraints
responses to mechanical stimuli were not measured for the agonist study). The effects of
co-administration of the p38 MAP kinase inhibitor SB 203580 or the p42/44 MAP kinase
pathway inhibitor U 0126 was also assessed. The effects of all drugs were measured until
recovery to pre-injection values. Since Ro 25-1553 caused relatively greater activation of
p38 than p42/44 and GR 64349 caused relatively greater activation of p42/44 than p38
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(see Section 4.3.9 below) and both time and resources were limited, only the blocker for
the more strongly implicated MAP kinase was tested on each agonist.
VPAC2 receptor agonist [see Figure 4.9 A]
The agonist for the VPAC2 receptor, Ro 25-1553 (0.5nmol) was injected in naive
animals. The baseline (pre-injection) bilateral paw withdrawal latency (PWL) was
measured as 15.4 ± 0.2 seconds (mean latency ± SEM; n=6). Ro 25-1553 caused a
significant sensitisation of the thermal response compared to that prior to injection for 55
mins post-injection (f p<0.05; One Way Repeated Measures ANOVA followed by
Dunnett's post-hoc analysis), with maximal reduction of latency to 10.5 ±1.2 seconds
(mean latency ± SEM) at 30 minutes post injection.
VPAC2 receptor agonist co-administered with the p38 MAP kinase inhibitor [see
Figure 4.9 B]
The agonist for the VPAC2 receptor Ro 25-1553 (0.5nmol) and the p38 MAP kinase
inhibitor SB 203580 (5nmol) were injected in nai've animals. The baseline (pre-injection)
bilateral paw withdrawal latency (PWL) was measured as 14.8 ± 0.4 seconds (mean
latency ± SEM; n=6), co-administration of the agonist Ro 25-1553 with SB 203580
prevented the development of the thermal sensitisation seen when Ro 25-1553 was
administered alone, such that co-administration resulted in reversal of latency to 14.5 ±
1.3 seconds (mean latency ± SEM) at 20-30 minutes post-injection, which was not
significantly different to pre-drug (baseline) values.
NK2 receptor agonist [see Figure 4.9 C]
The agonist for the NK2 receptor, GR 64349 (1.5nmol) was injected in naive animals. The
baseline (pre-injection) bilateral paw withdrawal latency (PWL) was measured as 14.6 ±
0.3 seconds (mean latency ± SEM; n=6). GR 64349 caused a significant sensitisation of
the thermal response compared to prior to injection for 35 mins post-injection (f p<0.05;
One Way Repeated Measures ANOVA followed by Dunnett's post-hoc analysis), with
maximal reduction of latency to 11.4 ± 0.7 seconds (mean latency ± SEM) at 20 minutes
post injection.
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NK2 receptor agonist co-administered with p42/44 MAP kinase pathway inhibitor
[see Figure 4.9 DJ
The agonist for the NK2 receptor, GR 64349 (1.5nmol) and the p42/44 MAP kinase
pathway inhibitor U 0126 (1.5nmol) were injected in naive animals. The baseline (pre-
injection) bilateral paw withdrawal latency (PWL) was measured as 14.4 ± 0.3 seconds
(mean latency ± SEM; n=6), co-administration of the agonist GR 64349 with U 0126
blocked the development of the thermal sensitisation seen when GR 64349 was
administered alone. That is co-administration resulted in reversal to 14.2 ± 1.4 seconds
(mean latency ± SEM) at 20-30 minutes post-injection, which was not significantly
different to pre-drug (baseline) values.
4.3.9 The incubation of the spinal cord with the VPAC? and the NK? receptor
agonists in naive animals resulted in increased activation of p38 and p42/44 MAP
kinases that was prevented by co-incubation of the glial inhibitor propentofylline
[see Fisure 4.10 and Table 4.1 Bl
CCI nerve injury results in an ipsilateral increase in the level of both phosphorylated p38
and p42/44 as shown above (Section 4.3.3). The incubation of the spinal cord with the
agonist for VPAC2 (Ro 25-1553; 30pM) and NK2 (GR 64349; 50pM) receptors resulted
in increased activation of both p38 (phospho-p38) and p42/44 (phospho-p42/44) MAP
kinases in naive animals when compared to saline controls. The incubation of the spinal
cord with saline (0.9%) did not significantly increase the levels of phosphorylated p38
(36.5 ± 4.2 arbitrary density units), or of phosphorylated p42/44 (39.0 ± 7.3 arbitrary
density units; from those in naive controls see Section 4.3.3; mean ± SEM; n=5).
Incubation of the spinal cord with Ro 25-1553 significantly increased the phosphorylation
ratios of both p38 to 60.7 ± 6.3 arbitrary density units and p42/44 to 67.1 ± 4.0 arbitrary
density units (mean ± SEM; p<0.05 Wilcoxon test; n=5) compared to saline controls. The
incubation of the spinal cord with GR 64349 significantly increased the phosphorylation
ratios of p38 to 53.2 ± 4.8 arbitrary density units and of p42/44 to 94.4 ± 5.8 arbitrary
density units (mean ± SEM; p<0.05 Wilcoxon test; n=5) compared to saline controls. The
VPAC2 receptor agonist caused a relatively greater activation of p38 MAP kinase than
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did the NK2 receptor agonist and the NK2 receptor agonist caused a relatively greater
activation of p42/44 than p38 MAP kinase.
The co-incubation of PPT (lOmM) with Ro 25-1553 (30pM) blocked the Ro 25-1553-
induced increase in the phosphorylation of p38 and p42/44, that is co-incubation did not
significantly increase the levels of phosphorylated p38 (39.9 ± 5.3 arbitrary density units)
or p42/44 (34.8 ± 4.6 arbitrary density units) compared to saline controls (mean ± SEM;
n=5). The co-incubation of PPT (lOmM) with GR 64349 (50pM) blocked the GR 64349-
induced increase in the phosphorylation of both p38 and p42/44, such that co-incubation
did not significantly increase the levels of phosphorylated p38 (43.3 ± 6.0 arbitrary
density units) or p42/44 (40.0 ±5.7 arbitrary density units) compared to saline controls
(mean ± SEM; n=5). The co-incubation of PPT with Ro 25-1553 and GR 64 349
suppressed the increased phosphorylation of both p38 and p42/44 MAP kinases, to levels
that were not significantly different from saline controls. There was no significant change
in the overall (pan) levels of p38 or p42/44 MAP kinase following the incubation of the
spinal cord with any of these drugs.
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Figure 4.1
The time course of development of thermal hyperalgesia, mechanical and cold
allodynia ipsilateral to nerve injury in a model of experimental mononeuropathy
(CCI).
Data show mean ± SEM responses prior to surgery (baseline) and following the induction
of CCI (post surgery; n=25). (A) Paw withdrawal latency (PWL) from a noxious thermal
stimulus (Hargreaves' thermal stimulator) ipsilateral to CCI (O) showed significant
differences between post-operative and pre-operative values (t p<0.05; One Way
Repeated Measures ANOVA followed by Dunnett's post-hoc analysis) and from post¬
operative contralateral (■) values (* p<0.05; Student's t-test). No thermal hyperalgesia
was seen on the contralateral side (■). (B) Paw withdrawal thresholds (PWT) from
mechanical stimulation (von Frey filaments) showed significant reductions in post¬
operative compared to pre-operative values ipsilateral (O) to CCI (f p<0.05; Friedman
test on ranks followed be Dunn's post-hoc analysis) and between post-operative
ipsilateral and contralateral values (* p<0.05; Wilcoxon test). No significant differences
were seen in the contralateral side (■). (C) The suspended paw elevation time (SPET) to
a cold water stimulus showed significant ipsilateral to CCI (O) differences between post¬
operative and pre-operative values (f p<0.05; Friedman test on ranks followed be Dunn's
post-hoc analysis) and from post-operative contralateral (■) values (* p<0.05; Wilcoxon
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Figure 4.2
Effects of the intrathecal administration of the p38 MAP kinase inhibitor SB 203580
and the p42/44 MAP kinase pathway inhibitor PD 098059 on nerve injury-induced
thermal hyperalgesia and mechanical allodynia.
(A-D) Data show mean ± SEM responses prior to (baseline) and following intrathecal
administration of SB 203580 (5nmol; n=6) or PD 098059 (2.5nmol; n=6). In all cases the
animals were at the peak of behavioural reflex sensitisation as a result of CCI to the
sciatic nerve, as determined by a significant reduction in ipsilateral (O) paw withdrawal
latency from a noxious thermal stimuli (PWL; * p<0.05, Student's t-test, A, C,) or paw
withdrawal threshold to mechanical stimuli (PWT; * p<0.05, Wilcoxon test, B, D)
compared to contralateral withdrawal responses (■). Following intrathecal injection
(shown by arrow), (A) SB 203580 or (C) PD 098059 significantly increased ipsilateral
thermal paw withdrawal latencies in comparison to pre-injection ipsilateral values (f
p<0.05, One-Way Repeated Measures ANOVA followed by a Dunnett's test) with
differences between ipsilateral and contralateral post-injection returning (* p<0.05,
Student's t-test), while there was no significant alteration in the contralateral response.
(B) SB 203580 and (D) PD 098059 show significantly increased ipsilateral mechanical
paw withdrawal thresholds in comparison to pre-injection ipsilateral values (f p<0.05,
Friedman test on ranks followed by a Dunn's post-hoc test), again with differences
between ipsilateral and contralateral post-injection returning (* p<0.05, Wilcoxon test),
no significant alteration in the contralateral response was noted. Full recovery to pre-drug




Effects of the intrathecal administration of the p42/44 MAP kinase pathway
inhibitor U 0126 and its less active analogue U 0124 on nerve injury-induced
thermal hyperalgesia and mechanical allodynia.
(A-D) Data show mean ± SEM responses prior to (baseline) and following intrathecal
administration of either U 0126 (1.5nmol; n=8) or U 0124 (1.5nmol; n=6). In all cases the
animals were at the peak of behavioural reflex sensitisation as a result of CCI to the
sciatic nerve, as shown by a significant reduction in ipsilateral (O) paw withdrawal
latency from a noxious thermal stimuli (PWL; * p<0.05, Student's t-test, A, C) or paw
withdrawal threshold to mechanical stimuli (PWT; * p<0.05, Wilcoxon test, B, D)
compared to contralateral withdrawal responses (■). Following intrathecal injection
(shown by arrow), (A) U 0126 significantly increased ipsilateral thermal paw withdrawal
latencies in comparison to pre-injection ipsilateral values (t p<0.05, One-Way Repeated
Measures ANOVA followed by a Dunnett's test) with differences between ipsilateral and
contralateral post-injection returning (* p<0.05, Student's t-test), while there was no
significant alteration in the contralateral response, while (C) U 0124 significantly
increased ipsilateral thermal paw withdrawal latencies to a lesser extent than the active
compound U 0126. (B) U 0126 significantly increased ipsilateral mechanical paw
withdrawal thresholds in comparison to pre-injection ipsilateral values (f p<0.05,
Friedman test on ranks followed by a Dunn's post-hoc test), again with differences
between ipsilateral and contralateral post-injection returning (* p<0.05, Wilcoxon test),
no significant alteration in the contralateral response was noted. (D) U 0124, the less
active analogue of U 0126, did not result in significant reversal of mechanical allodynia.































MAP kinase activation following experimental mononeuropathy (CCI) compared to
naive spinal cord.
Immunoblots showing the expression levels of phosphorylated p38 (phospho-p38), and
phosphorylated p42/44 (phospho-p42/44), and corresponding pan-immunoreactivity for
both kinases, pan-p38 and pan-p42/44 MAP kinase in spinal cord extracts of animals
displaying peak behavioural reflex sensitisation following CCI, on the side ipsilateral
(Ipsi; n=5) and contralateral (Con; n=5) to nerve injury and in naive (n=5) animals. All
tissue samples were taken at Day 12-14 following CCI when peak behavioural reflex
sensitisation was seen in all animals. CCI alone caused an ipsilateral increase in the levels
of activated phospho-p38 and phospho-p42/44 compared to the contralateral side and
naive animals. No significant alterations occurred in the overall levels of p38 (pan-p38)
or p42/44 (pan-p42/44) as a result of nerve injury. The image shows a sample









Intrathecal administration of a glial inhibitor or the TNF-a receptor antagonist
attenuates the behavioural reflex sensitisation that occurs following CCI.
(A-D) Data show mean ± SEM responses prior to (baseline) and following intrathecal
administration of the glial inhibitor propentofylline (PPT; 0.5pmol; n=5) or the TNF-a
receptor antagonist (WP9QY; 25pg; n=5). In all cases the animals were at the peak of
behavioural reflex sensitisation as a result of CCI to the sciatic nerve, as demonstrated by
a significant reduction in ipsilateral (O) paw withdrawal latency from a noxious thermal
stimuli (PWL; * p<0.05, Student's t-test, A, C) or paw withdrawal threshold to
mechanical stimuli (PWT; * p<0.05, Wilcoxon test, B, D) compared to contralateral
withdrawal responses (■). Following intrathecal injection (shown by arrow), both (A)
PPT and (C) WP9QY significantly increased ipsilateral thermal paw withdrawal latencies
in comparison to pre-injection ipsilateral values (f p<0.05, One-Way Repeated Measures
ANOVA followed by a Dunnett's test) with significant differences between ipsilateral
and contralateral post-injection returning (* p<0.05, Student's t-test), while there was no
significant alteration in the contralateral response. (B) PPT and (D) WP9QY,
significantly increased ipsilateral mechanical paw withdrawal thresholds in comparison to
pre-injection ipsilateral values (f p<0.05, Friedman test on ranks followed by a Dunn's
post-hoc test), with differences between ipsilateral and contralateral post-injection shown
(* p<0.05, Wilcoxon test). No significant alteration in the contralateral response was
noted. Previous experiments have shown that intrathecal injection of the vehicle used
had no effect on any behavioural reflex responses in CCI injured or naive animals with all
animals being of the same age, sex, weight and strain as to the animals used in this study
and with all behavioural testing carried out in a similar manner it was felt unwarranted





Inhibition of glia and TNF-a receptors suppresses the activation of p38 and p42/44
MAP kinases following CCI.
Immunoblots of spinal cord extracts show that incubation of the spinal cord with the glial
inhibitor propentofylline (PPT; lOmM; n=5), an antagonist of the pro-inflammatory
cytokine, TNF-a (WP9QY; 0.5mg/ml; n=5), or the inhibitor of TNF-a synthesis,
thalidomide (200pM; n=5) to nerve injured spinal cords, all inhibited the activation of
p38 (phospho-p38) and of p42/44 (phospho-p42/44) MAP kinase ipsilateral to CCI
(samples taken at the peak of CCI-induced behavioural reflex sensitisation). No
significant alterations occurred in the overall levels of p38 (pan-p38) or p42/44 (pan-
p42/44) with any treatment. The incubation of the spinal cord with saline did not affect
the activation of p38 (phospho-p38) or p42/44 (phospho-p42/44) MAP kinase observed
ipsilateral to CCI nerve injury.
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Intrathecal administration of either the VPAC2or NK2 receptor antagonists
reversed behavioural reflex sensitisation that occurs following CCI.
(A-D) Data show mean ± SEM responses prior to (baseline) and following intrathecal
administration of the VPAC2 (des(l-4), Arg16]-Ro 25-1553; O.lnmol; n=7) or NK2 (SR
48968; 5nmol; n=5) receptor antagonists. In all cases the animals were at the peak of
behavioural reflex sensitisation as a result of CCI, shown by a significant reduction in
ipsilateral (O) paw withdrawal latency from a noxious thermal stimuli (PWL; * p<0.05,
Student's t test, A, C) or paw withdrawal threshold to mechanical stimuli (PWT; *
p<0.05, Wilcoxon test, B, D) compared to contralateral withdrawal responses (■).
Following intrathecal injection (shown by arrow), both compounds (A) des(l-4), Arg16]-
Ro 25-1553 and (C) SR 48968 significantly increased ipsilateral thermal paw withdrawal
latencies in comparison to pre-injection ipsilateral values (f p<0.05, One-Way Repeated
Measures ANOVA followed by a Dunnett's test) with significant differences between
ipsilateral and contralateral post-injection returning (* p<0.05, Student's t-test), while
there was no significant alteration in the contralateral response. (B) des(l-4), Arg'6]-Ro
25-1553 and (D) SR 48968, show significantly increased ipsilateral mechanical paw
withdrawal thresholds in comparison to pre-injection ipsilateral values (f p<0.05,
Friedman test on ranks followed by a Dunn's post-hoc test), with differences between
ipsilateral and contralateral post-injection shown (* p<0.05, Wilcoxon test), no
significant alteration in the contralateral response was seen. Full recovery to pre-drug
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VPAC2, NK2 and NMDA receptor antagonists can suppress activation of p38 and
p42/44 MAP kinases following CCI.
Immunoblots of spinal cord extracts shows that incubation of the spinal cord with
antagonists to the VPAC2 ([des(l-4), Argl6]-Ro 25-1553: 2pM; n=5), NK2 (SR 48968;
lOOpM; n=5) and NMDA ((R)-CPP; 10pM; n=5) receptors suppressed the increased
activation of p38 (phospho-p38) and of p42/44 (phospho-p42/44) MAP kinase ipsilateral
to CCI (drugs incubation on the spinal cord at the peak of CCI-induced behavioural reflex
sensitisation). No significant alterations occurred in the overall levels of p38 (pan-p38) or
p42/44 (pan-p42/44) with any treatment. The incubation of the spinal cord with saline
(0.9%; n=5) did not affect the activation of p38 (phospho-p38) or p42/44 (phospho-
p42/44) MAP kinase observed ipsilateral to CCI nerve injury.
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Intrathecal administration of the VPAC2 or the NK2 receptor agonists in naive
animals results in behavioural reflex sensitisation that can be blocked by MAP
kinase pathway inhibitors.
(A-D) Data represents bilateral mean hindpaw withdrawal latency ± SEM in response to a
noxious heat stimulus prior to (baseline) and following intrathecal administration of (A)
VPAC2 (Ro 25-1553; 0.5nmol; n=6) or (C) NK2 (GR 64349; 1.5nmol; n=6) receptor
agonists or co-administration of (B) Ro 25-1553 with SB 203580 (a p38 MAP kinase
inhibitor; 5nmol; n=6) or co-administration of (D) GR 64349 with U 0126 (a p42/44
MAP kinase pathway inhibitor; 1.5nmol; n=6). The single administration of both agonists
caused behavioural sensitisation to thermal stimulation (A, C) in comparison to pre-
injection values (t p<0.05, One-Way Repeated Measures ANOVA followed by a
Dunnett's test). The effects of Ro 25-1553 were blocked when it was co-administered
with the p38 MAP kinase pathway inhibitor SB 203580 (B). Similarly, the effects of GR
64349 were blocked when co-administered with the p42/44 MAP kinase pathway
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Incubation of naive spinal cords with VPAC2 or the NK2 receptor agonists caused
activation of p38 and p42/44 MAP kinases that was suppressed by application with a
glial inhibitor.
Immunoblots of naive spinal cord extracts shows that incubation of the spinal cord with
the VPAC2 (Ro 25-1553; 30pM; n=5) and the NK2 (GR 64349; 50pM; n=5) receptor
agonists increased activation of p38 (phospho-p38) and of p42/44 (phospho-p42/44)
MAP kinase. The VPAC2 receptor agonist (Ro 25-1553) caused a relatively greater
activation of p38 MAP kinase (phospho-p38) than did the NK2 receptor agonist (GR
64349) compared to the application of saline. The NK2 receptor agonist (GR 64349) was
found to cause a relatively greater activation of p42/44 MAP kinase (phospho-p42/44)
than did the VPAC2 receptor agonist (Ro 25-1553), compared to the application of saline.
The increased activation of p38 and p42/44 MAP kinases was prevented when the glial
inhibitor propentofylline (PPT; lOmM; n=5 in each case) was co-incubated. Minimal
levels of either phospho-p38 or phospho-p42/44 immunoreactivity were detected in
controls where saline (0.9%; n=5) was incubated on the spinal cord instead. No
significant alterations occurred in the overall levels of p38 (pan-p38) or p42/44 (pan-












Immunoblot densitometric ratio scores for phosphorylated:pan p38 and p42/44
MAP kinases in naive spinal cord extracts or following CCI and incubation of naive
spinal cords with VPAC2, NK2 receptor agonists, saline, or with co-incubation of a
glial inhibitor
Data presented show the immunoblot densitometric ratio scores for phosphorylated-
p38:pan-p38 and phosphorylated-p42/44:pan-p42/44 (arbitrary density units; values are
mean ± SEM) in (A) Spinal cord extracts of CCI nerve injured animals at the peak of
behavioural reflex sensitisation ipsilateral (ipsi) and contralateral (con) to nerve injury
(n=5) and nai've spinal cord (n=5; shown in Figure 4.3). The ratio of both phosphorylated
-p38 and -p42/44 MAP kinases to pan-immunoreactivity was significantly increased
ipsilateral to nerve injury when compared to contralateral and naive samples (*p<0.05,
Wilcoxon test). (B) Spinal cord extracts of naive animals that have been incubated with
agonists for the VPAC2 receptor (Ro 25-1553; n=5) or the NK2 receptor (GR 64349; n=5;
shown in Figure 3.9). Both agonists resulted in significant increases in the ratio of both
phosphorylated -p38 and -p42/44 MAP kinases to pan-immunoreactivity in naive animals
when compared to saline controls (*p<0.05, Wilcoxon test). Co-incubation of the VPAC2
receptor agonist, Ro 25-1553 and the NK2 receptor agonist, GR 64349 with the glial
inhibitor propentofylline, PPT (n-5) blocked the increased phosphorylated p38 and
p42/44 MAP kinases to levels that were not significantly different from saline controls.
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A. Immunoblot densitometric ratio scores for phosphophorylated-p38:pan-p38
and phosphorylated-p42/44:pan-p42/44 (arbitrary density units)
CCI Spinal Cord Naive Spinal Cord
MAP
Kinase Ipsi Con Naive
p38 63.5 ±5.7* 48.4 ± 6.2 44.6 ± 4.6
p42/44 56.1 ±4.8* 35.9 ±3.6 39.6 ±7.1
B. Immunoblot densitometric ratio scores for phosphophorylated-p38:pan-p38
and phosphorylated-p42/44:pan-p42/44 (arbitrary density units)
MAP
Kinase Saline VPAC2 receptor agonist NK2 receptor agonist
p38 36.5 ±4.2 60.7 ± 6.3* 53.2 ±4.8*
p42/44 39.0 ±7.3 67.1 ±4.0* 94.4 ±5.8*
MAP
Kinase VPAC2 receptor agonist and PPT NK2 receptor agonist and PPT
p38 39.9 ±5.3 43.3 ± 6.0
p42/44 34.8 ±4.6 40.0 ±5.7
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Table 4.2
Immunoblot densitometric ratio scores for phosphorylated:pan p38 and p42/44
MAP kinases in spinal cord extracts following CCI and incubation of the spinal
cord with the glial inhibitor, TNF-a receptor antagonist or TNF-a synthesis
inhibitor or of the VPAC2, NK2 or NMDA receptor antagonists
Data presented shows the immunoblot densitometric ratio scores for phosphorylated-
p38:pan-p38 and phosphorylated-p42/44:pan-p42/44 (arbitrary density units; values are
mean ± SEM) in (A) Spinal cord extracts of CCI nerve injured animals at the peak of
behavioural reflex sensitisation ipsilateral (ipsi) and contralateral (con) to nerve injury
with either the glial inhibitor propentofylline, PPT (n=5), the TNF-a receptor
antagonist WP9QY (n=5) or the TNF-a synthesis inhibitor, thalidomide (n=5),
incubated on the spinal cord (shown in Figure 4.5). Each of these drugs prevented the
ipsilateral increase in phosphorylated of p38 and p42/44 MAP kinases seen as a result
of nerve injury when compared to saline controls (see C below). (B) Spinal cord
extracts of CCI nerve injured animals at the peak of behavioural reflex sensitisation
ipsilateral (ipsi) and contralateral (con) to nerve injury with either the VPAC2 receptor
antagonist, [des(l-4), Arg16]-Ro 25-1553 (n=5), the NK2 receptor antagonist, SR 48968
(n=5) or the NMDA receptor antagonist, (R)-CPP (n=5) incubated on the spinal cord
(shown in Figure 4.5). The incubation of the spinal cord these drugs prevented the
ipsilateral increase in phosphorylated of p38 and p42/44 MAP kinases seen as a result
of nerve injury when compared to saline controls (see C). (C) Spinal cord extracts of
CCI nerve injured animals at the peak of behavioural reflex sensitisation ipsilateral
(ipsi) and contralateral (con) to nerve injury with saline incubated on the spinal cord
(n=5; shown in Figure 4.5). The ratio of both phosphorylated -p38 and -p42/44 MAP
kinases to pan-immunoreactivity was significantly increased ipsilateral to nerve injury
when compared to contralateral (*p<0.05, Wilcoxon test).
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Immunoblot densitometric ratio scores for phosphophorylated-p38:pan-p38
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The mean percent reversal of ipsilateral sensitisation in CCI injured animals
following intrathecal administration of the VPACj, VPAC2 or PACi receptor
antagonists or of the NKi and NK2 receptor antagonists
Table presented shows the mean percent reversal of ipsilateral sensitisation from 15-30
min following intrathecal administration of each drug. Data represents mean percent
reversal ± SEM from 15-30 min following intrathecal injection of each drug for
measurements of thermal hyperalgesia and mechanical allodynia in animals at the peak
of ipsilateral reflex sensitivity as a result of nerve injury. Drugs assessed were
antagonists to the VPAC2 (n=7), VPACi (0=6) and PACi (n=6) receptors (see figure
4.6 A+B for VPAC2 receptor antagonist) and to NK2 (n=5) and NKi (n=6) receptors
(see figure 4.6 C+D for NK2 receptor antagonist) for their effect on behavioural reflex
sensitisation. Significant attenuation of thermal hyperalgesia was seen with the
administration of VPAC2, PACi and NK2 receptor antagonists (*p < 0.05, One Way
Repeated Measures ANOVA followed by a Dunnett's test) when compared to pre-
injection (baseline) ipsilateral values at each of the time points throughout this period.
Significant attenuation of mechanical allodynia was seen with the administration of
VPAC2, PACi and NKi and NK2 receptor antagonists (*p < 0.05, Friedman test on
ranks followed by a Dunn's post-hoc test) when compared to pre-injection (baseline)
ipsilateral values at each of the time points throughout this period. No significant
changes in contralateral responses were found at any time point.
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Mean percent reversal of ipsilateral sensitisation from 15-30 min following intrathecal
administration of each drug
Drug Thermal hyperalgesia Mechanical allodynia
VPAC/R antagonist
[Ac-His1, D-Phe2, Lys'5, Arg'6,
Leu'7- VIP(3- 7)GRF(8-2 7)
8.3 ±2.0 12.4 ±4.6
VPAC2R antagonist
[des(l-4), Argl6]-Ro 25-1553
93.6 ±5.2 * 41.2 ± 6.1*
PAC/R antagonist
PACAP6.38
27.6 ±4.1* 19.5 ±3.3*
NK/R antagonist
RP 67580
11.6 ±4.8 22.9 ±6.1*
NK2R antagonist
SR 48968
89.6 ±4.3* 73.2 ±6.5*
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4.4 Discussion
This study was carried out to investigate activation of the p38 and p42/44 MAP kinases
and involvement of the NK2 and VPAC2 peptidergic receptors and spinal glia in an
experimental model of mononeuropathy. The model used in this study was a modification
of the chronic constriction injury (CCI) model developed by Bennett and Xie (Bennett
and Xie, 1988). This model relies on partial nerve damage rather than complete
transection and produces a clinically relevant model with a combination of damaged and
undamaged (hypersensitive) fibres. The pharmacological profile of this CCI model is
similar to that seen in human neuropathic pain and the frequency of autotomy is lower in
this model than following sciatic nerve transection (Attal et al., 1990; Bennett and Xie,
1988). All animals used in this study developed a robust increased sensitivity to
previously innocuous mechanical and cold stimuli, indicating that CCI nerve injury
resulted in the development of mechanical and cold allodynia in the affected hind limb,
while also developing a marked reduction in response latency to a noxious heat stimulus.
The CCI-induced behavioural reflex sensitisation described here is in agreement with
previous reports using this CCI model (Dickinson et al., 1999). For all further
investigations here using this CCI model, animals displaying peak behavioural reflex
sensitisation following CCI nerve injury (ipsilateral to nerve injury) were used.
MAP kinase activation was shown here to be markedly enhanced in the spinal cord,
following CCI nerve injury, as illustrated by an ipsilateral increased phosphorylation of
both p38 and p42/44 MAP kinase when compared to the contralateral side and naive
controls. Previous findings from the laboratory illustrated that both p38 and p42/44 MAP
kinase inhibitors (SB 203580 and PD 098059 respectively) attenuated the sensitisation of
individual dorsal horn neurons as a result of mustard oil application, suggesting that both
MAP kinases may contribute to the central sensitisation induced by nerve injury.
Utilising this information, the present study investigated whether corresponding effects
would be observed on nerve injury-induced behavioural reflex sensitisation. The results
indicate that both p38 (SB 203580) and p42/44 (PD 098059 and U 0126) MAP kinase
pathway inhibitors, when intrathecally administered, indeed clearly attenuate nerve
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injury-induced behavioural reflex sensitisation. These findings are in agreement with
other reports where intrathecal administration of the p38 (SB 203580) MAP kinase
inhibitor, suppressed allodynia elicited by spinal nerve injury, blocked the
hypersensitivity that occurs following the application of substance P and attenuated both
formalin or Complete Freund's Adjuvant-induced inflammatory sensitisation (Jin et al.,
2003; Svensson et ah, 2003; Tsuda et ah, 2004). The use ofanother inhibitor of p38 MAP
kinase has also demonstrated antinociceptive effects in a model of diabetic neuropathy
(Sweitzer et ah, 2004). Equally inhibition of the p42/44 MAP kinase pathway through use
of U 0126 has been reported to reduce hypersensitivity induced by capsaicin, by
Complete Freund's Adjuvant-induced inflammation or by nerve transection (Dai et ah,
2002; Ji et ah, 2002a; Obata et ah, 2003). The p42/44 MAP kinase pathway inhibitor PD
098059 has also recently been shown to reduce nociceptive behaviours in a model of
chronic inflammatory articular pain (Cruz et ah, 2005). Here using the CCI model of
mononeuropathy, behavioural sensitisation was prevented with use of both the p38 and
p42/44 MAP kinase inhibitors.
Non-neuronal, glial cell activation appears to be a key element in both the generation and
maintenance of chronic pain states. Microglia and astrocytes have been shown to be
activated following both, inflammation and peripheral nerve injury (Garrison et ah, 1991;
Hashizume et ah, 2000; Sweitzer et ah, 1999). Activated p38 and p42/44 MAP kinases
have been localised to not only neurons but to astrocytes and microglia. Phosphorylation
of p38 MAP kinase occurs in microglia following formalin-induced inflammation, nerve
injury and axotomy (Jin et ah, 2003; Kawasaki et ah, 1997; Kim et ah, 2002; Svensson et
ah, 2003; Tsuda et ah, 2004), while phosphorylation of p42/44 MAP kinase occurs in
addition to spinal neurons, in astrocytes and microglia following nerve injury (Ji et ah,
1999; Ma and Quirion, 2002; Zhuang et ah, 2005). It has been noted that CCI nerve
injury is associated with activation of astrocytes, observed as an increased GFAP
expression that is believed to involve a mechanism dependent on the NMDA receptor
(Garrison et ah, 1991; Garrison et ah, 1994). However a similar increase in microglial
activation has not been observed in this CCI nerve injury model (Colburn et ah, 1997). It
has yet to be determined if the increased activation of these MAP kinases corresponds to
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glial activation (seen as increased GFAP expression) following nerve injury. As a first
approach to this question, the present study assessed the effect of attenuating glial
activation on both p38 and p42/44 MAP kinase activation.
Inhibiting glial function through use of the glial inhibitor, propentofylline and blocking
the proinflammatory cytokine TNF-a released by active glial cells using the TNF-a
receptor antagonist, WP9QY, both reversed behavioural reflex sensitisation following
CCI nerve injury. Additionally the enhanced phosphorylation of p38 and p42/44 MAP
kinases observed in the spinal cord as a result of nerve injury was seen to be prevented by
the application (incubated on the spinal cord) of the same glial and TNF-a inhibitors,
propentofylline and WP9QY and also by the inhibitor of TNF-a synthesis, thalidomide.
Propentofylline, a non-selective inhibitor of glial activation has been reported to attenuate
allodynia induced by nerve transection, as well as decreasing the formalin-induced
behavioural response (Dorazil-Dudzik et al., 2004; Sweitzer et al., 2001b). In this study a
more specific glial inhibitor, minocycline, which selectively blocks microglial activation
(Tikka et al., 2001), and the TNF-a synthesis inhibitor thalidomide were not investigated
for their effect on CCI induced behavioural sensitisation as minocycline has already been
shown to prevent the activation of MAP kinase caused by NMDA receptor stimulation
(Tikka and Koistinaho, 2001), and both compounds are known to attenuate behavioural
sensitisation in different chronic pain models (George et al., 2000; Raghavendra et al.,
2003a; Sommer et al., 1998a; Watkins and Maier, 2002).
It has been shown that expression of the pro-inflammatory cytokine TNF-a is
upregulated following peripheral nerve injury in the spinal cord (Bartholdi and Schwab,
1997; DeLeo et al., 1997; Wagner and Myers, 1996). Indeed local application of TNF-a
to afferents results in hyperalgesia and spontaneous activity in nociceptive afferent fibres
(Sorkin et al., 1997; Sorkin and Doom, 2000). Blocking the TNF-a receptor 1 through
use of a neutralising antibody was found to inhibit CCI nerve injury-induced behavioural
sensitisation and an antagonist to TNF-a receptor 2 also attenuates behavioural
sensitisation following nerve injury (Schafers et al., 2003; Sommer et al., 1998b;
Winkelstein et al., 2001). TNF-a can activate p38 MAP kinase and inhibit glutamate
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uptake, indeed blocking TNF-a results in reduction of nerve injury-induced p38
activation (Fine et al., 1996; Schafers et ah, 2003; Svensson et ah, 2005). Moreover
thalidomide (which inhibits TNF-a synthesis; Sampaio et ah, 1991) attenuates not only
the behavioural sensitisation seen following nerve injury but also reduces the increased
expression of TNF-a following CCI nerve injury (George et ah, 2000; Sommer et ah,
1998a). Together with the results presented here, these findings suggest that an increase
in the expression or release of TNF-a may play a part in the sensitisation found in
chronic pain states by activating either or both p38 and p42/44 MAP kinases in glial cells.
Another aspect of this study was looking at the involvement of the peptidergic receptors
VPAC2 and NK2; firstly the neurokinin receptors, NKj and NK2 whose ligands are SP
and NKA respectively. Here the CCI nerve injury-induced behavioural sensitisation was
prominently inhibited by the NK2 receptor antagonist with only mechanical allodynia
minimally inhibited by the NKi receptor antagonist. Correspondingly the CCI nerve
injury-induced enhanced activation of p38 and p42/44 MAP kinase was reduced by
incubation of the spinal cord with the NK2 and also by the NMDA receptor antagonists.
Secondly the peptidergic receptors for the excitatory peptide VIP, the VPAC2, VPACi
and the closely related PAC| receptors were also assessed. The VPAC2 receptor
antagonist markedly inhibited the CCI nerve injury-induced behavioural sensitisation,
while the VPACi receptor antagonist had no effect on behavioural sensitisation and the
PACi receptor antagonist only modestly reversed the behavioural sensitisation. The
VPAC2 receptor antagonist used here has been shown to have a high affinity (with a 100-
fold selectivity) for the VPAC2 receptor, whereas the PACi receptor antagonist, while
highly selective for the VPACi receptor, also has a moderately high affinity for the
VPAC2 receptor (Dickinson et al., 1997; Moreno et al., 2000), which may explain the
modest reversal in behavioural sensitisation observed here by the PACi receptor
antagonist. The enhanced activation of p38 and p42/44 MAP kinase following CCI nerve
injury was reduced by incubation of the spinal cord with the VPAC2 receptor antagonist.
This study also revealed that agonist stimulation of spinal VPAC2 receptors and to a
lesser degree, NK2 receptors, increases the activation of p38 MAP kinase, which was
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prevented when the glial inhibitor propentofylline was co-applied. Accordingly, the
VPAC2 receptor agonist resulted in behavioural sensitisation in naive animals that could
be prevented by co-administration of the p38 MAP kinase inhibitor SB 203580. Agonist
stimulation of NK2 receptors resulted in the activation of p42/44 MAP kinase to a greater
extent than that seen by VPAC2 receptor stimulation; this increased activation was again
blocked by co-applied propentofylline. The behavioural sensitisation induced in naive
animals by administration of the NK2 receptor agonist was correspondingly attenuated by
co-administration of the p42/44 MAP kinase inhibitor, U 0126. This suggests that p38
and p42/44 MAP kinase activation in the spinal cord may contribute to nerve injury-
induced sensitisation and that spinal VPAC2 and NK2 receptors respectively may be
important mediators of this injury-induced activation.
Glial cells express receptors for neurokinins, VIP and the excitatory amino acid
glutamate, all of which are implicated in chronic pain states. Neurokinins are known to
stimulate glial production of the pro-inflammatory cytokines IL-1 and TNF-a (Martin et
al., 1992). There is an increased phosphorylation of p38 MAP kinase in microglia
following the administration of SP, while Complete Freund's Adjuvant-induced
inflammation results in upregulation of both the NKi receptor and p42/44 MAP kinase
activation in the same dorsal horn neurons (Ji et al., 2002a; Svensson et al., 2003). NK2
receptors are thought to be specifically involved in the hyperexcitability of dorsal horn
neuron responses to noxious cutaneous stimuli (Fleetwood-Walker et al., 1990) and NK2
receptor antagonists were found to be antinociceptive when administered following nerve
injury (Coudore-Civiale et al., 1998; Fleetwood-Walker et al., 1990). Here the NK2
receptor antagonist attenuated behavioural sensitisation following CCI nerve injury to a
much greater extent than the NKi receptor antagonist. As a result, biochemical analysis
focused on NK2 receptors, which are located on spinal astrocytes, (also a site of p42/44
MAP kinase activation after nerve injury (Ma and Quirion, 2002). In addition to this the
activation of p42/44 MAP kinase in the dorsal horn following C-fibre stimulation is
known to involve neuronal NMDA receptors (Lever et al., 2003). It could be suggested
that the activation of p42/44 MAP kinase seen in this CCI nerve injury model could
partly be the result of glial NK2 receptor activation that leads to pro-inflammatory
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cytokine release and facilitation of the NMDA receptor's function. However with the
current results it is not possible to exclude the idea that part of this phosphorylation of
p42/44 MAP kinase as a result of NK2 receptor activation may be occurring in neurons
downstream of glial activation.
Following nerve injury, there is increased expression of the excitatory peptide VIP in
small primary sensory neurons of the DRG, in conjunction with a decreased SP
expression. These changes may represent a functional switch in peptides mediating
central sensitisation of nociception. Indeed expression of the VPAC2 receptor in the
dorsal horn is increased following nerve injury, corresponding to the marked inhibitory
effect of VPAC2 receptor antagonists on neuropathic sensitisation (Dickinson and
Fleetwood-Walker, 1999). VPAC2 receptors along with the other VPAC and PAC
receptor subtypes have been found to be expressed in astrocytes, VIP is capable of
inducing TNF-a release (in cultured astrocytes) and PACi receptor agonist stimulation of
cultured astrocytes induces p44 MAP kinase activation and an injury-induced increase in
TNF-a can be blocked by p38 MAP kinase inhibitors (Brenneman et al., 1990; Grimaldi
and Cavallaro, 1999; Jaworski, 2000; Joo et al., 2004; Kim et al., 2000; Schafers et al.,
2003). VIP acting through VPAC2 receptors can result in a mixture of cytokines being
released from astrocytes (including TNF-a) and can cause production of a
neuroprotective factor and astrocytogenesis (Brenneman et al., 2003; Delgado et al.,
2003; Zupan et al., 1998). Contrastingly VIP can inhibit TNFa production by injury or
lipopolysaccharide (LPS)-activated microglia when acting through the VPACi receptor
(Kim et al., 2000; Zusev and Gozes, 2004). One would not expect such qualitatively
different effects of VPACi and VPAC2 receptor activation (since their signalling
pathways are very similar) unless the localisation of these receptors is distinctively
different. In the present study the behavioural sensitisation caused by CCI nerve injury
was attenuated by the selective VPAC2 receptor antagonist, with little or no inhibition by
PACi or VPACi receptor antagonists. The increased phosphorylation of p38 MAP kinase
after CCI nerve injury was reduced by incubation of the spinal cord with the VPAC2
receptor antagonist and to a lesser degree by the NK2 receptor antagonist and applying a
VPAC2 receptor agonist to naive tissue resulted in activation of p38 MAP kinase
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(phosphorylation of p38 MAP kinase was induced to a smaller extent by the NK2 receptor
agonist). The corresponding behavioural study resulted in sensitisation in naive animals
upon administration of a VPAC2 receptor agonist that was reversed when co-administered
with the p38 MAP kinase inhibitor, SB 203580. Further experiments would have to be
conducted to determine if the p38 MAP kinase activation response is in VPAC2 receptor
containing cells, however these findings suggest that the VPAC2 receptors on spinal glial
cells could play an important role in nerve injury-induced p38 MAP kinase activation.
To summarise, peripheral nerve damage can result in the development of chronic pain
states that are highly resistant to classical analgesics. This current study reveals important
new evidence to support the developing hypothesis that glial cells play a key role in
spinal somatosensory processing. The results presented implicate the involvement of the
VPAC2, NK2 and NMDA receptors in the activation of p38 and p42/44 MAP kinases
following nerve injury, which contributes to the mechanism of sensitisation involved in
the chronic neuropathic pain state.
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5. Single point mutation of the SH3 domain of PSD-95 affects pain behaviours
5.1 Introduction
The Post Synaptic Density-95 protein (PSD-95) as reviewed in Chapter one (Section 1.7.3)
belongs to the membrane associated guanylate kinases (MAGUK) family of proteins that
can cluster ion channels on postsynaptic membranes at excitatory synapses and also
interact with signalling molecules and the cytoskeleton (Sheng, 2001; Sheng and Kim,
2002). PSD-95 is an adapter protein with multiple protein interaction domains that can
couple numerous proteins to for example the N-methyl-D-aspartate (NMDA) glutamate
receptor as identified by in vitro studies (Husi et al., 2000; Husi and Grant, 2001). To
reiterate, PSD-95 is comprised of three N-terminal PDZ (PSD-Dlg-ZO-1 homology)
domains, an SH3 (Src homology 3) domain and a GK (guanylate kinase-like) domain in its
C-terminal region (Figure 1.3). The importance of PSD-95 in plasticity was revealed with a
mouse germline mutant construct that abrogated several domains of PSD-95, resulting in
expression of a truncated form of PSD-95 lacking the PDZ 3, SH3 and GK domains,
known as PSD-95pdz1~2 (Migaud et al., 1998).
The PSD-95pdz1 2 mutant mice exhibited altered forms of NMDA receptor-dependent
forms of plasticity, such as learning, visual plasticity, cocaine sensitisation and neuropathic
pain (Fagiolini et al., 2003; Garry et al., 2003; Migaud et al., 1998; Yao et al., 2004).
Specifically the PSD-95pdz1"2 mutants were found to have enhanced LTP (long-term
potentiation) accompanied by severely impaired spatial learning (Migaud et al., 1998).
Using the PSD-95pdz1"2 mutant and wild type littermate mice, the functional impact of the
mutant PSD-95 construct on neuropathic behavioural reflex sensitisation was assessed
following nerve injury (CCI). In wild type mice, a progressive ipsilateral sensitisation was
shown by a reduction in latency of withdrawal to a thermal stimulus and of threshold to a
mechanical stimulus, along with an increased sensitivity to a cold stimulus when compared
to pre-surgical and contralateral values (Garry et al., 2003). However for the homozygous
PSD-95pdz1"2 mutants, hyperalgesia and allodynia associated with this model of
neuropathic pain were absent (Garry et al., 2003). This was consistent with a previous
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report showing a delay in the onset of hyperalgesia and allodynia development following
administration of a PSD-95 antisense reagent (Tao et al., 2001).
It was shown that the PSD-95pdz,~2 mutant and wild type mice both developed normal
inflammatory nociceptive behaviour following the injection of formalin that is both groups
displayed the same early and late phase formalin responses, therefore suggesting the
possibility that the requirement for PSD-95 may be selective for neuropathic rather than
inflammatory sensitisation (Garry et al., 2003). This phenotype may have stemmed from
functional loss of individual domains, the PDZ 3, SH3 or GK domains. This work raised
the idea that individual domains of PSD-95 might themselves have discrete functions in
different forms of sensitisation in different parts of the nervous system. This current study
aims to assess the role of one of these domains, the SH3 domain.
SH3 domains were first identified as regions of sequence similarity between divergent
signalling proteins such as the Src family of tyrosine kinases, the Crk adaptor protein and
phospholipase C-y (Mayer et al., 1988; Stahl et al., 1988). SH3 domains are found in many
signalling and cytoskeleton associated molecules, and are established as modular protein
interaction domains with a binding specificity for certain proline-rich motifs (Pawson and
Scott, 1997). The human proteome is estimated to contain over 400 copies of SH3 domain-
containing proteins spread among a diverse array of protein structures (Castagnoli et al.,
2004). The majority of SH3 domains characterized to date recognize class I and/or class II
peptides that share a core PXXP motif (Cohen et al., 1995; Erpel et al., 1995; Lim and
Richards, 1994; Mayer, 2001; Mayer and Eck, 1995; Sparks et al., 1998). The importance
of the SH3 domain in MAGUK function was revealed from mutational studies that resulted
in cellular mis-localisation and a severe phenotype of neoplastic overgrowth of imaginal
discs in Drosophila (Kohu et al., 2002; Woods et al., 1996). Knowledge of the consensus
SH3 binding motif, PXXP, has helped in the identification of some of PSD-95's SH3
binding partners, which include: Pyk 2, a non-receptor tyrosine kinase (Huang et al., 2001;
Seabold et al., 2003), Kainate KA2 receptor subunit (Garcia et al., 1998), Huntingtin
protein (Sun et al., 2001), A-Kinase-anchoring Protein (AKAP) 79/150 (Colledge et al.,
2000) and Mixed lineage kinase (MLK) 2 and 3 (Savinainen et al., 2001).
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The SH3 domain has been structurally analysed by X-ray crystallographic studies of
several proteins resulting in a prototypical SH3 domain structure (Borchert et al., 1994;
Guruprasad et al., 1995; Musacchio et al., 1992; Musacchio et al., 1994; Noble et al.,
1993), which confirmed the basis of the SH3 domain's interaction with proline-rich
sequences (Erpel et al., 1995; Lim and Richards, 1994). Such X-ray crystallography studies
also identified a key role played by tryptophan 470 in the SH3 domain of PSD-95, which
was found to correspond to the highly conserved tryptophan residue found in the
hydrophobic binding surface of SH3 domains that is thought to contribute to interaction
with proline-containing peptides (Erpel et al., 1995; Lim and Richards, 1994). A mutant
mouse construct was therefore generated by Seth Grant's group that carried a targeted
mutation to tryptophan 470 in PSD-95 so that SH3 domain interactions with polyproline
residues would be specifically disrupted whilst leaving the GK domain and all PDZ
domains of PSD-95 and their interactions intact. The corresponding amino acid substitution
of leucine to proline in the SH3 domain of the Drosophila homolog of PSD-95 (Discs large,
Dig) causes a severe mutant phenotype of loss of septate junctions and overproliferation of
imaginal discs, suggesting that the mutation is effective at disrupting SH3 domain function
and that such functions are of physiological importance (Woods et al., 1996). Using these
PSD-95sh3W470l mutant mice (and the wild type littermate mice as controls), we examined
their behavioural response to a model of experimental mononeuropathy (CCI), to a model
of persistent inflammation, Complete Freund's Adjuvant (CFA) and to formalin-induced
responses, the aim of this was to characterise the pain state phenotype that may occur as a
result of this mutation of the SH3 domain.
As noted in Chapter one (Section 1.4.2 and 1.7.3) NMDA receptors are crucially involved
in sensitisation of spinal dorsal horn neurons (Coderre and Melzack, 1992a; Davies and
Lodge, 1987; Dickenson and Sullivan, 1987a; Suzuki et al., 2001; Woolf and Thompson,
1991). The NMDA receptor has two principal subunits, NR1 and NR2, with the NR1
subunit being the core functional subunit of all NMDA receptor assemblies and NR2
subunit subtypes (A-D) determine the specific channel characteristics and engage in key
interactions (Monyer et al., 1992). PSD-95 binds directly to the C-termini of the NMDA
receptor subunits NR2A and NR2B via its PDZ domains (Chaplan et al., 1997). The
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expression of the NMDA receptor subunits NR1, NR2A and NR2B was therefore also
examined in the spinal cord. The family of MAGUK proteins expression in the spinal cord
was also assessed to determine if this mutation of the SH3 domain altered overall levels of
PSD-95 expression and also to see if any other MAGUK was compensating for the
mutation in PSD-95 by altering its level of expression.
5.2 Generation of the psp_95SH3W470L mutant mouse
This mouse line carrying a targeted mutation into the SH3 domain of PSD-95, termed PSD-
95s"3W470l mutant was generated in Seth Grant's laboratory (Wellcome Trust Sanger
Institute, Cambridgeshire, UK). As outlined above, tryptophan 470 of PSD-95 was found to
correspond to the highly conserved tryptophan residue found in the hydrophobic binding
surface of prototypical SH3 domains, which mediates interactions with proline-containing
peptides (Erpel et al., 1995). This point was chosen to introduce a single amino acid
mutation substituting leucine at this tryptophan site, thereby intending to selectively disrupt
SH3 domain polyproline interactions. This single amino acid mutation that created the
PSD-95SH3W470L mutant mice used a gene targeting construct that was transfected into
mouse embryonic stem (ES) cells. Homologous recombination into the PSD-95 locus was
detected by genomic Southern blotting and PCR (polymerase chain reaction). Positive ES
cells (i.e. carrying the targeted mutation) were injected into mouse blastocysts. Resulting
chimeric offspring were crossed onto the MF1 background for subsequent studies. PSD-
95sh3W470l |jtters were genotyped (by PCR) and homozygotes were found to be fertile,
show normal Mendelian transmission and no obvious seizure, tremor, ataxia or other overt
neurological abnormality was observed. [All of this work detailed in Section 5.2 was
carried out by Seth Grant's laboratory].
5.3 Methods
Throughout this study the experimenter was blinded to the genotype of the animals and
only homozygous PSD-95SH3W470L mutants and wild type littermate mice that were age
matched were used. Animals of both sexes were used since post-hoc analysis revealed no
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discernable differences in their responses in the case of either wildtype or mutant mice. As
outlined in Chapter 3 the following methods were used in this study: adult PSD-95sh3W470l
mutant (n=6) and wild type littermate (n=6) mice underwent surgery for a model of
experimental mononeuropathy, a unilateral chronic constriction injury to the sciatic nerve
(CCI; Section 3.2.1). PSD-95SH3W470L mutant (n=4) and wild type littermate (n=4) mice
were used for the Complete Freund's adjuvant model of experimental persistent
inflammation (CFA; Section 3.2.2). All animals were behaviourally tested (Section 3.4)
prior to surgery/injection (to obtain baseline values) and post surgery (from day 4)/ post
injection (from 30 minutes) until recovery (day 21 post surgery) from CCI and until 48
hours post injection of CFA. All animals were tested for signs of mechanical allodynia
using calibrated Von Frey filaments (Section 3.4.2) and for signs of thermal hyperalgesia
using the Hargreaves' thermal apparatus (Section 3.4.4). Adult PSD-95SH3W470L mutant
(n=9) and wild type littermate (n=8) mice that were used for intraplantar injection of
formalin (1.5% solution: Section 3.2.3) were assessed for their formalin-induced
behavioural response (Section 3.3), which consisted of flicking, flinching and licking of the
affected hind-paw, until recovery (70 minutes post-injection).
The expression of NMDA receptor subunits and of the MAGUK family of proteins in the
spinal cord was assessed in naive PSD-95sh3W470L mutant (n=2) and wild type littermate
(n=3) mice by western immunoblot. Animals were terminally anaesthetised prior to and
during dissection of all tissues and a laminectomy of the lumbar region of the mice was
performed and spinal cord tissue was homogenised in standard Laemmli lysis buffer to
prepare spinal cord extracts (Section 3.6.1). Extracts were then separated by electrophoresis
and transferred to PVDF membranes, blocked and probed for NMDA receptor subunits
(rabbit polyclonal anti-NRl, rabbit polyclonal anti-NR2A and rabbit polyclonal anti-
NR2B) or for MAGUK proteins (mouse monoclonal anti-PSD-95, rabbit polyclonal anti-
SAP-97, rabbit polyclonal anti-SAP-102 and rabbit polyclonal anti-PSD-93/Chapsyn 110)
and for the ubiquitous housekeeping protein GAPDH and detected by peroxidase-linked
secondary antibodies (goat-anti-mouse or goat-anti-rabbit) and enhanced
chemiluminescence (Section 3.6.3). Densitometry was performed to measure quantitatively
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the grey levels of positive protein bands and background grey levels relative to GAPDH
(with the absolute numerical values derived being arbitrary; Section 3.8.2).
5.4 Results
5.4.1 Analysis of behavioural reflex changes in pgp.95SH3W470L mutant and wild type
littermate mice with chronic constriction injury to the sciatic nerve (CCI).
All PSD-95SH3W470l mutant and wild type mice that underwent a unilateral CCI to the
sciatic nerve appeared healthy and had no signs of weight loss and were handled without
any distress being evident. During this study none of the PSD-95SH3W470L mutant and wild
type mice developed any signs of autotomy.
Thermal hyperalgesia (see Figure 5.1 A (wild type) and B (PSD-95SH3W470L mutants))
All animals were behaviourally tested for signs of thermal hyperalgesia, using the
Hargreaves' thermal apparatus (Section 3.4.4). In analysing the behavioural reflex changes,
the baseline (pre-surgical) paw withdrawal latency (PWL) was measured as ipsilateral, 8.9
± 0.6 seconds in wild type and 8.0 ± 0.5 seconds in PSD-95sh3W470l mutants and
contralateral, 8.2 ± 0.5 seconds in wild type and 8.1 ± 0.6 seconds in PSD-95sh3W470l
mutants (mean ± SEM responses; n=6 in all groups). At all time points from the fourth day
until the eighteenth day post-surgery, both wild type and PSD-95SH3W4701' mutants showed
significantly reduced PWL ipsilateral to the injury as compared to the contralateral side
(p<0.05 by Student's t-test) and a significant reduction in PWL was also seen between
post-surgical and pre-surgery values (p<0.05; One Way Repeated Measures ANOVA
followed by Dunnett's post-hoc analysis). No significant difference remained in the PWL
from the nineteenth to the twenty-first day post-surgery, the animals were no longer tested
after this time point. Both wild type and PSD-95SH3W470L mutants reached a peak of thermal
hyperalgesia between the thirteenth and fourteenth days post-surgery when the ipsilateral
PWL was 5.0 ± 0.9 seconds in wild type and 4.7 ± 0.9 seconds in PSD-95sh3w470l mutants
and contralateral 8.1 ± 0.9 seconds in wild type and 8.2 ± 1.0 seconds in PSD-95SH3W470L
mutants (mean ± SEM responses). The contralateral PWL showed no significant reduction
in its response.
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Mechanical Allodynia (see Figure 5.1 C (wild type) and D (PSD-95s"3W470L mutants))
Wild type and PSD-95sh3W470l mutant mice were tested for signs of mechanical allodynia
using calibrated Von Frey filaments (Section 3.4.2). In assessing the behavioural reflex
changes, the baseline (pre-surgical) paw withdrawal threshold (PWT) required to elicit a
paw withdrawal response ipsilaterally was 602.6 ± 34.6 mN/mm2 in wild type and 551.7 ±
37.2 mN/mm2 in PSD-95SH3W470L mutants and contralaterally was 616.6 ± 36.3 mN/mm2 in
wild type and 571.1 ± 35.0 mN/mm2 in PSD-95sh3W470L mutants (mean ± SEM response).
At all time points from the fourth day until the eighteenth day post-surgery, both wild type
and PSD-95sh3w470l mutants demonstrated an increased sensitivity to mechanical stimuli
with a significantly reduced PWT ipsilateral to the injury as compared to the contralateral
side (p<0.05 Wilcoxon test) and a significant reduction in PWT was also seen between
post-surgical and pre-surgery values (p<0.05; Friedman test on ranks followed by Dunn's
post-hoc analysis). Again, consistent with results for thermal hyperalgesia there was no
significant difference observed in the PWT from the nineteenth to the twenty-first day post-
surgery and animals were no longer tested after this time point. Both wild type and PSD-
95SH3w47ol mutants reached a peak of mechanical allodynia between the eighth and twelfth
days post-surgery when the ipsilateral PWT was 318.2 ± 48.3 mN/mm2 in wild type and
222.6 ± 17.0 mN/mm2 in PSD-95SH3W470L mutants and contralateral 449.9 ± 43.9 mN/mm2
in wild type and 485.0 ± 58.5 mN/mm2 in PSD-95SH3W470L mutants (mean ± SEM
response).
These results presented here for the development of both thermal hyperalgesia and
mechanical allodynia ipsilateral to nerve injury, are in agreement with previous reports
using this model of CCI in mice (Garry et al., 2003; Vogel et al., 2003).
5.4.2 Analysis of formalin-induced behavioural response in pgp_95SH3w470L mutant
and wild type littermate mice.
All PSD-95SH3W470l mutant and wild type mice, where formalin was injected
subcutaneously into the plantar surface of the hind paw, were allowed five minutes to
recover before analysis began, which consisted of counting the number of flick/flinch
responses per minute of the affected paw (see Figure 5.2).
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The baseline (pre-injection) number of flick/flinch responses per minute was ipsilateral 0 ±
0 flick/flinches per minute in wild type and 0 ± 0 flick/flinches per minute in PSD-
9^siI3W470L mutants an(j contralateral 0 ± 0 flick/flinches per minute in wild type and 0 ± 0
flick/flinches per minute in PSD-95SH3W470L mutants (mean ± SEM response; n=9 PSD-
95sh3W470l mutants an(j n=8 wild type mice). There was no significant alteration between
responses of wild type and PSD-95SH3W470L mutant mice in the initial acute phase (first
phase; 5-20 minutes post-injection of formalin), however in the late phase (second phase;
25-70 minutes post-injection), PSD-95sh3W470L mutant mice had a significant reduction in
responses, to 7.3 ± 0.5 flick/flinches per minute compared to wild type response of 14.9 ±
0.7 flick/flinches per minute, with contralateral values remaining at 0 ± 0 flick/flinches per
minute in both PSD-95sh3W470l mutants and wild type (p<0.05 Student's t-test; from 25-50
minutes post-injection). During the time points of 50-70 minutes post-injection no
significant difference between PSD-95sh3W470l mutants and wild type mice was noted. The
animals were not assessed beyond 70 minutes post-injection as they had recovered from the
formalin-induced behavioural response. Control animals were injected with an equal
volume of saline (Section 3.2.3) and assessed for their response. In the case of both wild
type and PSD-95SH3W470L mutant mice no response to saline was observed at any time point
(from 5-70 minutes post-injection).
5.4.3 Analysis of behavioural reflex responses in psp_95SH3w470L mutant and wild type
littermate mice following the Complete Freund's Adjuvant model of persistent
inflammation
All PSD-95SH3W470L mutant and wild type mice injected with CFA showed signs of
cutaneous inflammation within the first hour post-injection, showing an area of localised
erythema and oedema of the injected paw that was present throughout testing and was
similar between all animals.
Thermal Hyperalgesia (see Figure 5.3 A)
All animals were behaviourally tested for signs of thermal hyperalgesia, using the
Hargreaves' thermal apparatus (Section 3.4.4). In characterising the behavioural reflex
changes, the baseline (pre-surgical) paw withdrawal latency (PWL) was measured as
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ipsilateral, 8.9 ± 0.6 seconds in wild type and 8.0 ± 0.5 seconds in PSD-95SH3W470L mutants
and contralateral, 8.2 ± 0.5 seconds in wild type and 8.1 ± 0.6 seconds in PSD-95SH3W470L
mutants (mean ± SEM responses; n=4 in all groups). At 0-6 hours post-injection (no
discernable difference from 0.5 to 6 hours) both wild type and PSD-95SH3W470L mutants
showed significantly reduced PWL ipsilateral to CFA, to values of 2.4 ± 0.4 seconds in
wild type and 2.8 ± 0.4 seconds in PSD-95SH3W470L mutants, with contralateral values of
9.1 ± 1.7 seconds in wild type and 6.9 ±1.2 seconds in PSD-95SH3W470L mutants (mean ±
SEM response; p<0.05 by Student's t-test) and a significant reduction in PWL was also
seen between post-injection and pre-injection values (p<0.05 by One Way Repeated
Measures ANOVA followed by Dunnett's post-hoc analysis). At 24 hours post-injection
only wild type mice still showed a significantly reduced PWL response ipsilateral to CFA,
to 3.9 ± 0.7 seconds (with a now not significantly reduced response of 7.2 ± 0.5 seconds in
PSD-95SH3W470L mutants) as determined by Student's t-test (p<0.05; mean ± SEM
response). This was compared to the contralateral response of 9.3 ± 0.6 seconds in wild
type mice and 7.3 ± 0.5 seconds in PSD-95SH3W470L mutants. PSD-95sh3w470l mutants had a
significantly greater ipsilateral thermal response latency following CFA when compared to
the wild-type ipsilateral response as determined by Student's t-test (p<0.05; mean ± SEM
response). Again at 48 hours post CFA injection a significant PWL reduction was only seen
ipsilaterally in wild type mice, to 2.3 ± 0.1 seconds (with a response of 6.2 ± 0.6 seconds in
PSD-95SH3W470l mutants) compared to the contralateral values of 8.7 ± 1.1 seconds (6.6 ±
0.6 seconds in PSD-95sh3w470l mutants; mean ± SEM response). Again the PSD-95sh3w470l
mutants mean thermal response latency ipsilateral to CFA was significantly greater than the
ipsilateral values for the wild-type littermates as determined by Student's t-test (p<0.05;
mean ± SEM response). At 24 and 48 hours post-injection a significant ipsilateral reduction
in PWL was also seen between post-injection and pre-injection values in wild-type and at
48 hours in PSD-95SH3W470L mutants both ipsilateral and contralateral to CFA injection
(p<0.05 by One Way Repeated Measures ANOVA followed by Dunnett's post-hoc
analysis. At all other time points the contralateral PWL responses showed no significant
alterations. PSD-95SH3W470L mutants and wild type mice both developed thermal
hyperalgesia at the early stage of 0-6 hours post CFA injection, however this did not
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continue in the PSD-95sh3w470L mutants at 24 and 48 hours post CFA injection, but the
behavioural reflex sensitivity continued in the wild type mice .
Mechanical Allodynia (see Figure 5.3 B)
Wild type and PSD-95sh3w470L mutant mice were tested for signs of mechanical allodynia
using calibrated Von Frey filaments (Section 3.4.2). In determining the behavioural reflex
changes, the baseline (pre-surgical) paw withdrawal threshold (PWT) required to elicit a
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paw withdrawal response ipsilaterally was 602.6 ± 34.6 mN/mm in wild type and 551.7 ±
37.2 mN/mm2 in PSD-95sh3w470l mutants and contralaterally was 616.6 ± 36.3 mN/mm2 in
wild type and 571.1 ± 35.0 mN/mm2 in PSD-95SH3W470L mutants (mean ± SEM response).
At 0-6 hours post-injection, both wild type and PSD-95SH3W470L mutants demonstrated an
increased sensitivity to mechanical stimuli with a significantly reduced PWT ipsilateral,
231.1 ± 65.3 mN/mm2 in wild type and 318.19 ± 69.3 mN/mm2 in PSD-95SH3W470L mutants
compared to the contralateral response of 441.0 ± 70.2 mN/mm2 in wild type and 508.79 ±
55.1 mN/mm2 in PSD-95SH3W470L mutants (p<0.05 Wilcoxon test; mean ± SEM response).
Significant reductions in PWT were also seen ipsilateral to CFA between post-injection and
pre-injection values in both wild type and PSD-95SH3W470L mutants (p<0.05 Friedman test
on ranks followed by Dunn's post-hoc analysis), consistent with results observed for
thermal hyperalgesia. At 24 hours post-injection only wild type mice showed significantly
reduced ipsilateral PWT responses compared to contralateral controls (ipsilateral, 387.6 ±
52.2 mN/mm2 in wild type and 381.6 ± 27.7 mN/mm2 in PSD-95SH3W470L mutants) as
determined by Wilcoxon test (p<0.05; mean ± SEM response). Contralateral responses
were 497.6 ±81.1 mN/mm2 and 387.6 ± 26.5 mN/mm2 in PSD-95sh3W470L mutants. At 24
hours post CFA injection a significant ipsilateral reduction in PWL was seen between post-
injection and pre-injection values in wild-type and PSD-95SH3W470L mutants (p<0.05 by
One Way Repeated Measures ANOVA followed by Dunnett's post-hoc analysis. At 48
hours post CFA injection, no significant reduction could be seen in PWL ipsilateral to the
stimulus in wild type mice or in PSD-95SH3W470L mutants, with ipsilateral values of 326.9 ±
95.5.8 mN/mm2 in wild type and 385.2 ± 33.2 mN/mm2 in PSD-95SH3W470L mutants (as
determined by Wilcoxon test; p<0.05; mean ± SEM response). This compared to
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contralateral values of 490.4 ± 98.6 mN/mm2 in wild type and 254.9 ± 26.5 mN/mm2 in
PSD-95SH3W470L.
5.4.4 NMDA receptor subunit and MAGUK expression in the spinal cord of PSD-
9gSH3W470i> mu^an^ an(j type littermate mice
NMDA receptor subunits (see Figure 5.4 A and Table 5.1 A)
The levels of NMDA receptor subunits, NR1, NR2A and NR2B expression in spinal cord
extracts of naive wild type and PSD-95SH3W470L mutant mice were assessed by immunoblot.
As compared by quantitative densitometry to the expression of GAPDH, the ubiquitous
housekeeping protein, the level of NR1 expression was 66.8 ± 5.3% in PSD-95SH3W470L
mutants and 62.8 ± 3.8% in wild type, with NR2A expression 51.9 ± 2.1% in PSD-
95SH3w470l an(j 45 q ± 17% }n wjid type and NR2B expression 36.9 ± 3.4% in
PSD-95sh3W470l mutants and 37.4 ± 2.5% in wild type (mean ± SEM; percent of GAPDH
expression; n= 2 PSD-95SH3W470L mutants and n=3 wild type mice). These results show that
the levels of expression of the NMDA receptor subunits were unaltered by the PSD-
95SH3w47oi mutation when compared to wild-type (levels were found to be not significantly
different when assessed by Student's t-test).
MAGUK protein family (see Figure 5.4 B and Table 5.1 B)
In naive wild type and PSD-95SH3W470L mutant mice the expression of the four members of
the MAGUK family of proteins (PSD-95, SAP-97, PSD-93/Chapsyn 110 and SAP-102)
were assessed by immunoblot. The level of expression of PSD-95 was 74.5 ± 3.4% in PSD-
95SH3W470L mutants an(j 7Q 3 ± 3 2% in wild type, for SAP-97 expression was 76.1 ± 3.7%
in psd_95sh3W47ol mutants and 73.6 ± 3.9% in wild type, PSD-93 expression was 39.9 ±
0.4% in PSD-95SH3W4701 mutants and 41.2 ± 0.3% in wild type and SAP-102s expression
was 71.7 ± 2.9% in PSD-95SH3W470L mutants and 75.6 ± 2.6% in wild type (mean ± SEM;
percent of GAPDH expression; n= 2 PSD-95SH3W470L mutants and n=3 wild type mice).
These findings demonstrate that the expression of MAGUKs in the spinal cord is unaltered
by the PSD-95SH3W470L mutation when compared to wild type (levels were found to be not
significantly different between the two groups when assessed by Student's t-test).
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Figure 5.1
Behavioural analysis of PSD-95SH3W470L mutant and wild type littermate mice in a
model of experimental mononeuropathy (CCI).
Data show mean ± SEM responses prior to surgery (baseline) and following the induction
of a unilateral chronic constriction injury (CCI) to the sciatic nerve (post surgery). (A and
B) In wild type (A) and PSD-95SH3W470L mutant (B) mice (n=6 in both groups), paw
withdrawal latency (PWL) from a noxious thermal stimulus (Hargreaves' thermal
stimulator) ipsilateral to CCI (O) showed significant differences between post-operative
and pre-operative values (f p<0.05; One Way repeated-measures ANOVA followed by
Dunnett's post hoc analysis) and from postoperative contralateral (■) values (* p<0.05 by
Student's t-test). No thermal hyperalgesia was seen on the contralateral side (■) of either
wild type (A) or PSD-95sh3W470l mutant (B) mice. (C and D) Paw withdrawal thresholds
(PWT) from mechanical stimulation (von Frey filaments) for both wild type (C) and PSD-
95SH3W47ol mutant (£)) mice showed significant reductions in post-operative compared to
pre-operative values ipsilateral (O) to CCI (f p<0.05; Friedman on ranks test followed by
































































Behavioural analysis of PSD-95SH3W470L mutant and wild type littermate mice
following the intraplantar injection of formalin.
Data shows mean ± SEM number of paw flick/flinch responses per minute. There was no
significant difference between responses of wild type (♦) and PSD-95sh3W470L mutant (O)
mice (n=9 in PSD-95sh3W470L mutants and n=8 in wild type mice) in the initial acute phase
(5-20 minutes post-injection), however in the late (second; 25-70 minutes post-injection)
phase of the formalin test, PSD-95sh3w470l mutant (<C>)mice showed a significant reduction
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Figure 5.3
Behavioural analysis of PSD-95SH3W470' mutant and wild type littermate mice
following intraplantar injection of complete Freund's adjuvant.
Data show mean ± SEM responses prior to injection (baseline) and following the injection
of complete Freund's adjuvant (CFA). (A) In wild type (WT, white) and PSD-95SH3W470L
mutant (SH3"/_, grey) mice (n=4 in both groups), paw withdrawal latency (PWL) from a
noxious thermal stimulus (Hargreaves' thermal stimulator) showed a significant ipsilateral
(I) reduction in latency from contralateral (C) values at all time points in wild-type mice
(white dotted) and only at the earliest time point in PSD-95SH3W470L mutant mice (grey
dotted; *p<0.05 by Student's t-test). Significant differences between pre- and post-injection
values were determined by a-One Way repeated-measures ANOVA followed by Dunnett's
post-hoc analysis (f p<0.05). No thermal hyperalgesia was seen on the contralateral side of
either wild type or PSD-95SH3W470L mutant mice. At 24 and 48 hours post CFA a significant
increase in PWL ipsilateral to CFA was seen in PSD-95SH3W470L mutants when compared to
the wild type ipsilateral response (*p<0.05 by Student's t-test) indicating that sensitisation
was attenuated in the mutant mice. (B) In wild-type (WT, white) and PSD-95sh3w470l
(SH3"/_, grey), paw withdrawal thresholds (PWT) from mechanical stimulation (von Frey
filaments) were significantly reduced between ipsilateral (I; white and grey) and
contralateral (C; white dotted and grey dotted) paws (*p<0.05 by Wilcoxon test) at 0-6
hours post-injection. However, although a significant reduction was seen in wild-type mice
at 24 hours, there was no significant ipsilateral reduction in the threshold required to elicit a
response in PSD-95sh3w470L mutants. No significant ipsilateral reduction in threshold was
seen in either wild type or PSD-95SH3W470L mutants at 48 hours post CFA injection.
Significant differences between pre- and post-injection values were determined by
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Expression of NMDA receptor subunits and MAGUK proteins in the spinal cord of
PSD-95SH3W470L mutant and wild type mice.
(A) Immunoblots of the NMDA receptor subunits NR1, NR2A and NR2B and the
ubiquitous housekeeping enzyme GAPDH in spinal cord extracts of PSD-95sh3W470L
mutant n=2) and wild type (n=3) mice. (B) Immunoblots of MAGUK proteins; PSD-
95, SAP-97, PSD-93 and SAP-102 as well as GAPDH in spinal cord extracts of PSD-
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Table 5.1
The expression of NMDA receptor subunits and MAGUK proteins relative to
GAPDH expression in spinal cord extracts.
Data shows the percent expression ± SEM as determined by densitometric analysis in wild
type (n=3) and psD-95SH3w470L mutant n=2) mice of (A) NMDA receptor subunits and
(B) MAGUK proteins relative to GAPDH expression in spinal cord extracts. No significant
differences were found (when assessed by Student's t-test) in the expression levels of the
NMDA receptor subunits, NR1, NR2A and NR2B. The expression of the MAGUK
proteins, PSD-95, SAP-97, PSD-93 and SAP-102 were also found to be not significantly
different (when assessed by Student's t-test) between wild type and PSD-95SH3W470L mutant
(-/-) mice.
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Protein Wild type SH3W470L(-/~)
A. Expression of NMDA Receptor subunits as a percentage of GAPDH expression
in spinal cord extracts
NR1 62.8 ± 3.8 66.8 ± 5.3
NR2A 45.0 ± 1.7 51.9 ±2.1
NR2B 37.4 ±2.5 36.9 ±3.4
B. Expression of MAGUK proteins as a percentage of GAPDH expression in spinal
cord extracts
PSD-95 70.3 ± 3.2 74.5 ± 3.4
SAP-97 73.6 ±3.9 76.1 ±3.7
PSD-93 41.2 ±0.3 39.9 ±0.4
SAP-102 75.6 ±2.6 71.7 ±2.9
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5.5 Discussion
Research into the role played by PSD-95 in the development of spinal nociception, utilising
either antisense knockdown or mutant mice expressing a truncated form of PSD-95, (PSD-
95pdz'"2) have established the importance of PSD-95 in nociceptive sensory processing
(Garry et al., 2003; Tao et al., 2001). The present study was conducted to investigate the
effect of a single point mutation to the SH3 domain of PSD-95 on the plasticity of spinal
neuronal signalling involved in different pain states. The recent development of mice with
a mutation in the SH3 domain of PSD-95 (PSD-95SH3W470L mutants) have, now allowed
further investigation into the role of this domain in different pain states.
The PSD-95SH3W470l mutation was designed using available information from X-ray
crystallographic studies on several SH3 domains (Borchert et al., 1994; Guruprasad et al.,
1995; Musacchio et al., 1992; Musacchio et al., 1994; Noble et al., 1993), which identified
tryptophan 470 in the SH3 domain of PSD-95 as a conserved residue in the hydrophobic
binding surface of prototypical SH3 domains that mediates interaction with proline rich
peptides (Erpel et al., 1995; Lim and Richards, 1994). However recent investigations into
the structure of PSD-95's SH3 domain lead to the discovery of novel structural features of
this SH3 domain. Unlike typical SH3 domains, PSD-95's SH3 domain is composed of
discontinuous elements of sequence, divided by a large hinge region and the GK domain
(Shin et al., 2000). The SH3 domain of PSD-95 was found to contain an extra P strand in
its structure (six P strands (A-E) instead of five) and a large hinge region, which may
occlude the peptide binding region, thus suggesting that ligands may bind in an atypical
manner (McGee et al., 2001). The crystal structure of PSD-95 also revealed novel
intramolecular interactions between the SH3 and GK domain which did not involve the
polyproline binding site of the SH3 domain (Tavares et al., 2001). These studies suggest
that the SH3 domain of PSD-95 has alternative surfaces for intra- and inter-molecular
interactions, raising the possibility that this domain may contain multiple binding sites
(McGee et al., 2001; Tavares et al., 2001; Yaffe, 2002).
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The PSD-95sh3W470l mutation, a highly specific mutation designed to interfere with
particular protein-protein interactions, was shown here to not alter the expression of PSD-
95 in the spinal cord or indeed of other members of the MAGUK family when compared to
wild type littermates (Figure 5.4). As PSD-95 assembles with the NMDA receptor, thus
coupling the receptor to distinct intracellular pathways that may mediate downstream
changes, it was investigated whether the PSD-95SH3W470L mutation altered the expression
levels of NMDA receptor subunits. Expression of the NMDA receptor subunits was found
to be unaffected by the PSD-95SH3W470L mutation when compared to wild type littermates
(Figure 5.4). Thus the PSD-95SH3W470L mutation did not result in overall changes in levels
of NMDA receptor subunit or MAGUK expression in the spinal cord, therefore suggesting
that the phenotype displayed by this mutation may not have been the result of
compensation by other MAGUK proteins but is likely to be due to the mutation itself.
PSD-95SH3W470l mutants were found to develop the same behavioural reflex sensitivity to
both thermal (Hargreaves' thermal stimulator) and mechanical (von Frey filaments) stimuli
following peripheral nerve injury to that seen in wild type littermate mice. The PSD-
95sh3W470l mutants were tested to see if this mutation would disrupt sensitisation caused by
inflammation using the intraplantar injection of formalin (Chaplan et al., 1997). The
formalin test elicits a biphasic nociceptive response (Dubuisson and Dennis, 1977),
consisting of an early intense response (first phase) and a more prolonged response (second
phase). This biphasic response has been characterised by behavioural and
electrophysiological measures (Chaplan et al., 1997; Coderre and Melzack, 1992b;
Dickenson and Sullivan, 1987c; Dickenson and Sullivan, 1987b; Haley et al., 1990;
Wheeler-Aceto and Cowan, 1991). There appeared to be no difference between PSD-
95sh3W470l mutant mice ancj wiid type littermate responses in the first phase of the formalin
test. However PSD-95SH3W470L mutant mice had a greatly reduced second phase of the
response compared to wild type littermates.
The first phase of the formalin response is considered to be of peripheral origin that is, a
direct effect of formalin on peripheral nociceptive endings, where MAGUKs are generally
thought not to be expressed (Garry et al., 2003; Tao et al., 2003a). This may explain the
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findings presented here of an intact first phase response in both PSD-95SH3W470L mutant and
wild type littermate mice. The second phase of the formalin test appears to be driven by
both ongoing peripheral activity (Dallel et al., 1995; Puig and Sorkin, 1996; Taylor et al.,
1995) and by central sensitisation in the spinal cord (Chaplan et al., 1997; Coderre et al.,
1990; Coderre and Melzack, 1992b; Dickenson and Sullivan, 1990; Haley et al., 1990;
Villetti et al., 2003). This idea that the second phase of the formalin response may not be
mediated by central sensitisation alone, may explain why the PSD-95sh3W470l mutation
resulted in a blunted response rather that a complete lack of second phase response.
PSD-95sh3w470l mutants were assessed to see if their response to Complete Freund's
Adjuvant as a model of persistent inflammation was attenuated by this single point
mutation. PSD-95SH3W470L mutants and wild type mice both developed the same ipsilateral
behavioural reflex sensitivity to thermal and mechanical stimuli at the early stage of 0-6
hours post CFA injection. Interestingly this sensitivity does not continue in the PSD-
95sh3W47ol mutants at the later stages of 24 and 48 hours post CFA injection unlike wild
type mice which continued to display behavioural reflex sensitivity at these later times post
CFA injection (up to 24 hours for mechanical allodynia in wild type).
Previous findings have reported the CFA response as having an acute phase (seen around 4
hours post injection), a subacute phase (represented by day 4 post injection) and a chronic
phase (seen by day 14 post injection) (Parra et al., 2002; Raghavendra et al., 2004). Other
reports have described a broadly similar profile of the CFA response involving behavioural
sensitisation as early as 2-6 hours (Ji et al., 2002; Zhang et al., 2003) with recovery around
day 5 post CFA injection (Zhang et al., 2003) and sensitisation to a thermal stimulus seen
by 3 days but with recovery by 9 days post CFA injection (Molliver et al., 2005). The CFA
inflammatory response seems to be quite variable perhaps depending on site of injection,
however in most of these reports there seems to be an early onset of sensitisation followed
by a sustained stage of sensitisation that can last up to 5-14 days post injection.
It has been suggested that in contrast to later times following CFA, the early time point of 6
hours may be a result of peripheral inflammation, as the use of a specific inhibitor (of p38
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mitogen-activated protein (MAP) kinase), when administered into the intrathecal space via
a catheter (at the level of L4) attenuated thermal hyperalgesia at 24 and 48 hours post CFA
injection but had no effect at 6 hours post CFA injection and did not alter oedema or
macrophage number in the inflamed skin, suggesting that intrathecal administration of the
inhibitor did not alter peripheral inflammation (Ji et al., 2002). Here behavioural reflex
sensitisation is seen ipsilaterally at 0-6 hours but not observed at the later times of 24 and
48 hours post CFA injection in PSD-95SH3W470L mutants, the above report (Ji et al., 2002)
suggests that the early stage of the CFA response may be of peripheral origin, which could
explain why behavioural reflex sensitisation is still seen in PSD-95sh3W470l mutants at this
early time point in contrast to that at later times, which may be centrally mediated. The
PSD-95sh3W470l mutants here have highlighted the possibility of differences in the
behavioural response as a result of CFA injection, at different stages of the response, by
showing differences between the early and sustained stages.
However this does not explain why the PSD-95SH3W470L mutation itself has lead to such a
blunted inflammatory response. Due to previous findings of the persistence of the formalin
response in PSD-95pdzi~2 mutant mice, where the third PDZ, the SH3 and the GK domains
are absent, an explanation for an attenuated inflammatory response here in the PSD-
95SH3w47ol mutants might be explained by taking into account some novel structural
features as outlined above of PSD-95's SH3 domain. The PSD-95SH3W470L mutants have an
SH3 domain with a mutation to its hydrophobic binding surface (the region containing the
PXXP motif), which may prevent the intermolecular binding of the SH3 domain, thus
resulting in disruption of the inflammatory response in these PSD-95SH3W470L mutants. The
PSD-95pdz1"2 mutants show a formalin response equal to that of wild type, yet they lack
PDZ 3, SH3 and GK domains (Garry et al., 2003). This could be explained by the
possibility that although the SH3 domain intermolecular binding is prevented in the PSD-
95PDZi"2 mutation, so too is the intramolecular binding of the SH3 and GK domains in this
mutation. However in the PSD-95sh3W470l mutants, the intramolecular binding of the SH3
and GK domains was not thought to be targeted by the tryptophan 470 mutation. Indeed it
has been reported that the mutation of tryptophan 470 of PSD-95 to phenylalanine or
alanine (other nonpolar [hydrophobic] amino acids like tryptophan), did affect the
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intermolecular interaction but did not abolish the intramolecular interaction (McGee and
Bredt, 1999; Shin et al., 2000). This may suggest that the PSD-95sh3W470l mutation is able
to inhibit the inflammatory response through the mutation's prevention of intermolecular
binding in the SH3 domain while maintaining the intramolecular binding of the SH3 and
GK domains.
To summarize PSD-95pdz1"2 mutant mice lack the expected sensory sensitisation following
a peripheral nerve injury model while formalin-induced responses are entirely normal
(Garry et al., 2003). In contrast PSD-95SH3W470L mutant mice have intact neuropathic reflex
behaviours and blunted inflammatory responses, suggesting that even different domains of
the same molecule can contribute selectively to different pain states. It is striking that a
single point mutation in a binding site of PSD-95 can have just as profound an effect on
sensitised pain behaviours as domain deletions (Garry et al., 2003; Migaud et al., 1998)
antisense ablation (Tao et al., 2003a) and complete null mutations (Tao et al., 2003b). The
wider significance of this psD-95SH3W470L mutation may be in the design of novel
analgesics that could act to prevent the sensitisation of specific pain states.
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6. Investigation into the expression of PSD-95 and Pyk 2 in an experimental model
of mononeuropathy, persistent inflammation and formalin-induced inflammation,
focusing on their interaction in the experimental model of mononeuropathy
6.1 Introduction
As discussed previously (Section 1.7.3 and 5.1) PSD-95, a membrane associated
guanylate kinase (MAGUK) is of critical importance for the development of nerve injury
induced behavioural sensitization and is essential for spinal N-methyl-D-aspartate
(NMDA) receptor-mediated thermal hyperalgesia (Garry et al., 2003; Tao et al., 2003).
PSD-95 is composed of three N-terminal PDZ (PSD-Dlg-ZO-1 homology) domains, an
SH3 (Src homology 3) domain and a GK (guanylate kinase-like) domain in its C-
terminal region (see Figure 1.3). PSD-95 was first described, to be expressed in the
spinal cord but not in peripheral nervous tissue, such as dorsal root ganglion by Tao et al.
(Tao et al., 2001). PSD-95 immunoreactivity was found in the superficial dorsal horn of
the spinal cord, with distribution in lamina I and outer lamina II, while Garry et al.,
showed expression of PSD-95 to be restricted to lamina II through P-galactosidase
reporter gene staining of PSD-95 mutant mice (Garry et al., 2003; Tao et al., 2003). The
localisation of PSD-95 to lamina I and lamina II is of interest as this distribution overlaps
with that of the NMDA receptor subunits, in particular NR2B (Boyce et al., 1999; Garry
et al., 2003; Tao et al., 2000). The superficial dorsal horn of the spinal cord is the primary
area for processing noxious stimulation; it receives primary afferent termini from the
periphery and descending fibers from supraspinal structures, in addition to receiving
processes from the deep dorsal horn neurons (Rustioni and Weinberg, 1989). The fact
that PSD-95 is localized to this area of the spinal cord advocates its potential importance
in nociceptive processing.
The expression of spinal PSD-95 is not affected by spinal nerve axotomy or by
dorsolateral funiculus lesions (Tao et al., 2000). It has recently been shown that spinal
PSD-95 expression appeared similar between naive animals and animals thirty minutes
post complete Freund's adjuvant injection (Guo et al., 2004), although whether the
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expression of PSD-95 is affected by other experimental pain models has yet to be
clarified. The localization of PSD-95 expression in the spinal cord has been ascertained
using the well established enzyme-mediated immunodetection (using the avidin-
biotinylated horseradish peroxidase complex method; Tao et al., 2000) however this
method makes it difficult to conduct a multiple staining approach to assess the possible
association of PSD-95 with other antigens of interest. Immunofluoresence histochemistry
allows for multiple staining of tissue and has been used to establish the expression of
PSD-95 in the brain, however spinal PSD-95 has not been detected using this method
thus far (Castejon et al., 2004; Seabold et al., 2003).
The investigations carried out in the previous chapter (Chapter 5) revealed the importance
of a single domain of PSD-95, the SH3 domain, in the development of formalin- and
CFA-induced behavioural responses. It would therefore be of interest to look at the
possible interaction of PSD-95 with the binding partners of its SH3 domain as these
interactions may play a specific and crucial role in pain signalling. As discussed
previously SH3 domains (Section 1.7.3; Section 5.1) are protein interaction domains with
a binding specificity for proline rich sequences containing a PXXP motif (Erpel et al.,
1995; Lim and Richards, 1994; Mayer and Eck, 1995; Pawson and Scott, 1997). Until the
turn of this century the only proline rich binding partner for a MAGUK SH3 domain
identified was the kainaite subtype glutamate receptor subunit KA2 (Garcia et al., 1998).
However the SH3 domain of PSD-95 can not be looked at in isolation, as recent
investigations into its structure have revealed novel features, which show it to have an
atypical binding specificity (McGee et al., 2001; Shin et al., 2000; Tavares et al., 2001). It
was established that the SH3 domain and the GK domain form an integrated structural
unit, that is the SH3 domain is composed of discontinuous elements of sequence, with
four p strands (A-D) followed by a hinge region that separates P strands D and E, and the
GK domain is inserted between p strands E and F (McGee et al., 2001; Tavares et al.,
2001; see Figure 1.4). This shows the striking difference in structure of PSD-95's SH3
domain compared to typical SH3 domains, as it contains an extra p strand (six P strands
(A-F) instead of five) and the large hinge region (McGee et al., 2001). The structural
studies also illustrated novel intramolecular interactions between the SH3 and GK
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domain, that do not involve the SH3 domain's proline binding site and that such
intramolecular binding may be favoured over intermolecular binding (McGee and Bredt,
1999; Nix et al., 2000; Shin et al., 2000; Tavares et al., 2001). This research suggests that
the SH3 domain of PSD-95 has alternative surfaces for intra- and inter-molecular
interactions, raising the possibility that this domain may contain multiple binding sites
(McGee et al., 2001; Tavares et al., 2001; Yafife, 2002).
Understanding of the SH3 domain's structure may aid the identification of new binding
partners for the SH3 domain. The KA2 subunit has been demonstrated to bind to both the
SH3 and GK domains, interestingly binding and clustering of KA2 subunit is abolished
when both SH3 and GK domains are mutated or deleted but if one domain is left intact
clustering still occurs (Garcia et al., 1998). More recent investigations have identified
more MAGUK SH3 domain binding partners that include: Mixed lineage kinases (MLK)
2 and 3, which have been identified to interact with PSD-95 in cultured cells and in vivo
(Savinainen et al., 2001). The identification of MLK 2/3 as a specific binding partner of
PSD-95's SH3 domain was carried out using PSD-95 GST-fusion protein constructs, that
clearly identified MLK 2/3 binding to the SH3 or SH3-GK constructs but not the GK
only construct (Savinainen et al., 2001). Another protein identified as a possible SH3
binding partner is A-Kinase-Anchoring Protein (AKAP) 79/150, again using GST-fusion
protein constructs encompassing the domains of PSD-95 (Colledge et al., 2000). This
work showed AKAP 79/150 binding to both the SH3 and GK domains, indeed mutating
the SH3 proline-rich binding sequence did not affect the binding of AKAP 79/150,
although interestingly disrupting the intramolecular binding of SH3 and GK domains
diminished AKAP 79/150 binding (Colledge et al., 2000). Huntingtin protein, which is
encoded by the huntingtin gene, has also been identified as an SH3 domain binding
partner, when the huntingtin gene is defective a polyglutamine repeat in the protein
huntingtin is expressed, which results in Huntington's disease, a fatal neurodegenerative
disorder (Borrell-Pages et al., 2006). Huntingtin protein was identified as an SH3 domain
binding partner through PSD-95 GST-fusion protein constructs, again that clearly
identified huntingtin binding to the SH3 or SH3-GK constructs but not the GK only
construct (Sun et al., 2001). Another binding partner of the SH3 domain identified
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recently is Pyk 2, a non-receptor tyrosine kinase, which was shown to directly interact
with PSD-95 in rat brain (independent of the presence of the NMDA receptor) and
through GST-fusion protein constructs, Pyk 2 demonstrated binding to the SH3 domain
only and not to the GK domain (Huang et al., 2001; Seabold et al., 2003).
As the research into SH3's binding partners outlined above had revealed that the KA2
subunit and AKAP 79/150 bound to both the SH3 and GK domains, it was decided not to
focus on these proteins as they were not entirely SH3 domain specific. Since huntingtin,
Pyk 2 and MLK 2/3 were illustrated to bind to the SH3 domain construct but not the GK
domain construct it was therefore decided to focus on these proteins as they appeared to
be SH3 domain specific. However due to time and technical (adequate antibody
availability) limitations, only one of these proteins could be focused on, Pyk 2. This
candidate was chosen based on its clearly identified direct interaction with PSD-95's SH3
domain, its potential role in NMDA receptor dependent plasticity (Huang et al., 2001)
(and that of the subfamily of nonreceptor protein tyrosine kinases in synaptic plasticity
(Huang and Hsu, 1999; O'Dell et al., 1991) and the possible involvement of Pyk 2 in the
activation of mitogen-activated protein (MAP) kinases, including p42 and p44 MAP
kinases (Blaukat et al., 1999), whose importance in the development of neuropathic pain
sensitisation has been illustrated in Chapter four.
Protein tyrosine kinases can be sub-divided into receptor tyrosine kinases and non¬
receptor protein tyrosine kinases (which do not span the plasma membrane). Non¬
receptor protein tyrosine kinases have been classified into different subfamilies based on
sequence similarity and distinct structural characteristics (Hanks and Quinn, 1991). To
date there are nine subfamilies of non-receptor protein tyrosine kinases in addition to four
protein tyrosine kinases that do not appear to belong to the classified subfamilies, one
such subfamily is the focal adhesion family, which consists of the focal adhesion kinase
(FAK) and the proline-rich tyrosine kinase (Pyk 2) (Neet and Hunter, 1996), another
example of a subfamily is the Src family, which is comprised of nine protein tyrosine
kinases and include for example, Src, Fyn, Lck and Lyn (Neet and Hunter, 1996). Src has
been reported to be expressed in the DRG and in the spinal cord and is believed to
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contribute to the development and maintenance of inflammatory-induced hypersensitivity
(Guo et al., 2004; Igwe, 2003), additionally a recent report shows that nerve injury
induces the activation of Src, Lck and Lyn in spinal microglia and when such activation
is inhibited (through use of the Src-family tyrosine kinase inhibitor, PP2 ([4-amino-5-(4-
chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine])) nerve injury-induced mechanical
hypersensitivity was suppressed (Katsura et al., 2006). Here we will focus on Pyk 2,
which is also known as CAK-P, CADTK, RAFTK and FAK2 (Avraham et al., 1995;
Herzog et al., 1996; Lev et al., 1995; Sasaki et al., 1995; Yu et al., 1996) and is
predominantly expressed in the central nervous system and cells derived from
hematopoietic lineages, whereas its alternatively spliced isoform (Pyk 2-H) is specifically
expressed in T and B lymphocytes, monocytes, and natural killer cells (Dikic et al., 1998;
Lev et al., 1995). Pyk 2 has a molecular mass between 110-125 kDa and has a similar
domain structure to that of FAK, while FAK is localized to focal adhesion sites in
adherent cells, Pyk 2 is mainly diffused throughout the cytoplasm and is concentrated in
the perinuclear region (Andreev et al., 1999).
Pyk 2 can be activated in response to various stimuli, such as depolarization, growth
factor receptor activation that increase the intracellular calcium concentration, as well as
by protein kinase C (PKC) activation (Lev et al., 1995; Park et al., 2000). Pyk 2 can also
be activated in response to agonists of G-protein-coupled receptors such as bradykinin, L-
a-lysophosphatidic acid (LPA; Dikic et al., 1996). Furthermore Pyk 2 can be activated in
response to stress signals (such as tumor necrosis factor-a, changes in osmolarity) and in
such cases can trigger activation of the JNK cascade (Tokiwa et al., 1996; Yu et al.,
1996). Activation of Pyk 2 in response to an increase in intracellular free Ca2+ can be
prevented by use of PKC inhibitors (Hiregowdara et al., 1997; Raja et al., 1997; Siciliano
et al., 1996; Soltoff et al., 1998), although the exact mechanism of PKC's involvement is
unclear. Upon activation of Pyk 2, autophosphorylation at Tyr402 (tyrosine402) and
Tyr579/580 (tyrosine579/580) occurs, which allows for Pyk 2 to bind to the SH2 domain
of Src (Dikic et al., 1996) leading to the activation of Src by relieving autoinhibition
(Dikic et al., 1996; Thomas and Brugge, 1997; Xu et al., 1997). The phosphorylation of
Pyk 2 in leading to the recruitment of Src can result in the activation of the MAPK
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signalling cascade (Avraham et al., 1995; Lev et al., 1995), and furthermore, Src has a
number of important substrates which have been identified to include the NMDA
receptors (Wang and Salter, 1994; Yu et al., 1997; Zheng et al., 1998) (and GABAa
receptors, Moss et al., 1995; voltage-gated K+ channels, Holmes et al., 1996; Huang et
al., 1993), whose response is enhanced by phosphorylation. Pyk 2 has also been shown to
be associated with the ARF (ADP-ribosylation factor)-GAP protein, PAP (Pyk 2 C
terminus-associated protein; Andreev et al., 1999) and with a novel family of Pyk 2-
binding proteins designated Nirs (Pyk 2 N-terminal domain-interacting receptors; Lev et
al., 1999), which are calcium-binding proteins that possess phosphatidyl inositol transfer
activity. Activation of Pyk 2 can also lead to tyrosine phosphorylation of the adapter
protein She, focal contact proteins pl30cas and paxillin (Astier et al., 1997; Lev et al.,
1995; Li and Earp, 1997).
The purpose of this investigation is to illustrate for the first time the expression of Pyk 2
(both phosphorylated and pan [phosphorylation state-independent]) in the spinal cord
and to assess any changes in Pyk 2 or PSD-95 protein expression that may occur
following experimental models of mononeuropathy, persistent inflammation and
formalin-induced inflammation. The interaction of PSD-95 with Pyk 2 will also be
examined in the experimental model of mononeuropathy.
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6.2 Methods
All experiments were carried out using adult male Wistar rats (180-250g). As outlined in
Chapter three the following methods were used in this investigation: Animals (n=25)
underwent surgery for a model of experimental mononeuropathy, a unilateral chronic
constriction injury to the sciatic nerve (CCI; Section 3.2.1) and were behaviourally
assessed (Section 3.4) prior to surgery (to obtain baseline values) and post surgery (from
day 6) until recovery (day 19-25 post surgery) from CCI. Animals (n=8) that were used
for a model of persistent inflammation were injected subcutaneously with complete
Freund's adjuvant (CFA; Section 3.2.2) into the dorsum surface of the right hind paw. All
animals were behaviourally assessed (Section 3.4) prior to injection (to obtain baseline
values) and post injection from 0-2 hours until 5 days (120 hours) post injection. For both
models, all animals were tested for signs of mechanical allodynia using calibrated Von
Frey filaments (Section 3.4.2) and for signs of thermal hyperalgesia using the
Hargreaves' thermal apparatus (Section 3.4.4) and in the case of CCI injured animals for
cold allodynia (Section 3.4.3). Any effect of either CCI or CFA injury on behavioural
reflexes were analysed as detailed in Section 3.8.1. Animals (n=8) that were used for the
intraplantar injection of formalin (5% solution: Section 3.2.3) were assessed for their
formalin-induced behavioural responses (Section 3.3), which consisted of flicking,
flinching and licking of the affected hind-paw prior to injection until recovery (90
minutes post-injection), with any effect of formalin on the behavioural response analysed
as detailed in Section 3.8.1.
The expression of PSD-95, Pyk 2 and [PTyr402] Pyk 2 proteins in the spinal cord was
assessed in CCI (n=8) and CFA (n=6) injured animals that displayed peak behavioural
reflex sensitization and formalin (n=3) injured animals showing peak behavioural
responses, in saline injected animals (n=3) and naive (n=4) spinal cord and brain (n=2)
samples. Animals were terminally anaesthetised prior to and during dissection of all
tissues when a laminectomy of the spinal lumbar region was performed and spinal cord
tissue was homogenised in Laemmli lysis buffer to prepare spinal cord extracts (Section
3.6.1). The proteins of prepared spinal cord extracts were then separated by
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electrophoresis and transferred to PVDF membranes, blocked and probed for either
mouse monoclonal anti-PSD-95, rabbit polyclonal anti-phosphorylated-[Tyr402]-Pyk 2
or rabbit polyclonal anti-Pyk 2 ('pan': phosphorylation state-independent) or for the
ubiquitous housekeeping protein GAPDH, and detected by peroxidase-linked secondary
antibodies (goat-anti-mouse or goat-anti-rabbit) and enhanced chemiluminescence
(Section 3.6.4). Densitometry of spinal cord extracts immunoblots was performed to
measure quantitatively the grey levels of positive protein bands and background grey
levels relative to GAPDH (with the absolute numerical values derived being arbitrary;
Section 3.8.2).
The expression of PSD-95 and Pan Pyk 2 in the spinal dorsal horn was assessed
immunohistochemically in naive (n=4) and CCI (n=6) nerve injured animals that
displayed peak behavioural reflex sensitization (Section 3.7). All animals were terminally
anaesthetised and transcardially perfused with a 4% paraformaldehyde fixative solution
after which the spinal cord was removed and post-fixed (Section 3.7.1). Spinal cord
sections were cut on a freezing microtome, washed, quenched and underwent an antigen
retrieval step (sections treated with 3M Urea solution) prior to incubation with mouse
monoclonal anti-PSD-95 and/or rabbit polyclonal anti-Pyk 2 ('pan': phosphorylation
state-independent). Subsequently, sections were incubated with the appropriate
fluorescent or peroxidase linked secondary antibody (and if necessary amplification
reagent) before incubation with a nuclear marker (Section 3.7.2). All sections were
examined using a Leica TCSNT Confocal system to acquire single optical section images
at both low and higher (with x5 and x20 objective lens) magnification (Section 3.8.4).
Images were analysed by measuring the mean fluorescent intensity in lamina I, II, III and
IV of the ipsilateral and contralateral sides in CCI injured and naive dorsal horns using
Scion Image analysis, from 8-10 randomly selected sections from each of 4 naive animals
and of 6 CCI injured animals (Section 3.8.4). The total numbers of PSD-95 and Pan Pyk
2 immunopositive cells were counted in lamina I to III and the number of colocalised
cells and non-colocalised cells that were either PSD-95 or Pan Pyk 2 immunopositive
were measured using LCS-Lite software, from 6-8 randomly selected sections per 4 naive
animals and 6 CCI injured animals (Section 3.8.4).
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6.3 Results
6.3.1 Analysis of the development of behavioural reflex sensitisation ipsilateral to
sciatic nerve injury in the chronic constriction injury (CCI) model of experimental
mononeuropathy.
All the nerve-injured animals showed the behavioural changes characteristic of the CCI
model. All of the animals that underwent CCI surgery (Section 3.2.1) held the affected
limb in a protective manner, keeping it held flexed with claws tightly clasped. The
animals developed a limp gait and favoured the contralateral hind limb in locomotion.
These abnormalities are thought to be indications of spontaneous pain (Attal et al., 1990).
Apart from these changes post-operative animals appeared healthy, had no signs of
weight loss and were handled without any distress being evident. During this study none
of the animals developed any signs of autotomy.
Thermal Hyperalgesia [see Figure 4.1 A]
All animals were behaviourally tested for signs of thermal hyperalgesia, using the
Hargreaves' thermal apparatus (Section 3.4.4). Baseline (pre-surgical) paw withdrawal
latency (PWL) was measured as ipsilateral, 12.9 ± 1.8 seconds and contralateral 12.8 ±
1.7 seconds (data show mean latency ± SEM responses). At all time points from the sixth
day until the twenty fourth day post-surgery, all animals showed significantly reduced
PWL ipsilateral to the injury as compared to the contralateral side (p<0.05 by Student's t-
test) and a significant reduction in PWL was also seen between post-surgical and pre-
surgery values (p<0.05; one way repeated measures ANOVA followed by Dunnetts post
hoc analysis), no significant difference was observed in the PWL on the twenty fifth day
post-surgery. For all animals the contralateral PWL did not show significant reductions in
its response. All animals reached a peak of thermal hyperalgesia between the thirteenth
and nineteenth days post-surgery when the ipsilateral PWL was 3.4 ± 0.1 seconds and
contralateral was 11.9 ± 1.2 seconds (data show mean latency ± SEM responses). In
addition to developing such a reduced ipsilateral response to a noxious heat stimulus, the
animals also altered their response from a rapid flick of the hind paw returning to a
resting posture (observed in pre-operative animals) to that of a flick where the animals
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tended to hold the limb elevated for a longer period or shake and or lick the affected paw
before returning to a resting posture (observed in post-operative animals).
Mechanical Allodynia [see Figure 4.1 B]
All animals were tested for signs of mechanical allodynia using calibrated Von Frey
filaments (Section 3.4.2). The baseline (pre-surgical) paw withdrawal threshold (PWT)
required to elicit a response was ipsilateral 4830.6 ± 0 mN/mm2 and contralateral 4830.6
± 0 mN/mm2 (data show mean pressure ± SEM responses). At all time points from the
sixth day until the nineteenth day post-surgery, all animals demonstrated an increased
sensitivity to mechanical stimuli with a significantly reduced PWT ipsilateral to the
injury as compared to the contralateral side (p<0.05 Wilcoxon test) and a significant
reduction in PWT was also seen between post-surgical and pre-surgery values (p<0.05;
Friedman test on ranks followed by Dunn's post hoc analysis). There was no significant
reduction in the PWT response of the contralateral limb in all animals. Animals reached a
peak of mechanical allodynia around the fourteenth day post-surgery when the ipsilateral
PWT was 1429.0 ± 116.5 mN/mm2 and contralateral was 4830.6 ± 43.9 mN/mm2 (data
show mean pressure ± SEM responses).
Cold Allodynia [see Figure 4.1 C]
All animals were tested for signs of cold allodynia by detecting the animal's response to
iced water (4°C; Section 3.4.3), measuring the Suspended Paw Elevation Time (SPET)
during a 20 second time period. Prior to surgery naive rats showed no change in
behaviour in response to iced water with both an ipsilateral and contralateral baseline
SPET value of 0 ± 0 sec (data show mean ± SEM responses). At all time points from the
sixth day until the nineteenth day post-surgery, all animals demonstrated an increased
sensitivity to a cold stimulus with a significantly increased SPET value ipsilateral to the
injury as compared to the contralateral side (p<0.05; Wilcoxon test) and a significant
increase in SPET was also seen between post-surgical and pre-surgery values (p<0.05;
Friedman test on ranks followed by Dunn's post-hoc analysis). There was no significant
increase in the SPET response of the contralateral limb in all animals. Animals reached a
peak of cold allodynia around the thirteenth day post-surgery when the ipsilateral SPET
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was 14.0 ± 1.3 sec and contralateral remained unaffected at 0 ± 0 sec (data show mean ±
SEM responses).
6.3.2 Analysis of the development of behavioural reflex sensitisation following the
Complete Freund's Adjuvant (CFA) model of persistent inflammation.
All injured animals showed behavioural changes characteristic of the CFA model. All of
the animals that underwent CFA injections (Section 3.2.2) showed signs of cutaneous
inflammation within the first hour post-injection, demonstrated by an area of localized
erythema and oedema around the site of injection in the affected hind paw, which
remained present throughout testing and was similar between all animals. The animals,
unlike the CCI nerve-injured animals, did not develop a limp gait or tend to favour the
contralateral hind limb in locomotion. All post CFA injected animals appeared healthy,
had no signs ofweight loss and were handled without any distress being evident.
Thermal Hyperalgesia [see Figure 6.1 A]
All CFA-injected animals were behaviourally tested for signs of thermal hyperalgesia,
using the Hargreaves' thermal apparatus (Section 3.4.4). Baseline (pre-injection) paw
withdrawal latency (PWL) was measured as ipsilateral, 16.1 ± 0.7 seconds and
contralateral 16.9 ± 0.5 seconds (data show mean latency ± SEM responses). At all time
points from the first two hours until forty eight hours post-injection, all animals showed
significantly reduced PWL ipsilateral to the injury as compared to the contralateral side
(p<0.05 by Student's t-test) and a significant reduction in PWL was also seen between
post-surgical and pre-surgery values (p<0.05; one-way repeated measures ANOVA
followed by Dunnetts post hoc analysis). No significant difference was observed in the
PWL from seventy two to one hundred and twenty hours (days 3-5) post-injection,
measured as ipsilateral 10.3 ± 0.4 seconds and contralateral 13.4 ±1.5 seconds at 120
hours post injection (data show mean latency ± SEM responses). For all animals the
contralateral PWL did not show significant reductions. All animals reached a peak of
thermal hyperalgesia around twenty four/forty eight hours post-injection when the
ipsilateral PWL was 7.4/7.4 ± 0.6 seconds and contralateral was 12.5/11.4 ± 1.2 seconds
respectively (data show mean latency ± SEM responses).
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Mechanical AHodynia [see Figure 6.1 BJ
All animals were tested for signs of mechanical allodynia using calibrated Von Frey
filaments (Section 3.4.2). The baseline (pre-injection) paw withdrawal threshold (PWT)
required to elicit a response was ipsilateral 4830.6 ± 0 mN/mm2 and contralateral 4830.6
± 0 mN/mm2 (data show mean pressure ± SEM responses). At all time points from the
first two hours until one hundred and twenty hours (day 5) post-injection, all animals
demonstrated an increased sensitivity to mechanical stimuli with a significantly reduced
PWT ipsilateral to the injury as compared to the contralateral side (p<0.05 Wilcoxon test)
and from three-six hours until one hundred and twenty hours (day 5) post-injection a
significant reduction in PWT was also seen between post-surgical and pre-surgery values
(p<0.05; Friedman test on ranks followed by Dunn's post-hoc analysis). There was no
significant reduction in the PWT response of the contralateral limb in all animals.
Animals reached a peak of mechanical allodynia around forty eight/seventy two hours
post-injection when the ipsilateral PWT was 1609.5 ± 433.8 mN/mm2 at both time points
and contralateral was 4329.6 ± 500.9 mN/mm2 at both time points (data show mean
pressure ± SEM responses).
6.3.3 Analysis of the formalin-induced behavioural response [see Figure 6.2]
All animals were injected subcutaneously into the plantar surface of the hind paw and
allowed five minutes to recover before analysis began, which consisted of counting the
number of flick/flinch responses per minute of the affected paw. All animals developed
the formalin-induced behavioural response of an initial acute phase (5-20 minutes post-
injection) and a late phase (25-80 minutes post-injection), with all animals beginning to
show signs of recovery around 90-95 minutes post-injection whereupon behavioural
analysis was stopped. All animals had a significant increase in responses at all time
points following formalin injection when compared to the pre-injection response (p<0.05;
one-way repeated measures ANOVA followed by Dunnett's post-hoc analysis), with a
maximal increase to 39.5 ± 4.1 (data show mean number of flicks/flinches per minute ±
SEM).
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6.3.4 The level of expression of PSD-95 Pyk 2 and [PTvr402! Pvk 2 in the spinal cord
of CCI, CFA and formalin-injured animals and in the spinal cord and brain of naive
animals
PSD-95 expression [see Figure 6.3 and Table 6.1]
The level of PSD-95 protein expression was assessed in naive brain and spinal cord and
in CCI, CFA and formalin-injured spinal cord. The spinal cord extracts of CCI and CFA
injured animals were taken at the peak of behavioural reflex sensitization and for
formalin-injured animals at the peak of the late phase behavioural response. PSD-95
expression was significantly increased ipsilateral to CCI injury when compared to the
contralateral side and naive controls (data show percent ± SEM, percent expression of
GAPDH, the ubiquitous housekeeping protein, as determined by densitometric analysis;
p<0.05, Wilcoxon test). The respective values were 50 ± 2% (ipsilateral), 24 ± 6%
(contralateral) and 23 ± 4% (naive) with the absolute numerical values, derived from
densitometry, being arbitrary. While there appeared to be some increase in the level of
PSD-95 expression ipsilateral to formalin injury when compared to the contralateral,
saline and naive controls, this was not significant. The level of PSD-95 expression was
not affected by CFA as no ipsilateral increase was observed when compared to the
contralateral side, saline and naive controls. The level of PSD-95 expression was similar
in all cases between naive and saline spinal cord and the contralateral side of injured
spinal cord. The expression of PSD-95 in naive brain is also shown, the expression of
which can be seen to be greater than that observed in the spinal cord (see Table 6.1 for
relative quantification).
Pan-Pyk 2 expression [see Figure 6.4 and Table 6.1]
The level of Pan-Pyk 2 protein expression was assessed in naive brain and spinal cord
and in CCI, CFA and formalin-injured spinal cord. Again the spinal cord extracts of CCI
and CFA-injured animals were taken at the peak of behavioural reflex sensitization and
for formalin-injured animals at the peak of the late phase behavioural response. Pan-Pyk
2 expression was significantly increased ipsilateral to CCI injury when compared to the
contralateral side and naive controls (data show percent ± SEM, percent expression of
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GAPDH, as determined by densitometric analysis; p<0.05, Wilcoxon test). The
respective values were 31 ± 1% (ipsilateral), 24 ± 1% (contralateral) and 23 ± 1% (naive)
with the absolute numerical values, derived from densitometry, being arbitrary. Pan-Pyk
2 expression was unaltered by either CFA or formalin injury when the ipsilateral side was
compared to the contralateral side, saline and naive controls. Also the level of Pan-Pyk 2
expression did not differ between naive and saline spinal cord and the contralateral side
of injured spinal cord. The expression of Pan-Pyk 2 in naive brain is also shown, the
expression of which can be seen to be greater than that observed in the spinal cord (see
Table 6.1 for relative quantification).
Phosphorylated Pyk 2 ([PTyr402] Pyk 2) expression [see Figure 6.5 and Table 6.1]
The level of [PTyr402] Pyk 2 protein expression was assessed in naive brain and spinal
cord and in CCI, CFA and formalin-injured spinal cord. All injured spinal cord extracts
were taken from animals at the peak of injury induced behavioural reflex sensitisation or
in the late phase of the formalin behavioural response. Relative levels of [PTyr402] Pyk 2
expression were not affected in any of the injury models explored here, the CCI, CFA or
formalin models, when the ipsilateral side of each was compared to the contralateral side,
saline and naive controls. Again the level of [PTyr402] Pyk 2 expression did not differ
between naive spinal cord and the contralateral side of injured spinal cord. The
expression of [PTyr402] Pyk 2 in naive brain is also shown (see Table 6.1 for relative
quantification).
6.3.5 Immunohistochemical analysis of the expression of PSD-95 and Pyk 2 in the
spinal dorsal horn of naive and CCI injured animals at low magnification.
PSD-95 expression [see Figure 6.6]
The expression of PSD-95 was assessed in the dorsal horn of naive and CCI-injured
spinal cord by means of immunofluorescence histochemistry. All injured spinal cord
sections were taken from animals at the peak of CCI injury-induced behavioural reflex
sensitization. CCI resulted in a significant ipsilateral increase in the expression of PSD-
95 (measured by the level of fluorescent staining intensity) in Lamina I and II when
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compared to the contralateral side and naive animals. Within the regions of interest in
Lamina I and II (refer to section 3.8.4 and Figure 3.2), there was a significant ipsilateral
increase in the mediolateral region to 112.8 ±5.1 (mean fluorescence intensity in
arbitrary absolute values ± SEM) when compared to the contralateral side 88.4 ± 4.7
(p<0.05, Student's paired t-test) and naive animals 87.9 ± 2.3 (p<0.05, Student's unpaired
t-test). There was also a significant ipsilateral increase in the intermediate region to 117.8
± 5.0 and lateral region to 125.1 ± 5.7 (mean fluorescence intensity in arbitrary absolute
values ± SEM) when compared to the contralateral side 85.2 ± 4.6; 93.4 ± 4.3,
respectively (p<0.05, Student's paired t-test) and naive animals 89.8 ± 1.9; 92.3 ± 2.6,
respectively (p<0.05, Student's unpaired t-test). The expression of PSD-95 was not
altered by CCI injury in either Lamina III or IV when the ipsilateral side was compared to
the contralateral side or naive animals.
Pyk 2 expression [see Figure 6.7]
Immunofluorescence histochemical techniques were also utilized to assess the expression
of Pyk 2 in the dorsal horn of naive and CCI-injured spinal cord. All injured spinal cord
sections were taken from animals at the peak of CCI injury-induced behavioural reflex
sensitization. The expression of Pyk 2 was significantly increased (measured by the level
of fluorescent staining intensity) ipsilateral to CCI injury in Lamina I and II when
compared to the contralateral side and nai've animals. This increase was observed in the
regions of interest in Lamina I and II (refer to section 3.8.4 and Figure 3.2), firstly with a
significant ipsilateral increase in the mediolateral region to 74.3 ± 4.7 (mean fluorescence
intensity in arbitrary absolute values ± SEM) when compared to the contralateral side,
62.6 ± 2.8 (p<0.05, Student's paired t-test) and naive animals, 60.9 ± 1.5 (p<0.05,
Students unpaired t-test). There was also a significant ipsilateral increase in the
intermediate region to 74.5 ± 4.5 and lateral region, 77.8 ± 5.3 (mean fluorescence
intensity in arbitrary absolute values ± SEM) when compared to the contralateral side
63.3 ± 2.9; 62.9 ± 3.3, respectively (p<0.05, Student's paired t-test) and naive animals
61.2 ± 1.2; 60.2 ± 1.2, respectively (p<0.05, Student's unpaired t-test). Within Lamina III
and IV the expression of Pyk 2 was not altered by CCI injury when the ipsilateral side
was compared to the contralateral side or naive animals.
- 197-
6.3.6 Immunohistochemical analysis of the cellular expression of PSD-95 and Pvk 2
in the spinal dorsal horn of naive and CCI-injured animals.
PSD-95 expression [see Figure 6.8 and 6.9]
The number of PSD-95-immunopositive cells in the regions of interest (ROI) in the
dorsal horn of naive and CCI injured spinal cord (see Section 3.8.4) were counted from
single optical section images from 6-8 randomly selected sections per 4 naive animals
and 6 CCI injured animals. The number of PSD-95-immunopositive cells were counted in
lamina I, II and III using LCS-Lite software, where only cells that were associated with
To-pro staining (nuclear marker) and whose intensity was at least twice background
intensity were counted as immunopositive (refer to Section 3.8.4 and Figure 3.4). With
regard to CCI-injured animals only spinal cord sections from animals at the peak of
injury induced behavioural reflex sensitization were used for analysis. The number of
PSD-95 immunopositive cells was increased ipsilateral to CCI injury when compared to
the contralateral side and naive animals. There was a significant increase in the number
of PSD-95-immunopositive cells in Lamina I of the dorsal horn ipsilateral to injury to
541 ± 16 (total cell number per ROI ± SEM) when compared to the contralateral side
369 ± 12 (p<0.05; Student's paired t-test) and to nai've animals 361 ± 12 (p<0.05;
students unpaired t-test). A significant increase in the number of PSD-95-immunopositive
cells in Lamina II of the dorsal horn ipsilateral to injury was also noted, to 684 ± 18 (total
cell number per ROI ± SEM) when compared to the contralateral side 407 ± 11 (p<0.05;
student's paired t-test) and to naive animals 379 ± 13 (p<0.05; Student's unpaired t-test).
There was no difference in the number of PSD-95 immunopositive cells ipsilateral to CCI
injury in Lamina III when compared to the contralateral side and naive animals.
Pyk 2 expression [see Figure 6.10 and 6.11]
The number of Pyk 2-immunopositive cells in the dorsal horn of nai've and CCI injured
spinal cord were counted as above (also refer to Section 3.8.4). Animals at the peak of
injury-induced behavioural reflex sensitization were used for CCI injury analysis. The
number of Pyk 2 immunopositive cells increased ipsilateral to CCI injury when compared
to the contralateral side and nai've animals. A significant increase in the number of Pyk 2-
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immunopositive cells in lamina I of the dorsal horn ipsilateral to injury was noted,
increasing to 521 ± 15 (total cell number per ROI ± SEM) when compared to the
contralateral side 361 ± 12 (p<0.05; student's paired t-test) and nai've animals 378 ± 13
(p<0.05; Student's unpaired t-test). The number of Pyk 2-immunopositive cells in
Lamina II of the dorsal horn significantly increased ipsilateral to injury to 700 ± 18 (total
cell number per ROI ± SEM) when compared to the contralateral side 423 ± 12 (p<0.05;
Student's paired t-test) and to nai've animals 402 ± 13 (p<0.05; Student's unpaired t-test).
In Lamina III no significant difference in the number of Pyk 2-immunopositive cells
ipsilateral to CCI injury was seen when compared to the contralateral side and naive
animals.
6.3.7 Immunohistochemical analysis of the colocalisation of PSD-95 and Pyk 2 in the
spinal dorsal horn of naive and CCI injured animals.
Colocalisation of PSD-95 with Pyk 2 [see Figure 6.12, 6.13 and 6.14]
The colocalisation of PSD-95 with Pyk 2 in naive and CCI injured animals in the spinal
dorsal horn was assessed. Colocalisation was determined by profiling each cell using
LCS-Lite software (refer to section 3.8.4 and Figure 3.4), whereby the intensity of each
fluorochrome was measured in each cell and graphed, if the fluorochrome graph for PSD-
95 and Pyk 2 overlapped in a cell that again showed To-pro staining and signal was at
least twice background intensity for both PSD-95 and Pyk 2 the cell was counted as a
colocalised cell. If the profile of the cell showed the intensities not to overlap then the
cell was counted as a non-colocalised cell that was either PSD-95 or Pyk 2
immunopositive. The spinal cords of CCI-injured animals were taken at the peak of
behavioural reflex sensitization. The total number of colocalised cells per ROI (Lamina I,
II or III) was found to be increased ipsilateral to CCI injury when compared to the
contralateral side and naive animals. The increase in colocalisation was significant in
Lamina I of the dorsal horn to 461 ± 13 (total number of colocalised cells per ROI ±
SEM) when compared to the contralateral side 264 ± 9 (p<0.05; student's paired t-test)
and to nai've animals 307 ± 10 (p<0.05; Student's unpaired t-test). A significant increase
in the number of colocalised cells was also observed in Lamina II of the dorsal horn to
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596 ± 15 (total number of colocalised cells per ROI ± SEM) when compared to the
contralateral side 285 ± 8 (p<0.05; Student's paired t-test) and to naive animals 295 ± 10
(p<0.05; Student's unpaired t-test). No ipsilateral increase in the number of colocalised
cells was observed in Lamina III of the dorsal horn when compared to the contralateral
side and naive animals.
Non-Colocalised cells that were PSD-95-immunopositive [see Figure 6.13 and 6.15]
While assessing the colocalisation of PSD-95 with Pyk 2 in naive and CCI injured
animals in the spinal dorsal horn, the number of cells that were not colocalised but PSD-
95-immunopositive was also investigated, as described previously by the profiling of
each individual cell using LCS Lite software (refer to Section 3.8.4 and Figure 3.4),
whereby the intensity of each fluorochrome was measured in each cell and graphed, if the
fluorochrome graph for PSD-95 and Pyk 2 showed the intensities not to overlap then the
cell was counted as a non-colocalised cell that was either PSD-95 or Pyk 2-
immunopositive. Again where each cell showed To-pro staining and signal was at least
twice background intensity for both PSD-95 and Pyk 2. The total number of non-
colocalised PSD-95-immunpositive cells was found to be increased ipsilateral to CCI
injury when compared to the contralateral side and naive animals. The increase in non-
colocalised PSD-95-immunopositive cells was significant in Lamina I of the dorsal horn
to 80 ± 2 (total number of non-colocalised PSD-95-immunopositive cells per ROI± SEM)
when compared to 28 ± 1 on the contralateral side (p<0.05; student's paired t-test) and to
29 ± 1 in naive animals (p<0.05; Student's unpaired t-test). The number of non-
colocalised PSD-95-immunopositive cells was also significantly increased in Lamina II
of the dorsal horn to 88 ± 2 (number of non-colocalised PSD-95 immunopositive cells per
ROI ± SEM) when compared to 29 ± 1 on the contralateral side (p<0.05; student's paired
t-test) and to 37 ± 2 in naive animals (p<0.05; students unpaired t-test). A significant
ipsilateral increase in the number of non-colocalised PSD-95 immunopositive cells was
also noted in Lamina III of the dorsal horn to 47 ± 4 (number of non-colocalised PSD-95-
immunopositive cells per ROI ± SEM) when compared to 32 ± 3 on the contralateral side
(p<0.05; Student's paired t-test) and to 20 ± 2 in naive animals (p<0.05; Student's
unpaired t-test).
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Non-Colocalised cells that were Pyk 2-immunopositive [see Figure 6.13 and 6.15]
During the analysis of colocalisation of PSD-95 with Pyk 2 in naive and CCI-injured
animals in the spinal dorsal horn, the number of cells that were not colocalised but Pyk 2
immunopositive was also determined, as descirbed above (refer to Section 3.8.4 and
Figure 3.4). An ipsilateral increase in the number of non-colocalised Pyk 2-
immunopositive cells was found to be significant in Lamina II of the dorsal hom to 104 ±
2.7 (total number of non-colocalised Pyk 2-immunopositive cells per ROI ± SEM) when
compared to 52 ± 2 on the contralateral side (p<0.05; Student's paired t-test) and to 54 ±
3 in nai've animals (p<0.05; Student's unpaired t-test). The number of non-colocalised
Pyk 2-immunopositive cells was not significantly increased ipsilateral to CCI injury in




The time course of development of thermal hyperalgesia and mechanical allodynia
following intraplantar injection of complete Freund's adjuvant.
Data show mean ± SEM responses prior to injection (baseline) and following the
injection of CFA (n=8). (A) Paw withdrawal latency (PWL) from a noxious thermal
stimulus (Hargreaves' thermal stimulator) ipsilateral to CFA injection (O) showed
significant differences between post-injection and pre-injection values (f p<0.05; one¬
way repeated measures ANOVA followed by Dunnett's post-hoc analysis) and from
post-injection contralateral (■) values (* p<0.05; Student's t-test). No thermal
hyperalgesia was seen on the contralateral side (■). (B) Paw withdrawal thresholds
(PWT) from mechanical stimulation (von Frey filaments) showed significant reductions
in post-operative compared to pre-operative values ipsilateral (O) to CCI (t p<0.05;
Friedman test on ranks followed by Dunn's post hoc analysis) and between post¬
operative ipsilateral and contralateral values (♦ p<0.05; Wilcoxon test). No significant
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The time course of development of the behavioural response following the
intraplantar injection of formalin.
Data shows mean ± SEM number of paw flick/flinch responses per minute prior to
injection and following the injection of formalin (n=8;^). All animals displayed both
acute (5-20 minutes post-injection) and late (25-80 minutes post-injection) phases of the
formalin test, with signs of recovery observed around 90-95 minutes post-injection. At all
time points following formalin injection a significant increase in the number of
flicks/flinches was observed when compared to pre-injection values (* p<0.05; one-way





The expression of PSD-95 in the spinal cord following CCI, CFA or Formalin
compared to saline and naive controls
Immunoblots showing the expression of PSD-95 and the ubiquitous housekeeping
enzyme GAPDH following experimental mononeuropathy (CCI; n=8), complete
Freund's adjuvant model of persistent inflammation (CFA; n=6) and formalin-induced
inflammation (Formalin; n=3) compared to saline injected (Saline; n=3) and naive spinal
cord (n=4). Expression levels are from spinal cord extracts of animals displaying, peak
behavioural reflex sensitisation following CCI and CFA, and peak late phase behavioural
response to formalin on the side ipsilateral (Ipsi) and contralateral (Con) to injury and in
saline injected animals ipsilateral (Ipsi) and contralateral (Con) to injection. Expression
levels are also shown in spinal cord and brain (n=2) extracts of naive animals. CCI
resulted in a significant ipsilateral increase in the level of PSD-95, while formalin caused
a modest but non-significant ipsilateral increase when compared to the contralateral side,








The expression of Pan-Pyk 2 in the spinal cord following CCI, CFA or Formalin
compared to saline and nai've controls
Immunoblots showing the expression of Pan-Pyk 2 and the ubiquitous housekeeping
enzyme GAPDH following experimental mononeuropathy (CCI; n=8), complete
Freund's adjuvant model of persistent inflammation (CFA; n=6) and formalin-induced
inflammation (Formalin; n=3) compared to saline injected (Saline; n=3) and naive spinal
cord (n=4). Expression levels are from spinal cord extracts of animals displaying, peak
behavioural reflex sensitisation following CCI and CFA, and peak late phase behavioural
response to formalin on the side ipsilateral (Ipsi) and contralateral (Con) to injury and in
saline injected animals ipsilateral (Ipsi) and contralateral (Con) to injection. Expression
levels are also shown in spinal cord and brain (n=2) extracts of naive animals. CCI alone
resulted in a significant ipsilateral increase in the level of Pan-Pyk 2 when compared to












The expression of [PTyr402] Pyk 2 in the spinal cord following CCI, CFA or
Formalin compared to saline and naive controls
Immunoblots showing the expression of phosphorylated Pyk 2 ([PTyr402] Pyk 2) and the
ubiquitous housekeeping enzyme GAPDH following experimental mononeuropathy
(CCI; n=8), complete Freund's adjuvant model of persistent inflammation (CFA; n=6)
and formalin-induced inflammation (Formalin; n=3) compared to saline injected (Saline;
n=3) and naive spinal cord (n=4). Expression levels are from spinal cord extracts of
animals displaying, peak behavioural reflex sensitisation following CCI and CFA, and
peak late phase behavioural response to formalin on the side ipsilateral (Ipsi) and
contralateral (Con) to injury and in saline injected animals ipsilateral (Ipsi) and
contralateral (Con) to injection. Expression levels are also shown in spinal cord and brain
(n=2) extracts of naive animals. [PTyr402] Pyk 2 expression appears not to be altered by
any of the models employed here when expression is compared to the contralateral side,












Immunofluorescence histochemistry for PSD-95 in the spinal dorsal horn following
experimental mononeuropathy and in naive controls.
(A) Low magnification images (x5 objective lens) illustrating the expression of PSD-95
(green) in the spinal dorsal horn following experimental mononeuropathy (CCI; n=6)
compared to naive (n=4) spinal cord. Expression of PSD-95 in spinal cord sections of
animals that displayed peak behavioural reflex sensitization following CCI on the side
ipsilateral (Ipsi) and contralateral (Con) to injury and from naive animals. Following CCI
there was an ipsilateral increase in the expression of PSD-95 when compared to the
contralateral side and naive animals. Scale bar 50pm, (L= Lateral edge of the dorsal
horn). (B) The intensity of the fluorescent staining of PSD-95 was measured using Scion
Image [refer to Section 3.8.4], Data show the mean fluorescence intensity ± SEM (in
arbitrary units). As a result of experimental mononeuropathy the expression of PSD-95
was significantly increased ipsilateral to injury when compared to the contralateral side (*
p<0.05; Student's paired t-test) and naive animals (f p<0.05; Student's unpaired t-test).

















Immunofluorescence histochemistry for Pan-Pyk 2 in the spinal dorsal horn
following experimental mononeuropathy and in naive controls.
(A) Low magnification images (x5 objective lens) illustrating the expression of Pan-Pyk
2 (red) in the spinal dorsal horn following experimental mononeuropathy (CCI; n=6)
compared to naive (n=4) spinal cord. Expression of Pan-Pyk 2 in spinal cord sections of
animals that displayed peak behavioural reflex sensitization following CCI on the side
ipsilateral (Ipsi) and contralateral (Con) to injury and from naive animals. Following CCI
there was an ipsilateral increase in the expression of Pan-Pyk 2 when compared to the
contralateral side and naive animals. Scale bar 50pm, (L= Lateral edge of the dorsal
horn). (B) The intensity of the fluorescence staining of Pan-Pyk 2 was measured using
Scion Image [refer to Section 3.8.4], Data shows the mean fluorescence intensity ± SEM.
(in arbitrary units). The expression of Pan-Pyk 2 as a result of experimental
mononeuropathy was significantly increased ipsilateral to injury when compared to the
contralateral side (* p<0.05; Student's paired t-test) and naive animals (t p<0.05;
Student's unpaired t-test). This significant increase was seen in Lamina I and II but not in
Lamina III or IV of the dorsal horn.
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Figure 6.8
Immunofluorescence histochemistry for PSD-95 in the spinal cord, an example of
high power images used for counting cells.
(A). Images taken at higher magnification (x20 objective lens) to show cells that are
positive for PSD-95 immunofluorescent staining (green) in the spinal dorsal horn
following experimental mononeuropathy (CCI; n=6) and in naive (n=4) animals. The
number of PSD-95-immunopositive cells was increased ipsilateral to CCI when
compared to the contralateral side and naive sections (see Figure 6.9 for graphs). Scale
bar 25pm, (L= Lateral edge of the dorsal horn). (B). Inset image showing an example
spinal cord with boundaries marked for Lamina I, II and III used in counting PSD-95




Gross quantification of numbers of PSD-95-immunopositive cells in the spinal
dorsal horn following experimental mononeuropathy and in naive controls.
PSD-95-immunopositive cells were counted in the ROI (Lamina I, II and III) in the
dorsal horn of naive (n=4) and following experimental mononeuropathy (CCI; n=6)
spinal cords from single optical section images captured at higher magnification (x20
objective lens), using LCS-Lite software, where only cells that were associated with To-
pro staining (nuclear marker) and whose intensity was at least twice background intensity
were counted as immunopositive (refer to Section 3.8.4 and Figure 3.4). Data expressed
as total cell number (of PSD-95-immunopositive cells) per ROI ± SEM. CCI resulted in a
significant ipsilateral increase in the number of PSD-95-immunopositive cells when
compared to the contralateral side (* p<0.05; Student's paired t-test) and to naive animals
(t p<0.05; Student's unpaired t-test). This significant increase was seen in Lamina I (A)
and Lamina II (B) but not in Lamina III (C) of the dorsal horn.
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Figure 6.10
Immunofluorescence histochemistry for Pan-Pyk 2 in the spinal cord, an example of
high power images used for counting cells.
(A). Images taken at higher magnification (x20 objective lens) to show cells that are
positive for Pan Pyk 2 fluorescent staining (red) in the spinal dorsal horn following
experimental mononeuropathy (CCI; n=6) and in naive (n=4) animals. The number of
Pan-Pyk 2 immunopositive cells is increased ipsilateral to CCI when compared to the
contralateral side and naive sections (see Figure 6.11 for graphs). Scale bar 25pm, (L=
Lateral edge of the dorsal horn). (B). Inset image showing an example spinal cord with
boundaries marked for Lamina I, II and III used in counting Pan-Pyk 2 immunopositive










Gross quantification of numbers of Pan-Pyk 2-immunopositive cells in the spinal
dorsal horn following experimental mononeuropathy and in nai've controls.
Pan-Pyk 2-immunopositive cells were counted in the ROI (Lamina I, II and III) in the
dorsal horn of naive (n=4) and following experimental mononeuropathy (CCI; n=6)
spinal cords from single optical section images captured at higher magnification (x20
objective lens), using LCS-Lite software, where only cells that were associated with To-
pro staining (nuclear marker) and whose intensity was at least twice background intensity
were counted as immunopositive (refer to Section 3.8.4 and Figure 3.4). Data expressed
as total cell number (of Pan-Pyk 2-immunopositive cells) per ROI ± SEM. A significant
ipsilateral increase in the number of Pan-Pyk 2-immunopositive cells occurred as a result
of CCI when compared to the contralateral side (* p<0.05; student's paired t-test) and to
naive animals (f p<0.05; students unpaired t-test). This significant increase was seen in

























Immunofluorescence histochemistry for colocalisation of PSD-95 with Pyk 2 in the
spinal cord, an example of high power images used for counting colocalised cells.
(A) Single optical section images captured at higher magnification (x20 objective lens) to
show the colocalisation of PSD-95-immunopositive cells (green) with Pyk 2-
immunopositive cells (red) in the spinal dorsal horn following experimental
mononeuropathy (CCI; n=6) and in naive (n=4) animals. The number of colocalised cells
per ROI was increased ipsilateral to CCI when compared to the contralateral side and
naive animals (see Figure 6.14 for graphs). (Scale bar 25pm; L- Lateral edge of the
dorsal horn). The dashed line box indicates the origin of the magnified images in Figure
6.14, highlighting the region of interest (the box covers Lamina II and the edges of
Lamina I and III), to show individual colocalised and non-colocalised cells. (B) Inset
image showing an example spinal cord with boundaries marked for Lamina I, II and III
used in counting the colocalisation of PSD-95-immunopositive cells with Pyk 2-





Immunofluorescence histochemistry for colocalisation of PSD-95 with Pyk 2 in an
example of a region of interest in the spinal cord
Single optical section images (slice width of 0.8pm) captured at higher magnification
(x20 objective lens) using the Leica TCSNT Confocal system, illustrate the region of
interest (part of ROI indicated in Figure 6.12 covering Lamina II) that was magnified
from the images shown in Figure 6.12, indicated by a dashed line box. These images
display colocalisation of PSD-95-immunopositive cells (green) with Pyk 2-
immunopositive cells (red) in the spinal dorsal horn following experimental
mononeuropathy (CCI; n=6) and in naive (n=4) animals. Examples of cells that are
colocalised are indicated by an arrowhead, cells that are Pyk 2-immunopositive but PSD-
95-immunonegative are designated by a thin arrow, while cells that are PSD-95-
immunopositive but Pyk 2-immunonegative are pointed out by a thick arrow. The
number of colocalised cells per ROI was increased ipsilateral to CCI when compared to
the contralateral side and naive animals (see Figure 6.14 for graphs). The number of cells
per ROI that are not colocalised but are either PSD-95- or Pyk 2-immunopositive was
also increased ipsilateral to CCI when compared to the contralateral side and naive







Gross quantification of numbers of cells where PSD-95 is colocalised with Pyk 2 in
the spinal dorsal horn following experimental mononeuropathy and in naive
controls.
The number of cells that showed colocalisation of PSD-95 with Pyk 2 were counted in
the ROI (Lamina I, II and III) following experimental mononeuropathy (CCI; n=6) and in
naive (n=4) spinal dorsal horns from single optical section images captured at higher
magnification (x20 objective lens), using LCS-Lite software (refer to section 3.8.4 and
Figure 3.4), whereby the intensity of each fluorochrome was measured in each cell and
graphed, if the fluorochrome graph for PSD-95 and Pyk 2 overlapped in a cell that again
showed To-pro staining and signal was at least twice background intensity for both PSD-
95 and Pyk 2 the cell was counted as a colocalised cell. Data is expressed as total number
of colocalised cells (colocalisation of PSD-95 with Pyk 2) per ROI ± SEM. A significant
ipsilateral increase in the number of colocalised cells occurred as a result of CCI when
compared to the contralateral side (* p<0.05; Student's paired t-test) and to naive animals
(t p<0.05; Student's unpaired t-test). This significant increase was seen in Lamina I (A)
and Lamina II (B) but not in Lamina III (C) of the dorsal horn.
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Gross quantification of numbers of cells where PSD-95 is not colocalised with Pyk 2
in the spinal dorsal horn following experimental mononeuropathy and in naive
controls.
The number of cells that did not show colocalisation of PSD-95 with Pyk 2 were counted
in the ROI (Lamina I, II and III) following experimental mononeuropathy (CCI; n=6) and
in naive (n=4) spinal dorsal horns from single optical section images captured at higher
magnification (x20 objective lens), using LCS-Lite software (refer to section 3.8.4 and
Figure 3.4), whereby the intensity of each fluorochrome was measured in each cell and
graphed, if the fluorochrome graph for PSD-95 and Pyk 2 showed the intensities not to
overlap then the cell was counted as a non-colocalised cell that was either PSD-95 or Pyk
2-immunopositive. Again where each cell showed To-pro staining and signal was at least
twice background intensity for both PSD-95 and Pyk 2. Data is expressed as total number
of non-colocalised cells (that are either PSD-95 or Pyk 2-immunopositive) per ROI ±
SEM. A significant ipsilateral increase in the number of non-colocalised cells that were
PSD-95-immunopositive occurred as a result of CCI when compared to the contralateral
side (* p<0.05; Student's paired t-test) and to naive animals (t p<0.05; Student's
unpaired t-test) in Lamina I (A) Lamina II (C) and in Lamina III (E) of the dorsal horn.
CCI also resulted in a significant ipsilateral increase in the number of non-colocalised
cells that were Pyk 2-immunopositive when compared to the contralateral side (* p<0.05;
Student's paired t-test) and to naive animals (f p<0.05; Student's unpaired t-test) in
Lamina II (D) only, with no significance seen in Lamina I (B) and Lamina III (F) of the
dorsal horn.
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The effects of CCI, CFA or formalin challenges on spinal cord expression of PSD-
95, Pan-Pyk 2 and [PTyr402] Pyk 2 relative to GAPDH.
Data presented show the expression of Pan-Pyk 2, phosphorylated Pyk 2 ([PTyr402] Pyk
2) and PSD-95 proteins as a percent of GAPDH expression in spinal cord and naive brain
extracts. Since all values are derived from densiometry with different antibodies and
incubation conditions, the absolute numerical values, hence percentages calculated, are
purely arbitrary. Meaningful comparisons can therefore only be made across treatments
with the same antibody and not between antibodies. Data show the percent expression ±
SEM as determined by densitometric analysis in spinal cord extracts of CCI (n=8), CFA
(n=6) injured animals at the peak of behavioural reflex sensitization and of formalin-
injured (n=3) animals at the peak of the late phase behavioural response and in saline
injected (n=3) animals, in all cases ipsilateral (ipsi) and contralateral (con) to injury and
in naive brain (n=2) and spinal cord (n=4) [illustrated in Figure 6.4, 6.5 and 6.6]. The
expression of Pan-Pyk 2 was found to be significantly increased ipsilateral to injury only
following CCI when compared to contralateral and naive samples (*p<0.05, Wilcoxon
test). The expression of [PTyr402] Pyk 2 was not affected by any of the injury models. The
expression of PSD-95 was significantly increased ipsilateral to CCI injury when
compared to contralateral and naive samples (*p<0.05, Wilcoxon test), however the level























































This study was conducted using three different models; the first was a unilateral chronic
constriction injury (CCI) of the sciatic nerve model developed by Bennett and Xie
(Bennett and Xie, 1988). As discussed in Chapter four (Section 4.4) all the animals that
underwent CCI surgery developed an increased sensitivity to a previously innocuous
mechanical and cold stimuli together with a marked reduction in latency response to a
noxious heat stimulus. Maximal behavioural reflex sensitisation was reached around day
thirteen to fourteen post surgery in all cases. For all the ensuing investigations using this
CCI model only animals displaying peak behavioural reflex sensitisation following CCI
nerve injury (ipsilateral to injury) were used. The injection of complete Freund's adjuvant
(CFA) was used as a model of persistent inflammation. All animals developed a clear
reduction in latency response to a noxious heat stimulus with maximal effect one to two
days post injection, a striking sensitivity to a previously innocuous mechanical stimulus
also developed, with greatest sensitivity seen two to three days post injection.
Earlier research has reported that the CFA challenge results in behavioural sensitization
as early as two to six hours (Ji et al., 2002a; Ji et al., 2002b; Zhang et al., 2003) or three
days post CFA injection (for thermal hyperalgesia) (Molliver et al., 2005), with recovery
of behavioural reflex sensitisation observed around five or nine days post CFA injection
(Molliver et al., 2005;Zhang et al., 2003). These findings are in agreement with the CFA
model developed in this study where early sensitisation is observed at thirty minutes to
two hours post injection and continues for two to three days post injection (with
mechanical allodynia lasting longer). Recovery of thermal hyperalgesia occurs around
four to five days post injection, however mechanical allodynia was still observed five
days post injection, perhaps recovery would be seen a few days later (this was not
characterized in this study). The slight variations in the timings of the CFA induced
sensitisation could be due to the site of CFA injection and according to whether a
saline:CFA solution or CFA alone is used for the injections in addition to the final
volume injected.
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Unlike the model of formalin-induced inflammation, the CFA model is not as well
characterised to determine if each stage of the response is driven by periperhal activity
and/or central sensitisation in the spinal cord. Intraplantar injection of formalin elicits a
biphasic nociceptive response (Dubuisson and Dennis, 1977), that has been characterised
by behavioural and electrophysiological measures to consist of an early intense response
(first phase) and a more prolonged response (second phase) (Chaplan et al., 1997;
Coderre and Melzack, 1992; Dickenson and Sullivan, 1987c; Dickenson and Sullivan,
1987b; Haley et al., 1990; Wheeler-Aceto and Cowan, 1991). As discussed in Chapter
five (section 5.5) the first phase is considered to be of peripheral origin, with the second
phase a result of both ongoing peripheral activity and central sensitisation in the spinal
cord (Chaplan et al., 1997; Coderre et al., 1990; Coderre and Melzack, 1992; Dickenson
and Sullivan, 1990; Haley et al., 1990; Villetti et al., 2003). In the subsequent analysis of
the CFA model we used only animals displaying peak behavioural reflex sensitisation
(ipsilateral to injection) and in the case of formalin induced inflammation, only animals
that demonstrated peak second phase responses following injection.
As mentioned in Chapter one (section 1.4.2 and 1.7.3) NMDA receptors are critically
involved in the mechanism of central sensitisation in the spinal cord (Davies and Lodge,
1987; Dickenson and Sullivan, 1987a; Suzuki et al., 2001; Woolf and Thompson, 1991),
and the role of these receptors in chronic pain may be dependent upon the MAGUK
proteins, two of which, PSD-95 and Chapsyn 110/PSD 93, have through genetic and
antisense techniques been implicated in chronic pain states (Garry et al., 2003; Tao et al.,
2003; Zhang et al., 2003). PSD-95 expression was shown here to be markedly enhanced
in the spinal cord, following CCI nerve injury, as illustrated by an ipsilateral increase
when compared to the contralateral side and naive controls. However such an
amplification of expression was not seen ipsilateral to CFA injection and although a
modest increase was observed ipsilateral to formalin injection, this was not significant
when compared to the contralateral side, saline and naive controls. It must be noted that
CCI-induced nerve-injury has a longer time course of sensitisation than either CFA or
formalin-induced inflammation and whether this difference has an influence on detecting
the involvement of PSD-95 cannot be ruled out. The level of expression of other
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members of the MAGUK family was not looked at specifically in this study, but has been
investigated by the lab (S.M. Fleetwood-Walker and colleagues, unpublished
communication) and found to be unaltered in the spinal cord as a result of CCI injury.
The findings presented here link with previous investigations that revealed the
importance of PSD-95 in the development of nerve injury behavioural reflex sensitisation
(Garry et al., 2003; Tao et al., 2001).
Since PSD-95 assembles with the NMDA receptor thereby coupling the receptor to
diverse intracellular pathways that may mediate downstream changes, one of its
signalling-associated binding partners was examined. Pyk 2 was chosen as outlined above
and was not only shown to be expressed in the spinal cord but to display an ipsilateral
increase following CCI nerve injury when compared to the contralateral side and naive
controls. This increase in expression was observed in 'pan-'(or phosphorylation state-
independent) Pyk 2, whereas phosphorylated Pyk 2 ([PTyr402] Pyk 2) remained
unchanged by CCI nerve injury. Both [PTyr402] Pyk 2 and pan-Pyk 2 were unaltered in
their expression in the spinal cord ipsilateral to either CFA or formalin injection when
compared to the contralateral side, saline and naive controls. These findings demonstrate
for the first time the potential involvement of this tyrosine kinase in CCI nerve injury. As
to why the phosphorylated form of Pyk 2 was found to be unaltered could be explained
by the fact that Pyk 2 is phosphorylated on multiple tyrosine residues which regulate both
its enzymatic activity and pathway selectivity. Pyk 2 has four sites of tyrosine
phosphorylation which include; Tyr402 (tyrosine402), an autophosphorylation site which
also forms the binding site for SH2 domains of Src family kinases, Tyr881 (tyrosine881)
the grb2-SH2 domain binding site, and two regulatory sites in the activation loop of the
kinase domain Tyr579/580 (tyrosine579/580)(Avraham et al., 2000;Li et al., 1999). The
site targeted by the anti-phosphorylated Pyk 2 antibody used in this study (Tyr402)
appears to have remained unchanged in the models investigated.
Activation of Pyk 2 is thought to involve autophosphorylation at Tyr402, as well as
transphosphorylation at the activation loop site Tyr580 and other sites, a pattern similar to
the phosphorylation of FAK at homologous residues Tyr397 and Tyr577 (Salazar and
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Rozengurt, 2001), but whether this sequential model of activation, as established for
FAK, accounts for the activation of Pyk 2 is unclear. A recent report has shown that Pyk
2 is Ca^-dependent at the activation loop site Tyr580, but not at Tyr402, following
GPCR stimulation, suggesting that auto- and transphosphorylation sites differ in their
response to Ca^, thus proposing that Ca^-independent signalling mechanisms may be
responsible for autophosphorylation of Pyk 2 (Wu et al., 2006). It would be of interest to
look at anti-phosphorylated Pyk 2 that targets Tyr580 site to see whether this site of
phosphorylation differs in its response to the chronic pain states investigated here.
Whether any of the other sites of phosphorylated Pyk 2 are altered remains to be
determined. The increase observed in Pan-Pyk 2 expression, but not in [pTyr402] Pyk 2
levels might suggest that the excess Pyk 2 expressed after CCI is not in an activated state,
at least as monitored by Tyr402 phosphorylation.
For the remainder of this study it was decided to look at the interaction and expression of
PSD-95 and Pan-Pyk 2 in the spinal dorsal horn following experimental
mononeuropathy, due to their increased protein expression in the spinal cord in this
model.
Immunohistochemical analysis to localise PSD-95 in the spinal cord involved the
development of a new immunofluoresence staining technique, which proved to be
challenging. This was partly due to the fixation process (of the tissue), which often alters
the available immunoreactive antigenic epitopes or indeed results in their loss as a result
of protein-protein and/or nucleic acid cross-linking (which is a special form of chemical
modification involving the joining of two molecular components by covalent bonds).
Fixation may induce a change in protein conformation or a change in accessibility of the
residues encoding the antigenic epitope, thus masking the tissue antigenicity. An optimal
antigen retrieval (AR) system was developed to give access to the antigenic epitopes,
which involved the pretreating of fixed tissue with a heat-induced AR method, as cross-
linkages between formalin and protein can be reversed by high temperature heating or
strong alkaline treatment (Fraenkel-Conrat et al., 1947). AR alone was not the only
modification required, suggesting that there were still antigens for which available
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antigenic epitopes were still too sparse to be visualized after fixation. To resolve this
dilemma, the combination of the optimised AR system (heat-treatment in a urea solution)
and a signal amplification step was used. Signal amplification allows the signal to be
enhanced so that the antigens that have been unmasked in the AR step can be visualized.
A powerful amplification step, the ImmunoMax method (Merz et al., 2005) (the tyramine
enhancement technique), using a biotinyl-tyramine amplification step whereby
amplification is accomplished by covalent deposition of biotin molecules was employed
(Merz et al., 2005). The combination of an AR step with this biotinylated tyramine
enhancement step has been found to result in a 100-10,000 fold boost in sensitivity
(compared to conventional avidin-biotinylated enzyme complex (ABC) procedures)
(Merz et al., 2005). The development of this method (using both the AR and tyramine
enhancement step) allowed for the visualization in the spinal cord of PSD-95 and of Pan-
Pyk 2 (which only required the AR step).
Analysis involved capturing single optical sections of each spinal cord section at low
magnification (x5 objective lens; captured image is 2000pm x 2000pm), which enabled
both dorsal horns of the spinal cord to be captured in one image. Having one image with
both dorsal horns intact ensured that any possible increase or decrease in fluorescent
intensity found would be the result of the injury model and not due to any potential
differences in capturing of the images were only one dorsal horn captured in each image.
All images (at both low and high magnification) were captured using the Leica TCSNT
Confocal system, which involves sequentially scanning the section with individual lasers
to detect fluorescence in each channel ensuring that any possible spectral bleed-through is
minimized thus producing an accurate merged image of fluorphore distribution (refer to
Section 3.8.4). Single optical sections (optical width of 0.8pm) captured at higher
magnification (x20 objective lens; captured image is 500pm x 500pm) were used to look
at individual cell staining for either PSD-95 or Pyk 2 and of their colocalisation in the
same cell in the regions of interest, namely Lamina I, II and III of the spinal dorsal horn
(refer to Section 3.8.4). Colocalisation was determined using LCS-Lite software, where
the intensity of each fluorochrome was measured in each cell and graphed, if the
fluorochrome graph for PSD-95 and Pyk 2 overlapped in a cell that showed To-pro
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(nuclear marker) staining and signal was at least twice background intensity for both
PSD-95 and Pyk 2 the cell was counted as a colocalised cell, if the intensity of each
fluorochrome graphed did not overlap then the cell was counted as a non-colocalised cell
that was either PSD-95 or Pyk 2-immunopositive.
The intensity of both PSD-95 and Pyk 2 immunoreactivity was found to be markedly
increased ipsilateral to nerve injury in lamina I and II of the dorsal spinal cord when
compared to the contralateral side and naive controls, with no difference observed in
Lamina III or IV. Concurring with the intensity analysis, the number of immunopositive
cells for both PSD-95 and Pyk 2 increased in lamina I and II with no alteration observed
in lamina III ipsilateral to nerve injury when compared to the contralateral side and naive
controls. These findings are in agreement with the analysis of protein expression of both
PSD-95 and Pyk 2 in the spinal cord as outlined before. The observations reiterate the
importance of PSD-95 in the CCI nerve injury model and illustrate the potential
significance of its binding partner Pyk 2 in this model. To investigate whether the
increase in PSD-95 and Pyk 2 were occurring in the same cells and thereby possibly
indicating an interaction of these two proteins, colocalisation analysis was conducted.
PSD-95 and Pyk 2 were found to be colocalised in greater number in lamina I and II
ipsilateral to injury but not in lamina III when compared to the contralteral side and naive
controls. These results point toward the possibility of PSD-95 and its binding partner Pyk
2 interacting both physically and functionally with a consequence of such an interaction
being the potential activation of downstream signalling cascades.
While analyzing Pyk 2-immunopositive cells in Laminae I-III, a number of Pyk 2-
immunopositive cells were noted in the deeper laminae of the spinal dorsal horn
(Laminae IV-VI), which was not thought to differ as a result of nerve injury, although
complete analysis was not conducted into the deeper laminae, additionally a number of
Pyk 2-immunopositive cells were noted in the ventral horn of the spinal cord that did not
appear to differ as a result of nerve injury. However for PSD-95 the number of
immunopositive cells in the deeper laminae was far fewer and PSD-95-immunopositive
cells were not observed in the ventral horn of the spinal cord, suggesting the expression
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of PSD-95 is more restricted than that of Pyk 2 to the primary area for processing noxious
stimulation in the spinal dorsal horn.
Following nerve-injury the colocalisation of PSD-95 with Pyk 2 increased in lamina I and
II of the dorsal horn but not in lamina III, suggesting that these two proteins may
physically interact in the superficial dorsal horn as a result of peripheral nerve injury. As
a result of nerve injury 85% and 87% of PSD-95-immunopositive cells (ipsilateral to
nerve injury) were also positive for Pyk 2 in lamina I and II respectively. CCI nerve
injury-induced a greater number of PSD-95-immunopositive cells than the number of
cells that were colocalised for PSD-95 and Pyk 2 in laminae I, II and III. Suggesting that
in the PSD-95-immunopositive cells in laminae I, II and III that do not appear to contain
Pyk 2, PSD-95 may be interacting with other binding partners, perhaps indicating that the
nerve-injury enhanced expression of PSD-95 may lead only in part to interaction with
Pyk 2, which is also enhanced in expression following nerve injury. It must be noted that
limitation of the sensitivity of antibody detection can not be ruled out, therefore it could
be suggested that a cell that appears not to express Pyk 2 may contain some functional
Pyk 2 that was undetected here. While colocalisation of PSD-95 with Pyk 2 was
increased in lamina I and II (with 88% and 85% of Pyk 2-positive cells colocalising with
PSD-95 in lamina I and II respectively) as a result of CCI-induced nerve injury, the
number of Pyk 2-immunopositive cells that did not colocalise with PSD-95 was
significantly increased only in Lamina II ipsilateral to nerve injury. Possibly indicating
that within Lamina II Pyk 2-positive cells that show no interaction with PSD-95, may
have distinct roles independent of the NMDA/PSD-95 complexes. As there was no
increase in the number of Pyk 2-immunopositive cells that did not colocalise with PSD-
95 in Lamina I and III following nerve-injury, it could be suggested that within these
laminae when Pyk 2 is expressed it may be especially involved with PSD-95 and thereby
NMDA receptor function.
In conclusion this investigation has corroborated the importance of PSD-95 in the
development of chronic pain as a result of peripheral nerve damage. This study also
reveals new evidence that may point to an increased interaction of PSD-95 and Pyk 2
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(pan) following peripheral nerve injury that could contribute to the mechanism involved
in the development of a chronic neuropathic pain state. The factors regulating the
association of PSD-95 with Pyk 2 need to be further explored to fully understand the role
that PSD-95 :Pyk 2 complexes might play in chronic pain states.
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7. Summary and Conclusions
Chronic pain is a major health care problem; common sources of chronic pain include
cancer pain, neuropathic pain, arthritic pain, back pain and headache. A recent survey
established that chronic pain of moderate to severe intensity occurs in 19% of adult
Europeans (Breivik et al., 2006). Chronic pain can seriously affect the daily activities,
social and working lives of sufferers thereby resulting in a major socio-economic burden.
Neuropathic pain is a form of chronic pain due to dysfunction in the peripheral or central
nervous system, with associated symptoms including numbness, weakness, abnormal
sensations and pain (Scadding, 1981). The chronic pain that develops manifests as
hyperalgesia, allodynia and spontaneous pain. There are currently few viable options for
the treatment of neuropathic pain conditions. Indeed, in the current situation, most patients
have to undergo multiple drug therapy attempts in the hope of finding some treatment to
alleviate their suffering. Classical opioid analgesics have often been reported to be
ineffective (Arner and Meyerson, 1988; Bennett, 1994; Lee et al., 1994; Mao et al., 1995),
frequently producing unwanted side effects. Indeed a drug can be considered successful if
approximately 20-30% of the patient's respond (McQuay et al., 1996; McQuay et al.,
1994), whereby responding means reporting less pain, not the eradication of the pain. One
of the main problems experienced with currently available drugs to treat neuropathic pain
are the side effects associated with them. For example, NMDA receptor antagonists (such
as ketamine), which initially appeared promising in their therapeutic potential, exhibit
toxicity, low safety margins and psychotropic side effects which limit their use.
Anticonvulsant drugs (such as carbamazepine) have been shown to attenuate painful
diabetic neuropathy and trigeminal neuralgia (McCleane, 1999; Zakrzewska and Patsalos,
1992). Side effects associated with anticonvulsants include sedation and cerebellar
symptoms, such as tremor and un-coordination (Jensen, 2002). Gabapentin, which is
thought to target specific Ca' channel subunits, is also currently used for the treatment of
chronic pain conditions (Fink et al., 2000; Gustafsson et al., 2003). Although its exact
mechanism of action is not fully understood, gabapentin has been reported to have some
potential in the treatment of painful diabetic neuropathy and postherpetic neuralgia
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(Backonja, 2000; Rice and Maton, 2001; Rowbotham et al., 1998). However the results
can be contradictory with some studies failing to distinguish gabapentin from placebo
(Gorson et ah, 1999; Hemstreet and Lapointe, 2001). Some of the side effects associated
with gabapentin include, dizziness, headache, peripheral oedema and sedation (Bosnjak et
ah, 2002; Rowbotham et ah, 1998). Another drug used is pregabalin, which is a GABA
analogue closely related to gabapentin. Pregabalin has mixed reports of success in the
treatment of neuropathic pain. When tested alongside another drug, amitriptyline (a
tricyclic anti-depressant), pregabalin was found not to be more effective than placebo
while amitriptyline was found to be significantly better (2005). The associated side effects
of pregabalin are similar to those of gabapentin, including mainly neuropsychological
reactions (dizziness and drowsiness) and peripheral oedema.
Advances in the development of efficacious therapeutic treatments depend on progress in
understanding the underlying mechanisms in chronic pain states. These mechanisms are
complex, involving both peripheral and central changes that can persist long after the
initial injury has healed. Here we used a modification of the chronic constriction injury
(CCI) model of mononeuropathy developed by Bennett and Xie (Bennett and Xie, 1988),
in which the sciatic nerve was exposed in the region of the trifurcation and four (in the rat)
or three (in mice) chromic cat gut ligatures were tied loosely to constrict the peroneal and
tibial nerves leaving the smallest sural nerve intact. This modification employs a partial
nerve damage rather than complete transection thereby emphasising the contribution of
both injured and non-injured inputs from the same peripheral fields. This animal model of
mononeuropathy results in the development of increased sensitivity to previously
innocuous mechanical and cold stimuli, showing that partial CCI nerve injury results in
the development of mechanical and cold allodynia in the affected hind limb, while also
developing a marked reduction in response latency to a noxious heat stimulus. Maximal
behavioural reflex sensitisation occurred approximately ten to fourteen days following
nerve-injury. The sub-cutaneous injection of complete Freund's adjuvant (CFA) was used
as a model of persistent inflammation. As discussed previously, the CFA challenge has
been reported to result in behavioural sensitization from as early as two to six hours Ji et
al., 2002b; Zhang et al., 2003) or three days post-injection (Molliver et al., 2005), with
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recovery of behavioural reflex sensitisation observed around five to nine days post-
injection (Molliver et al., 2005; Zhang et al., 2003). Here, all animals developed a clear
reduction in latency response to a noxious heat stimulus with maximal effect one to two
days post injection, sensitivity to a previously innocuous mechanical stimulus also
developed, with greatest sensitivity seen one to three days post injection. However the
CFA model, unlike the model of formalin-induced inflammation, is not as well
characterised as to whether each stage of the response is driven by peripheral activity
and/or central sensitisation in the spinal cord. Intraplantar injection of formalin elicits a
biphasic nociceptive response (Dubuisson and Dennis, 1977), that has been characterised
by behavioural and electrophysiological measures to consist of an early intense response
(first phase) and a more prolonged response (second phase) (Chaplan et al., 1997; Coderre
and Melzack, 1992; Dickenson and Sullivan, 1987a; Haley et al., 1990; Wheeler-Aceto
and Cowan, 1991). The first phase is considered to be of peripheral origin, with the
second phase a result of both ongoing peripheral activity and central sensitisation in the
spinal cord (Chaplan et al., 1997; Coderre et al., 1990; Dallel et al., 1995; Dickenson and
Sullivan, 1990; Puig and Sorkin, 1996; Taylor et al., 1995). For all the ensuing
investigations only animals displaying peak behavioural reflex sensitisation (ipsilateral to
injury) following CCI nerve injury or CFA challenge and only animals that demonstrated
peak second phase responses following formalin injection were used.
The work presented here utilises behavioural, pharmacological, biochemical and
immunohistocehmical techniques to examine some of the mechanisms involved in the
development and maintenance of neuropathic pain, while at times also looking at
mechanistic differences between neuropathic and inflammatory chronic pain states. This
thesis has been concerned with the role of p38 and p42/44 MAP kinase signalling
pathway activation via the peptidergic NK2 and VPAC2 receptors and the ionotropic
glutamate NMDA receptor, in addition to glial involvement of such activation in
neuropathic pain states. The above techniques were also employed to investigate the
association of the NMDA receptor complex adapter protein, PSD-95 with a downstream
signalling partner Pyk 2, and to study the involvement of the SH3 domain of PSD-95 in
the neuropathic pain state.
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7.1 p38 and p42/44 MAP kinase activation in neuropathic pain
Long lasting changes in neuronal excitability can occur through activation of
transcription factors via signalling pathways, for example, the MAP kinase signalling
pathways, which are key mediators of transcriptional responses to extracellular signals
(Whitmarsh, 2006; Hokfelt et al., 1994; Ji and Woolf, 2001). MAP kinase signalling can
result in short-term modification of proteins via phosphorylation and long-term changes
via activation of the transcription factor, CREB (cAMP response element binding protein;
Xing et al., 1996) and is believed to be involved in the mechanisms of sensitisation in
chronic pain states. Here, the involvement of p38 and p42/44 MAP kinases in mediating
thermal hyperalgesia and mechanical allodynia was firstly examined by intrathecal
injection of p38 and p42/44 MAP kinase pathway inhibitors (SB 203580 and (PD 98059
and U 0126), respectively) in animals with established neuropathic reflex sensitisation
following nerve injury. Both p38 and p42/44 MAP kinase pathway inhibitors were found
to attenuate the nerve injury-induced behavioural reflex sensitisation, these observations
are consistent with previous reports indicating a role for MAP kinase signalling in the
development and maintenance of behavioural reflex sensitisation in a number of chronic
pain states (Cruz et al., 2005; Dai et al., 2002; Ji et al., 2002a; Jin et al., 2003; Obata et
al., 2003; Svensson et al., 2003; Tsuda et al., 2004). To understand the role of these
intracellular signalling cascades in chronic pain states we then looked at how these
pathways are activated as a result of peripheral nerve injury.
Non-neuronal (glial) cell activation is currently viewed as a crucial component of the
generation and maintenance of chronic pain states. Here we showed that inhibition of
glial activation by use of the non-selective glial inhibitor, propentofylline (which can
decrease the activation of both spinal astrocytes and microglia) or of the pro¬
inflammatory cytokine TNF-a (using the TNF-a receptor antagonist, WP9QY) alleviated
nerve-injury-induced behavioural reflex sensitisation. Interestingly activated states of
both p38 and p42/44 MAP kinases have been localised not only to neurons but also to
astrocytes and microglia: Phosphorylation of p38 MAP kinase occurs in microglia
following formalin-induced inflammation, nerve injury and axotomy (Jin et al., 2003;
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Kawasaki et al., 1997; Kim et al., 2002; Svensson et al., 2003; Tsuda et al., 2004) and
phosphorylation of p42/44 MAP kinase occurs (in addition to spinal neurons), in
astrocytes and microglia following nerve injury (Ji et al., 1999; Ma and Quirion, 2002;
Zhuang et al., 2005). Here we showed that the enhanced activation of p38 and p42/44
MAP kinases (revealed by their increased phosphorylation) in the spinal cord ipsilateral
to nerve injury was prevented by spinal application of the same TNF-a and glial
inhibitors used above (propentofylline, WP9QY) and by the TNF-a synthesis inhibitor,
thalidomide. Our findings show agreement with other reports where propentofylline was
reported to attenuate allodynia following spinal nerve transaction (Sweitzer et al., 2001)
and reduce formalin-induced inflammatory pain by suppressing TNF-a (Dorazil-Dudzik
et al., 2004). The expression of TNF-a in the spinal cord that is upregulated after
peripheral nerve injury (Bartholdi and Schwab, 1997; DeLeo et al., 1997; Wagner and
Myers, 1996) can be reduced through use of thalidomide (George et al., 2000), which has
also been reported to be effective in delaying the development of behavioural reflex
sensitisation induced by peripheral nerve injury (Sommer et al., 1998). It is possible that
TNF-a, through its increased expression or release, may contribute to the sensitisation
found in chronic pain states by inducing further activation of p38 and/or p42/44 MAP
kinases in glial cells.
We examined the possibility of the involvement of the peptidergic NK2 and VPAC2
receptors in the activation of p38 and p42/44 MAP kinase pathways. Here we found that
the NK2 receptor antagonist prominently inhibited the nerve injury-induced behavioural
reflex sensitisation (compared to the NK] receptor antagonist) and reduced the CCI nerve
injury-induced activation of spinal p38 and p42/44 MAP kinases. The greater
involvement of the NK2 receptor in attenuating nerve-injury induced behavioural
sensitisation agrees with work showing this receptor to be specifically involved in the
hyperexcitability of dorsal horn neuron responses to noxious cutaneous stimuli
(Fleetwood-Walker et al., 1990) and of the antinociceptive ability of the NK2 receptor
antagonist when administered following nerve injury (Coudore-Civiale et al., 1998).
Additionally NK2 receptors have been localised to spinal astrocytes, also a site of p42/44
MAP kinase activation following nerve injury (Ma and Quirion, 2002; Zerari et al.,
-246-
1998). We also showed that the nerve-injury induced activation of p38 and p42/44 MAP
kinase was reduced by incubation of an NMDA receptor antagonist on the spinal cord.
We then confirmed that agonist stimulation of NK2 receptors resulted in activation of
p42/44 MAP kinase (to a greater extent compared to VPAC2 receptor stimulation) and
that this could be blocked with co-application of the glial inhibitor, propentofylline.
Focusing on the possible NK2 receptor activation of p42/44 MAP kinase, we showed in
parallel that the NK2 receptor agonist induced a behavioural reflex sensitisation in naive
animals that could be attenuated by co-administration of the p42/44 MAP kinase
inhibitor, U 0126. These findings suggest the possibility that activation of p42/44 MAP
kinase as a result of glial NK2 receptor activation in this model of mononeuropathy could
lead not only to pro-inflammatory cytokine release but also to the facilitation of NMDA
receptor function, while the involvement of any neuronal NK2 receptors in such activation
of p42/44 MAP kinase needs to be investigated.
The behavioural reflex sensitisation induced by nerve injury was also found to be
attenuated by a selective VPAC2 receptor antagonist, with little or no inhibition seen with
PACi or VPACi receptor antagonists. Previous reports have indicated the importance of
VPAC2 receptors in neuropathic pain, showing increased expression of the VPAC2
receptor in the dorsal horn following nerve injury and a marked inhibitory effect of
VPAC2 receptor antagonists on neuropathic sensitisation (Dickinson et al., 1999;
Dickinson and Fleetwood-Walker, 1999). VPAC2 receptors (along with the other VPAC
and PAC receptor subtypes) have been found to be expressed in astrocytes (Brenneman et
al., 1990; Grimaldi and Cavallaro, 1999; Jaworski, 2000). Having seen a greater
activation of p42/44 MAP kinase by agonist stimulation of NK2 receptors compared to
VPAC2 receptors, we found, in contrast, that agonist stimulation of VPAC2 receptors
increased the activation of p38 MAP kinase to a greater extent compared to NK2 receptor
stimulation. This response was again prevented by co-application of the glial inhibitor,
propentofylline. We also showed that the increased activation of p38 MAP kinase
following nerve injury was reduced by incubation of the spinal cord with the VPAC2
receptor antagonist. The corresponding behavioural study showed behavioural
sensitisation in naive animals following administration of a VPAC2 receptor agonist, a
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response that was alleviated by co-administration of the p38 MAP kinase inhibitor, SB
203580. These findings suggest an involvement of glial VPAC2 receptors in the spinal
cord in the activation of p38 MAP kinase following nerve injury, although they do not
show whether this activation occurs directly in VPAC2 receptor-containing cells.
To further understand the mechanisms involved in the activation of p38 and/or p42/44
MAP kinases in glial cells, investigation into the localisation of these MAP kinase
proteins could be conducted to see the involvement of glial NK2 or VPAC2 receptor-
containing cells as against neuronal NK2 or VPAC2 receptor-containing cells in the
activation of these proteins as a result of peripheral nerve-injury. The involvement of the
pro-inflammatory cytokines, IL-1 and IL-6, also released by activated glia, were not
specifically examined in this thesis and their involvement in the activation of p38 and/or
p42/44 MAP kinases in glial cells cannot be ruled out. The activation of the MAP kinase
signalling pathways in response to peripheral nerve injury appears to be an undeniably
complex process involving multiple receptor mechanisms.
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7.2 The SH3 domain of PSD-95 and its signalling partner Pvk 2 in chronic pain states
PSD-95 is a key adapter protein in the NMDA receptor complex that has been implicated
in chronic pain states through genetic and antisense techniques (Garry et al., 2003; Tao et
al., 2001). We examined here the expression of spinal PSD-95 in a number of chronic
pain states and found an ipsilateral increase in protein levels following nerve injury, with
no alteration in levels following either CFA or formalin-induced inflammation when
compared to control. Of course it must be noted that CCI-induced nerve-injury has a
longer time course of sensitisation than either CFA or formalin-induced inflammation
and whether this difference has an influence on detecting the involvement of PSD-95
cannot be ruled out. Given the marked ipsilateral increase in PSD-95 expression as
identified through Western immunoblotting, we utilised immunofluorescence techniques
to localise the expression of PSD-95 in both nai've and nerve-injured animals. We show a
marked ipsilateral increase in both the intensity of PSD-95 immunoreactivity and in the
number of PSD-95-immunopositive cells in the spinal dorsal horn following nerve injury.
The ipsilateral increase in PSD-95 expression appears to be restricted to the superficial
dorsal horn (lamina I and lamina II), which is the main area for primary afferent
termination and overlaps with the distribution of NMDA receptor subunits, in particular
NR2B (Boyce et al., 1999; Garry et al., 2003; Tao et al., 2000), indicating the likely
importance of PSD-95 in mediating neuropathic sensitisation. This specific localisation
of PSD-95 to the superficial dorsal horn is in agreement with previous work, where PSD-
95 was found to be mainly expressed in lamina I and II of the dorsal horn (Garry et al.,
2003; Tao et al., 2000).
Mice expressing a truncated form of PSD-95 which lack PDZ 3, SH3 and GK domains,
known as PSD-95pdz1"2 mutants, do not develop either hyperalgesia or allodynia as a
result of peripheral nerve injury (Garry et al., 2003), indicating a central role for PSD-95
in mediating NMDA receptor-dependent plasticity. We investigated the effect of a single
point mutation to the SH3 domain of PSD-95 in different chronic pain states. This PSD-
95 SH3W470L mutation js a single point mutation that targets the highly conserved
tryptophan residue (tyrptophan 470) found in the hydrophobic binding surface of SH3
domains that is thought to be crucial for the interaction of SH3 domains with proline-rich
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ligands. Thus this PSD-95SH3W470L mutation is designed to specifically disrupt SH3
domain interactions with polyproline residues whilst leaving the GK domain and all PDZ
domains of PSD-95 and their interactions intact. Adult PSD-95sh3W470L mutant mice or
wild-type littermates were utilised to determine any potential role of the SH3 domain in
the development and maintenance of neuropathic behavioural reflex sensitisation. We
found that PSD-95SH3W470L mutants developed the same behavioural reflex sensitivity to
both thermal and mechanical stimuli following peripheral nerve injury to that seen in
wild type littermate mice. We examined the involvement of this mutation in the
development of sensitisation following formalin-induced inflammation. As discussed
above, the formalin test elicits a biphasic nociceptive response (Dubuisson and Dennis,
1977). We found no difference between PSD-95SH3W470L mutant mice and wild type
littermate responses in the first (acute) phase, but the PSD-95sh3W470l mutant mice had a
greatly reduced second (inflammatory) phase of the response compared to wild type
littermates. We also investigated whether the PSD-95SH3W470L mutation affected the
behavioural sensitisation caused by CFA-induced inflammation and found that while
both PSD-95SH3W470L mutant and wild-type mice developed ipsilateral sensitivity 0-6
hours post-CFA, the mutant mice no longer displayed this behavioural sensitivity at 24
and 48 hours post-CFA, unlike the wild-type mice. These findings, of intact neuropathic
behavioural reflex sensitisation and blunted inflammatory responses in PSD-95SH3W470L
mutant mice, suggest that within the one molecule of PSD-95, different domains may
contribute selectively to different pain states.
As PSD-95, a member of the MAGUK family of proteins, assembles with the NMDA
receptor, we examined whether this PSD-95sh3W470L mutation altered the expression
levels ofNMDA receptor subunits in the mutant spinal cord. We found the expression of
the NMDA receptor subunits was unaffected by the mutation when compared to wild
type littermates. We found that this point specific mutation did not alter the expression of
PSD-95 itself in the spinal cord. As members of the MAGUK family of proteins share a
high degree of homology between their domains, it is possible that other MAGUKs
present in the spinal cord might compensate in the regulation of the NMDA receptor
pathway. However we found no alteration in the expression of Chapsynl 10/PSD-93,
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SAP-102 or SAP-97 in mutant spinal cord when compared to wild-type littermates. These
findings show that the highly specific PSD-95SH3W470L mutation did not result in overall
changes in levels of NMDA receptor subunit or MAGUK expression in the spinal cord,
thereby suggesting that the phenotype displayed by this mutation may not have been the
result of compensation by other MAGUK proteins but is more likely due to interactions
disrupted by the mutation itself.
To fully understand how this specific mutation of the SH3 domain (that leads to
disruption of protein-protein interactions without altering the expression of PSD-95) can
result in blunted inflammatory responses requires further research. It is possible that the
PSD-95sh3W4701 mutation inhibits the inflammatory response through the resultant
prevention of intermolecular binding of the SH3 domain while maintaining the
intramolecular binding of the SH3 and GK domains. It would therefore be of interest to
look at a point mutation of the intramolecular binding site of the SH3 domain, to examine
the functional implication of disruption to intramolecular binding of the SH3 and GK
domains while leaving the intermolecular binding site of SH3 intact. A small number of
partners for the SH3 domain of PSD-95 have been identified to date. Indeed as new
techniques are currently being developed to model the structure of multidomain proteins
(Korkin et al., 2006), predictions of new theoretical binding partners will be made, which
could then be assessed for their involvement in nerve injury-induced behavioural reflex
sensitisation. It is possible that the identification of the binding partner(s) disrupted by
this mutation may lead eventually to the design of a novel analgesic that could prevent
sensitisation of specific pain states.
As these findings suggest the importance of the SH3 domain of PSD-95 in chronic pain
states, the involvement of Pyk 2 (a signalling associated binding partner of PSD-95 that
binds to the SH3 domain) was assessed. Spinal Pyk 2 expression in a number of chronic
pain states was examined and we found an ipsilateral increase in Pan-Pyk 2 protein levels
following nerve injury, with no alterations observed following either CFA or formalin-
induced inflammation when compared to control. No alteration in levels of
phosphorylated (i.e. activated) Pyk 2 expression was seen in any of the chronic pain
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states explored here, which might suggest that the increased levels of Pyk 2 following
nerve injury may not represent the enzyme in an activated state, as assessed by Tyr402
phosphorylation. Whether other phosphorylation sites on Pyk 2 are activated following
nerve injury or indeed if the sensitivity of phosphorylated Tyr402 Pyk 2 antibody detection
is limited cannot be ruled out. Focusing on Pan-Pyk 2, we found a marked ipsilateral
increase in both the intensity of Pan-Pyk 2 immunoreactivity and in the number of Pan-
Pyk 2 immunopositive cells following nerve injury in the spinal dorsal horn. The
ipsilateral increase in expression of Pan-Pyk 2 following nerve-injury was found to be
localised to the superficial dorsal horn, a pattern that overlaps with the distribution of
PSD-95, thus suggesting a potential importance of Pyk 2 in the mechanisms underlying
nerve-injury induced sensitisation.
The molecular interaction of Pyk 2 with PSD-95 was assessed in this model of peripheral
nerve injury to identify if the increases in PSD-95 and Pyk 2 were occurring in the same
cells. Following nerve-injury the colocalisation of PSD-95 and Pan-Pyk 2 was increased
in lamina I and II of the dorsal horn but not in lamina III, suggesting that these two
proteins may physically interact in the superficial dorsal horn as a result of peripheral
nerve injury. Peripheral nerve injury induced a greater number of PSD-95
immunopositive cells than the number of cells that were colocalised for PSD-95 and Pan-
Pyk 2. It is possible that in the PSD-95 immunopositive cells which do not appear to
contain Pyk 2 (although the limitations of antibody sensitivity cannot be excluded), PSD-
95 may interact with other binding partners, thereby suggesting the nerve-injury induced
increase in PSD-95 may result in part in interaction with the increasingly expressed Pan-
Pyk 2. In lamina II the number of Pan-Pyk 2 immunopositive cells that were not
colocalised with PSD-95 was increased ipsilateral to nerve-injury, however there was no
increase in the number of Pan-Pyk 2 only immunopositive cells in lamina I and III; this
may suggest that in lamina II there are a number of Pyk 2-positive cells that do not
interact with PSD-95 and may thereby have a distinct role independent of NMDA/PSD-
95 complexes.
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It would be of interest to identify the cells in the spinal dorsal horn in which PSD-95
colocalises with Pan-Pyk 2. It could be suggested that within lamina I and III these dorsal
horn cells are projection neurons, which enter ascending spinal tracts and transmit
sensory information to the brainstem, midbrain and thalamic nuclei, via the spinothalamic
(STT), spinomesencephalic (SMT), spinocervical (SCT) tracts or of the postsynaptic
dorsal column (PSDC). The cells that show colocalisation of PSD-95 and Pan-Pyk 2 in
lamina II are more likely to be intrinsic interneurons, which have an extensive local
integration, given the fact that very few lamina II neurons project to the brainstem
(Giesler et al., 1976; Willis et al., 1979). As discussed above, non-neuronal cells are
involved in the underlying mechanisms of central sensitisation, as to whether some of the
PSD-95 and or Pyk 2 immunopositive cells are glial remains to be examined.
In conclusion, the findings of this study have highlighted a potential role for the SH3
domain of PSD-95 and its binding partners in the development of sensitisation in chronic
pain states, leading to the possibility of a new molecular target being identified for the
development of novel therapeutic agents. Additionally this thesis has illustrated the
functional importance of glia in the activation of spinal signalling pathways involved in
somatosensory processing, suggesting the possibility of targeting non-neuronal cells in
future treatment of chronic pain. Further investigations to provide a clearer insight into
these complex mechanisms involved in the development of chronic pain states may result
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Activation and role of p42/44 MAP kinases by VPAC2 receptors in the spinal dorsal
horn following neuropathic nerve damage
A Delaney1, E M Garry1, G. Blackburn-Munro3, R Mitchell2 and S M Fleetwood-Walker1
'Dept. Preclinical Veterinary Sciences, R (D) SVS, Summerhall, 2MRC Membrane and
Adapter Proteins Co-op, 2 Membrane Biology Group, School of Biomedical and Clinical
Laboratory Sciences, University of Edinburgh, 3 NeuroSearch AG, Copenhagen,
Denmark.
Neuropathic pain is a pervasive clinical condition in need of novel targets for therapeutic
treatment. Stimulation of peripheral nociceptive inputs causes downstream activation of
kinases in the spinal dorsal horn which can facilitate dorsal horn neuron (DHN)
responsiveness and contribute to the behavioural hyperalgesia observed in animal models
of chronic pain. Here, using the CCI model of neuropathic pain we examine the roles of
the p42/44 extracellular signal-regulated kinases (ERKs) and their activation by the
VPAC2 receptor, the expression of which we have previously shown to be increased in
neuropathic pain. Electrophysiology at the level of single dorsal horn neurons revealed
the ability of the ERK inhibitor, PD 098059, to block the sensitisation of responsiveness
following mustard oil stimulation, confirming the role of ERKs in this neuropathic
model. Intrathecal injection of the same compound showed a reversal of the hyperalgesic
and allodynic behaviours that develop following CCI. In addition, protein levels of
phosphorylated p42/44 ERK were increased ipsilateral to CCI injury and following
topical application of a VPAC2 receptor agonist while pan p42/44 ERK levels remained
unaltered. Furthermore, a specific VPAC2 receptor antagonist inhibited the sensitisation
following nerve injury, but showed no effects following inflammatory stimulation. This
is consistent with evidence that VIP expression in DRG is induced in neuropathic, but not
inflammatory pain states. The regulation of the ERKs by the neuropathic-specific VPAC2
receptor serves to isolate a specific signalling pathway that could represent a novel
therapeutic target.
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Activation of intracellular signaling pathways involving p38 and p42/44
MAP kinases may contribute importantly to synaptic plasticity under¬
lying spinal neuronal sensitization. Inhibitors of p38 or p42/44
pathways moderately attenuated responses of dorsal horn neurons
evoked by mustard oil but not brush and alleviated the behavioral
reflex sensitization seen following nerve injury. Activation of p38 and
p42/44 MAP kinases in spinal cord ipsilateral to constriction injury was
reduced by antagonists of NMDA, VPAC, and NK2 (but not related)
receptors, the glial inhibitor propentofylline and inhibitors of TNF-cx.
A VPAC2 receptor agonist enhanced p38 phosphorylation and caused
behavioral reflex sensitization in naive animals that could be blocked
by co-administration of p38 inhibitor. Conversely, an NK2 receptor
agonist activated p42/44 and caused behavioral sensitization that could
be prevented by co-administration of p42/44 inhibitor. Thus, spinal p38
Abbreviations: MAP kinase, mitogen-activated protein kinase; TNF-a,
tumor necrosis factor-a; PPT, propentofylline; VIP, vasoactive intestinal
polypeptide; PACAP, pituitary adenylate cyclase-activating peptide; CCI,
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and p42/44 MAP kinases are activated in neuropathic pain states by
mechanisms involving VPAC2, NK2, NMDA receptors and glial
cytokine production.
© 2005 Elsevier Inc. All rights reserved.
Introduction
Peripheral nerve damage can result in chronic neuropathic pain
that is resistant to current analgesic treatments. The p38 and p42/44
(ERK1/2) classes of mitogen-activated protein (MAP) kinases are
thought to participate in chronic pain mechanisms. Phosphoryla¬
tion of p38 MAP kinase is induced in the ipsilateral superficial
dorsal horn of the spinal cord and dorsal root ganglia following
peripheral nerve injury or inflammation, and inhibition prevents
behavioral sensitization (Kim et al., 2002; Svensson et al., 2003;
Jin et ah, 2003; Ji et ah, 2002a). Inflammation or C-fiber
stimulation also induces phosphorylation of p44/42 MAP kinase
in the trigeminal nucleus and the superficial dorsal horn and
behavioral sensitization that is reversed by p42/44 MAP kinase
inhibition (Huang et ah, 2000; Ji et ah, 1999, 2002a). Furthermore,
these kinases are expressed not only in neurons but also in spinal
glial cells, with sensory stimulus-induced activation of p38 and
p42/44 MAP kinases being differentially localized to microglia and
astrocytes, respectively (Jin et ah, 2003; Ma and Quirion, 2002).
The MAP kinases can be activated by Ca2+-permeable
ionotropic receptors such as the NMDA receptor (Xia et ah,
1996; Kawasaki et ah, 1997) and by a variety of G-protein-coupled
receptors (GPCRs) (Marinissen and Gutkind, 2001; Yamauchi et
ah, 1997). Such GPCRs in spinal cord include neurokinin (NK) and
vasoactive intestinal polypeptide (VIP) receptors, both ofwhich are
prominently involved in nociception and hyperalgesia (Coderre and
1044-7431/$ - see front matter © 2005 Elsevier Inc. All rights reserved,
doi: 10.1016/j .mcn.2005.08.016
524 E.M. Garry et al. / Mol. Cell. Neurosci. 30 (2005) 523- 537
Melzack, 1992; Laird et al., 1993; Dickinson and Fleetwood-
Walker, 1999). Neurokinin A (NKA), the endogenous ligand for
NK2 receptors, is localized to unmyelinated C-fibers, can produce
spinal hyperexcitability and is depleted following nerve transection
(Dalsgaard et al., 1985; Hokfelt et al., 1994; Ogawa et al., 1985; Xu
et al., 1991). Furthermore, dorsal horn neuron excitability and
sensitization following nerve injury can also be blocked by NK2
receptor antagonists (Yashpal et al., 1996; Fleetwood-Walker et al.,
1990; Coudore-Civiale et al., 1998). NK2 receptor binding sites are
present in spinal cord (Quirion and Dam, 1988), where a substantial
proportion is thought to be located on astrocytes (Zerari et al.,
1998). The VPAC2 receptor, a target for VIP, is normally present in
spinal cord at low levels, but the expression ofVIP in fine afferents
and the VPAC2 receptor in dorsal horn are increased following
nerve injury (Nahin et al., 1994; Dickinson et al., 1999) that
corresponds to the marked inhibitory effect of VPAC2 receptor
antagonists on neuropathic sensitization (Dickinson and Fleet¬
wood-Walker, 1999; Dickinson et al., 1999). VIP and VPAC2
receptors have been associated with glial regulation in spinal and
other regions (Knyihar-Csillik et al., 1993; Brenneman et al., 1990).
It is becoming increasingly apparent that glial cells, namely
astrocytes and microglia, are important in the generation and
maintenance of chronic pain states (Watkins and Maier, 2002;
Garrison et al., 1991). Glial activation in the spinal cord parallels
the development of pain behaviors (Honore et al., 2000) and glial
inhibitors such as fluorocitrate and minocycline attenuate allodynia
and hyperalgesia in various nerve injury models (Watkins and
Maier, 2002). Also, inhibitors of the synthesis and action of glially
generated pro-inflammatory cytokine tumor necrosis factor-a
(TNF-a), including propentofylline (PPT) and thalidomide, are
analgesic in chronic pain states (Raghavendra et al., 2003a; George
et al., 2000, Sommer et al., 1998a).
Here, we examined the activation of p38 and p42/44 MAP
kinases in the spinal cord following nerve injury, their functional
role in behavioral reflex sensitization and the contribution made by
NK2, VPAC2 and NMDA receptors as well as spinal glial cells to
these effects.
Results
Single dorsal horn neuronal responses to sensory stimulation are
reduced by inhibitors of the MAP kinase pathway
Spinal MAP kinases are activated in response to noxious
cutaneous stimuli and following C-fiber and noxious stimulation
(Ji et al., 1999, 2002a; Galan et al., 2002). To investigate whether
MAP kinases play a particular role in mechanisms of neuropathic
sensitization, we examined the effects of MAP kinase inhibitors on
brush and mustard oil-evoked responses of single dorsal horn
neurons (DHNs) in neuropathic compared to control animals.
Brush will activate low threshold mechanoreceptors, and mustard
oil will activate high threshold polymodal nociceptors. CCI
animals were used at the peak of injury-induced behavioral
sensitivity and were compared with nai've animals. In parallel
studies, the non-noxious 0.5-g and the noxious 25-g responses
were increased from 3.8 + 0.8 to 14.8 ± 4.2 action potentials per
second and from 11.7 ± 1.8 to 22.8 ± 3.9 action potentials per
second, respectively. We showed that following CCI, there was
sensitization in both sensory ranges corresponding to the brush and
mustard oil responses investigated here. We examined any differ¬
ential effect on responses to sensory stimulation with the C-fiber
selective algogen mustard oil compared to innocuous brush
stimulation. In all of the DHNs studied, activation occurred in
response to either innocuous brush or noxious mustard oil stimuli.
The duration over which these ongoing stimuli were applied was
typically about 50 min, and the firing rates reported here were
generally well maintained through that period. These were
recorded from depths previously characterized as corresponding
to location in laminae III-V (Moss et al., 2002).
Ionophoresis of the p38 MAP kinase inhibitor SB 203580 (100
pM in 0.3% dimethylformamide/H20) had no significant effects on
innocuous brush-evoked activity at currents up to 60 nA in either
naive (13 ± 12%, n = 12, Fig. la) or neuropathic rats (5 ± 6%, n =
12, Fig. lc). In nai've animals, SB 203580 consistently caused a
partial inhibition of mustard oil-evoked activity at 30-40 nA (by
38 + 6%; paired t test, P < 0.05; n = 11, Fig. lb), while there was
often a much greater inhibition of neuronal responses in 6 out of 10
neurons from neuropathic animals at the lower current of 20 nA (by
58 ± 10%; paired t test, P < 0.05; n = 10, Fig. Id). The remaining
neurons were inhibited to a similar extent to those in naive animals.
Correspondingly, in naive animals, following intravenous injection
of SB 203580 (0.5-0.75 mg/kg), while neuronal activity due to
brush stimulation of the peripheral receptive field was unchanged
(increasing by only 2 ± 3%; n = 3), the mustard oil-evoked activity
of these neurons was significantly reduced (by 45 + 10% (paired t
test, P < 0.01; n = 6). Administration of vehicle had no effect on
either brush-evoked (6 ± 7% inhibition; n = 4) or mustard oil-
evoked (1 ± 2% inhibition; n = 4) activation of DHNs.
Ionophoresis of the p42/44 MAP kinase pathway inhibitor PD
98059 (50 pM in 0.3% dimethylformamide/H20) had minimal
effects on innocuous brush-evoked activity at currents up to 50 nA
in naive rats (8 ± 6% inhibition; n = 8, Fig. 2a), while there was
moderate inhibition at low currents in neuropathic rats (46 ± 13%,
paired t test, P < 0.05; n = 7, Fig. 2c). PD 98059 caused moderate
but statistically significant reductions in mustard oil neuronal
responses in nai've rats (paired t test, P < 0.05 in each case; Fig. 2b)
which appeared to be greater in neuropathic rats (Fig. 2d).
Although effects were generally more modest than those with the
p38 inhibitor, the percentage inhibition of mustard oil-induced
firing at low currents of PD 98059 (such as 20 nA) appeared to be
consistently greater in neuropathic than in naive animals (47 ± 8%
and 26 ± 11%, respectively, n = 6). Neither of the kinase inhibitors
affected spontaneous firing of neurons from naive or neuropathic
animals. Also, there was no discernible change in neuronal activity
following the ejection of either saline or vehicle at currents up to 50
nA. These results indicate that both p38 and p42/44 MAP kinases
may play a role in maintained activity of dorsal horn neurons
following prolonged noxious stimulation but have minimal effects
on innocuous transmission and suggest that both contribute to the
central sensitization brought about by nerve injury.
Intrathecal injections ofp38 or p42/44 MAP kinase pathway
inhibitors attenuate neuropathic reflex sensitization following CCI
Since p38 and p42/44 MAP kinase pathway inhibitors affected
single dorsal horn neuron responses to sensory stimulation, we
next asked whether corresponding effects were observed on reflex
pain behavior. Intrathecal administration of the p38 MAP kinase
inhibitor SB 203580 (5 nmol in 0.3% dimethylformamide/saline,
doses of 0.5 nmol and 20 nmol were also injected to investigate
dose-response relationships) in rats at the peak of the ipsilateral















Fig. 1. Effects of ionophoretically applied SB 203580 (a p38 MAP kinase inhibitor) on evoked activity in spinal dorsal horn neurons. Records show typical
examples of the effects of SB 203580 on the firing of individual neurons, driven by either continuous motorized brush (a) and (c) or mustard oil (b) or (d)
applied to the cutaneous receptive field. Neuronal firing is displayed as action potentials per second (Hz), plotted against time. Brush-evoked firing was
unaffected by SB 203580 at ionophoretic currents up to 60 nA in both naive animals (a) and animals with established ipsilateral sensitization of behavioral
reflexes following CCI (c). Mustard oil-evoked firing in naive animals was inhibited in a current-dependent manner by SB 203580 ionophoresis (b), while that
in CCI animals appeared to be reduced to a greater extent at lower currents (d). Full recovery after cessation of ionophoresis was seen in each case.
Ionophoresis of SB 203580 at currents up to 60 nA had no apparent effect on spontaneous firing in nai've or CCI animals (data not shown). Vehicle or saline
ejection at currents up to 60 nA had no effect on any neuronal activity (data not shown).
reflex sensitization following CCI caused a significant reversal of
thermal hyperalgesia for 75 min post-injection (Fig. 3a) and of
mechanical allodynia for 55 min post-injection (Fig. 3b). Similarly,
intrathecal administration of the p42/44 MAP kinase pathway
inhibitor PD 98059 (2.5 nmol in 0.3% dimethylformamide/saline,


















Fig. 2. Effects of ionophoretically applied PD 98059 (an inhibitor of the p42/44 MAP kinase pathway) on evoked activity in spinal dorsal horn neurons.
Records show typical examples of the effects of PD 98059 on the ongoing firing of individual neurons, displayed as action potentials per second (Hz), plotted
against time. Brush-evoked firing was unaffected by PD 98059 at ionophoretic currents up to 50 nA in nai've animals (a) but was moderately inhibited at low
currents in animals with established ipsilateral sensitization of behavioral reflexes following CCI (c). Mustard oil-evoked activity in naive animals was
moderately inhibited by PD 98059 ionophoresis at low currents (b), while that in CCI animals appeared to be reduced to a greater extent at similar currents (d).
Full recovery after cessation of ionophoresis was seen in each case. Ionophoresis of PD 98059 at currents up to 50 nA had no apparent effect on spontaneous
firing in naive or CCI animals (data not shown). Vehicle or saline ejection at currents up to 50 nA had no effect on any neuronal activity (data not shown).
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Fig. 3. Effects of the intrathecal administration of the p38 inhibitor SB 203580 and the p42/44 MAP kinase pathway inhibitors PD 98059 and U 0126 on
nerve injury-induced thennal hyperalgesia and mechanical allodynia. Data represent the average hindlimb withdrawal latency (PWL; seconds) to noxious heat
(a, c, e) and withdrawal threshold to mechanical stimuli (PWT; mN/mm2; b, d, f) ± SEM before or following the intrathecal injection of either SB 203580 (5
nmol, a, b; n = 6), PD 98059 (2.5 nmol, c, d; n - 6) orU 0126 (1.5 nmol, e, f, n = 8). Rats were at the peak of ipsilateral reflex sensitization, as determined by
a significant reduction in ipsilateral paw withdrawal latency to thermal stimuli (PWL; *P < 0.05, Student's I test, a, c, e) or paw withdrawal threshold to
mechanical stimuli (PWT; *P < 0.05, Wilcoxon test, b, d, f; O) compared to contralateral withdrawal responses (■). Following intrathecal injection (at arrow),
SB 203580 (a), PD 98059 (c) and U 0126 (e) significantly increased ipsilateral thermal paw withdrawal latencies in comparison to pre-injection ipsilateral
values ('P < 0.05, one-way repeated measures ANOVA followed by a Dunnett's test), while there was no significant alteration in the contralateral response.
Graphs (b, d and f) show that the corresponding kinase inhibitors significantly increased ipsilateral mechanical paw withdrawal thresholds in comparison to
pre-injection ipsilateral values CP < 0.05, Friedman test followed by a Dunn's post-hoc test), while there was no significant alteration in the contralateral
response. Full recovery to pre-drug response levels was seen in each case.
dose-response relationships) caused a significant reversal of
thermal hyperalgesia for up to 55 min post-injection (Fig. 3c)
and reversed the mechanical allodynia response for 40 min (Fig.
3d). A further p42/44 MAP kinase pathway inhibitor U 0126 (1.5
nmol in 0.3% dimethylformamide/saline) caused a significant
inhibition of thermal hyperalgesia for 60 min post-injection (Fig.
3e) with a briefer (35 min) effect on mechanical allodynia (Fig. 3f).
Full recovery to pre-injection response levels was documented in
each case within the 90-min post-drug recording period of the
experiment. An inactive analogue U 0124 at the same dose had
minimal effects with the mean percent reversal of reflex sensitiza¬
tion over the first 35 min of drug administration being 9.7 ± 2.0%
and 8.8% + 4.3 for mechanical allodynia and thermal hyperalgesia,
respectively (mean% ± SEM; n = 7). None of the compounds
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tested had any significant effects on the contralateral hindpaw nor
when administered to naive animals (data not shown). These data
indicate that either p38 or p42/44 MAP kinase pathway inhibition
can alleviate peripheral nerve injury-induced sensitization. Intra¬
thecal administration of a low dose (0.5 nmol) of SB 203580
caused no significant reversal of either thermal hyperalgesia
(contralateral 16.4 ± 1.2 s; ipsilateral 9.3 ± 0.3 s) or mechanical
allodynia (contralateral 4830.6 ± 0.0 mN/mm2; ipsilateral 1188.4 ±
210.6 mN/mm2). A higher dose (20 nmol) of SB 203580 caused a
similar reversal of thermal hyperalgesia (contralateral 16.7 ± 0.8 s,
ipsilateral 15.4 ± 2.2 s) and a moderately longer reversal (65 min)
of mechanical allodynia (contralateral 4830.6 ± 0.0 mN/mm2,
ipsilateral 3828.7 ± 572.7 mN/mm2) as was seen for the 5 nmol
dose presented in Figs. 3a and b. Intrathecal administration of a
low dose (0.5 nmol) of PD 98059 did not affect thermal
hyperalgesia (contralateral 15.8 ± 0.9 s, ipsilateral 8.6 ± 1.8 s) or
mechanical allodynia (contralateral 4830.6 ± 0.0 mN/mm2, ipsi¬
lateral 1451.6 ± 141.3 mN/mm2). A high dose (7.5 nmol) of PD
98059 caused a similar reversal of thermal hyperalgesia (contrala¬
teral 15.9 ± 1.7 s, ipsilateral 16.2 ± 3.0 s) for a longer time of 65
min and mechanical allodynia (contralateral 4830.6 ± 0.0 tnN/
mm2, ipsilateral 3703.4 ± 501.3 mN/mm2) for 40 min post-
injection as was seen for the 2.5 nmol dose presented in Figs. 3c
and d. These observations indicate that the partial inhibitory effects
of the MAP kinase inhibitors were essentially of maximal
magnitude at the doses shown in Fig. 3, but that some increases
in the duration of effects were seen at higher doses.
The glial inhibitor propentofvlline and the TNF-a inhibitor
WP9QY both attenuate neuropathic reflex sensitization following
CCI
Glial activation is now known to be involved in the genesis
and maintenance of chronic pain (Watkins and Maier, 2002). We
examined the effects of disrupting the function of both
astrocytes and microglia using propentofylline (PPT). Glial
release of TNF-a also contributes to chronic pain (Sommer et
al., 1998a,b), thus we also examined any effects of the TNF-a
receptor antagonist WP9QY following CCI-induced peak sensi¬
tivity. Intrathecal injection of PPT (0.5 pmol in saline and 1.5
pmol in saline; Figs. 4a, b) or WP9QY (0.025 mg in saline;
Figs. 4c, d) reversed thermal hyperalgesia for 35-40 min and
mechanical allodynia for 30-40 min. The higher dose (1.5
pmol) of PPT reversed thermal hyperalgesia for slightly longer
(50 min) post-injection and reversed mechanical allodynia for
the same amount of time (40 min) post-injection. Full recovery
to pre-injection response levels was documented within 60 min
post-drug in each case. These results suggest that both astrocytes
and microglia could be involved in nerve injury-induced
sensitization.
Involvement ofspecific receptors for afferent neuropeptide
transmitters in behavioral reflex sensitization following nerve
injury
In rats with established thermal hyperalgesia and mechanical
allodynia following CCI, we intrathecally injected selective
antagonists for VPAQ (0.1 nmol [Ac-His1, D-Phe2, Lys15,
Arg16, Leu17]-VIP (3-7) GRF (8-27)), VPAC2 (0.1 nmol [des
(1- 4), Arg16]-Ro 25-1553) and PAC, (0.1 nmol PACAP„ 3S)
receptors and for NKj (5 mol RP 67580) and NK, (5 nmol SR
48968) receptors. Although these agents had no significant effects
on withdrawal responses in naive animals or contralateral to CCI,
VPAC2 receptor and NK2 receptor antagonists demonstrated
marked antinociceptive effects on sensitized thermal and mechan¬
ical responses ipsilateral to CCI (Fig. 5, Table 1). Under identical
conditions, the selective antagonists of VPACi, PACi and NK|
receptors caused only minor or no significant attenuation of such
sensitized responses (Table 1). The PAC, receptor-selective
antagonist is known to also have significant affinity for VPAC2
receptors (Dickinson et al., 1999). These data emphasize the
importance of VPAC2 and NK2 receptors in central sensitization
following CCI.
Assessment of the effects of VPAC2, NK2 and NMDA receptor
antagonists and glial inhibitors on MAP kinase activation
Following CCI, we found increases in the levels of phosphory-
lated (active) p38 (Fig. 6a) and phosphorylated (active) p42/44
(Fig. 5b) in the ipsilateral spinal cord in comparison to the
contralateral spinal cord and naive animals. The activation of p38
and p42/44 MAP kinases can occur via a number of routes. For
example, NMDA and neurokinin 1 (NK0 receptor stimulation can
activate p38 and p42/44 MAP kinase elsewhere (Kawasaki et al.,
1997; Fiebich et al., 2000; Svensson et al., 2003; Sweatt, 2001). In
addition, antagonists of NMDA, NK2 and VPAC2 receptors block
CCI-induced reflex sensitization (Fig. 5, Table 1; Mao et al., 1993;
Coudore-Civiale et al., 1998; Dickinson et al., 1999). Here, we
further found that the enhanced activation (phosphorylation) of
both p38 and p42/44 MAP kinase that occurred following CCI
could be reduced by topical spinal application of NMDA, NK2 and
VPAC2 receptor antagonists ((R)-CPP, SR 48968 and [des (1-4),
Arglf']-Ro 25-1553, respectively), but not saline vehicle (Figs. 6c,
d and Table 2).
Glial cells are known to express p38 and p42/44 MAP
kinases, so we examined any effects of glial blockade on MAP
kinase activation. We show that the functional inhibitor of glia,
PPT, as well as the TNF-a receptor antagonist WP9QY and the
TNF-a synthesis inhibitor thalidomide could suppress increases
in activation of p38 (Fig. 6c, Table 2) and p42/44 (Fig. 6d,
Table 2) MAP kinases that occurred following CCI. There was
no change in the overall (pan) levels of p38 or p42/44 MAP
kinase following administration of these reagents (Figs. 6c and
d, lower panels).
Activation ofVPAC2 and NK2 receptors increases phosphoiylation
ofp38 and p42/44 MAP kinases and causes behavioral reflex
sensitization that is blocked by a glial inhibitor
Immunoblot analysis of naive spinal cord following the topical
application of the selective VPAC2 receptor agonist Ro 25-1553
revealed a marked increase in the level of phosphorylated p38
MAP kinase in comparison to saline treatment (Fig. 7a, Table 3),
while there was a lesser, but still significant activation of p38 MAP
kinase following application of the NK2 receptor agonist GR
64349 (Fig. 7a, Table 3).
Conversely, there was a much greater increase in levels of
phosphorylated p42/44 MAP kinase following application of the
NK2 receptor agonist, GR 64349 than seen for VPAC2 receptor
agonist stimulation, although both were statistically significant
(Fig. 7b, Table 3). Both VPAC2 receptor and NK2 receptor
agonist-induced increases of either MAP kinase could be










20 30 40 50 60 70 80
Time post-injection (mins)






Fig. 4. The glial inhibitor propentofylline and the TNF-ot receptor antagonist WP9QY reverse the behavioral sensitization that occurs following CCI.
Data represent the average hindlimb withdrawal latency (PWL; seconds) to noxious heat (a, c) and withdrawal threshold to mechanical stimuli (PWT;
mN/mm2; b, d) ± SEM before or following the intrathecal injection of either propentofylline (0.5 pmol, PPT; a, b; n = 5) or WP9QY (0.025 mg, c, d;
n = 5). Rats were used at the peak of ipsilateral reflex sensitization, as determined by a significant reduction in ipsilateral paw withdrawal latency to
thennal stimuli (PWT; *P < 0.05, Student's t test, a, c) or paw withdrawal threshold to mechanical stimuli (PWT; *P < 0.05 Wilcoxon test, b, d; O)
compared to contralateral withdrawal responses (■). Both compounds significantly increased ipsilateral thermal paw withdrawal latencies (a, c) in
comparison to pre-injection ipsilateral values CP < 0.05, one-way repeated measures ANOVA followed by a Dunnett's test), while there was no
significant alteration in the contralateral response. Similarly, both compounds significantly increased ipsilateral mechanical paw withdrawal thresholds in
comparison to pre-injection values CP < 0.05, Friedman test followed by a Dunn's post-hoc test), while there was no significant alteration in the
contralateral response. Full recovery to pre-drug response levels was seen in each case.
reduced to saline control levels when agonists were co¬
administered with the glial inhibitor PPT (Figs. 7a and b, Table
3). Overall (pan) levels of either p38 or p42/44 MAP kinase did
not significantly differ between any of the drug-treated groups
(Figs. 7a and b).
To establish that agonist-induced responses in p38 or p42/44
phosphorylation were reflected in functional alterations of spinal
responsiveness, we performed intrathecal injections with combi¬
nations of receptor agonist/kinase antagonist. For these experi¬
ments, we selected the receptor agonists that had caused the
greatest change in either p38 or p42/44 phosphorylation. In nai've
animals, intrathecal administration of the VPAC2 receptor agonist
Ro 25-1553 (0.5 nmol) caused bilateral behavioral sensitization to
thermal stimuli (Fig. 7c) and mechanical stimuli (data not shown)
that was abolished when Ro 25-1553 was co-administered with
the p38 MAP kinase inhibitor, SB 203580 (5 nmol) (Fig. 7d).
Similarly, the NK2 receptor agonist GR 64349 produced bilateral
behavioral sensitization to thermal stimuli (Fig. It) and mechanical
stimuli (data not shown) that was blocked when GR 64349 (1.5
nmol) was co-administered with the p42/44 MAP kinase pathway
inhibitor U 0126 (1.5 nmol) (Fig. 7f).
Discussion
The present data indicate that both p38 and p42/44 MAP
kinases play an important role in mediating nociceptive afferent
inputs at the spinal dorsal hom level. We show that p38 and p42/44
inhibitors attenuate the sensitization of individual dorsal hom
neurons resulting from mustard oil application and inhibit the
thermal and mechanical behavioral reflex sensitization that occurs
following peripheral nerve constriction injury (CCI). The anti¬
nociceptive effects of MAP kinase pathway inhibitors were of
rapid onset, probably on account of their delivery to the close
proximity of the site of action by the ionophoretic technique,
thereby minimizing diffusion distances. Additionally, inhibition of
glial activation (propentofylline) or of TNF-a (using WP9QY or
the synthesis inhibitor, thalidomide) reverses CCI-induced behav¬
ioral reflex sensitization. Furthermore, the enhanced phosphoryla¬
tion of p38 and p42/44 MAP kinase that occurs in the ipsilateral
spinal cord following CCI can be prevented by spinal application
of the same TNF-a and glial inhibitors. The CCI-induced
behavioral sensitization was prominently inhibited by VPAC2
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Fig. 5. VPAC2 and NK2 receptor antagonists reverse the behavioral sensitization that occurs following CCI. Data represent the average hindlimb withdrawal
latency (PWL; seconds) to noxious heat (a, c) and withdrawal threshold to mechanical stimuli (PWT; mN/mm2; b, d) ± SEM before or following the
intrathecal injection of either a VPAC2 receptor antagonist (0.1 nmol [des (1 -4), Arg16]-Ro 25-1553; a, b; n = 7) or an NK2 receptor antagonist (5 nmol SR
48968; c, d; n - 5). Rats were used at the peak of ipsilateral reflex sensitization, as determined by a significant reduction in ipsilateral paw withdrawal latency
to thermal stimuli (PWT; *P < 0.05, Student's t test, a, c) or paw withdrawal threshold to mechanical stimuli (PWT; *P < 0.05 Wilcoxon test, b, d; O)
compared to contralateral withdrawal responses (■). Both compounds significantly increased ipsilateral thermal paw withdrawal latencies (a, c) ( P < 0.05,
one-way repeated measures ANOVA followed by a Dunnett's test) and ipsilateral mechanical paw withdrawal thresholds (1P < 0.05, Friedman test followed
by a Dunn's post-hoc test) in comparison to pre-injection ipsilateral values. There was no significant alteration in the contralateral response. Full recovery to
pre-drug response levels was seen in each case.
PACi and NK, receptor antagonists. Correspondingly, the CCI-
induced p38 and p42/44 phosphorylation is reduced by spinal
application of VPAC2 and NK2 receptor antagonists and also by a
blocker of the NMDA receptor, which is implicated in mechanisms
Table 1
Mean % reversal of ipsilateral sensitisation from 15 to 30 min following
drug administration
Compound Thermal hyperalgesia Mechanical allodynia
VPAC, R antagonist 8.3 ± 2.0 12.4 ± 4.6
VPAC2R antagonist 93.6 ± 5.2* 41.2 ± 6.1*
PAC|R antagonist 27.6 + 4.1* 19.5 + 3.3*
RP 67580 NKtR antagonist 11.6 ± 4.8 22.9 ±6.1*
SR 48968 NK2R antagonist 89.6 ± 4.3* 73.2 ± 6.5*
Summary of the effects of intrathecal administration of VPAC2, VPAC[,
PACi, NK2 and NK1 receptor antagonists on pain-related behavioral reflex
responses. Data represent mean percent reversal ± SEM from 15 to 30 min
following intrathecal injection of each compound for measurements of
thermal hyperalgesia and mechanical allodynia in rats at the peak of
ipsilateral reflex sensitivity. "Indicates a significantly attenuated ipsilateral
thermal hyperalgesia (P < 0.05, one-way ANOVA followed by a Durmett's
test) or mechanical allodynia (P < 0.05, Kmska I W'allis ANOVA followed
by a Dunn's test) in comparison to pre-injection ipsilateral values at each of
the time points throughout this period. There were no significant changes in
contralateral responses at any time.
of central sensitization. Agonist stimulation of spinal VPAC2 (and
to a lesser extent, NK2) receptors increases the phosphorylation of
p38 MAP kinase; a response that was inhibited by the glial
inhibitor propentofylline. In addition, behavioral sensitization
induced by a VPAC2 receptor agonist in naive rats was prevented
when the p38 inhibitor SB 203580 was co-administered. Finally,
agonist stimulation of NK2 receptors induced phosphorylation of
p42/44 MAP kinase to a greater extent than the VPAC2 receptor
agonist, and this again could be prevented by propentofylline.
Correspondingly, the NK2 receptor agonist-induced sensitization of
behavioral responses in naive rats was inhibited by co-admin¬
istration of the p42/44 MAP kinase inhibitor U 0126. These results
suggest that p38 and p42/44 activation in the spinal cord
contributes to neuropathic sensitization, that spinal VPAC2
receptors and NK2 receptors are significant mediators of the p38
and p42/44 activation respectively, and that glial activation and
TNF-a action may be important in both cases.
MAP kinases are known to be phosphorylated in sensory
afferents and in the spinal cord following selective C-fiber
stimulation or noxious stimulation (Ji et al., 1999, 2002a,b; Galan
et al., 2002; Kim et al., 2002; Obata et al., 2003,2004; Mizushima et
al., 2005). Here, the increased responsiveness ofdorsal horn neurons
bought about by mustard oil stimulation of C-fibers and CCI-
induced reflex sensitization could be reduced by inhibitors of either
p38 or p42/44 pathways. These findings are in agreement with others
530 EM. Garry et al. /Mol. Cell. Neurosci. 30 (2005) 523-537


























\<f \N» 00<> sS» cf \<f
m up s * H'-l


















Fig. 6. Phospho-specific immunoblot evidence that VPAC2, NK2 and NMDA receptor antagonists and glial inhibitors can suppress activation of MAP kinases
following CC1. Immunoblots from spinal cord samples at the peak of CCl-induced behavioral sensitization (n = 5) or naive (n = 5) animals showing the
expression levels of activated phospho-p38 (a) or phospho-p42/44 (b) (together with corresponding pan immunoreactivity for the kinases) on the side ipsilateral
(ipsi) to CCI in comparison to the contralateral (con) side and naive levels. CCI alone (CCI) caused an increase in the levels of activated phospho-p38 (a) and
phospho-p42/44 (b) in the ipsilateral spinal cord compared to the contralateral side and naive spinal samples. Topical application of antagonists to the VPAC2
([des (1-4), Arg16]-Ro 25- 1553), NK2 (SR 48968) and NMDA ((R)-CPP) receptors to CCI spinal cords could all suppress the increased activation of both
p38 (c) and p42/44 (d) MAP kinases, whereas saline vehicle had no effect. Similarly, topical application of the glial inhibitor propentofylline (PPT), an
antagonist of the pro-inflammatory cytokine, TNF-a (WP9QY) and the inhibitor of TNF-a synthesis, thalidomide, could all inhibit p38 (a) and p42/44 (b)
MAP kinase activation ipsilateral to CCI. No significant alterations occurred in the overall levels of p38 (pan-p38) or p42/44 (pan-p42/44) with any treatment
(lower panels).
where p38 MAP kinase inhibition by intrathecal SB 203580 can
suppress spinal nerve injury-induced allodynia, the hypersensitivity
that occurs following substance P application and formalin- or
Complete Freund's Adjuvant (CFA)-induced inflammation (Tsuda
et al., 2004; Jin et al., 2003; Svensson et al., 2003). Similarly,
inhibition of the p42/44 MAP kinase pathway with U 0126 reduces
capsaicin-, inflammation- and nerve transection-induced hyper¬
sensitivity (Obata et al., 2003; Dai et al., 2002; Ji et al., 2002a).
Non-neuronal (glial) cell activation is now seen as a crucial
component of the generation and maintenance of chronic pain
states. Microglia and astrocytes can be activated in response to
inflammation and peripheral nerve injury (Sweitzer et ai., 1999;
Hashizume et al., 2000; Garrison et al., 1991). Formalin, axotomy
and nerve injury can activate p38 MAP kinase in microglia (Kim et
al., 2002; Kawasaki et al., 1997; Jin et al., 2003; Svensson et al.,
2003; Tsuda et al., 2004), and phosphorylation of p42/44 MAP
kinase occurs in spinal neurons following peripheral inflammation
and in astrocytes after partial nerve ligation (Ji et al., 1999; Ma and
Quirion, 2002). It is now known that p42/44 is activated not only
in neurons but also in microglia and astrocytes following nerve
injury (Zhuang et al., 2005). The non-selective glial inhibitor
propentofylline (which can decrease the activation of both spinal
astrocytes and microglia) attenuates allodynia following spinal
nerve transection (Sweitzer et al., 2001) and reduces formalin-
induced inflammatory pain by suppressing TNF-a (Dorazil-Dudzik
et al., 2004). Here, intrathecal propentofylline reversed the CCI-
induced behavioral reflex sensitization. Minocycline, a blocker of
microglial activation (Tikka et al., 2001) can inhibit MAP kinase
activation caused by NMDA receptor stimulation (Tikka and
Koistinaho, 2001) and prevent the development of pain behaviors
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Table 2
lmmunoblot densitometric ratio scores for phospho-p38:pan-p38 and phospho-p42/44:pan-p42/44 (arbitrary density units)
Treatment CCI with saline VPAC2 receptor antagonist
[des (1 -4), Argl6]-Ro 25-1553
NK2 receptor antagonist SR 48968
MAP kinase Ipsi Con Ipsi Con Ipsi Con
p38
p42/44
63.5 + 5.7* 48.4 ± 6.2
56.1 + 4.8* 35.9 ±3.6
39.3 ± 7.3 35.8 ± 6.0
39.7 ±4.4 41.4 ±5.0
47.3 + 5.5 45.6 + 4.8
37.9 ± 3.9 37.1 ±5.2
Treatment NMDA receptor antagonist (R)-CPP Glial inhibitor PPT TNF-a receptor antagonist WP9QY
MAP kinase Ipsi Con Ipsi Con Ipsi Con
p38
p42/44
42.3 ± 7.6 44.1 ± 7.1
39.6 ± 4.9 42.8 ± 4.3
37.4 ± 5.9 39.8 ± 4.7
30.9 ± 4.3 38.3 ± 4.6
40.3 ± 5.0 36.3 ± 7.5
41.3 ± 8.3 34.8 ± 5.2
Treatment TNF-a synthesis inhibitor thalidomide No treatment
MAP kinase Ipsi Con Naive spinal cord
p38
p42/44
41.5 ± 6.8 39.6 ±4.8
35.0 ± 6.2 45.9 ± 6.9
44.6 ± 4.6
39.6 ± 7.1
Values are mean + SEM values (n = 5) derived from quantitative densitometry of co-processed immunoblots (shown in Figs, 6c and d). p42/44 represents the
mean value from the densitometric analysis ofp42 and p44. Statistically significant differences in the ratio ofphospho to pan immunoreactivity compared to the
contralateral, uninjured side in saline controls are shown as *P < 0.05 by Wilcoxon test. The levels of p38 expression and p42/44 expression in naive animals
were not significantly different from those on the contralateral side of CCI animals treated with saline or indeed, with any other drugs.
following nerve injury (Raghavendra et al., 2003b). Astrocyte
activation (in terms of increased GFAP expression) can occur
following CCI and is thought to involve NMDA receptors
(Garrison et al., 1994), although no microglial activation has been
reported in this model (Colbum et al., 1997). The MAP kinase
activation response following nerve injury may not however
correspond directly to the classical astrocyte activation (GFAP
expression) response. Nevertheless, minocycline or the inhibitor of
TNF-a synthesis, thalidomide, is already known to be effective in
reducing sensitization in various chronic pain models (Watkins and
Maier, 2002; Raghavendra et al., 2003b; George et ah, 2000;
Sommer et ah, 1998a), suggesting that increased TNF-a expression
or release may contribute to sustained pain processing by further
activation of p38 and/or p42/44 MAP kinases in glial cells.
Pro-inflammatory cytokines including TNF-a can be released
from astrocytes and microglia in the CNS (Sawada et ah, 1989), and
spinal expression of TNF-a is upregulated after peripheral nerve
injury (De Leo et ah, 1997; Bartholdi and Schwab, 1997; Wagner
and Myers, 1996). Local application of TNF-a to afferents induces
pain and spontaneous activity in nociceptive fibers (Sorkin and
Doom, 2000; Sorkin et ah, 1997). Neutralizing antibody blockade
of the TNF-a receptor 1 (TNRF1) can block CCI-induced pain in
mice (Sommer et ah, 1998b), and a TNF-a antagonist can attenuate
nerve injury-induced allodynia behavior (Schafers et ah, 2003;
Winkelstein et ah, 2001). TNF-a activates p38 MAP kinase and
inhibits glutamate uptake (Schafers et ah, 2003; Fine et ah, 1996);
both actions consistent with sensitization, while TNF-a blockade
can reduce nerve injury-induced p38 activation (Svensson et ah,
2005). Furthermore, thalidomide, which inhibits the synthesis of
TNF-a (Sampaio et ah, 1991), prevents behavioral sensitization
following nerve injury (Sommer et ah, 1998a) and reduces the CCI-
induced increase in spinal TNF-a expression (George et ah, 2000).
A variety of neurotransmitter receptors are expressed in glia as
well as neurons. Neurokinins can stimulate glial production of IL-1
and TNF-a (Martin et ah, 1992), and intrathecally applied
substance P (SP) causes increased phosphorylation of p38 MAP
kinase in microglia (Svensson et ah, 2003). CFA-induced
inflammation upregulates both NKj receptor and p42/44 MAP
kinase activation in the same dorsal horn neurons (Ji et ah, 2002a).
Ftowever, NK2 receptors have also been specifically implicated in
NKA-induced enhancement of dorsal horn neuron responses to
noxious cutaneous stimuli (Fleetwood-Walker et ah, 1990). NK2
receptor antagonists are antinociceptive when administered intra¬
thecally following CCI (Coudore-Civiale et ah, 1998), and a non-
peptide NK2 receptor antagonist reduced sensitization of thermal
and mechanical responses to a greater extent here than an NIG
receptor antagonist of similar potency. The activation of p42/44 in
dorsal horn following C-fiber stimulation is known to involve
neuronal NMDA receptors (Lever et ah, 2003). NK2 receptors are
located on spinal astrocytes (Zerari et ah, 1998), also a site of p42/
44 MAP kinase activation following nerve injury (Ma and Quirion,
2002), so the activation of p42/44 MAP kinase seen here could
partly be the result of glial NK2 receptor activation leading to
cytokine release and facilitation of NMDA receptor function. It is
not possible to exclude that at least part of the MAP kinase
phosphorylation resulting from NK2 receptor activation may be
occurring indirectly in neurons downstream of glial activation.
This may be consistent with the sensitivity of the MAP kinase
response to the NMDA receptor antagonist since the relevant
NMDA receptors may be neuronally located.
VPAC2 receptors are also important in neuropathic pain (Dick¬
inson and Fleetwood-Walker, 1999; Dickinson et ah, 1999, 1997).
The expression of the VPAC2 receptor ligand vasoactive intestinal
polypeptide (VIP) in small DRG cells (and decreased expression of
SP) following nerve injury may represent a functional switch in the
central mediation of nociception. VIP can also be expressed in
spinal glial cells, and this is increased following nerve damage
(Brenneman et ah, 1990; Knyihar-Csillik et ah, 1993). All subtypes
of VIP receptor, including VPAC2, have been reported in
astrocytes (Grimaldi and Cavallaro, 1999; Jaworski, 2000; Joo et
ah, 2004), and p44 MAP kinase activation is reported to be induced
by application of the broad-spectrum agonist PACAP in cultured
astrocytes (Moroo et ah, 1998). VIP is reported to elicit TNF-a
release from cultured astrocytes, and injury-induced upregulation
of TNF-a can be blocked by a VPAC, receptor agonist and p38
MAP kinase antagonists (Brenneman et ah, 1990; Kim et ah, 2000;
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Fig. 7. Topical spinal application of VPAC2 and NK2 receptor agonists in naive animals causes increased phosphorylation of p38 and p42/44 MAP kinase and
behavioral reflex sensitization that can by blocked by MAP kinase and glial inhibitors, (a, b) Immunoblots from naive spinal cord samples (n = 5 per
treatment) following the topical application of either saline, Ro 25-1553 (VPAC2 receptor agonist), GR 64349 (NK2 receptor agonist), or either Ro 25-1553
or GR 64349 co-administered with propentofylline (PPT; glial inhibitor). Upper blots in panels (a) and (b) show the levels of immunoreactivity for activated
(phosphorylated) 'ph°spho-p38' (a) and activated (phosphorylated) 'phospho-p42/44' (b). Lower panels show overall 'pan' levels for p38 (a) and p42/44 (b).
In panel (a), VPAC2 receptor agonist caused a relatively greater activation of p38 MAP kinase than did the NK2 receptor agonist compared to saline, and both
of these responses were prevented when agonists were co-administered with PPT. In panel (b), NK2 receptor agonist caused a relatively greater activation of
p42/44 MAP kinase than did the VPAC2 receptor agonist, compared to saline, and both of these responses were prevented when PPT was co-applied. Minimal
levels of phospho-p38 or phospho-p42/44 immunoreactivity were detected in controls where the saline vehicle control was topically applied instead, (c-f)
Data represent bilateral hindpaw withdrawal latency (seconds) to noxious heat before and following the intrathecal injection of the VPAC2 receptor agonist Ro
25 -1553 alone (0.5 nmol) (c) or when co-administered with SB 203580 (5 nmol), (d) or the NK2 receptor agonist GR 64349 alone (1.5 nmol), (e) or when
co-administered with U 0126 (1.5 nmol) (f). Both agonists caused behavioral sensitization to thermal stimulation when administered alone (c, e) in
comparison to pre-injection ipsilateral values ('/' < 0.05, one-way repeated measures ANOVA followed by a Dunnett's test). The effects of Ro 25-1553 were
blocked when it was co-administered with the p38 MAP kinase inhibitor SB 203580 (d). Similarly, the effects of GR 64349 were blocked when co¬
administered with the p42/44 MAP kinase pathway inhibitor U 0126 (f).
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Table 3
imraunoblot densitometric ratio scores for phospho-p38:pan-p38 and phospho-p42/44:pan-p42/44 (arbitrary density units)
Treatment Saline VPAC2 receptor agonist Ro 25-1553 NK2 receptor agonist GR 646349 Ro 25-1553 + PPT GR 646349+PPT
p38 MAP kinase 36.5 ± 4.2 60.7 ± 6.3* 53.2 ± 4.8* 39.9 ± 5.3 43.3 ± 6.0
p42/44 MAP kinase 39.0 + 7.3 67.1 + 4,0* 94,4 + 5.8* 34.8 + 4.6 40.0 + 5,7
Values are mean + SEM values (n = 5) derived from quantitative densitometry of co-processed immunoblots (shown in Figs. 7a and b). Statistically significant
differences in the ratio of phospho to pan immunoreactivity compared to saline controls are shown as *P < 0.05 by Wilcoxon test.
Schafers et al., 2003). Acting through VPAC2 receptors, VIP
releases a mixture of cytokines, including TNF-a, from astrocytes
to cause production of a neuroprotective factor and astrocyto-
genesis (Brenneman et al., 2003; Zusev and Gozes, 2004; Zupan et
al., 1998). In contrast, VIP can inhibit TNF-a production (Delgado
et al., 2003) by injury- or lipopolysaccharide-activated microglia
but, in this case, via VPACi receptors (Kim et al., 2000). Here, the
behavioral reflex sensitization to thermal and mechanical stimuli
following CCI was reduced by a highly selective VPAC2 receptor
antagonist, but only to little or no extent by PAC4 or VPACi
receptor antagonists. Correspondingly, the p38 MAP kinase
activation seen following nerve injury could be reduced to basal
levels with topical spinal application of a VPAC2 receptor
antagonist and to a lesser extent by NK2 receptor antagonist.
Also, p38 MAP kinase phosphorylation could be evoked in nai've
animals by the topical application of a VPAC2 receptor agonist
(and less so by an NK2 receptor agonist), while the corresponding
behavioral sensitization was inhibited by co-administration of the
p38 MAP kinase inhibitor, SB 203580. Although our data do not
specify that the p38 activation response is directly within VPAC2
receptor-containing cells, taken together, these findings suggest
that VPAC2 receptors on spinal glial cells play a significant role in
nerve injury-induced p38 activation and spinal sensitization.
In conclusion, it is clear that glia no longer can be viewed as
playing a solely supportive role for spinal neurons. The present
data add to an increasing body of evidence for the functional
importance of glia in spinal somatosensory processing. These
studies implicate VPAC2, NK2 and NMDA receptors in leading to
the activation of p38 and p42/44 MAP kinases in spinal glial cells
following afferent nerve injury and thereby contributing signifi¬
cantly to the mechanisms of sensitization underlying chronic
neuropathic pain.
Experimental methods
All experiments were performed in accordance with the UK
Animals (Scientific Procedures) Act, 1986.
Drugs
All drugs were purchased from Merck Biosciences (Notting¬
ham, UK) unless otherwise stated and were administered in vehicle
of 0-0.3% dimethylformamide (DMF) in deionized water for
ionophoresis and in saline for other experiments. Previous experi¬
ments established that these vehicles had no discernable effect on
neuronal firing, behavioral or biochemical responses. Drugs
included the p38 inhibitor SB 203580, the p42/44 MAP kinase
pathway inhibitors PD 98059 and U 0126 and its inactive analogue
U 0124, the TNF-a receptor antagonist WP9QY (Takasaki et al.,
1997), the TNF-a synthesis inhibitor thalidomide and the glial
inhibitor propentofylline, PPT (Sigma-Aldrich, Poole, Dorset), the
selective VPAC, receptor antagonist ([Ac-His1, D-Phe2, Lys15,
Arg16, Leul7]-VIP (3-7) GRF (8-27), gift from P. Robberecht),
the selective VPAC2 receptor antagonist, des (1-4), Arg16-Ro25-
1553 (gift from P. Robberecht), the selective VPAC2 receptor
agonist, Ro 25-1553 (gift from P. Robberecht), the selective PAQ
receptor antagonist, PACAP 6-38 (Bachem UK Ltd., St. Helens,
Merseyside), the selective NK! receptor antagonist, RP 65780 (gift
from C Garret, Rhone-Poulenc Rorer), the selective NK2 receptor
antagonist, SR 48968 (gift from X. Emonds-Alt, Sanofi
Recherche), the selective NK2 receptor agonist GR 646349 (gift
from P. Birch, Glaxo, Smith-Kline) and the selective NMDA
receptor antagonist (R)-CPP (Tocris, Avonmouth, UK).
Antibodies
The following reagents were used: rabbit polyclonal antibodies
specific to phospho-[Thrl80/Tyr!82]-p38 MAP kinase (1:250, Cell
Signalling Technology Inc., Beverly, MA) and p38 MAP kinase
('pan': phosphorylation state-independent; 1:500, Cell Signalling),
or phospho-[Thrl 202/Tyr204]-p42/44 MAP kinase (1:250, Cell
Signalling) and p42/44 MAP kinase ('pan': phosphorylation state-
independent; 1:500, Cell Signalling), the housekeeping enzyme
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1:750,
Chemicon International Ltd., Harrow, UK).
Methods
Chronic constriction injury
Adult male Wistar rats (250-320 g, Charles River, Kent, UK)
were anesthetized with sodium pentobarbital (Sagatal 0.36 mg/kg,
i.p.; Rhone Merieux, Essex, UK) and supplemented with halo-
thane/02 (Zeneca, Cheshire, UK). Under aseptic conditions, a
unilateral chronic constriction injury (CCI; Bennett and Xie
(1988)) was induced as described previously (Garry et al., 2003).
Behavioral testing ofneuropathic rats
Quantitative sensory reflex testing of mechanical allodynia and
thermal hyperalgesia was performed to ensure each rat had
developed maximal behavioral sensitization (typically 10-14 days
post-surgery).
The latency of withdrawal (seconds) for thermal hyperalgesia
was assessed with a Hargreaves' thermal stimulator (Linton
Instrumentation, Diss, UK) for the uninjured contralateral and
injured ipsilateral paw and recorded as the paw withdrawal latency
(PWL). Mechanical allodynia was assessed with calibrated
Semmes-Weinstein von Frey filaments (Stoelting, Wood Dale,
Illinois, USA), and the indentation pressure (mN/mm2) required to
elicit a response in each hindpaw was recorded as the paw
withdrawal threshold (PWT), as described previously (Moss et al.,
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2002). Only animals with fully established maximal ipsilateral
behavioral sensitization were used in the electrophysiology, intra¬
thecal and immunoblotting experiments.
Electrophysiological recordings
Under initial halothane anesthesia, the jugular vein and trachea
were cannulated in naive control (n = 8) or neuropathic rats (n = 7).
Animals were then anesthetized using intravenous a-chloralose (60
mg/kg) and urethane (1.2 mg/kg), with supplementary doses of a-
chloralose given as required, enabling a laminectomy (segments
L3-L6) to be performed, as described previously (Moss et al.,
2002; Dickinson et al., 1997). Extracellular recordings were made
from multireceptive single neurons located in laminae III—V of the
spinal cord (ipsilateral to the nerve injury in neuropathic animals
and from both sides of the cord in naive rats), as described
previously (Moss et al., 2002).
To investigate the involvement of the p38 and p42/44 MAP
kinases in the processing of somatosensory information at the spinal
cord level, the effects of the p38 inhibitor SB 203580 and the p42/44
inhibitor PD 98059 were examined on sustained sensory inputs in
both normal and neuropathic animals. The inhibitors were applied
by ionophoresis at increasing currents from 10 to 60 nA, over a set
period of time, until clear effects were seen. The mean percentage
inhibition was calculated through the 30-s period encompassing the
maximal change from control, pre-drug firing levels.
Sustained innocuous inputs were produced by means of a
motorized, rotating brush, giving a steady neuronal firing rate of
10-35 Hz. Also, a sustained noxious input was produced by hindpaw
topical application ofthe C-fiber selective chemical algogen mustard
oil. This irritant was repeatedly applied over an area ofapproximately
2 cm2 and after 2-5 applications, separated by 5-min intervals,
steady elevated firing rates were observed (9-30 Hz).
Intrathecal injections
For intrathecal injections, all drugs were administered at a
volume of 50 pi in saline using a 25-gauge needle microsyringe
(BD Biosciences, Oxford, UK), as described previously (Moss et
al., 2002; Garry et al., 2003). The effects of intrathecal injection of
the p38 MAP kinase inhibitor SB 203580 and the p42/44 MAP
kinase pathway inhibitors PD 98059, U 0126 and its inactive
analogue U 0124, the TNF-a receptor antagonist WP9QY and
propentofylline (PPT) and selective antagonists ofVPAQ, VPAC2,
PAC|, NK, and NK2 receptors were examined in animals (n = 6-8
per drug) that had undergone chronic constriction injury and were
at the peak of neuropathic behavioral reflex sensitization. We also
assessed the effects of the intrathecal injection of a selective
VPAC2 receptor agonist, Ro 25-1553 or an NK2 receptor agonist
GR 64349 on the behavioral reflexes of nai've animals. In addition,
we examined the effects of Ro 25-1553 co-administration with the
p38 MAP kinase inhibitor SB 203580, or GR 64349 co¬
administration with the p42/44 pathway inhibitor U 0126 in naive
animals. Baseline measurements were recorded for thermal hyper¬
algesia (Hargreaves' test) and mechanical allodynia (von Frey
filament test) immediately prior to injection. Then animals were
briefly anesthetized with halothane and 02 and intrathecally
injected at the L5 level of the spinal cord with drug or vehicle
controls. Testing began 15 min following injection (to allow for
anesthetic recovery) and was perfonned at 5-min intervals for both
tests until readings returned to baseline levels.
Immunoblotting
Tissue
In na'fve animals, prior to removal of L3-6 spinal segments, the
cord was treated (as described previously, Garry et al., 2003) with
either saline control, the agonists for VPAC2 receptor, Ro 25-1553
(30 pM) or NK2 receptor, GR 64349 (50 pM) and either Ro 25-
1553 or GR 64349 in combination with the glial inhibitor PPT (10
mM in saline; n = 5 per drug). In nerve-injured animals prior to the
removal of L3-6 spinal segments, the cord was treated with either
saline control, the VPAC2 receptor antagonist ([des (1-4), Arg16]-
Ro 25-1553), the NMDA receptor antagonist ((R)-CPP; 10 pM in
saline), PPT, a TNF-a receptor antagonist (WP9QY; 0.5 mg/ml) or
the TNF-a synthesis inhibitor, thalidomide; 200 pM in 0.3%
dimethylformamide/saline (n = 5 per drug). All drugs were left in
contact with the cord for 30 min, then the spinal tissue (L3-6) was
removed and hemisected to separate ipsilateral and contralateral
sides, and samples were prepared for immunoblotting as described
previously (Moss et al., 2002). Untreated CCI and naive spinal
cords (n = 5 per group) were prepared in parallel as a comparison.
Homogenization was in standard Laemmli buffer and denatured at
100°C for 5 min. Extracts were separated by electrophoresis on
pre-cast 10% polyacrylamide gels (BioRad, Hemel Hempstead,
UK), transferred to PVDF membrane and blocked overnight at 4°C
in 4% Marvel, 0.1% Tween-20. Blots were probed with rabbit
polyclonal antibodies specific to [Thrl80/Tyrl82] phospho-p38
MAP kinase (1:250) and pan p38 MAP kinase ('pan': phosphor¬
ylation state-independent) (1:500), or [Thrl202/Tyr204] phospho-
p42/44 MAP kinase (1:250, Cell Signalling) and pan p42/44 MAP
kinase ('pan': phosphorylation state-independent) (1:500) and
immunoreactive bands were detected by peroxidase-linked secon¬
dary antibody-enhanced chemiluminescence.
Blots were also probed for the ubiquitous housekeeping enzyme
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1:750,
Chemicon) for protein level normalization. Relative levels of
GAPDH between samples were similar to those of both pan p38
and pan p42/44 (data not shown). Densitometry was performed
using 'Scan Analysis' software whereby grey levels of positive
protein bands and background grey levels were quantitatively
measured. The grey levels of the phosphorylated form of both p38
and p42/44 MAP kinases were meaned and calculated as
densitometric ratios against pan MAP kinase levels.
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Abstract
Reactivation of latent varicella zoster virus (VZV) within sensory trigeminal and dorsal root ganglia (DRG) neurons produces shingles
(zoster), often accompanied by a chronic neuropathic pain state, post-herpetic neuralgia (PHN). PHN persists despite latency of the virus
within human sensory ganglia and is often unresponsive to current analgesic or antiviral agents. To study the basis of varicella zoster-induced
pain, we have utilised a recently developed model of chronic VZV infection in rodents. Immunohistochemical analysis of DRG following
VZV infection showed the presence of a viral immediate early gene protein (IE62) co-expressed with markers of A- (neurofilament-200; NF-
200) and C- (peripherin) afferent sensory neurons. There was increased expression of neuropeptide Y (NPY) in neurons co-expressing NF-
200. In addition, there was an increased expression of a251 calcium channel, Navl .3 and Navl .8 sodium channels, the neuropeptide galanin
and the nerve injury marker, Activating Transcription Factor-3 (ATF-3) as determined by Western blotting in DRG of VZV-infected rats.
VZV infection induced increased behavioral reflex responsiveness to both noxious thermal and mechanical stimuli ipsilateral to injection
(lasting up to 10 weeks post-infection) that is mediated by spinal NMDA receptors. These changes were reversed by systemic administration
of gabapentin or the sodium channel blockers, mexiletine and lamotrigine, but not by the non-steroidal anti-inflammatory agent, diclofenac.
This is the first time that the profile of VZV infection-induced phenotypic changes in DRG has been shown in rodents and reveals that this
profile appears to be broadly similar (but not identical) to changes in other neuropathic pain models.
© 2005 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Keywords: Post-herpetic neuralgia; Varicella zoster virus; Dorsal root ganglia; Sodium channels; Neuropeptide Y; Galanin; Gabapentin
1. Introduction
Chronic pain arising from nerve injury is difficult to treat.
New effective pain-killers are urgently needed. Varicella
zoster virus (VZV) is a neurotropic human herpesvirus that
remains latent in sensory ganglia following primary
* Corresponding author. Tel.: +44 131 650 6091; fax: +44 131 650
6576.
E-mail address: s.m.fleetwood-walker@ed.ac.uk (S.M. Fleetwood-
Walker).
infection (chickenpox or varicella; Cohrs et al., 2004).
Virus reactivation produces localised skin lesions, shingles
(zoster) at sites innervated by the affected sensory ganglia
(Arvin, 1996; Cohrs et al., 2004). Following lesion
resolution, post-herpetic neuralgia (PHN) can persist
(Cohrs et al., 2004). Predisposition to PHN is not under¬
stood, although it is a major cause of morbidity and is
unresponsive to current analgesics (Bowsher, 1995; Tenser,
2001). PHN is characterized by the development of
hyperalgesia (a facilitated behavioral response to painful
stimuli), mechanical allodynia (the perception of innocuous
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stimuli as painful), and spontaneous pain, all features of
neuropathic pain (Rowbotham and Fields, 1996).
Investigation of the neural mechanisms underlying PHN
has been facilitated by the introduction of a rat model of
VZV persistent infection (Sadzot-Delvaux et al., 1990) with
striking reflex pain behaviours (Fleetwood-Walker et al.,
1999). At least five VZV-encoded transcripts and proteins
(genes 4, 21, 29, 62 and 63) are present in human and rat
ganglia during latent VZV infection (Cohrs et al., 1996;
Lungu et al., 1998; Sadzot-Delvaux et al., 1990). Although
their precise functions in PHN are unknown, the immediate
early protein 62 (IE62) is essential for VZV gene expression
in host cells (Sato et al., 2003).
A key factor in the neural plasticity underlying
neuropathic pain is altered gene expression in sensory
dorsal root ganglia (DRG) neurons (Cummins et al., 2000;
Hokfelt et al., 1994; Woolf and Salter, 2000; Xiao et al.,
2002). Injury to sensory nerves induces neurochemical,
physiological and anatomical modifications to afferent and
central neurons, such as afferent terminal sprouting
and inhibitory interneuron loss (Moore et al., 2002; Woolf
and Salter, 2000). Following nerve damage, Na+ channel
accumulation causes hyperexcitability (Matzner and Devor,
1994; Omana-Zapata et al., 1997), downregulation of the
TTX-resistant Nav1.8 (sensory neuron specific, SNS1)
channel and upregulation of TTX-sensitive Nav1.3 (brain
type III) channels (Dib-Hajj et al., 1999; Kim et al., 2001).
These changes contribute to increased NMDA glutamate
receptor-dependent excitability of spinal dorsal horn
neurons (Laird and Bennett, 1993; Mayer et al., 1999;
Palecek et al., 1992) and are restricted to the ipsilateral
(injured) side (Bennett and Xie, 1988; Kim et al., 1997). A
combination of these factors could contribute to the
neuropathic pain state of PHN.
Although the underlying pathophysiological mechanisms
may be similar to other forms of neuropathic pain, it is
unclear how latent VZV infection interacts with the nervous
system to induce these changes. We therefore used markers
to identify the subpopulation of sensory neurons that co-
express the virus latency protein IE62 and to characterise
sensory neuron phenotypic changes compared with other
neuropathic pain models. Since the anticonvulsant gaba-
pentin and sodium channel blockers are effective in the
treatment of PHN pain (Pappagallo, 2003; Rowbotham et al.,
1998), we investigated their effectiveness in this model.
2. Materials and methods
2.1. Cell infectivity and preparation prior to injection
VZV-infected cells (generated from a wild-type VZV isolate
from an otherwise healthy child (designated strain KMcC; Neff
et al., 1981) and passaged in MRC-5 human diploid fibroblast cells
to passage 9) were stored in vapour phase liquid nitrogen. Prior to
injection, 500 pi of infected cells were thawed and diluted in saline
1:10, centrifuged for 5 min at 1000 Xg, supernatant was removed
and the cells were resuspended in saline which displayed a titre of
3.2X107 plaque-forming cells/ml (64% infectious cells). Two
serial 5-fold dilutions leading to titres of 6.4X 105 (1:5) and 12.8X
104 (1:25) plaque-forming cells/ml were also used.
All experiments were performed in accordance with the UK
Animals (Scientific Procedures) Act, 1986. Adult male Wistar rats
(200-300 g, Charles River, Kent, UK) were anaesthetised with
halothane/02 (Zeneca, Cheshire, UK) and under aseptic con¬
ditions, VZV-infected cells were injected into the dorsum of the
right hind paw at a volume of 65 pi per rat (n = 22 for full dilution
and n = 6 for each of the five-fold dilutions) using a 25.1 g syringe.
For sham infection, each rat (n = 8) was briefly anaesthetised and
cells (CCL-171, MRC-5 human fibroblast cells, LGC Promochem,
Middlesex, UK) were injected at the same concentrations as above.
Infectivity, not cell type, was the only defining factor, as VZV and
sham-infected cells were both derived from human fibroblast cells.
2.2. Assessment of behavioral reflex responses in VZV
and sham-infected animals
To establish a time course of VZV infection-induced behavioral
sensitivity, baseline measurements for all animals were obtained
immediately prior to injection, and behavioral testing recom¬
menced on day 6/7, 1 week following infection and continued
either every day or every week (depending on cell dilutions) until
evidence of recovery was observed. Behavioral tests were carried
out as previously described (Garry et al., 2003), using quantified,
sensory stimuli delivered to the mid-plantar glabrous surface of the
hind paw. Mechanical allodynia was assessed by measuring the
paw withdrawal threshold (PWT) in response to graded mechanical
stimuli with calibrated von Frey filaments (Stoelting, Wood Dale,
IL, USA). Thermal hyperalgesia was monitored as paw withdrawal
latency (PWL) from a quantified noxious radiant heat (48 °C;
Hargreaves' thermal device, Linton Instruments, Diss, UK). The
behavioral responses obtained at each time point were calculated
as the mean±SEM for each test and data were analysed by
SigmaStat software (version 2.03). In tests of mechanical
allodynia, the ipsilateral value was compared to the contralateral
value at each time point using a Wilcoxon test and each compared
to pre-injection or pre-drug baseline using a repeated measures
ANOVA on ranks (Friedman test), with post hoc analysis using
Dunn's test. In tests of thermal hyperalgesia, the ipsilateral value
was compared to the contralateral value at each time point using a
paired Student's /-test, then each was compared to pre-injection or
pre-drug baseline using a one-way repeated measures ANOVA,
with post hoc analysis using Dunnett's test.
2.3. Immunofluorescent/immunohistochemical localisation of VZV
IE62 protein with NF-200 and peripherin and neuropeptide Y
(NPY) with NF-200 in DRG
Fresh DRGs from lumbar segments L4-L6 were removed
immediately following induction of anaesthesia with halothane/02
(Zeneca, Cheshire, UK) and the animals killed by decapitation.
DRGs were either sham or ipsilateral or contralateral to VZV
28 days following administration, at maximal behavioral reflex
sensory sensitivity (n = 4 in each case). The tissue was snap frozen
and embedded in OCT embedding matrix (Cell Path pic.
Powys. Wales, UK) before being cryostat sectioned (10 pm)
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and thaw-mounted on poly-L-lysine slides (Merck-BDH). VZV
IE62-expressing fibroblast cells (PR Kinchington) were used as a
positive control for VZV IE62 expression.
Sections were pre-incubated in buffer (0.1 M PBS, pH 7.4,
0.2% Triton X-100, 4% fish skin gelatin) containing 10% normal
goat serum for 1 h at room temperature and then incubated with
primary antibodies diluted in buffer (0.1 M PBS, pH 7.4, 0.2%
Triton X-100, 2% gelatin) overnight at 4°C. For VZV protein
IE62, co-localisation with the A-afferent marker neurofilament-
200 kDa (NF-200) or the C-afferent fiber marker, peripherin, or for
NPY co-localisation with NF-200, antisera were used at the
following concentrations: rabbit polyclonal anti-VZV IE62 (1:250,
PR Kinchington), rabbit polyclonal anti-NPY (1:250, Peninsula
Laboratories, Belmont, CA, USA), mouse monoclonal anti-NF-
200 (1:1000, Sigma) and mouse monoclonal anti-periphcrin (I:
250, Chemicon). Sections were then washed in buffer and
incubated with the appropriate secondary antibodies (goat anti-
rabbit Alexa Flour 568, 1:1000 or goat anti-mouse Alexa Fluor
488, 1:500; Molecular Probes, OR, USA) for 2 h at room
temperature. Following three washes with 0.1 M PBS, sections
were incubated with the nuclear stain, To-Pro (1:1000, To-pro-3-
iodide, Molecular Probes) and washed a further three times in
0.1 M PBS before coverslipping with Vecta Shield (Vector
Laboratories, Burlingame, CA, USA). Control sections were
processed as above omitting the primary antisera.
Analysis was carried out using a Leica TCSNT Confocal
System (Leica Microsystems GMBH, Germany) on six randomly
selected sections of DRG (separation of 100 pm) from each group
of four animals. At least 500 neurons were counted per group and
only neurons that were To-pro positive were used for analysis.
Using Image Tool software (UTHSCSA Image Tool Version 3.0),
the median point between the mean background intensity and the
mean IE62- or NPY-immunopositive cell intensity was taken as the
minimum intensity value required for a IE62- or NPY-immuno-
positive cell to be counted. All sections were counted for IE62 or
NPY-immunopositive cells in this manner and for NF-200- or
peripherin-positive cells that were To-pro positive. Results were
expressed as the percentage of IE62/NF-200 or IE62/peripherin-
positive or NPY/NF-200-positive cells from the total number of
NF-200- or peripherin-positive cells, from all sections. Any
statistically significant differences between groups were deter¬
mined by a Mann-Whitney rank sum test.
2.4. Assessment of NPY, galanin, ATF-3, VZV 1E62, Nav1.3,
Nav1.8, and a251channel protein expression levels by Western
immunoblotting
When animals were at the peak ofbehavioural sensitivity 28 days
following VZV-infection, lumbar 4-6 DRG were pooled from five
animals and Western blotting was carried out using methodology
described previously (Garry et al., 2003). Blots were probed with
rabbit polyclonal primary antibodies to VZV IE62 (1:100,
Chemicon, International Ltd, Harrow, UK), NPY (1:100, Autogen
Bioclear UK Ltd (Santa Cruz Biotechnology, Wiltshire), galanin
(1:100, Autogen Bioclear UK Ltd) or ATF-3 (1:200, Autogen
Bioclear UK Ltd), a281 voltage-gated calcium channel (1:100,
Chemicon), Nav1.3 (1:200; Alomone Labs, Towcester, UK) or
Nav1.8 (Wallace et al., 2003) and detected by peroxidase-linked
secondary antibody enhanced chemiluminescence. To assess any
relationship between viral titre and the level ofVZV IE62 expression
in DRG, we also carried out western blotting on DRG from animals
2 weeks following infection with either 1:5 or the 1:25 cell titres and
probed these samples for VZV IE62. The ubiquitous housekeeping
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH,
1:750, Chemicon, International Ltd, Harrow, UK) was monitored
as a control for protein level normalisation.
2.5. Gabapentin, sodium channel blocker and anti-inflammatory
agent administration
We examined any effects of gabapentin, the sodium channel
inhibitors, mexiletine and lamotrigine and the non-steroidal anti¬
inflammatory drug (NSAID), diclofenac. Drug doses were based
on pharmacological characterisation of the Chung and spared
nerve injury pain models (Merck in-house data; Erichsen and
Blackburn-Munro, 2002). In experiments involving drug admin¬
istration by oral gavage, only VZV-infected animals that showed
clear signs of thermal hyperalgesia and mechanical allodynia were
used. Due to solubility of drugs, gabapentin, mexiletine and
diclofenac were both dissolved in sterile water, while lamotrigine
was dissolved in a solution of 5% ethanol, 15% Tween80 and 8.5%
sterile water and stirred overnight. Gabapentin (lOOmg/kg),
lamotrigine (100 mg/kg), mexiletine (100 mg/kg) and diclofenac
(100 mg/kg) were administered once only by oral gavage, at a
volume of 2 ml/kg. In all cases of oral gavage, animals (n = 8 per
group) fasted 10-12 h prior to gavage until the end of drug effect
testing the following day. Behavioral testing commenced 1, 2, 4, 6
and 24 h post-gavage and at 48 h to ensure recovery of behavioral
reflex sensitivity. Equivalent administration of vehicle was found
to have no discernable effect on behavioral reflexes.
2.6. Intrathecal administration of NMDA receptor antagonist
and p. opioid receptor agonist
Baseline measurements were carried out in VZV-infected
animals at the peak of behavioural sensitivity for mechanical
allodynia and thermal hyperalgesia prior to injection. Animals were
briefly anaesthetised with halothane and 02 and injected intrathe-
cally at the level of the L5 spinal vertebra using a 25.1 g needle with
either the NMDA receptor antagonist (R)-CPP ([3-((R)-2-carbox-
ypiperazine-4-yl)-propyl-l-phosphonic acid] Tocris Cookson Ltd,
Bristol, UK; 2.5 nmoles/50 pi saline) or the selective p-opioid
receptor agonist D-Ala2, MePhe4, Gly-ol enkephalin (DAMGO;
Tocris Cookson; 1 pmol/50 pi saline). To determine the effects of
the drugs on both mechanical allodynia and thermal hyperalgesia,
behavioral reflex testing commenced 15 min following injection to
allow recovery from anaesthesia and continued every 5 min
thereafter until readings returned to baseline levels. Extensive
control studies have shown that intrathecal injections of saline had no
effect on these behavioral reflex measures.
3. Results
3.1. VZV infection induces behavioral mechanical allodynia
and thermal hyperalgesia
Following preparation of the rat model of VZV infection
by unilateral injection of virus into the hindpaw (Fleetwood-
Walker et al., 1999; Sadzot-Delvaux et al., 1990),
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Fig. 1. Time course of VZV-induced neuropathic reflex behaviors. Mean ± SEM responses to sensory stimulation of the hindpaw for a week prior to (Baseline),
and each week (a, b) or days (c-f) following VZV infection, (a) Paw withdrawal thresholds (PWT, g) from calibrated von Frey filaments ipsilateral to VZV-
injection (O) showed significant differences between pre- and post-infection values (+><0.05; Repeated measures ANOVA on ranks; Friedman's test with
Dunn's post hoc analysis) and from post-operative, contralateral (■) values (*P<0.05 by Wilcoxon test) from 1 to 10 weeks following VZV infection
(standard titre). (b) Paw withdrawal latency (PWL, s) from a noxious thermal stimulus (Hargreaves' thermal stimulator) ipsilateral to VZV-injection (O)
showed significant differences between post- and pre-infection values l'/'<0.05; Repeated measures ANOVA with Dunnett's post-hoc analysis) and from
post-operative, contralateral (H) values (*/><0.05 by Student's paired r-test) from 3 to 8 weeks post infection (standard titre). (c and d) showed significant
differences between post- and pre-infection values (tP<0.05; Repeated measures ANOVA on ranks; Friedman's test with Dunn's post hoc analysis) and from
post-operative, contralateral (■) values (*P<0.05 by Wilcoxon test) for PWT (c) and significant differences ('PC0.05; Repeated measures ANOVA with
Dunnett's post hoc analysis) and from post-operative, contralateral (■) values (*/><0.05 by Student's paired r-test) for PWL (d) following VZV infection (1:
5). The second dilution (1:25) showed no significant differences between post- and pre-infection values or from post-operative, contralateral values for either
PWT (e) or PWL (f).
VZV-infected rats (n = 22) displayed a markedly lowered
threshold in behavioral reflex tests of mechanical (Fig. la)
and thermal (Fig. lb) sensitisation ipsilateral, but not
contralateral, to the site of injection. The heightened
sensitivity to both tests was apparent from day 7 (week 1)
after VZV infection, but reached peak values from day 28
(week 4) until day 56 (week 8) post-infection. Typically,
at peak behavioral sensitivity following VZV infection,
von Frey withdrawal thresholds were reduced from
approximately 122 + 3.5 to 36 + 6.4 g on average (Fig. la)
and thermal withdrawal latencies were reduced from
approximately 18.5+0.3 to 12 + 0.6s (Fig. lb). All
behavioral sensitivities recovered to baseline levels by 11
weeks for mechanical allodynia and by 9 weeks post¬
infection for thermal hyperalgesia. To establish whether
there was a relationship between VZV-infected cell titre and
the development of behavioural sensitisation, VZV-infected
cells were diluted prior to injection. Behavioural sensitivity
was dose-dependently diminished with each of two serial
5-fold dilutions of the original viral titre (n = 6 in each case,
Fig. 1, c-f). Approximately, half the level of sensitisation
occurred at five times dilution (1:5; n — 6) for both
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mechanical withdrawal threshold (Fig. lc) and thermal
withdrawal latency (Fig. Id). At peak behavioural sensi¬
tivity following infection with 1:5 of original cell
concentration, von Frey withdrawal thresholds were
reduced from 125.9 + 0.Og to 75.6 + 7.8 g (Fig. lc) and
thermal withdrawal latencies reduced from 15.1+0.7 to
12.0 + 0.5 s (Fig. Id). Rats that received only 1:25 of the
original viral cell titre (n = 6) did not differ significantly
post-infection with von Frey withdrawal thresholds main¬
tained at 109.2+13.6 g (Fig. le) and thermal withdrawal
thresholds of 14.9 + 0.7 s (Fig. If) on average throughout
the time period tested. Furthermore, animals that had sham
cell injections (n = 8) showed no change from baseline, with
von Frey threshold withdrawal values of between 117.5 and
125.9 g and thermal paw withdrawal latencies of approxi¬
mately 17 s at all time points tested (data not shown). In
both VZV- and sham-injected animals no consistent
changes were detected contralateral to injection. There
was no evidence of overt motor deficits or skin lesion
development following either VZV or sham cell injection.
*
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Fig. 2. VZV infection induces VZV IE62 protein expression in DRG. (a) Typical immunofluorescence images showing (i) the presence of VZV IE62 protein
(red) in DRG neurons ipsilateral to VZV-infection 3 weeks following VZV infection. Positive- (arrow) and negative-labelled cells (asterisk) are indicated, (ii)
Negligible expression of VZV IE62 is found in contralateral DRG neurons at the same time point (ii). Scale bar 25 pm. (b) Phase contrast images showing
control VZV expressing fibroblast cells confirm VZV IE62 expression (i) while negatively expressing fibroblast cells show no expression (ii). (c) Mean (+
SEM) number of neurons per DRG section that express VZV IE62 showing the marked induction of VZV IE62 in DRG neurons ipsilateral to VZV infection in
comparison to contralateral and sham-infected DRG sections.
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3.2. VZV protein IE62 is detected in DRG neurons
of VZV-infected animals
The VZV immediate early protein IE62 is a major
component of varicella zoster virus particles (Kinchington
et al., 1992) and can act to alter neuropeptide expression
(Meier and Straus, 1995). To confirm viral presence in
sensory afferents, qualitative assessment of VZV IE62
protein in DRG from VZV-injected animals (at the peak
of behavioral reflex sensitisation) and from sham-injected
animals was carried out using immunofluorescence and
Western blotting. VZV IE62 was present in VZV-infected
tissue in a total of 609 small and large DRG cell bodies
ipsilateral to injection (Fig. 2a(i), c), whilst expression in
sham-treated tissue was negligible (Fig. 2c). While
behavioral data indicated no significant contralateral
effects of VZV injection, some contralateral staining (in
a total of 77 cells) of VZV IE62 was found (Fig. 2a(ii), c).
Control VZV IE62-expressing fibroblast cells confirmed
positive protein expression (Fig. 2b(i)) compared with the
negative fibroblast control cells, which did not express
VZV IE62 (Fig. 2b(ii)). Positive VZV IE62 protein
induction in VZV-infected DRG was also confirmed by
Western blot, while expression in sham-infected DRGs
was entirely absent (Fig. 5a, Table 1). Fig. 5c (and
Table 1) shows that the level of IE62 expression in DRG,
ipsilateral to infection, was proportional to the viral titre
administered; matching behavioral reflex data (Fig. 1),
indicating corresponding functional changes in nocicep¬
tive responsiveness. Naive DRG cells also had no
expression of VZV IE62 protein (data not shown). The
housekeeping protein GAPDH was assessed as an internal
control and showed similar expression in both VZV and
sham-infected DRG samples, indicating no difference in
overall levels of cellular proteins following VZV infection
(Fig. 5b, Table 1).
Table 1
Immunoblot mean expression in VZV- or sham cell-infected DRG as
percentage of GAPDH expression (arbitrary density units)
Protein VZV-infected Sham-infected
VZV IE62 82.3 ±8.6* 0.0 ±0.0
NPY 17.5 ±2.6* 5.4 ±1.9
Galanin 23.8 ±4.6* 8.3±3.9
ATF-3 16.5 ±2.7* 0.0 ±0.0
a251 46.0 ±5.3* 20.9 ±6.0
Nav1.3 29.7±5.0* 0.0 ±0.0
Nav1.8 53.8±4.7* 12.6 ±2.2
VZV infectiv- VZV (full titre) VZV (1:5 VZV (1:25
ity: dilution) dilution)
VZV IE62 79.2±5.8 33.6 ±8.2 19.7 ±7.3
Values are mean % + SEM values {n — 5) derived from quantitative
densitometry of co-processed immunoblots for 1E62 (shown in Fig. 5).
Statistically significant differences in the levels of protein expression as
percent GAPDH between VZV- and sham cell-infection controls are shown
as *, PC0.05 by Wilcoxon test.
3.3. VZVprotein IE62 is detected in both myelinated A- and
unmyelinated C-afferent sensory neurons in VZV-infected
animals, as revealed by co-expression with the cell markers
peripherin and NF-200
To identify which sensory afferent neuronal subtypes
express the viral latency protein, IE62, we analysed the
expression of peripherin (Fig. 3a), a type III intermediate
filament protein, which is normally expressed selectively by
unmyelinated sensory neurons (Amaya et al., 2000) and NF-
200 (Fig. 3b) which labels the larger diameter, myelinated
DRG cell population (Fawson et al., 1993). No significant
difference was observed in the number of either peripherin
(ipsilateral 28.3 + 1.4; contralateral 22.9+ 1.6) or NF-200-
positive (ipsilateral 13.7+1.2; contralateral 12.2+1.0)
DRG neurons per section. This represents a mean proportion
of NF-200-positive cells out of a total of NF-200- plus
peripherin-positive cells of 33% (ipsilateral) and 35%
(contralateral). We analysed the expression of IE62 in the
DRG of VZV-infected rats, which were at the peak of
neuropathic behavioral reflex sensitisation following infec¬
tion. There we found expression of IE62 in 82.3 + 3.4% of
DRG neurons also positive for peripherin (Fig. 3c)
compared to 84.2+15.4% of DRG neurons also positive
for NF-200 (Fig. 3d) ipsilateral to infection. This is
compared with an JE62 expression of 12.0 + 9.0% for
peripherin-positive and 21.3 + 9.1% for NF-200-positive
neurons contralaterally. Under control sham-infected con¬
ditions we found no IE62-positive cells (Fig. 3c and d).
There were no significant differences between the mean
diameters of NF-200-positive cells that did or did not
express IE62, ipsilateral to infection (33.3+0.9 and 30.0 +
0.8 pm, n = 85, respectively) or for peripherin-positive
cells, with corresponding values of 13.8 + 0.03 and 14.6 +
0.05 pm (n = 77). Under the present experimental con¬
ditions, IE62 staining was only observed in the cytoplasm
and not in the nucleus of VZV-infected NF-200 or
peripherin-positive DRG neurons (n=100 randomly
counted cells in each case), corresponding to the obser¬
vations of Fungu et al. (1998).
3.4. VZV infection alters the expression of neuropeptide Y
(NPY) in sensory DRG neurons co-expressing NF-200
Following traumatic injury to the peripheral nerve, a
number of neurochemical and morphological changes take
place both in peripheral nerve fibers and centrally in the
spinal cord (Hokfelt et al., 1994). These changes contribute
to the altered sensory transmission associated with chronic
pain states. Phenotypic changes occur in many primary
afferent DRG neurons, resulting in the altered expression of
neuropeptides including downregulation of the afferent
peptides SP and CGRP and upregulation of VIP, GAF and
NPY (Hokfelt et al., 1994). We therefore investigated
whether such changes occur in the VZV-induced
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Fig. 3. Immunohistochemical co-localisation of unmyelinated C- and myelinated A-afferent markers, peripherin and NF-200 with VZVIE62 in DRG cells after
VZV-infection. Immunohistochemical co-localisation of VZV IE62 with the C-fiber cell body marker peripherin (a) or the myelinated A fiber cell body marker
NF-200 (b) in dorsal root ganglia sections taken three weeks following VZV infection (i) ipsilateral or (ii) contralateral to VZV-infection and (iii) following
sham cell injection are shown. Images show VZV IE62 immunopositive cells (in a and b) labelled with Alexa Fluor 568 (red) and peripherin (in a) or NF-200
(in b) labelled with Alexa Fluor 488 (green). The nuclear stain To-Pro is shown (blue). Ipsilateral DRG neurons that were double labelled for VZV IE62 and
either peripherin (a) or NF-200 (b) are indicated (arrow). Scale bar 25 pm. There was a significant increase in the expression of VZV IE62 co-localised with
peripherin (c) or NF-200 (d) ipsilateral to VZV-infection when compared with contralateral or sham infection. Statistical significance (*P<0.05) was
determined using a Mann-Whitney rank sum test.
hypersensitive state in order to compare the changes with
those occurring in other models of neuropathic pain.
DRG cells express only low levels of NPY under normal
conditions, but its expression is induced predominantly in
the large neuron population following axotomy (Hokfelt
et al., 1994), nerve injury (Ma and Bisby, 1998; Munglani
et al., 1995) and demyelination (Wallace et al., 2003). Using
NPY as a phenotypic marker, we therefore investigated
whether any change in NPY expression occurs in sensory
neurons of VZV-infected animals. Expression of NPY was
co-localised with NF-200, which labels large diameter,
myelinated DRG cells (Fig. 4a and c). We observed NPY
immunoreactivity in approximately 90+1.0% of NF-200
immunopositive cells after VZV infection (Fig. 4a and c) in
comparison to approximately 12+0.7% immunoreactivity
in cells in naive or sham-infected animals (Fig. 4b and c).
Induction of NPY expression in VZV-infected DRG was
confirmed by Western blot, while expression in sham-
infected DRGs was entirely absent (Fig. 5a, Table 1). The
housekeeping protein GAPDH was assessed as an internal
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VZV Sham
Fig. 4. VZV infection induces VZV IE62 and NPY expression in myelinated DRG cells. Immunohistochemical co-localisation of the larger-diameter,
myelinated DRG cell population with neuropeptide NPY in VZV-infected (a) or sham infected (b) DRG sections three weeks following VZV infection. Images
show NF-200 immunopositive cells labelled with Alexa Fluor 488 (green) and NF-200/NPY co-localised immunopositive cells labelled with Alexa Fluor 568
(red) in VZV treated DRG (a) with no NF-200/NPY co-localised immunopositive cells in sham DRG (b). Scale bar 25 pm. Double labelled cells are indicated
by an arrow, (c) Number of NPY/NF-200 immunopositive cells expressed as a percent of total NF-200 immunopositive cells. Post-VZV treatment, there was a
significant increase (*P<0.05; Mann-Whitney rank sum test) in the number of cells expressing NPY, which were all positive for NF-200, when compared to
sham DRG.
control and showed similar expression in both VZV and
sham-infected DRG samples, indicating no difference in
overall levels of cellular proteins following VZV infection
(Fig. 5a, Table 1).
3.5. Afferent expression of the neuropeptide galanin
and nerve injury marker ATF-3, are inducedfollowing
VZV infection
Galanin is expressed at very low levels under normal
conditions and is upregulated mainly in unmyelinated small
and medium DRG cells following peripheral nerve injury
(Hokfelt et al., 1994). We observed a similar upregulation in
galanin protein expression in DRG ipsilateral to VZV
injection (Fig. 5a, Table 1). ATF-3 expression is induced in
DRG neurons following nerve injury but not demyelination
(Wallace et al., 2003) and is thus thought to be a marker
of axonal damage (Tsujino et al., 2000). We also saw an
increase in ATF-3 protein expression following VZV
infection (Fig. 5a, Table 1), indicating axonal damage
may occur in this model. The phenotypic changes reported
here that mimic those seen following peripheral nerve injury
may underlie the behavioral sensitisation resulting from
VZV infection.
3.6. VZV infection induces upregulation of the a.251
voltage-gated calcium channel and Nav1.3 and Nav1.8
sodium channels in DRG
The anticonvulsant gabapentin can be an effective
treatment in animal models of neuropathic pain (Chapman
et al., 1998a; Christensen et al., 2001; Erichsen and
Blackburn Munro, 2002; Kanai et al., 2004) and following
PHN (Rowbotham et al., 1998). Gabapentin is thought to
exert its actions via the a251 subtype of voltage-gated
calcium channel (Bayer et al., 2004). Fig. 5b shows that
immunoreactivity for the a2Sl calcium channel subunit was
increased in extracts of DRG ipsilateral to VZV injection
compared to sham controls.
The tetrodotoxin (TTX)-sensitive Nav1.3 channel is
normally only found in DRG during development and
consistent with this we could not detect any expression of
this channel in naive DRG (data not shown). However,
expression of Nav1.3 has been reported to increase in
sensory neurons following axotomy (Cummins et al., 2000)
and nerve ligation (Kim et al., 2001). As VZV infection
shares the behavioral correlates of many nerve damage
models, we investigated whether any changes in sodium
channel expression occur in DRG of VZV-infected animals.
We found that VZV infection can induce the expression of
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Fig. 5. VZV infection results in increased protein expression of Nav1.3, Nav1.8, galanin and ATF-3. (a) Immunoblots showing the presence of VZV IE62, NPY,
galanin, ATF-3 and GAPDH in VZV- and sham cell-infected DRG. For full viral cell infection, samples were taken 3 weeks following VZV infection, the time
of maximal behavioral sensitisation. There is positive expression of VZV 1E62, NPY, galanin and ATF-3 protein in VZV-treated DRG, with minimal or no
detectable expression in sham-treated DRG. (b) Immunoblots showing the expression of the a251 subunit of Ca2+ channel and Nav1.3 and Nav1.8 sodium
channel protein in VZV- and sham cell-infected DRG. All were upregulated ipsilateral to VZV infection with minimal or no detectable expression in sham-
treated DRG. Normalised protein loading was determined by uniform expression of housekeeper gene GAPDH in both VZV- and sham cell-treated DRG (n — 5
in each case), (c) There is reduced VZV IE62 expression with diluted viral infections in samples taken 2 weeks following infection, when maximal changes in
behavioural sensitisation had been reached.
Nav1.3 protein in ipsilateral DRG while no protein could be
detected in sham cell-infected DRG (Fig. 5b, Table 1).
We also examined the TTX-resistant Nav1.8 sodium
channel, which has also been implicated in chronic pain
(Gold et al., 2003; Novakovic et al., 1998; Porreca et al.,
1999). We found that this channel was also upregulated in
DRG following VZV infection (Fig. 5b, Table 1). Due to
technical limitations of the available antibodies, we could
not establish immunofluorescence of either Nav1.3 or
Nav1.8. The presence of upregulated Nav1.3 and Nav1.8
sodium channels indicated that there are neuropathic type
changes in VZV-infected rats.
3.7. Neuropathic pain behaviors are attenuated
by gabapentin administration
Given the upregulation of the <*251 channel in VZV-
infected tissue (Fig. 5b), we assessed the effect of orally
administered gabapentin in VZV-infected rats. Rats at the
peak of VZV-induced behavioral reflex sensitivity (n = 8 at
4 weeks post-infection) received gabapentin (100 mg/kg) by
oral gavage, and were tested 2, 4, 6, 24 and 48 h post-
treatment. Gabapentin reversed the VZV-induced reduction
in paw withdrawal threshold to mechanical stimulation
using von Frey filaments (Fig. 6a) and the reduction in paw
withdrawal latency to noxious heat (Fig. 6b). Effects were
seen over a 24 h period for mechanical allodynia with
recovery to VZV-induced sensitivity by 48 h. Results were
similar for thermal hyperalgesia, although effects appeared
to be shorter lasting, with recovery occurring between the 6
and 24 h periods of testing (Fig. 6a and b). Maximal effects
of gabapentin were seen 2 h post-gavage with no significant
difference between virus-treated and untreated sides for
mean mechanical (contralateral and ipsilateral both 125.9 +
0.0 g) or thermal (contralateral 19.4 + 0.2 s; ipsilateral
18.7 + 0.4 s) withdrawal responses. Thus, there appears to
be a similar gabapentin sensitivity following VZV infection
as seen in models of peripheral nerve injury.
3.8. Sodium channel blockers reduce VZV-induced
neuropathic pain behaviors
Voltage-gated sodium channels initiate and propagate
neuronal action potentials, thus regulating neuronal excit¬
ability. Post-injury changes in the distribution and activity
of sodium channels within DRG neurons and at the site of
injury can regulate a state of hyperexcitability (Baker and
Wood, 2001; Cummins et al., 2000). The involvement of
sodium channels in PHN has been suggested following
effective use of peripheral analgesic lidocaine patches (Brau
et al., 2001; Davies and Galer, 2004). Indeed, sodium
channel blockers are also known to be effective in models of
nerve damage (Cantrell and Catterall, 2001; Cummins et al.,
2000). Since Nav1.3 and Nav1.8 sodium channel expression
increased following VZV infection, we tested whether
orally administered sodium channel blockers were effective
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Fig. 6. Oral administration of the anticonvulsant, gabapentin and sodium channel blockers, mexiletine and lamotrigine attenuate sensitised behavioral reflex
responses in VZV-infected animals. Mean + SEM responses of the paw withdrawal threshold to an innocuous mechanical stimulus (a, c, e) and paw withdrawal
latency to noxious thermal stimulation (b, d, f) following oral gavage of either gabapentin (a, b), lamotrigine (c, d) or mexiletine (e, f) ipsilateral (O) or
contralateral (■) to VZV injection in animals at peak behavioral sensitivity following VZV infection. Mean+SEM responses of withdrawal thresholds (g) and
withdrawal latency (h) following the intrathecal injection of the NMDA receptor antagonist (R)-CPP. In (a, c, e, g), * represents a significant ipsilateral to
contralateral difference at each time point, P < 0.05 by Wilcoxon test, and t represents a significant difference at each time point when compared to pre-drug
baseline, P<0.05 by repeated measures ANOVA on ranks (Friedman's test) followed by Dunn's post hoc test. In (b, d, f, h), * represents a significant
ipsilateral to contralateral difference at each time point, PC0.05 by paired r-test and t represents a significant difference at each time point when compared to
pre-drug baseline, PC0.05 by repeated measures ANOVA followed by Dunnett's post hoc test.
in reversing the sensitised pain behaviors observed. The
effect of sodium channel blockers on VZV-induced
neuropathic behaviors has not been previously investigated.
We used two voltage-dependent sodium channel blockers,
mexiletine and lamotrigine. Again, animals at the peak
of VZV-induced behavioral reflex sensitivity (rz = 8 for
each drug) received mexiletine and lamotrigine (both at
lOOmg/kg) by oral gavage and were tested 1, 2, 4, 6, 24
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and 48 h post-treatment. Mexiletine produced a reversal of
behavioral sensitivity to mechanical (Fig. 6c) and thermal
stimuli (Fig. 6d), whereby the inhibition of allodynia
recovered to VZV-induced sensitivity after 2 h and for
hyperalgesia after 4 h. Maximal effects of mexiletine were
seen 2 h post-gavage with mean thermal withdrawals of
16.9 + 0.3 s for contralateral and 14.5+0.6 s for ipsilateral
hindpaws. Mean mechanical responses for contralateral
(125.9 + 0.0 g) and ipsilateral (116.5 ±9.4 g) paws were not
significantly different. Lamotrigine also effectively reversed
thermal hyperalgesia behaviors over a time course of
6 h (Fig. 6f), while similar effects were only seen for up
to 2 h for mechanical allodynia (Fig. 6e). At peak reversal
1-2 h post-gavage, there was no significant difference in the
mean mechanical responses (contralateral 125.9 + 0.0 g;
ipsilateral 119.6 + 6.3 g) or in thermal responses (contral¬
ateral 19.6 + 0.2 s; ipsilateral 19.1+0.3 s). At the time of
maximal analgesic effects of gabapentin, mexilitine and
lamotrigine (2 h post-gavage), there was no significant
effect seen with the NSAID diclofenac, which failed to
reverse both the ipsilateral-specific mechanical allodynia
(contralateral 125.9 + 0.0 g; ipsilateral 17.2 + 3.2 g) and
thermal hyperalgesia (contralateral 17.0 + 0.6 s; ipsilateral
10.3 +1.2 s), which was similar to that seen in untreated
VZV-infected animals (Fig. 1).
3.9. VZV-induced neuropathic pain behaviors are depen¬
dent on spinal NMDA receptor-dependent changes
Sensitisation of cells in the dorsal horn of the spinal cord
is a key change in other neuropathic pain states and is
thought to crucially involve activation of the NMDA
receptor (Coderre and Melzack, 1992). We found that
spinal NMDA receptors also play a role in the mechanical
allodynia seen in animals with VZV-infection, since
behavioral sensitisation was reversed following spinal
administration of the selective NMDA receptor antagonist
(R)-CPP (Lehmann et al., 1987; Fig. 6g). Similarly, the
reduction in thermal nociceptive response latency ipsilateral
to VZV-infection was reversed by (R)-CPP (Fig. 6h). The
mean percent reversal of sensitisation over the first 30 min
of drug administration being 63.6 + 4.2 and 90.4 + 5.6 for
mechanical allodynia (Fig. 6g) and thermal hyperalgesia
(Fig. 6h), respectively (mean + SEM; n = 5). There was no
effect of (R)-CPP on thermal or mechanical responses
contralateral to VZV-infection. Activation of spinal opioid
receptors can produce analgesia in models of inflammation
(Malmberg and Yaksh, 1993), but is largely ineffective in
neuropathic pain conditions (Amer and Meyerson, 1988).
To assess any potential opioid regulation of this model of
VZV-induced sensitisation, we performed intrathecal
injections with the highly selective p-opioid receptor
agonist, DAMGO. No discernable effect on thermal and
mechanical nociceptive reflexes was seen following
injection of DAMGO (at the highest dose possible before
motor dysfunction was observed), indicating that opioids
are not effective modulators of the behavioural sensitisation
in this model (data not shown). Equivalent injections of the
saline vehicle had no effect on mechanical or thermal reflex
responses (data not shown). These findings suggest that the
spinal NMDA receptor plays a key role in the development
of VZV-induced neuropathic behavioral reflex sensitisation.
4. Discussion
Abnormal sensory phenomena including spontaneous
pain, hyperalgesia and allodynia are associated with human
primary VZV infection and its recurrence (Bowsher, 1995).
Since the underlying mechanisms are poorly understood, it
is important to characterise some of the functional and
phenotypic changes occurring in a VZV-induced pain
model.
4.1. VZV infection-induced allodynia and hyperalgesia
Sensory neuronal damage following VZV infection and
PHN development often causes chronic pain and allodynia
(Rowbotham and Fields, 1996). We show a unilateral
mechanical allodynia and thermal hyperalgesia matched
by increased DRG expression of the nerve injury marker,
ATF-3. Evidence that central (spinal) changes in excit¬
ability are essential to this sensitised, VZV-induced pain
state is provided by its marked attenuation by intrathecal
injection of an antagonist of the NMDA receptor (a key
mediator of synaptic sensitisation), but does not involve
opioids. The time course of behavioral sensitisation is
similar to that seen in other models of neuropathic pain and
its persistence for up to 10 weeks is in agreement with
another recent report of VZV-induced allodynia (Dalziel
et al., 2004). Our finding that allodynia was longer lasting
than thermal hyperalgesia mirrors the clinical finding of
marked allodynia in PHN patients (Bowsher, 1995).
4.2. Presence of VZV viral protein in sensory neurons
in the DRG
It is important to establish the presence of viral
products, one of several viral genes, in subpopulations of
sensory neurons in DRG. A number of viral genes are
expressed in human DRG following latent infection with
VZV, such as VZV IE62 (Cohrs et al., 1996; Kennedy
et al., 2001). The function of these genes is unknown, but
they may alter nociceptive processing. Extending previous
findings in this model showing mRNA for genes 62, 63
and 4 (Sadzot- Delvaux et al., 1995) and IE63 protein
(Fleetwood-Walker et al., 1999), we show that IE62
protein is co-localised in both A- (NF-200-) and C-
(peripherin-) positive neurons in VZV-infected DRG and is
largely localised to the sensitised side.
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4.3. Phenotypic changes in neuropeptide and ion channel
expression in sensory neurons in the DRG
Following peripheral nerve damage, phenotypic changes
occur in peptide expression in DRG that may contribute to
sensory sensitisation and chronic pain (Hokfelt et al,, 1994).
Neuropeptide changes in PHN have not previously been
described. We observed an upregulation ofNPY and galanin in
the DRGs of VZV-infected rats, mimicking that seen in other
nerve injury models (Hokfelt et al., 1994) with NPY being
largely restricted to the NF-200-positive myelinated cells (Ma
and Bisby, 1998; Munglani et al., 1995; Wallace et al., 2003).
Chronic nerve injury is also associated with subunit
redistribution and altered subunit compositions of sodium and
calcium channels that may predispose afferent neurons in
sensory pathways to fire inappropriately (Cummins et al.,
2000; Matzner and Devor, 1994; Rogawski and Loscher,
2004). After some peripheral nerve injuries, and here
following VZV infection, the expression of the Ca2+ channel
a251 subunit in DRG neurons is upregulated (Luo et al.,
2002; Newton et al., 2001). In such situations gabapentin does
show antiallodynic effects, suggesting that gabapentin may
block neuropathic pain by inhibiting the DRG hyperexcit-
ability resulting from an upregulation of a25 channels.
Changes accompanying both VZV infection and nerve
injury include an increase in DRG Nav1.3 (type III) Na+
channels, leading to functional changes in afferent sodium
currents (Cumminset al., 2000; Dib-Hajj et al„ 1999; Kim et al.,
2001). TTX-sensitive Nav1.3 channels produce fast sodium
currents that recover rapidly from inactivation, permitting
high-frequency ectopic firing (Cummins et al., 2001).
Recent evidence indicates that increased expression of
the Nav1.8 channel (Akopian et al., 1996; Sangameswaran
et al., 1996) in nociceptive sensory neurons near the site of
injury results in spontaneous ectopic discharges and lowered
mechanical activation thresholds leading to the conse¬
quences of neuropathic and inflammatory pain (Gold et al.,
2003; Novakovic et al., 1998; Roza et al., 2003; Tanaka
et al., 1998). Some reports suggest that nerve injury
downregulates Nav1.8 expression (Cummins et al., 2000;
Decosterd et al., 2002), although antisense knockdown can
alleviate sensitisation following nerve injury (Porreca et al.,
1999). We saw increased expression of Nav1.8 protein in
DRG following VZV infection, which might explain why
the agents used here, which block TTX-resistant sodium
channels (Brau et al., 2001), were notably effective. Thus,
specific sodium channel-blocking agents could be effective
analgesics following VZV infection as in nerve injury-
induced pain (Chabal et al., 1992; Devor et al., 1993;
Omana-Zapata et al., 1997; Rizzo, 1997).
4.4. Gabapentin and sodium channel blockers alleviate
VZV- induced sensitisation
Gabapentin inhibits both the allodynia following nerve
injury and ectopic discharges of nociceptive afferents
(Pan et al., 1999) as well as attenuating the increased
responses of spinal cord dorsal horn neurons and afferents to
noxious stimulation in the post-injury state (Chapman et al.,
1998a; Kanai et al., 2004; Stanfa et al., 1997). Gabapentin
binds with high affinity to the voltage-gated calcium
channel a251 and a252 subunits and is thought to inhibit
high voltage-activated Ca2+ currents through channels that
contain these subunits (Rogawski and Loscher, 2004).
Gabapentin is effective in the treatment of neuropathic pain,
specifically post-herpetic neuralgia (Beydoun, 1999; Mao
and Chen, 2000) and is antinociceptive following nerve
injury (Erichsen and Blackburn Munro, 2002; Laughlin
et al., 2002; Pan et al., 1999). We find gabapentin to be
effective in reducing VZV-induced mechanical allodynia
for up to 24 h and thermal hyperalgesia for up to 6 h
following oral administration. This matches previous
reports of effectiveness against PHN in humans (Rowbo-
tham et al., 1998). Although the mechanism of analgesic
action of gabapentin is unclear, recent findings suggest it
reduces fast glutamatergic and glycinergic spinal synaptic
transmission downstream of its inhibition of P/Q-type Ca2+
channels, the a281 subunit of which it is thought to target
and which is upregulated in the DRG and spinal cord
following nerve injury (Bayer et al., 2004; Luo et al., 2002).
The sodium channel blockers, mexiletine and lamotrigine
both block TTX-resistant sodium channel currents and are
thought to act by direct channel binding, thus potentially
preventing sodium influx and reducing action potential
duration in nociceptive afferents (Brau et al., 2001; Clare
et al., 2000; Ragsdale and Avoli, 1998). Mexiletine,
currently in clinical use for neuropathic pain (Chabal et al.,
1992), decreases spontaneous activity and mechanical
sensitivity associated with neuroma formation, and the
spontaneous activity of spinal neurons in nerve-ligated rats
(Chabal et al., 1989; Chapman et al., 1998b). Mexiletine can
alleviate hyperalgesia and allodynia in models of neuro¬
pathic pain (Erichsen and Blackburn Munro, 2002; Jett et al.,
1997) and inhibits acute herpetic pain (Asano et al., 2003).
Lamotrigine can also suppress repetitive firing of sodium-
dependent, fast action potentials (Cheung et al., 1992) and
attenuates both hyperalgesia (Erichsen et al., 2003) and
allodynia (Laughlin et al., 2002) in models of neuropathic
pain. It also reduces dorsal horn neuronal excitation elicited
by the chemical algogen mustard oil (Blackburn-Munro
and Fleetwood-Walker, 1997) and reverses prostaglandin
E2 and streptozotocin-induced mechanical hyperalgesia
(Nakamura-Craig and Follenfant, 1995). Both lamotrigine
and mexilitine were effective inhibitors of thermal hyper¬
algesia and allodynia in the present model.
In summary, we demonstrate a number of similarities
between VZV infection and other neuropathic pain states in
both functional changes and in the phenotypic changes that
occur in the DRG. The presence of VZV in DRG neurons in
this model was directly confirmed by both immunoblot and
immunohistochemical evidence for the specific expression
of VZV IE62. The induction of ATF-3 ipsilateral to VZV
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infection indicates that sensory cells are stressed/injured
following VZV infection. NPY is also upregulated in
NF-200 positive DRG cells, whilst sodium channel
involvement in the VZV-induced pain state is suggested
by the observation that Navl .3 and Nav1.8 channel subtypes
as well as the neuropeptide, galanin are upregulated in
the DRG.
The anticonvulsant, gabapentin and the sodium channel
blockers lamotrigine and mexiletine were effective in
reducing VZV-induced pain behaviors, while the anti¬
inflammatory agent diclofenac was not. Thus several
aspects of the pharmacological sensitivity of VZV-induced
pain behaviors and phenotypic changes are closely aligned
with models of nerve injury-induced pain. Further work will
reveal whether there are distinct biochemical and functional
changes that are specific to this model.
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Abstract
Chronic pain states arise from peripheral nerve injury and are inadequately treated with current analgesics. Using intrathecal drug
administration in a rat model of neuropathic pain, we demonstrate that AMPA receptors play a role in the central sensitisation that is thought
to underpin chronic pain. The GluR2 subunit of the AMPA receptor binds to a number of intracellular adapter proteins including GRIP,
PICK.1 and NSF, which may link the receptor to proteins with signalling, scaffolding and other roles. We implicate for the first time a
possible role for GRIP, PICK1 and NSF in neuropathic sensitisation from experiments with cell-permeable blocking peptides mimicking
their GluR2 interaction motifs and also demonstrate differential changes in expression of these proteins following peripheral nerve injury.
These studies suggest a critical involvement of protein:protein complexes associated with the AMPA receptor in neuropathic pain, and the
possibility that they may have potential as novel therapeutic targets.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Neuropathic pain is a hypersensitive chronic pain state,
which is poorly treated with current analgesics. Glutamate is
important in neurotransmission from primary afferent inputs
and several studies suggest a role for the AMPA subtype of
glutamate receptor in sensitisation. AMPA receptor agonists
depolarise nociceptive spinal neurons and increase re¬
sponses to noxious and innocuous stimulation as well as
enhancing acute nociceptive behaviours (Aanonsen et al.,
1990; Dougherty et al., 1992; Budai and Larson, 1994;
Cumberbatch et al., 1994; Aanonsen and Wilcox, 1987),
while AMPA receptor antagonists disrupt acute nociceptive
* Corresponding author. Fax: +44-131-650-6576.
E-mail address: s.m.fleetwood-walker@ed.ac.uk (S.M. Fleetwood-
Walker).
1 Current address: Department of Anatomy and Developmental Biol¬
ogy, Medawar Building, University College London, Gower St., London,
WC1E 6BT, UK.
behavioural responses and chronic pain, including neuro¬
pathic pain (Mao et al., 1992; Chaplan et al., 1997; Sorkin
et al., 2001; Nishiyama et al., 1998). The molecular mech¬
anisms underlying these actions of AMPA receptors are
however unknown.
Of the four AMPA receptor subunits (GIuRl-4; Holl-
mann and Heinemann, 1994), the GluR2/3 subunits have
received particular attention since a number of proteins
interact with a PDZ domain target motif at their C-terminus.
GluR2, but not GluR3, is abundant in the dorsal spinal cord
(Jakowec et al., 1995). The PDZ domain-containing pro¬
teins that can dock to GluR2 include the GRIP (Glutamate
Receptor Interacting Protein) family (Dong et al., 1997,
1999; Srivastava et al., 1998; Bruckner et al., 1999) and
PICK1 (Protein Interacting with C Kinase 1) (Xia et al.,
1999; Dev et al., 1999). GRIP is enriched in the postsyn¬
aptic density (PSD) but is also cytosolic (Wyszynski et al.,
1998). PICK1 (originally identified by its interaction with
PKCa; Xia et al., 1999; Dev et al., 1999) may act to bring
1044-7431/03/$ — see front matter © 2003 Elsevier Science (USA). All rights reserved,
doi: 10.1016/S1044-7431 (03)00134-9
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the kinase close to plasma membrane substrates, including
the AMPA receptor (Staudinger et al., 1997; Perez et al.,
2001). Disruption of the GluR2 C-terminal SVKI motif
interactions suggests that GRIP and PICK1 are important in
the synaptic clustering of AMPA receptors (Dong et al.,
1997; Osten et al., 2000) for unmasking silent glutamatergic
synapses in somatosensory inputs (Li et al., 1999) and for
the expression of long term changes in the excitability of
hippocampal and cerebellar neurons (Xia et al., 2000; Kim
et al., 2001). Both GRIP and PICK1 proteins have been
implicated in the cell surface clustering of GluR2-contain-
ing AMPA receptors (Xia et al., 1999; Osten et al., 2000),
while PICK1 appears to be involved in AMPA receptor
endocytosis (Perez et al., 2001). NSF (N-ethylmaleimide-
Sensitive Fusion protein), a non-PDZ domain protein in¬
volved in membrane fusion, is enriched in the PSD and has
been shown to dock to the GluR2 subunit at a different site
on its C-terminus (VAKNAQ, Osten et al., 1998; Song et
al., 1998). This interaction may contribute to stabilising
excitatory currents in hippocampal neurons (Nishimune et
al., 1998; Song et al., 1998), to the movement of AMPA
receptors to the cell surface (Noel et al., 1999; Liithi et al.,
1999; Luscher et al., 1999) and to Long Term Potentiation
(LTD) (Lledo et al., 1998).
In the present study we asked whether AMPA receptors
and GluR2 subunit adapter proteins might play a specific
role in the sensitised responsiveness of spinal cord neurons
that underlies neuropathic pain.
Results
AMPA receptor antagonists attenuate neuropathic reflex
sensitisation following CCI
To examine the question of a role for the AMPA receptor
in neuropathic pain conditions, we assessed the contribution
of spinal AMPA receptors to CCI-induced changes in so¬
matosensory behavioural reflexes by carrying out intrathe¬
cal administration of the AMPA receptor antagonists
NBQX, NS-257 and SYM 2206 (Fig. la and b, Table 1).
Intrathecal injection of the AMPA/kainate receptor antago¬
nist NBQX and the highly selective AMPA receptor antag¬
onists NS-257 and SYM 2206 in rats at the peak of behav¬
ioural reflex sensitisation attenuated the ipsilaterally
sensitised behavioural measures of thermal hyperalgesia.
NBQX, NS-257 and SYM 2206 had similar but somewhat
less marked effects on mechanical allodynia following CCI.
None of the antagonists caused any alteration in sensory
responses elicited from the contralateral (uninjured) side of
CCI animals or from sham/nai've animals at the concentra¬
tions that were found to clearly modify ipsilateral responses
after CCI. Intrathecal injection ofvehicle had no discemable
effect on thermal hyperalgesia or mechanical allodynia fol¬
lowing CCI (Table 1). These data indicate a pre-eminent
role for AMPA receptors in the spinal cord in mediating the
sensitised nociceptive transmission that occurs following
peripheral nerve damage. This role of AMPA receptors in
sensitisation is more readily disrupted by antagonists than
the contribution of AMPA receptors to acute nociceptive or
non-nociceptive inputs, since nociceptive reflexes from the
contralateral (non-sensitised) side of CCI animals (Fig. 1)
and in naive animals (data not shown) were unaffected by
the doses of AMPA receptor antagonists used here.
Effects ofmyristoylated GluR2 domain peptides on
neuropathic sensitisation
Since there is little in vivo functional evidence on the
spinal role of proteins that interact with the C-terminus of
the GluR2 subunit, we assessed the effects of the local
application of myristoylated peptides (designed to obscure
the site of interaction of the GluR2 subunit with GRIP,
PICK1 or NSF) on CCI-induced behavioural reflex changes.
Intrathecal injection of the inhibitory peptide blocking the
NSF binding site, myr-GluR2g46_g56 significantly attenu¬
ated the thermal hyperalgesic state for up to 35 min (Fig. lc)
but had a much smaller and very short-lasting effect on
mechanical allodynia (Fig. Id). The inactive control peptide
([N854S]myr-GluR2g46_g56; Noel et al., 1999) had no effect
at any time tested (Fig. 2a, b). Similarly, administration of
myr-GluR2g74_gg3 (to block the site of both GRIP and
PICK1 binding on the extreme GluR2/3 C-terminus) mark¬
edly alleviated the CCI-induced ipsilateral thermal hyperal¬
gesia for up to 50 min following injection (Table 1, Fig. le),
but failed to significantly affect mechanical allodynia (Fig.
If). Point mutation of S880 to E in this sequence produces
a peptide that is no longer recognised by GRIP but still
interacts with PICK1 (Li et al., 1999; Chung et al., 2000;
Daw et al., 2000). [S880E]myr-GIuR2g74_gg3 significantly
attenuated thermal hyperalgesia (Fig. 2c), while effects on
mechanical allodynia (Fig. 2d) were less pronounced. The
inactive control peptide [1883E]myr-GluR2g74_gg3 (Li
et al., 1999; Osten et al., 1999) had no effect on reflex
behaviours at any time (Fig. 2ef), nor did a further control
myristoylated peptide of unrelated sequence (Table 1).
These data indicate for the first time a functional role in
vivo for AMPA receptor-interacting proteins in persistent
neuropathic pain, suggesting that interactions of both
GluR2:GRIP/PICKl and GluR2:NSF docking domains may
contribute to the maintenance of neuropathic thermal hy¬
peralgesia with a lesser effect on mechanical allodynia.
Since the effects of myr-GluR2g74_gg3 (which blocks both
GRIP and PICK1 interactions) were essentially mimicked
by [S880E]myr-GluR2g74_gg3, which still interacts with
PICK1 but not GRIP, it appears that the PICK1 interaction
in particular may be important in neuropathic sensitisation.
None of the inhibitory peptides had any significant effect on
contralateral responses or when tested in naive rats (data not
shown).
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Fig. I. Effects of intrathecal administration of the AMPA receptor antagonist SYM 2206, or the myristoylated peptides myr-GluR2g46_856 (NSF motif) and
myr-GluR2s74_883 (PDZ target motif) on nerve injury-induced thermal hyperalgesia and mechanical allodynia. Data represent the average hindlimb
withdrawal latency (sec) to noxious heat (a, c, e) and withdrawal threshold to mechanical stimuli (mN/mm2; b, d, f) ± SEM before or following the intrathecal
injection of either SYM 2206 (1.5 nmol/50 p.1, a, b), myr-GluR2K46 856 (4.5 nmol/50 pi, c, d) or myr-GIuR2874_g83 (4.5 nmol/50 pi, e, f). Rats at the peak
of ipsilateral reflex sensitisation, as determined by a significant reduction in baseline ipsilateral paw withdrawal latency to thermal stimuli (PWL; *P < 0.05
Student's t-test, a, c, e) or paw withdrawal threshold to mechanical stimuli (PWT; *P < 0.05 Mann-Whitney Rank Sum test, b, d, f) compared to contralateral
withdrawal responses, were intrathecally injected (at arrow). Following injection, SYM 2206 (a), myr-GluR2846_856 (c) and myr-GluR2g74_gg3 (e)
significantly attenuated the accentuated ipsilateral thermal responses (O) in comparison to pre-injection ipsilateral values (fP < 0.05, One-way ANOVA
followed by a Dunnett's test) while there was no significant alteration in the contralateral (■) response. Paw withdrawal thresholds to mechanical stimulation
ipsilateral to CCI (O) showed significant differences between pre- and post-injection values (fP < 0.05, Kruskal-Wallis ANOVA followed by a Dunn's test)
for SYM 2206 (b) and a transient response only for myr-GluR2846_ 856 (d), with no significant change due to myr-GluR2g74 883 (f). Contralateral responses
(■) were not significantly altered by any of the reagents.
Immunoblotting for the. GluR2 AMPA receptor subunit
and associated proteins
In order to examine expression levels following CCI,
semi-quantitative analysis of immunoblots following SDS-
PAGE was carried out for GluR2, GRIP, NSF and PICK1
ipsilateral and contralateral to injury in CCI animals, com¬
pared to sham and naive spinal cord. An antibody that
recognises both isoforms of GRIP was used. Expression
levels were compared to those for GAPDH, a ubiquitous
and constitutively expressed housekeeping enzyme, the ex¬
pression of which does not change following peripheral
nerve damage (Medhurst et al., 2000).
We found that levels of GluR2 (Fig. 3a, lane I, Table 2)
and GRIP (Fig. 3b, lane I, Table 2) were selectively in¬
creased in the spinal cord ipsilateral to CCI with little
variation in protein levels between contralateral (C), sham
(S) and naive (N) samples. Blots were stripped and reprobed
for GAPDH (Fig. 3, lower panels) to ensure equivalent
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Table 1
Summary of the effects of AMPA receptor antagonists and GluR2
adapter protein-blocking peptides on pain-related behavioural reflex
responses
Mean % reversal of ipsilateral sensitisation from 15-30 min following
drug administration
Blocker (dose) Thermal Mechanical
hyperalgesia allodynia
a) General AMPA receptor antagonists
NBQX (5 nmol) 88.9 8.1* 55.1 -+- 3.4f
NS-257 (83 nmol) 82.9 fr 8.2* 27.5 2.9f
SYM 2206 (1.5 nmol) 87.4 ■+ 7.0* 48.5 -+- 4.6f
Vehicle 9.0 2.6 5.5 3.0
b) Myristoylated domain-blocking peptides
myr-GluR2g46 85<s (4.5 79.6 10.5* 13.5 -h 2.6§
nmol) (NSF target motif)
[N854S]myr-GluR2s46_g56(4.5 -3.6 -+■ 4.2 9.9 5.1
nmol) (inactive on NSF
motif)
myr-GluR2874_883 (4.5 74.2 4.8* 12.4 2.5
nmol) (PDZ target motif)
[S880E]myr-GluR2g74_gg3 91.9 -t- 4.3* 44.8 11.5$
(4.5 nmol) (inactive on
GRIP but not PICK1
interaction)
[1883EJmyr-GluR2s74ggg 11.3 H- 5.6* 11.2 ■jr 4.1
(4.5 nmol) (inactive on
PDZ target motif)
myr-GRRNAIHDE (4.5 7.6 ■+■ 3.4 3.7 2.5
nmol) (inactive unrelated
control)
Note. Data represent mean percent reversal ± SEM from 15-30 min
following intrathecal injection of each compound for measurements of
thermal hyperalgesia and mechanical allodynia in rats at the peak of
ipsilateral reflex sensitivity. * indicates a significantly attenuated ipsilat¬
eral thermal hyperalgesia in comparison to pre-injection ipsilateral values
at each of the time points throughout this period (P < 0.05, One-way
ANOVA followed by a Dunnett's test), (indicates a significant attenuation
of ipsilateral mechanical allodynia in comparison to pre-injection ipsilat¬
eral values at each of the time points throughout this period (P < 0.05,
Kruskal-Wallis ANOVA followed by a Dunn's test), fjindicates results
showing statistical significance only at some time points. There were no
significant alterations in the pre-/post-injection contralateral responses.
ing of proteins). No significant increase was seen in the
levels of PICK1 (Fig. 3c, Table 2) under the same con¬
ditions, but in contrast to this, levels of NSF protein (Fig.
3d, Table 2) were significantly decreased ipsilateral to in¬
jury (I).
ISHH examination of GluR2, GRIP and NSF mRNA levels
following CCI
The distribution of AMPA receptors but not their dock¬
ing proteins in the spinal cord has been previously docu¬
mented under normal conditions. Flowever, it is unknown
whether the expression of GluR2-interacting proteins is
altered in neuropathic pain states (Furuyama et al., 1993;
Tolle et al., 1993; Harris et al., 1996). Indeed, there is little
evidence for the specific localisation of AMPA receptor-
associated proteins in the spinal cord and it was of interest
to determine whether there were any localised alterations in
their expression levels following the establishment of neu¬
ropathic sensitisation. Here we analysed expression of
GluR2, GRIP, and NSF mRNA in the spinal cord following
CCI. The GRIP2 isoform was examined in particular as it is
reported to be the predominant form in the adult nervous
system (Bruckner et al., 1999). No probe for rat PICK1 was
available. In naive animals, GluR2, GRIP2, and NSF
mRNA-labelled neurons were located throughout laminae
I-V of the dorsal horn and to a lesser extent in ventral hom
motoneurons (Fig. 4). Following CCI, there was a signifi¬
cant increase in the levels of both GluR2 (Fig. 4a) and
GRIP2 mRNA (Fig. 4b) in superficial dorsal horn laminae I
and II ipsilateral to injury (at the sites of primary afferent
termination). While an increase in GluR2 expression was
seen only in terms of silver grain density (Fig. 4a), the
increase in GRIP2 mRNA was seen in terms of both the
silver grain density of mRNA expression and in the number
of cells expressing GRIP2 mRNA in LI and II (Fig. 4b).
These increases in mRNA expression are in agreement with
our assessment of protein levels of GluR2 and GRIP that
were both significantly increased ipsilateral to CCI. Mini¬
mal alterations in GluR2 and GRIP expression levels were
seen in the lower laminae (III-V), or indeed in the ventral
horn motoneurons for GRIP, and levels did not significantly
differ between contralateral, sham or naive samples.
Following CCI, there was a small but significant de¬
crease (in agreement with protein analysis for NSF) in the
silver grain density ofNSF mRNA ipsilateral to injury in LI
of the superficial dorsal horn (Fig. 4c), while there was no
detectable alteration in the number of cells expressing NSF
mRNA. The level ofNSF mRNA did not significantly differ
between contralateral, sham or naive samples.
Direct association of GluR2 with GRIP and PICK1
In order to investigate direct association between GluR2
and GRIP and PICK1 in the spinal cord we carried out
GluR2-directed immunoprecipitations on spinal cord ex¬
tracts solubilised under mild detergent conditions. Extracts
were immunoprecipitated with a GluR2 antibody (directed
against an N-terminal epitope) before probing Western blots
of the immunoprecipitated complex for levels of the GluR2
C-terminus-interacting proteins GRIP and PICK1. Both
GRIP and PICK1 were clearly co-immunoprecipitated with
GluR2, but not in controls where non-immune IgG was used
instead of the GluR2 immunoprecipitating antibody (Fig.
5a). As an example of the effectiveness of myr-peptides at
interrupting GluR2 interactions, we showed that the co-
immunoprecipitation of GRIP with GluR2 was reduced by
topical treatment of the spinal cord with myr-GluR2874_883
(but not myr-control peptide) prior to extraction (Fig. 5b).
This confirms not only that motif selectivity is displayed by
topically-applied myristoylated peptides, but also that they
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Fig. 2. Effects of myr-GluR2 domain peptides with point mutations on nerve injury-induced thermal hyperalgesia and mechanical allodynia. Data represent
the average hindlimb withdrawal latency (sec) to noxious heat (a, c, e) and withdrawal threshold to mechanical stimuli (mN/mm2; b, d, f) ± SEM before
or following the intrathecal injection of [N854S]myr-GluR2g4<s_g56 (an inactive NSF-binding motif peptide; 4.5 nmol/50 pi, a, b). [S880E]myr-GluR2g74_883
(a selective disruptor of PICK 1, but not GRIP interaction; 4.5 nmol/50 pi, c, d) or [I883E]myr-GluR2874_gg3 (an inactive analogue for the GRIP/PICK!
binding site; 4.5 nmol/50 pi, e, f). Rats at the peak of ipsilateral reflex sensitisation, as determined by a significant reduction in baseline ipsilateral paw
withdrawal latency to thermal stimuli (PWL; *P < 0.05 Student's t-test, a, c, e) or paw withdrawal threshold to mechanical stimuli (PWT; *P < 0.05
Mann-Whitney Rank Sum test, b, d, f) compared to contralateral withdrawal responses, were intrathecally injected (at arrow). Following injection,
[S880E]myr-GluR2874 883 (c) significantly attenuated the accentuated ipsilateral thermal responses (O) in comparison to pre-injection ipsilateral values (j P <
0.05, One-way ANOVA followed by a Dunnett's test) while there was no significant alteration in the contralateral (■) response. [N854S]myr-GIuR2g46_g56
(a) and [I883E]myr-GIuR2g74_gg3 (e) had no discernable effect. Paw withdrawal thresholds to mechanical stimulation ipsilateral to CCI (O) showed significant
differences between pre- and post-injection (fP < 0.05, Kruskal-Wallis ANOVA followed by a Dunn's test) for [S880E]myr-GluR2g74_g83 only (d) and not for the
other peptides (b) and (f). Contralateral responses (■) were not significantly altered by any of the reagents.
must penetrate to a significant degree into spinal cord tissue
following this method of application.
Alterations in the subcellular distribution of GluR2, GRIP
and PICK1 in spinal cordfollowing topical AMPA
treatment
These experiments involved the centrifugal fractionation
of spinal cord homogenates into a dense membrane fraction
and a light microsomal compartment in order to assess
AMPA-induced translocation of GluR2, GRIP and PICK1
immunoreactivity. AMPA was topically administered to the
dorsal surface of the spinal cord in naive, anaesthetised rats.
In whole spinal cord lysate, the overall levels of GluR2,
GRIP and PICK1 were similar in either saline or AMPA-
treated animals (Fig. 6a, b and c, respectively). Interest¬
ingly, there was a marked decrease in the amount of GluR2,
GRIP or PICK1 associated with the dense membrane frac-
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Fig. 3. Western blot analysis of GluR2, GRIP, PICK1 and NSF protein expression following CCI. Western blots of spinal cord samples from neuropathic,
sham and naive rats, (a) shows an increase in GluR2 protein levels ipsilateral (I) to CCI as compared to contralateral (C), sham (S) and naive (N) controls,
(b) shows an increase in GRIP protein levels ipsilateral to CCI as compared to contralateral, sham and naive controls, (c) shows no apparent alteration in
the levels of PICK1 protein in any of the conditions tested while (d) shows a small reduction in NSF protein levels ipsilateral to CCI as compared to
contralateral, sham and naive levels (see also Table 2). No significant difference was noted when contralateral protein levels were compared to sham or naive
samples. The lower panels in each case represent the levels of GAPDH, a ubiquitous housekeeping enzyme used to establish relative protein input levels
between samples tested. See Table 2 for quantitative analysis. Molecular weights from standard marker proteins are shown on the right.
tion (M,) after AMPA receptor stimulation when compared
to saline treatment, while the levels of GRIP (b) and PICK1
(c) in the light microsomal fraction (S,) were similar to
control. Since the S, fraction reflects a much greater pro¬
portion ofcell volume than Mls it is only to be expected that
translocation of proteins from Mj to S, would not result in
an obvious proportional increase in their S, content, despite
an obvious loss from M,. So, following AMPA receptor
stimulation there was a significant movement of GluR2,
GRIP and PICK1 from the membrane, presumably into the
light microsomal fraction, since each protein was still de¬
tectable at its correct (not degraded) molecular weight. This
indicates that a substantial proportion of GRIP and PICK1
in the spinal cord is associated with the GluR2 subunit of
the AMPA receptor under normal conditions. This AMPA-
induced translocation could be prevented by topical appli-
Table 2
Densitometric analysis of Western blots for GluR2 and adapter proteins
in spinal cord following CCI
Expression of protein in the spinal cord as % of GAPDH expression
Ipsilateral Contralateral Sham Naive
CCI CCI
GluR2 55.8 ± 1.9* 41.6 ± 2.9 43.2 ± 2.9 43.5 ± 3.4
GRIP 126.6 ± 3.5* 98.9 ± 3.1 96.4 ± 2.5 97.8 ± 3.8
PICK1 17.5 ± 2.6 15.4 ± 2.4 14.1 ± 2.2 17.4 ± 2.8
NSF 8.5 ± 2.0* 11.2 ± 1.8 12.4 ± 6.5 14.3 ± 4.5
Mole. Data represent GluR2, GRIP, PICK1 and NSF protein levels as a
percentage of GAPDH expression in terms of relative arbitrary grey scale
values following quantitative densitometry of ECL films. Data represent
mean ± SEM (*P < 0.05 from corresponding contralateral CCI values,
paired Student's t-test).
cation of monodansylcadaverine and concanavalin A, inhib¬
itors of endocytosis through the clathrin-coated vesicle
pathway (Fig. 6d, Table 3). Therefore, AMPA-induced
GluR2 translocation in the spinal cord appears to occur via
clathrin-coated vesicle endocytosis and GRIP and PICK1
may share similar pathways of translocation, perhaps due to
their (at least temporarily) continued association with
GluR2.
Discussion
Damage to peripheral nerves results in long-lasting phys¬
iological and phenotypic alterations in the peripheral and
central nervous system and brings about a state of hyper¬
sensitivity within the dorsal hom of the spinal cord. This
hypersensitivity contributes to the development of the hy¬
peralgesia and allodynia that characterise the neuropathic
pain condition. We provide evidence that proteins interact¬
ing with the C-terminal domain of the GluR2 subunit of
AMPA receptor play an important role in the cellular mech¬
anisms underlying neuropathic pain.
There is preliminary evidence that AMPA receptor an¬
tagonists can inhibit thermal hyperalgesia and mechanical
allodynia following CCI (Mao et al., 1992; Chaplan et al.,
1997). The characteristics of this effect and its cellular
mechanism of action have been little investigated to date.
Studies here utilising the intrathecal injection of several
structurally distinct AMPA receptor antagonists confirmed
this, whereby NBQX, NS-257, and SYM 2206 showed a
reversible inhibition of neuropathic thermal hyperalgesia
with less marked, but still clear effects on mechanical alio-















Fig. 4. In situ hybridisation analysis of the levels of GluR2, GRIP2 and NSF mRNA expression in the spinal cord following CCI. A photographic
representation of the main region of GluR2 mRNA expression in lamina II of dorsal horn ipsilateral to CCI is shown as an example of silver grain expression
levels (a) (Scale bar = 100 /urn). In panels a, b and c, the histogram to the left shows the mean number of cells (± SEM) expressing GluR2, GRIP2 or NSF
mRNA for the mediolateral dorsal horn laminae I-V (LI-V) ipsilateral and contralateral to CCI, compared to sham-operated and naive animals (n = 4 rats,
5 sections per condition for each rat). Significant ipsilateral differences are indicated when compared to contralateral (*P < 0.05, Student's t-test) or to sham
and naive levels (f, P < 0.05, One-way ANOVA followed by a Dunnett's test). The histograms to the right represent the mean density (±SEM) of silver
grains per cell expressing GluR2, GR1P2 or NSF mRNA for the mediolateral dorsal hom laminae I-V (LI-V). Significant ipsilateral differences are indicated
when compared to contralateral (*P < 0.05, Student's t-test) or to sham and naive levels (fP < 0.05, One-way ANOVA followed by a Dunnett's test). ■
= Ipsilateral; □ = contralateral; □ = sham; gg = naive.
dynia (Table 1). There were no effects at these doses on the
contralateral side or in sham or naive animals. The limited
effects of AMPA receptor agents alone on mechanical al-
lodynia may be consistent with reports that co-activation of
AMPA and metabotropic receptors is required for the de¬
velopment of mechanical allodynia (Meller et al., 1993).
GluR2 immunoreactivity is reported to increase in the
ipsilateral dorsal horn following CCI (Harris et al., 1996).
We confirmed this in the present study with immunoblotting
(Fig. 3) and also at the level of ISHH, where quantitative
analysis indicated a significant increase in the density of
GluR2 mRNA expression in spinal cord LI and II cells from
rats at the peak of behavioural reflex sensitisation, with no
significant change in the number of cells expressing GluR2
mRNA in this region (Fig. 4a).
The functional impact of blocking the shared GRIP/
PICK1 site within the GluR2 C-terminus was examined by
the intrathecal injection of a myristoylated peptide corre¬
sponding to the interaction motif. This reagent was striking
in its attenuation of thermal hyperalgesia following CCI
(Fig. le). A similar reagent with a point mutation in this
sequence [S880E], which markedly reduces its affinity for
GRIP, but not for PICK1, also had a striking effect on
thermal hyperalgesia (Fig 2c). Since the [S880E]myr-
GluR2874 g83 peptide can still recognise PICK1, its effects
here may be due to selective blockade of the GluR2:PICKl
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Fig. 5. Co-immunoprecipitation of GRIP and PICKI with GluR2 from
spinal cord and the effects of topical administration of the GRIP interac¬
tion-blocking peptide myr-GluR2874 _883. (a) shows GRIP and PICKI im-
munoreactivity, recovered in association with GluR2-directed spinal cord
immunoprecipitates from spinal cord (lower panels) together with confir¬
mation that GluR2 was being specifically pulled down (upper panels).
Non-immune IgG (IgG) was used as a negative control and produced
negligible pull-down ofGluR2, GRIP or PICKI under these conditions. In
b) the co-immunoprecipitation of GRIP with GluR2 was investigated in
spinal cord from animals to which the GRIP:interaction site blocking
peptide, myr-GluR2874_883 had been topically applied for 30 min prior to
extraction. An inactive myr-peptide was used as control. Mean relative
densitometric values for GRIP:GluR2 ratios were 36.4 ± 2.3% for myr
GluR2874 _883 and 78.1 ± 3.4 % for the control reagent
interaction. The effects of these peptides on mechanical
allodynia were however, much less (Figs. Ifand 2d), which
may correspond to a differential involvement of AMPA
receptors in the afferent pathways involved in the process¬
ing of thermal nociceptive and low intensity mechanical
inputs. In addition, a significant increase in both the silver
grain density and number of cells expressing GRIP2 mRNA
was found in the superficial dorsal horn ipsilateral to CCI
(Fig. 4b). Western blot analysis of spinal cord following
CCI confirmed the increase in the overall levels of GRIP
protein ipsilateral to injury (Fig. 3b). In contrast, PICKI
expression appeared to be unaltered ipsilateral to CCI (Fig.
3c). We showed that both GRIP and PICKI proteins were
specifically associated with GluR2 immunoprecipitates
from spinal cord tissue and this interaction could be reduced
by topical spinal application of a myristoylated peptide,
designed to block the C-terminal PDZ target motif, prior to
extraction (Fig. 5a, b). The turnover of GluR2:GRIP/PICKl
complexes may be increased by the additional glutamatergic
input resulting from CCI. An increase in GluR2 and GRIP
expression could contribute to replacing these components.
The specific location of GluR2 in LII as well increases in
GluR2 and GRIP mRNA (with corresponding increases in
protein levels of GluR2 and GRIP) in areas innervated by
specific subsets of fine aflferents suggests that they may play
a key role in mediating neuropathic pain. The role of GRIP
in neuropathic sensitisation may relate to its involvement in
synaptic accumulation of GluR2, which could depend on a
reduction in rate of endocytosis (Osten et al., 2000), or to its
additional PDZ domain interactions with other proteins.
Due to the lack of an available cDNA sequence for rat
PICKI, in situ hybridisation analysis of PICKI mRNA
expression was not carried out, and the properties of the
PICKI antibody prevented immunohistochemical analysis
of regional expression. Western blots indicated that there
was no apparent alteration in the overall levels of PICKI
protein ipsilateral to CCI in the spinal cord (Fig. 3c).
Nevertheless, our behavioural reflex results with the
[S880E]myr-GluR2g74_8g3 peptide suggest that PICKI is
likely to play a role in neuropathic pain. Phosphorylation of
the serine in the (—3) position in the carboxy terminal tail of
GluR2 reduces the affinity of GluR2 for GRIP, but not
PICKI (Matsuda et al., 1999; Chung et al., 2000). Point
mutation of this residue in GluR2 to the phosphoserine
surrogate, glutamate or to alanine causes a similar effect
(Matsuda et al., 1999; Chung et al., 2000; Osten et al.,
2000). Peptides based on these modified sequences retain
their selectivity, with the phosphoserine or glutamate-based
sequences (that showed low affinity for GRIP) displaying
minimal ability to disrupt GluR2:GRIP interactions (Ma¬
tsuda et al., 1999; Li et al., 1999), while showing affinity for
PICKI (Li et al., 1999) and disrupting GluR2:PICKl dock¬
ing (Daw et al., 2000). Interestingly, a GluR2 tail peptide
but not a mutant sequence (which should act as a selective
disruptor of native GluR2:PICKl interactions) prevents
5-HT-induced synaptic facilitation in dorsal hom neurons
and LTD in hippocampal neurons (Li et al., 1999; Daw et
al., 2000), whereas in our experiments on neuropathic sen¬
sitisation both peptides were effective. This suggests that
whereas GRIP but not PICKI may be involved in 5-HT-
induced facilitation, or any LTD-like events in dorsal hom
neurons, PICKI is likely to play a role, probably in addition
to GRIP, in neuropathic sensitisation. Disruption of PICKI
interactions with GluR2 may exert inhibitory effects here by
inhibiting cell surface clustering ofAMPA receptors or their
organisation into complexes with signalling proteins, such
as the PICKI-associating protein, PKCa (Xia et al., 1999;
Perez et al., 2001). Any signalling events related to GluR2
endocytosis and perhaps receptor resensitisation might also
be attenuated by disruption of GluR2:PICKl interactions
because PICKI plays a key role in mediating GluR2 endo¬
cytosis (Perez et al., 2001).
The subcellular distributions ofGluR2, GRIP and PICKI
were examined in response to topical application of either
saline or AMPA to the dorsal spinal cord, in order to assess
whether stimulation-induced intracellular translocation of
these proteins might play a role in influencing their GluR2
association and overall function. In agreement with previ¬
ous work (Wyszynski et al., 1998), we found that GRIP
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Fig. 6. Translocation of GluR2, GRIP and PICK1 from the membrane following AMPA stimulation is blocked by endocytosis inhibitors. Western blots for
GluR2 (a) GRIP (b) and PICK1 (c) following topical application of either AMPA (500 /xl of 50 pM AMPA in saline) or saline vehicle to the dorsal surface
of the spinal cord. Whole spinal cord lysates showed no apparent difference in expression levels of GluR2, GRIP or PICK1 following either saline vehicle
or AMPA topical administration. A corresponding mid-speed membrane fraction (M,) and supernatant fraction containing light microsomal membrane
fragments (S,) originated from the same samples of spinal cord from which whole lysates were prepared. Membrane preparations (M,) showed a marked
reduction in the content of GluR2, GRIP and PICK! following AMPA receptor stimulation in comparison to saline vehicle treatment. The light microsomal
supernatant (S,) preparations showed no difference in the content ofboth proteins following either saline or AMPA topical application, (d) Concurrent topical
application of the endocytosis inhibitors, monodansylcadaverine and concanavalin A (20 pM and 0.25 mg/ml, respectively, 500 pi for 30 min), attenuated
the AMPA-induced translocation of GRIP out of the dense membrane fraction without reducing the content in the light microsomal 'supernatant' fraction.
See Table 3 for quantitative analysis.
appeared to be in both membrane and supernatant fractions
and reveal that stimulation of AMPA receptors caused a
relative translocation of GRIP out of the membrane-associ¬
ated (M,) fraction presumably towards a supernatant (mi¬
crosomal, S,) fraction (Fig. 6b). Even though disruption of
GluR2 association with GRIP diminishes GluR2 synaptic
surface accumulation, possibly by limiting its endocytosis
(Xia et al., 1999), the present evidence suggests that not
only GluR2 but also GRIP may be internalised following
AMPA stimulation. A similar AMPA-induced translocation
from the membrane was noted for PICK1 (Fig. 6c), which is
consistent with the proposed role for PICK1 in endocytosis
of GluR2 (Perez et al., 2001). PICK1 is diffusely distributed
in transfected cells, although when co-transfected with
GluR2 the proteins form clusters, some but not all of which
may be at the cell surface (Xia et al., 1999; Dev et al., 1999).
Activation-induced translocation of these docking proteins,
as well as that of GluR2, is an important factor to consider
in their possible roles during neuropathic pain states. NSF
could not be examined under these conditions as there was
Table 3
Translocation of GRIP is prevented by endocytosis inhibitors
Relative densitometry values for GRIP immunoreactivity
Treatment Saline AMPA AMPA+monodansylcadaverine AMPA+concanavalin A
Input (whole homogenates) 76.9 ± 3.2
M, 74.0 ± 4.1










Note. Data represent means ± SEM for densitometry analysis of Western blots shown in Fig 6d. No values were significantly different for input levels.
*P < 0.05 (Mann-Whitney Rank Sum test) represents a significant difference for AMPA and AMPA + monodansylcadaverine from saline in the M, fraction,
tP < 0.05 (Mann-Whitney Rank Sum test) represents a significant reversal of the AMPA-induced loss of GluR2 from M, following topical AMPA +
monodansylcadaverine and AMPA + concanavalin A treatment.
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insufficient signaI:noise ratio with the available reagents.
The AMPA-induced translocation of GluR2, GRIP and
PICK1 away from a dense membrane fraction, presumably
to the light microsomal "supernatant" fraction, was attenu¬
ated by topical co-administration of inhibitors of endocyto-
sis through the "clathrin-coated vesicle" pathway, mono-
dansylcadaverine and concanavalin A (Fig. 6d). These
observations on AMPA receptor internalisation in spinal
cord are consistent with reports in hippocampal neurons
(Carroll et al., 1999; Luscher et al., 1999; Lin et al., 1999)
and additionally demonstrate AMPA-induced translocation
of GRIP and PICK1.
Blocking the distinct NSF interaction site in the GluR2
C-terminal domain alleviated the thermal hyperalgesia char¬
acteristic of the CCI model with little effect on mechanical
allodynia (Fig. lc, d). Infusion of the same inhibitory pep¬
tide in hippocampal neurons reduces AMPA receptor cur¬
rent and synaptic abundance (Nishimune et al., 1998; Song
et al., 1998; Noel et al., 1999). Given the role of NSF in
vesicular trafficking, it would be predicted that blocking this
site may affect AMPA receptor transport to the synapse and
perhaps affect the receptor's ability to relay nociceptive
information (Song et al., 1998; Luthi et al., 1999). The
levels of NSF mRNA decreased in silver grain density
ipsilateral to injury specifically in LI, while there was no
detectable alteration in the number of cells expressing NSF
mRNA (Fig. 4c). NSF protein was also slightly decreased in
the spinal cord ipsilateral to CCI (Fig 3d, Table 2). Since the
GluR2:NSF interaction may play a role in moving GluR2 to
the cell surface (Noel et al., 1999; Luthi, 1999; Luscher,
1999), a downregulation of NSF may imply a reduction in
AMPA receptor recycling and such reduced trafficking of
the AMPA receptor could limit the maintenance of the
sensitised pain state.
In conclusion, we have shown that AMPA receptors play
a greater role in the sensitised sensory responses that are
brought about in a neuropathic pain model than in normal
nociceptive or non-nociceptive reflex behavioural re¬
sponses. Blocking interactions of GluR2/3 subunits with the
intracellular proteins GRIP/PICK 1 or NSF by means of
intrathecally injected myristoylated peptides can selectively
inhibit the neuropathic reflex sensitisation characteristic of
peripheral nerve damage. It seems likely that there are
distinct roles for GRIP, PICK1 and NSF in neuropathic
sensitisation. Our observations on AMPA receptor-depen¬
dent sensitisation in neuropathic pain are consistent with
observations from other parts of the CNS where the GRIP/
PICK1 or NSF interactions of GIuR2 play a role in AMPA
receptor function or plasticity. Like GluR2, the expression
of GRIP is increased in the spinal dorsal horn ipsilateral to
injury, while the levels of NSF are decreased and the ex¬
pression of PICK1 protein shows no apparent alteration.
Furthermore, AMPA receptor activation causes relative
translocation of GRIP and PICK1 (similar to GluR2) out of
the membrane fraction, corresponding to a diminished pres¬
ence of GRIP or PICK1 in association with GluR2 receptors
on the cell surface. The interface between GluR2 and its
adapter proteins, as well as cellular mechanisms that regu¬
late these interactions may provide novel therapeutic targets
for the alleviation of neuropathic pain.
Experimental methods
All experiments were performed in accordance with the
UK Animals (Scientific Procedures) Act, 1986. Adult male
Wistar rats (200-300 g, Charles River, Kent, UK) were
anaesthetised under aseptic conditions. The Bennett and Xie
(Bennett and Xie, 1988) chronic constriction injury model
was performed as described previously (Moss et al., 2002).
Behavioural reflex testing
Sensory reflex testing was carried out to assess the de¬
velopment and progression of the neuropathic pain sensiti¬
sation characteristic to the CCI model, as indicated by the
presence of hyperalgesia and allodynia. Thermal hyperalge¬
sia was monitored using the Hargreaves' thermal stimulator
(Linton Instrumentation, Diss, UK), as previously described
(Moss et al., 2002). The latency of withdrawal was recorded
for the ipsilateral (injured) and the contralateral (uninjured)
hindpaws (PWL, paw withdrawal latency). Responses were
recorded at 5 min intervals, which ensured no hypersensi¬
tivity to the test was established, and mean values taken.
Mechanical allodynia was measured as the withdrawal
threshold to calibrated Semmes-Weinstein von Frey fila¬
ments (Stoelting, Wood Dale; IL), as previously described
(Moss et al, 2002). The mean threshold required to elicit a
withdrawal response was recorded (PWT, paw withdrawal
threshold). Data were expressed as the threshold indentation
pressure (i.e. the bending force/per cross-sectional area at
the tip of the filament, mN/mm2).
Intrathecal injections
Drugs
All chugs were administered in a volume of50 pi according
to methods described previously (Moss et al. 2002). NBQX
(2,3-dioxo-6-nitro-l,2,3,4-tetrahydrobenzo[f]quinoxaline-7-
sulphonamide disodium; 1.5—15 nmol; Tocris-Cookson Ltd.,
Bristol, UK, Zeman and Lodge, 1992); NS-257 (1,2,3,6,7,8-
hexahydro-3-(hydroxyimino)-N,N7-trimethyl-2-oxo-
benzo[2,l-b 3,4-c']dipyrrole-5 sulfonamide) hydrochloride;
28-166 nmol; Sigma-RBI, Poole, Dorset or provided by Neu-
roSearch A/S, Watjen et al., 1994); SYM 2206 ((±>4-(4-
aminophenyl)-1,2-dihydro-1 -methyl-2-propylcarbamoyl-6,7-
methylenedioxyphthalazine; 1.5 nmol; Tocris-Cookson Ltd.,
Bristol, UK, Pelletier et al., 1996). The myristoylated peptides,
myr-GIuR2g46_856 (myr-AKRMKVAKNAQ) and its inactive
control, [N854S]myr-GluR2g46_g56 (Nishimune et al., 1998;
Song et al., 1998), myr-GluR2X74_883 (myr-NVYGIESVKI),
its inactive control, [1883E]myr-GluR2g74_gs3 and the selec-
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tive PICK1-targeting analogue, [S880E]myr-GluR2g74_gg3
(Matsuda et al., 1999; Li et al., 1999; Chung et al., 2000; Osten
et al., 2000; Daw et al., 2000) were synthesised and purified by
Pepsyn Ltd., University of Liverpool, UK. The inactive control
myristoylated peptide of irrelevant sequence (myr-
GRRNAIHDE) was a gift from Roger Clegg, Hannah Re¬
search Institute. All myristoylated peptides were administered
intrathecally at a dose of 4.5 nmol and injections of vehicle
(0.3% dimethylformamide in saline) or saline were shown to
have no discemable effect on behavioural reflex responses.
The effects of each compound on behavioural reflex
responses were examined. Baseline measurements were re¬
corded for thermal hyperalgesia (Hargreaves' test) and me¬
chanical allodynia (von Frey filament test) (n = 8 naive; n
= 10 neuropathic) in animals at the peak of neuropathic
behavioural reflex sensitisation and intrathecal injections
were carried out as described previously (Moss et al., 2002).
In situ hybridisation histochemistry (ISHH)
ISHH was carried out as described previously (Parker et
al., 1993). Oligonucleotide probes (synthesised and HPLC
purified by Oswel Chemicals, University of Southampton,
UK) for GluR2, GRIP2, and NSF mRNA complementary to
2032-2076 for GluR2 (Keinanen et al., 1990), 2148-2186
for GRIP2 (Bruckner et al., 1999), and 76-120 for NSF
were used. Cell counts and silver grain analysis was carried
out as described previously (Parker et al., 1993; Blackburn-
Munro and Fleetwood-Walker, 1997) to assess any changes
in the relative expression of mRNA following chronic con¬
striction injury in comparison to sham and na'ive expression
(n = 5 sections, n = 4 animals per condition).
Western blotting
Western blotting was carried out using methodology
described previously (Moss et al., 2002). Blots were probed
with primary antibodies to GluR2 (1:1000, Chemicon In¬
ternational Ltd., Harrow, UK), GRIP (1:500, Becton Dick¬
inson, London, UK), NSF (1:1,000, Chemicon), or PICK1
(1:200, Santa Cruz Biotechnology, Autogen Bioclear, Wilt¬
shire, UK) and detected by peroxidase-linked secondary
antibody enhanced chemiluminescence. The ubiquitous
housekeeping enzyme glyceraldehyde-3-phosphate dehy¬
drogenase (GAPDH, 1:750, Chemicon International Ltd.,
Harrow, UK) was used as a control, for protein level nor-
malisation.
AMPA-induced translocation of GluR2, GRIP and PICKI
Prior to removal of L4—6 spinal cord segments, the cord
was treated topically for 30 min with 500 jul saline or
AMPA (50 pM) in saline. In some cases the treatment
solution additionally contained 20 /xM monodansylcadav-
erine or 0.25 mg/ml concanavalin A.
To examine the relative membrane and supernatant con¬
tent of GluR2, GRIP and PICKI, samples of the spinal cord
were homogenised to prepare whole lysates which were
then centrifuged at 12,000 X g for 30 min at 4°C to prepare
corresponding mid-speed membrane (M,) and supernatant
(Sj) fractions. The supernatant fraction was subsequently
centrifuged at 82,000 X g for 30 min to obtain a microsomal
pellet which constituted the vast majority of the relevant
proteins recovered from the initial (S,) supernatant fraction.
Co-immunoprecipitation of GluR2 with associated
proteins
A laminectomy (L3-6) was performed on anaesthetised
rats and the spinal cord was rapidly removed to cold buffer
on ice. Following homogenisation (in IP buffer; PBS, pH
7.5 containing 1% CHAPS, 0.75% sodium deoxycholate, 2
/xg/ml aprotinin, 4 /ug/ml leupeptin, 1 mM AEBSF (4-(2-
aminoethyl) benzene sulphonyl fluoride, Alexis Corpora¬
tion, Nottingham, UK), 2 /ig/ml pepstatin, 1 mM vanadate,
1 mM sodium fluoride, 5 mM sodium molybdate and soya
bean trypsin inhibitor (50 /xg/ml)), samples were incubated
at 4°C for 1 h and centrifuged at 12,000 X g for 15 min at
4°C. Immunoprecipitation was carried out with an antibody
directed against an N-terminal domain of the GluR2 recep¬
tor (Becton Dickinson) so as not to compromise C-terminal
association of adapter proteins. The GluR2 immunoprecipi-
tating antibody (10 /xg/ml) was incubated with Protein G-
Sepharose 4B fast flow (Sigma Aldrich Company Ltd., UK,
20 ju.l/ml) for ~1 h at 4°C before addition of supernatant
and samples were then left rolling overnight at 4°C. The
beads were precipitated by pulse centrifugation, washed in
IP buffer and PBS before 40 p.1 of 2X Laemmli buffer was
added for samples derived from 1 ml of original superna¬
tant. Extracts were separated by electrophoresis on pre-cast
polyacrylamide gels (BioRad, Hemel Hempstead, UK),
transferred onto polyvinylidene difluoride membranes (Im-
mobilonPSQ, Millipore UK Ltd.) and blocked overnight at
4°C in PBS with 5% Marvel and 0.1% Tween20. Blots were
probed with primary antibodies to GluR2 (1:500, Chemi¬
con), GRIP (1:500, Becton-Dickinson) or PICKI (1:200,
Santa Cruz Biotechnology) and detected by peroxidase-
linked secondary antibody enhanced chemiluminescence.
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Chronic pain due to nerve injury is resistant to current
analgesics. Animal models of neuropathic pain show
neuronal plasticity and behavioral reflex sensitization
in the spinal cord that depend on the NMDA receptor
[1, 2], We reveal complexes of NMDA receptors with
the multivalent adaptor protein PSD-95 [3, 4] in the
dorsal horn of spinal cord and show that PSD-95 plays
a key role in neuropathic reflex sensitization. Using
mutant mice expressing a truncated form of the PSD-
95 molecule [5], we show their failure to develop the
NMDA receptor-dependent hyperalgesia and allodynia
seen in the CCI model of neuropathic pain [6], but
normal inflammatory nociceptive behavior following
the injection of formalin. In wild-type mice following
CCI, CaM kinase II inhibitors attenuate sensitization
of behavioral reflexes, elevated constitutive (autopho-
sphorylated) activity of CaM kinase II is detected in
spinal cord, and increased amounts of phospho-Thr286
CaM kinase II coimmunoprecipitatewith NMDA recep¬
tor NR2A/B subunits. Each of these changes is pre¬
vented in PSD-95 mutant mice although CaM kinase
II is present and can be activated. Disruption of CaM
kinase II docking to the NMDA receptor and activation
may be responsible for the lack of neuropathic behav¬
ioral reflex sensitization in PSD-95 mutant mice.
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Results
PSD-95 Expression in Spinal Cord
Using histochemical staining for the fi-galactosidase re¬
porter gene, we showed that PSD-95 expression is spe¬
cifically restricted to lamina II of the spinal dorsal horn, a
prime location for the processing of nociceptive afferent
inputs (Figure 1A), and is found throughout lumbar and
thoracic spinal cord (Figure 1B). This distribution over¬
laps with those of NMDA receptor subunits (particularly
NR2B) throughout lumbar and thoracic spinal cord [2].
PSD-95 expression was not detected in dorsal root entry
zones (Figure 1B, arrow), dorsal root ganglion (DRG),
dorsal roots, or sciatic nerve (data not shown). Using
coimmunoprecipitation, we could isolate NMDA recep¬
tor complexes from spinal cord that contained NR1,
NR2A, NR2B, and PSD-95, similar to those found in
forebrain [3, 4] (Figure 1C).
PSD-95 Mutant Mice Lack Behavioral Reflex
Sensitization Following CCI
We used the CCI model of neuropathic pain to examine
the effects of sciatic nerve injury in homozygous PSD-
95 mutant mice and their wild-type littermates. Over
7-10 days following CCI (under halothane anesthesia),
wild-type mice progressively developed marked ipsilat-
eral thermal hyperalgesia (reduced paw withdrawal la¬
tency, PWL; Figure 2A), mechanical allodynia (reduced
paw withdrawal threshold, PWT; Figure 2C), and cold
allodynia (increased suspended paw elevation time,
SPET; Figure 2E). All responses from the contralateral
hind limb remained unaltered. Thermal hyperalgesia and
mechanical allodynia were absent in PSD-95 mutant
mice (Figures 2B and 2D), while cold allodynia was se¬
verely attenuated, reaching statistical significance at
only one time point (Figure 2F). No differences in motor
function or coordination (as measured by the rotarod
test) were observed in PSD-95 mutants compared to
wild-type mice. In addition, there was no evidence for
anatomical alterations in afferents of the mutant mice,
with similar axon diameter and myelin thickness profiles
for AfJ, A5, and C fibers between naive wild-type and
homozygous PSD-95 mutant mice (in accordance with
previous findings [7, 8]), and the extent of CCI-induced
changes in afferent fibers was unaltered.
PSD-95 Mutant Mice Display Normal Responses
to Inflammatory Nociceptive Stimuli
Sensitization of nociceptive reflexes can also be brought
about by peripheral inflammatory stimuli [9], but inflam¬
matory and neuropathic states display a number of dis¬
tinct characteristics [1,10]. We therefore tested whether
PSD-95 mutant mice also display a deficit in behavioral
responses to inflammation by intraplantar injection of
formalin (10 jd of 1.5% solution in saline, during brief
halothane anesthesia [11,12]). PSD-95 mutant mice and
wild-type littermates displayed the same responses of
paw licking and flicking in the early acute phase of the
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Figure 1. Expression of PSD-95 and Components of the NMDA Receptor Complex in Spinal Cord
Heterozygous PSD-95 (wt/mutant) animals (n - 5) were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer. 10 |>.m sections were
washed with ice-cold PBS/MgCI2 and then 0.041 % MgCI2, 0.01 % Na deoxycholate, 0.02% Nonidet-NP40, in 0.1 M PBS. Sections were stained
at 22°C in 0.042% potassium ferrocyanide, 0.033% potassium ferricyanide in detergent buffer with 1 ng/ml 5-bromo-4-chloro-3-indolyl-B-D-
galactoside, and incubated at 37°C in the dark for 4-6 hr.
(A) Transverse section, showing specific distribution of 0-galactosidase-positive cells in lamina II (outlined with dashed line) of the superficial
dorsal horn.
(B) Longitudinal section showing staining in dorsal horn, but not at the site of dorsal root entry (arrow). Scale bar equals 10 |xm.
(C) Immunoblots for the presence of NMDA receptor complex proteins in NR2A/B-directed immunoprecipitates of L3-L6 spinal cord from
wild-type mice.
formalin test (5-10 min following injection), and the late
(inflammatory) phase of the response (25 min to 1 hr)
was also indistinguishable between the mutant and wild-
type mice (Figure 2G), in striking contrast to the lack of
neuropathic behavioral reflex sensitization seen in the
mutants. The degree of peripheral inflammation as as¬
sessed by paw volume was the same for PSD-95 mutant
and wild-type mice.
NMDA Receptor-Dependent Hyperalgesia
and Allodynia in Wild-Type, but not
PSD-95 Mutant Mice
Intrathecal administration of the selective NMDA recep¬
tor antagonist (R)-CPP (under brief halothane anesthe¬
sia) completely reversed thermal hyperalgesia and me¬
chanical allodynia that had developed ipsilateral to CCI
in wild-type mice, with no detectable effect on contralat¬
eral responses or in naive animals. At 10-30 min follow¬
ing injection of (R)-CPP (100 pmole), the ipsilateral:
contralateral differences in PWL and PWT (thermal hy¬
peralgesia and mechanical allodynia) were reduced to
11.6% ± 5.9% and 8.3% ± 3.5% of predrug differences
(n = 6, p < 0.05 by Wilcoxon test in each case). Recovery
was complete by 60-80 min. The equivalent values for
saline were 94.8% ± 3.9% and 90.0% ± 5.3%, respec¬
tively. The behavioral changes brought about following
CCI were bilaterally mimicked in naive wild-type mice
by intrathecal administration of NMDA (250 pmole),
showing a 45.9% ± 5.1 % reduction in mechanical paw
withdrawal threshold (PWT) and a 36.2% ± 3.9% reduc¬
tion in thermal paw withdrawal latency (PWL) over 10-30
min following injection (p < 0.05 in each case by Mann-
Whitney U test). In contrast, behavioral responses of
PSD-95 mutant mice following CCI were unaffected by
intrathecal administration of (R)-CPP, with PWL and
PWT values (which, as described, displayed no sensiti¬
zation in these animals) remaining at 98.4% ± 7.2% and
94.5% ± 4.9% of predrug controls. Correspondingly,
naive PSD-95 mutants showed no changes in PWL and
PWT following intrathecal injection of NMDA, with values
remaining at 96.4% ± 5.0% and 99.4% ± 6.3% of pre¬
drug controls. These findings suggest that NMDA recep-
tor:PSD-95 interactions in spinal cord play a key role in
the development of neuropathic behavioral reflex sensi¬
tization. In both wild-type mice and PSD-95 mutant
mice, the second (inflammatory) phase of the nocicep¬
tive reflex response to formalin was completely inhibited
by intrathecal injection of 100 pmol (R)-CPP. The mean
number of paw flinches/flicks over the peak 15 min of
the second phase formalin response was reduced by
(R)-CPP to 11.5% ± 4.3% of control in wild-type and
by 10.1% ± 5.2% in PSD-95 mutants (n = 4; p < 0.05
by Student's t test). Intrathecal injection of saline had
no detectable effect on formalin responses with corre¬
sponding values remaining within 6% of those from un¬
injured controls. This indicates that while this inflamma¬
tory nociceptive behavioral response involves the NMDA
receptor, it does not share the additional requirement
for intact PSD-95 that is seen in the behavioral reflex
sensitization induced by CCI.
CaM Kinase II Inhibitors Alleviate
Neuropathic Sensitization
NMDA receptor:PSD-95 complexes in the forebrain in¬
corporate the Ca2 -dependent protein kinase, CaM ki¬
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Figure 2. Behavioral Analysis of Wild-Type and PSD-95 Mutant Mice with Chronic Constriction Injury (CCI) to the Sciatic Nerve
Data show mean ± SEM responses for each day before and following the induction of CCI. A variation of the chronic constriction injury (CCI)
model for rat [6] was used, whereby (under halothane anesthesia) three ligatures separated by 1 mm were tied loosely to constrict the tibial
branch of the sciatic nerve.
(A and B) In wild-type mice (A), paw withdrawal latency (PWL) from a noxious thermal stimulus (Hargreaves' thermal stimulator) ipsilateral to
CCI (open circle) showed significant differences between postoperative and preoperative values (dagger indicates p < 0.05; Kruskal-Wallis
one-way ANOVA) and from postoperative, contralateral (closed square) values (asterisk indicates p < 0.05 by Student's t test). No thermal
hyperalgesia was seen on the contralateral side (closed square) of wild-type mice (A) or in PSD-95 mutant mice (B) on either side.
(C and D) Paw withdrawal thresholds (PWT) from mechanical stimulation (von Frey filaments) for wild-type mice showed significant differences
between postoperative and preoperative values on the side ipsilateral (open circle) to CCI (dagger indicates p < 0.05; Dunn's Method ANOVA
on ranks) and between postoperative ipsilateral and contralateral values (asterisk indicates p < 0.05, Mann-Whitney U test). No significant
differences were seen on the contralateral side (closed square) of wild-type mice (C) following nerve ligation or in PSD-95 mutants (D).
(E and F) The suspended paw elevation time (SPET) in response to a cold water (4°C) stimulus is shown for the ipsilateral paw (open circle)
and contralateral paw (closed square) in wild-type mice (E) and in PSD-95 mutant mice (F). Following nerve ligation, SPET scores for the
contralateral paw were always zero for both wild-type and mutant mice. Statistically significant differences between postsurgery and presurgery
ipsilateral values are indicated by a dagger (p < 0.05, Dunn's Method ANOVA on ranks), and an asterisk (p < 0.05, Mann-Whitney U test)
indicates statistically significant differences between postsurgery ipsilateral and contralateral responses.
(G) Data represent the number of paw flinch/flick responses per minute following the intraplantar injection of formalin. There was no significant
difference between responses of wild-type (closed diamond) and PSD-95 mutant (open diamond) mice in either the initial stage or the second
(inflammatory) stage of this test, n = 5-9 in each case.
is predicted to play a particular role in NMDA receptor-
mediated synaptic plasticity [16]. Recent studies indi¬
cate that Ca2+/calmodulin stimulation induces auto-
phosphorylation at Thr286 CaM kinase II and docking of
the active kinase to the C-terminal domain of NR2B [17],
We first investigated whether CaM kinase II is necessary
for the NMDA receptor-dependent sensitization of spi¬
nal neurons in CCI. Intrathecal administration of the se-
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Table 1. Effects of Acute Topical Drug Administration and of CCI on CaM Kinase II Activation in Spinal Cord of Wild-Type and
PSD-95 Mutant Mice
Topical Application to Spinal Dorsal
Horn













In Mice with Established CCI CCI Ipsi CCI Contra CCI Ipsi CCI Contra
Saline
(R)-CPP (5 nmole)
28.8 ± 3.1* 16.8 ± 2.0
14.3 ±1.5 17.5 ± 3.0
16.1 ± 2.1 14.9 ± 1.7
Agents were topically applied in a volume of 500 pi for 15 min to the dorsal surface of L3-L6 spinal cord before rapid removal of tissue and
homogenization prior to CaM kinase II immunoprecipitation and kinase activity assay. The concentrations of NMDA/glycine and ionomycin
used were selected to provide maximal intensity stimuli and ensure detectability of changes in enzyme activity within the heterogeneous
tissue samples taken. The mean maximal CaM kinase II activity in immunoprecipitates from naive PSD-95 mutant mice spinal cord (stimulated
by Ca2'/calmodulin addition in vitro) was unaltered from that in wild-type mice (108.3 ± 13.7 and 97.8 ± 13.1 pmoles "P/min/p.g original
extract protein, respectively). Data are expressed as the percentage of maximal CaM kinase II activity (means ± SEM, n = 8-10). Statistically
significant differences are indicated by asterisk (p < 0.05 by Mann Whitney U test, compared to corresponding saline values in naive mice
and by Wilcoxon test compared to corresponding contralateral values in mice with established CCI).
lective CaM kinase II inhibitors, KN-93 (120 pmole [18])
and myristoyl-autocamtide 2-related inhibitory peptide
(myr-AlP, myr-KKALRRQEAVDAL, 1 nmole [19]), clearly
reversed the neuropathic thermal hyperalgesia and
mechanical allodynia seen in wild-type mice following
CCI, whereas a control myristoylated peptide (myr-
GRRNAIHDE, 1 nmole) or saline vehicle were without
effect. Cell permeability of myr-AlP has been docu¬
mented [19], and we have shown that it can effectively
attenuate CaM kinase II autophosphorylation in spinal
cord following topical application (unpublished results).
At 10-30 min following injection, the ipsilaterahcontralat-
eral difference in PWL (thermal hyperalgesia) was signifi¬
cantly reduced to 18.2% ± 3.6%* and 21.2 ± 2.3%* of
predrug control values by KN-93 and myr-AlP, respec¬
tively (n = 6-9, *p < 0.05 by Wilcoxon test), but not by
myr-control peptide (90.5% ± 8.6%) or saline (above).
Corresponding values for the lateral difference in PWT
(mechanical allodynia) were 3.3% ± 1.4%, 37.3% ±
5.9%*, and 96.3% ± 5.8%. Recovery from the effects
of each reagent was largely complete by 60-80 min.
Thus, the NMDA receptor-dependent sensitization of
spinal neurons that is lacking in PSD-95 mutant mice
crucially requires CaM kinase II to exert its functional
influence.
CaM Kinase II Activation in Response to Spinal
NMDA Receptor Stimulation or CCI
We directly monitored the activation state of spinal cord
CaM kinase II, isolated by immunoprecipitation from
tissue extracts. Following CCI, the proportion of CaM
kinase II activity that was constitutive (a read-out of
previous activation by Ca2+/calmodulin) was signifi¬
cantly greater in spinal cord ipsilateral to nerve injury
compared to contralateral in wild-type animals, but not
in PSD-95 mutants (Table 1). This CCI-induced incre¬
ment could be completely prevented by topical (R)-CPP,
confirming the requirement for NMDA receptors in medi¬
ating the necessary Ca2+ entry. The maximal activity of
CaM kinase II from spinal cord that could be evoked in
vitro by Ca2+/calmodulin addition was unchanged be¬
tween wild-type and PSD-95 mutant mice. Furthermore,
topical application of a maximally effective concentra¬
tion of NMDA (with glycine) or of ionomycin elicited the
same extent of CaM kinase II activation in naive PSD-
95 mutant mice as seen in wild-type littermates (Table
1). Thus, the spinal complement of CaM kinase II is
fully able to respond to Ca2+-elevating stimuli in PSD-
95 mutant mice. Nevertheless, the NMDA receptor-
mediated Ca2+ entry that occurs physiologically during
CCI appears to activate CaM kinase II more effectively in
wild-type than in PSD-95 mutant mice. PSD-95 therefore
seems to play an important role in facilitating the func¬
tional coupling between the NMDA receptor and CaM
kinase II in CCI.
Molecular Mechanisms Disrupted
in PSD-95 Mutant Mice
Changes either in protein phosphorylation or in pro-
tein:protein interactions might underlie the facilitated
NMDA receptor:CaM kinase II coupling in CCI. The
NMDA receptor is known to be phosphorylated by PKC
and PKA at Ser896 and Ser897, respectively, within the
NR1 subunit [20], and PSD-95 is thought to bind the
PKA/PKC-docking protein AKAP79/150 [21 ] through do¬
mains that are lacking in the mutant PSD-95 protein
here, suggesting that regulatory phosphorylation of the
NMDA receptor may be disturbed in the mutant mice.
Figure 3A shows that NR1 -directed immunoprecipitates
demonstrated a small increase in phospho-Ser^'-NRI
immunoreactivity ipsilateral to CCI, which tended to be
less in PSD-95 mutant mice. No clear signal was ob¬
tained for phospho-Ser836 immunoreactivity. Pan-NR1
control blots were also carried out to confirm that the
proportion of NR1 phosphorylated at Ser897 was in¬
creased (Figure 3A). Small reductions in the levels of
pan-NR1 immunoreactivity were seen ipsilateral to CCI
(in accordance with a previous report [22] and our un¬
published data from the rat CCI model), and these reduc¬









Mean relative phospho-Ser 89'NR1: pan
NR1 immunoreactivity (grey scale ratios
relative to wt contra)
Wild type ipsi 4.67 ± .63
Wild type contra 1.0 (as defined)
"
ipsi 1.35 ±0.22
a contra 1.02 ±0.17
Figure 3. Immunoblots for Phospho-Ser897-
NR1 and PKA-Related Proteins in NR1 and
NR2 Immunoprecipitatesfrom Wild-Type and
PSD 95 Mutant Mice Either Following CCI
Surgery or in Naive Samples
(A) Western blot analysis of NR1 immunopre-
cipitates from spinal cord following sciatic
CCI carried out 12 days previously. Immuno-
precipitates from wild-type (wt) or PSD-95
mutant (open triangle) mice, ipsilateral or
contralateral to the injury, were probed for
phospho-Ser^-NRI or pan-NR1 (n = 5). The
mean ratio of phospho-Ser^-NRI :pan-NR1
immunoreactivity appeared to be increased
in wild-type ipsilateral samples, but not those
from the mutant mice. Approximate molecu¬
lar weights are shown on the left.
(B) Western blot analysis of spinal cord pro¬
teins captured by "pep6" NR2B C-terminal
(SIESDV) peptide-affinity resin [4]. Samples
derived from wild-type (wt) or PSD-95 mutant
(open triangle) mice were probed with anti¬
bodies for NR1, PKA-Rlla, PKA-Rllp, and
AKAP150 (n = 8). There was no detectable
difference in the levels of any of these cap¬
tured proteins when wild-type extracts were
compared to PSD-95 mutant extracts.
NR1 PKA-Rlla PKA-Rllp AKAP150
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wild-type littermates. However, affinity capture of NMDA
receptor complexes and associated proteins using an
NR2B tail peptide affinity resin [3,4] showed consistently
no changes in NR1, PKA-Rlla, PKA-RllfS, or AKAP150
immunoreactivity between complexes from wild-type or
PSD-95 mutant spinal cord (Figure 3B). This suggests
that altered AKAP-mediated kinase targeting to the
NMDA receptor complex in the PSD-95 mutant mice
does not underlie their neuropathic sensitization-resis-
tant phenotype.
To examine the coexistence of CaM kinase II and
NMDA receptors in molecular complexes in the spinal
cord following CCI and to assess any difference caused
by the mutant PSD-95 protein, we immunoprecipitated
NR2A/B subunits from spinal cord following CCI and
probed for the levels of total and autophosphorylated
(activated) CaM kinase lla immunoreactivity bound to
the receptor, in wild-type spinal cord, we found high
levels of CaM kinase lla associated with the receptor,
with an increase in CaM kinase lla levels ipsilateral to
CCI compared to contralateral (Figure 4A). Similarly,
there was a marked increase in the levels of NR2A/B
bound phospho-Thr286 CaM kinase lla ipsilateral to injury
in wild-type mice (Figure 4B) where under the same
conditions in PSD-95 mutant mice, minimal levels of
CaM kinase lla (Figure 4A) or phospho-Thr286 CaM kinase
lla (Figure 4B) were bound to NR2A/B subunits. When
blots were probed for control pull-down of NR2A and
NR2B subunits, uniform immunoreactivity was seen in
wild-type and PSD-95 mutant tissue (Figure 4C). Simi¬
larly, the tissue levels of CaM kinase II expression were
unaltered between wild-type and PSD-95 mutant mice
(Figure 4D). These data reveal a profound loss of NMDA
receptor-associated CaM kinase lla and phospho-Thr286
CaM kinase lla (an autonomously active form of the
enzyme) in the PSD-95 mutant mice. Disruption of this
interaction could provide a unified explanation of the
linked dependence of sensitization on NMDA receptors
and CaM kinase II, together with the lack of CCI-induced
behavioral reflex sensitization and CCI-induced CaM
kinase II activation seen in the PSD-95 mutants.
Discussion
Using transgenic mice and a behavioral reflex model of


























Whole spinal cord lysate
Figure 4. Immunoblots for CaM Kinase lla Association with Spinal
NR2A/B Immunoprecipitates
(A) Western blot of NR2A/B immunoprecipitates from wild-type (wt)
and PSD-95 mutant (open triangle) spinal cord at the peak of behav¬
ioral sensitization following CCI (n = 8). Ipsilateral to injury (ipsi)
wild-type mice show increased levels of receptor bound CaM kinase
II when compared to the contralateral (contra) spinal cord. In com¬
parison, the levels of receptor bound CaM kinase II in PSD-95 mutant
spinal cord were greatly reduced both ipsilateral and contralateral
to injury. Approximate molecular weights are shown on the left.
(B) Western blots probed for phospho-Thr286 CaM kinase II show
increased levels of NR-associated immunoreactivity ipsilateral to
nerve injury in wild-type mice, but not PSD-95 (open triangle) mu¬
tants.
(C) Recovery of NR2A and NR2B from the immunoprecipitates
showed no detectable differences between wild-type and PSD-95
mutant samples.
(D) Western blot of whole spinal cord lysate from naive wild-type
(wt) mice and PSD-95 mutant mice (open triangle) probed for CaM
kinase II shows that the total content of CaM kinase II was similar
in wild-type and PSD-95 mutant mice.
addressed the role of the NMDA receptor-adaptor pro¬
tein PSD-95 in neuropathic pain. Histochemical staining
for the p-galactosidase reporter incorporated into the
mutant construct showed specific expression in many
cells within lamina II of the superficial dorsal hom. This
corresponds to regions of high NMDA receptor expres¬
sion, to the termination of fine sensory afferents, and
matches a recent report of native PSD-95 immunoreac¬
tivity in spinal cord [23]. In spinal cord of wild-type mice,
NR2 subunit immunoprecipitates additionally pulled
down both NR1 and PSD-95, confirming the presence
of spinal complexes of NMDA receptor subunits with
PSD-95.
The functional impact of the mutant PSD-95 construct
on neuropathic behavioral reflex sensitization was strik¬
ing. Thermal hyperalgesia, mechanical allodynia, and
cold allodynia brought about by peripheral nerve injury
were all virtually absent in homozygous PSD-95 mutant
mice, despite the entirely undiminished nociceptive re¬
flex behavior that they displayed following intraplantar
formalin. The enduring lack of neuropathic sensitization
seen in this phenotype is consistent with a brief report of
transient delays in the development of such sensitization
following a PSD-95 antisense reagent [23]. The current
report reveals for the first time that the requirement for
PSD-95 is both selective for neuropathic rather than
inflammatory sensitization and is absolute. Intrathecal
injection of NMDA receptor antagonist confirmed that
the neuropathic hyperalgesia and allodynia are depen¬
dent on spinal NMDA receptors, matching other results
in neuropathic pain models [1], Similar sensitivity to
NMDA receptor antagonist was seen for the late phase
inflammatory formalin response, as in other reports [11,
12]. Intrathecal injection of NMDA did not produce hy¬
peralgesia and allodynia in PSD-95 mutant mice, at a
dose that was effective in naive wild-type mice. This is
consistent with a recent report of attenuated NMDA-
induced thermal hyperalgesia in the tail flick test when
animals were treated with a PSD-95 antisense reagent
[24]. The present data demonstrate that failure of a key
signal from spinal NMDA receptors in the PSD-95 mutant
mice is likely to underlie their inability to develop neuro¬
pathic sensitization. Inflammatory sensitization, although
also requiring NMDA receptors, appears to be indepen¬
dent of such PSD-95-mediated coupling of the NMDA
receptor to other proteins.
The sensitivity of NMDA receptor/PSD-95-dependent
neuropathic sensitization to CaM kinase II inhibitors
suggests that this enzyme may play a key role down¬
stream of the complex in producing the sensitized state.
This idea is consistent with evidence that NMDA recep¬
tor-mediated CaM kinase II translocation to synapses
and activation is important in long-term potentiation in
hippocampus [13, 25, 26], and spinal cord data showing
that CaM kinase II can elicit and mediate sensitization
caused by the activator of nociceptive afferent fibers,
capsaicin [27, 28]. Accordingly, we found that CCI
caused a partial activation of CaM kinase II in spinal
cord. This was monitored by ex vivo enzyme assays, as
a constitutively active (autophosphorylated, previously
activated) form of the enzyme. PSD-95 mutant mice
failed to show CCI-induced activation of CaM kinase II,
however, suggesting that PSD-95 is essential in assem¬
bling an in vivo connection between the NMDA receptor
and CaM kinase II under these conditions. Total CaM
kinase II activity and immunoreactivity were unaltered
by CCI or by the PSD-95 mutation. The fact that a high
concentration of NMDA (plus glycine) could readily
evoke CaM kinase II activation in PSD-95 mutant ani-
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mals while CCI-induced enzyme activation was pre¬
vented could suggest that the CCI response involves a
particular subpopulation of the enzyme, perhaps assem¬
bled in a specific functional arrangement.
An alternative hypothesis could be that the CCI-
induced CaM kinase II response, but not that induced
by NMDA (plus glycine) alone, might rely on auxiliary
regulatory events, for which phosphorylation of the
NMDA receptor would be a strong candidate. Although
we detected some increase in phosphorylation of NR1 -
Ser*97 (a PKA target) in CCI, we could find no evidence for
altered association of PKA or AKAP79/150 with spinal
NMDA receptor complexes in PSD-95 mutant mice. This
argues against a failure of AKAP-mediated localization
of kinases in the proximity of the NMDA receptor being
the functionally critical deficit in the PSD-95 mutant
mice.
In contrast, we found that the levels of overall CaM
kinase lla and phospho-Thr286 CaM kinase lla that could
be immunoprecipitated with NR2A/B subunits were
clearly increased ipsilateral to CCI in wild-type, but not
PSD-95 mutant mice. CaM kinase II is a major compo¬
nent of NMDA receptor complexes [3,4] and can translo¬
cate to synapses upon further NMDA receptor activation
[25]. It is known that CaM kinase II can associate directly
with NR2A/B subunits, and this interaction may be re¬
duced when PSD-95 is docked to receptor carboxy-tail
sequences [29]. Nevertheless, here in a physiological
model of neuropathic pain, the injury-induced associa¬
tion of CaM kinase II with the NMDA receptor is shown
to be PSD-95 dependent, suggesting that its assembly
into multiprotein complexes may be a key factor for in
vivo function. Such functional microdomains organized
in the vicinity of NMDA receptor complexes [30] may well
be critical for neuropathic sensitization. While altered
interactions of PSD-95 with other potential partners in
the mutant mice may make a contribution to their lack
of neuropathic reflex sensitization, the present evidence
indicates that disruption of NMDA receptonPSD-95:CaM
kinase II functional microdomains plays a key role.
Supplementary Material
Supplementary material including detailed Experimental Proce¬
dures and data on morphological analysis of sciatic nerve fibers is
available at http://images.cellpress.com/supmat/supmatin.htm.
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